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Preface
The research in amyotrophic lateral sclerosis (ALS) has dramatically increased in the last 20
years, greatly improving our understanding of the pathological mechanisms involved in the
disease. The number of hypothesis on the pathogenic causes of ALS and the mechanisms of
motor neuron death keeps growing. Twenty years ago there was a general agreement that
ALS was a motor neuron disease. All other symptoms were secondary to the primary cause
that was the death of upper and lower motor neurons. Today there are several hypotheses
suggesting that dysfunction in other cell types, such as astrocytes, is the primary cause of
the disease that leads to motor neuron death. Twenty years ago there were not animal mod‐
els for ALS, now there are multiple rodent and non-mammalian models of the disease.
The more accepted hypotheses for the causes of ALS are reviewed in the first chapter by
Rossi and coauthors. This chapter reviews the potential pathogenic mechanism involved in
the etiology of ALS providing short description of each mechanism.
The chapter by Shin and Lee reviews the cellular mechanisms found to potentially partici‐
pate in the degeneration of motor neurons in ALS. This chapter provides a cellular approach
to the proposed mechanisms of motor neuron death in ALS, supporting the hypothesis that
multiple molecular pathways could be involve in motor neuron death in different patients.
Diamanti and collaborators provide further support for the hypothesis of multiple molecu‐
lar mechanisms in ALS by reviewing correlations between genotype and disease presenta‐
tion. Using studies of Italian ALS patients, the authors provide evidence showing the
correlation between different phenotypic presentations of ALS with known genetic causes of
the disease.
The chapter by Bowerman and collaborators reviews up to day evidence of the role of neu‐
roinflammation in the pathology of ALS. The role of astrocytes and other inflammatory cells
is reviewed in detail. The authors also discuss in depth the possible inflammatory mediators
and molecular mechanism involved in the induction of motor neuron death.
Franco and collaborators review the highly controversial participation of oxidative stress in
the pathology of ALS. The chapter focuses on the oxidative mechanisms proposed to explain
the gain-of-function of ALS-linked mutant SOD.
Ferraiuolo and coauthors provide a new interpretations of the ALS literature based on the
recent discovery that a plethora of new genetic mutations affecting a variety of genes are
linked to ALS. The review provides an unique perspective on the strengths and weaknesses
of classic and new animal models of the disease based on performance and similarities to
the human disease.
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linked to ALS. The review provides an unique perspective on the strengths and weaknesses
of classic and new animal models of the disease based on performance and similarities to
the human disease.
The chapter by Aggarwal describes studies in at risk presymtomatic individuals carrying
mutant SOD. The research uses MUNE to determine motor neurons status and the thera‐
peutic benefits of riluzole. The methods described in this chapter could provide and early
diagnosis in patients carrying mutations linked to ALS allowing presymtomatic treatments.
Bocci and collaborators found by Macro-EMG, that there is a possible compensatory over‐
branching in ALS motor neurons, which provides a possible explanation for the adult onset
of the disease.
Abe and collaborators provided a review of the last advances of eye-gaze systems, which
allows ALS patient to communicate after almost other voluntary mobility is lost. The tech‐
nology reported here is relatively inexpensive and for those patients unable to communicate
by other means could represent a significant improvement on quality of life.
Alvaro G. Estévez, Ph.D.
Burnett School of Biomedical Sciences,
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1. Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder character‐
ized by death of pyramidal neurons in the motor cortex (upper motor neurons) and motor
neurons in the brain stem and central spinal cord (lower motor neurons). This results in
muscle weakness, progressive motor disability, and finally death by respiratory failure or
an associated infection (Shook and Pioro, 2009). There are two types of ALS familiar (fALS)
and sporadic ALS (sALS). They are both clinically undistiguishale one from the other; fALS
accounts for 10% of all cases being the rest of the cases sALS (Pasinelli and Brown, 2006).
In the last few years, there had been an explosion of genetic studies associating ALS with
several  genetic  mutations  in  genes  codifying  for  different  proteins:  Cu/Zn  superoxide
dismutase, (SOD1), transactive response binding protein 43 (TARDBP), fused in sarcoma
(FUS),  and valosin containing protein (VCP).  Most recently,  a  genetic  defect  was identi‐
fied with an expansion of the noncoding GGGGCC hexanucleotide repeat in the chromo‐
some  9,  open  reading  frame  72  (C9ORF72),  associated  with  ALS  with  and  without
frontotemporal dementia (Boeve et al., 2012).
Despite of all these discoveries the etiology of ALS remains elusive. A number of potential
pathogenic mechanisms have been associated with ALS including excitotoxicity, mitochon‐
drial dysfunction, apoptosis, glial activation, RNA-processing, growth factor abnormalities,
etc. These potential pathogenic processes are reviewed in this chapter.
2. Pathology
ALS is characterized by upper motor neuron (corticospinal motor neurons) and lower motor
neuron (bulbospinal motor neurons) degeneration and death as well as reactive gliosis
© 2013 Rossi et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
The chapter by Aggarwal describes studies in at risk presymtomatic individuals carrying
mutant SOD. The research uses MUNE to determine motor neurons status and the thera‐
peutic benefits of riluzole. The methods described in this chapter could provide and early
diagnosis in patients carrying mutations linked to ALS allowing presymtomatic treatments.
Bocci and collaborators found by Macro-EMG, that there is a possible compensatory over‐
branching in ALS motor neurons, which provides a possible explanation for the adult onset
of the disease.
Abe and collaborators provided a review of the last advances of eye-gaze systems, which
allows ALS patient to communicate after almost other voluntary mobility is lost. The tech‐
nology reported here is relatively inexpensive and for those patients unable to communicate
by other means could represent a significant improvement on quality of life.
Alvaro G. Estévez, Ph.D.
Burnett School of Biomedical Sciences,
College of Medicine,




Pathophysiology of Amyotrophic Lateral Sclerosis
Fabian H. Rossi, Maria Clara Franco and
Alvaro G. Estevez
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/56562
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder character‐
ized by death of pyramidal neurons in the motor cortex (upper motor neurons) and motor
neurons in the brain stem and central spinal cord (lower motor neurons). This results in
muscle weakness, progressive motor disability, and finally death by respiratory failure or
an associated infection (Shook and Pioro, 2009). There are two types of ALS familiar (fALS)
and sporadic ALS (sALS). They are both clinically undistiguishale one from the other; fALS
accounts for 10% of all cases being the rest of the cases sALS (Pasinelli and Brown, 2006).
In the last few years, there had been an explosion of genetic studies associating ALS with
several  genetic  mutations  in  genes  codifying  for  different  proteins:  Cu/Zn  superoxide
dismutase, (SOD1), transactive response binding protein 43 (TARDBP), fused in sarcoma
(FUS),  and valosin containing protein (VCP).  Most recently,  a  genetic  defect  was identi‐
fied with an expansion of the noncoding GGGGCC hexanucleotide repeat in the chromo‐
some  9,  open  reading  frame  72  (C9ORF72),  associated  with  ALS  with  and  without
frontotemporal dementia (Boeve et al., 2012).
Despite of all these discoveries the etiology of ALS remains elusive. A number of potential
pathogenic mechanisms have been associated with ALS including excitotoxicity, mitochon‐
drial dysfunction, apoptosis, glial activation, RNA-processing, growth factor abnormalities,
etc. These potential pathogenic processes are reviewed in this chapter.
2. Pathology
ALS is characterized by upper motor neuron (corticospinal motor neurons) and lower motor
neuron (bulbospinal motor neurons) degeneration and death as well as reactive gliosis
© 2013 Rossi et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
replacing death neurons (Leigh and Garafolo, 1995). As corticospinal motor neuron degenerate
the cells suffer from a retrograde axonal loss with secondary myelin pallor and gliosis. These
changes are most severed at the brainstem and upper spinal cord, but are extended throughout
the spinal cord (Brownell et al., 1970). ALS motor cortex shows astrocytic gliosis, especially in
the deeper layers at the gray matter and underlying the subcortical white matter. Irregular
immunoreactivity to GFAP is identified in the motor strip (Kamo, et al. 1987; Ince, 2000). The
lysosomal marker CD68 also revealed that most of the glial response at the cortical and spinal
tracts corresponds to microglia activation and active macrophages (Cagnin et al., 2001; Sitte et
al., 2001). ALS affects spinal motor neurons of the ventral horn and brainstem motor neurons.
The autopsy of ALS patients shows loss of motor neurons and atrophic motor neurons with
basophilic appearance suggesting a programmed cell mechanism (Martin, 1999). The ventral
roots become thin with loss of large myelinated fibers in motor nerves leading to denervation
atrophy with evidence of reinnervation in affected muscles. Frontal temporal dementia ALS
(FTD-ALS) is a neurodegenerative disorder associated with ALS that presents typical patho‐
logical findings of the disease in addition to neuronal loss of the frontal or temporal cortex,
hippocampus and amygdale, and spongiform changes of the neocortex with (Leigh PN and
Garofolo, 1995). Non-motor findings encountered in ALS pathology are posterior columns
demyelination and reduced density of myelinated sensory fibers (Ince, 2007)
2.1. Inclusion bodies
The hallmark finding of lower motor neuron (LMN) pathology in ALS is the presence of
intracellular inclusion bodies in neuronal soma and proximal dendrites as well as glia (Barbeito
et al., 2004).
2.1.1. Ubiquitylated Inclusions (UBI)
UBI are the most common and specific inclusion in ALS, found at LMN of the spinal cord and
brainstem (Matsumoto et al., 1993) and also at the corticospinal tract upper motor neurons
(UMN) (Sasaki and Maruyama, 1994). UBI morphological spectrum goes from thread-like
ubiquitylated profiles, through skeins of different compactness to more spherical bodies (Ince
et al, 1998). The compacted lesions may be eosinophilic, basophilic and “Lewy-like” in
appearance. The composition of UBI remains unknown but several proteins were identified
in UBI such as ubiquitin (Leigh et al., 1991), peripherin (He and Hays, 2004), Cu/Zn SOD1
(Shibata 1996) and dorfin (Niwa et al., 2002). UBI are present in near 100% of sALS (Ince et al.,
2003). However, UBI are found in FTD with ubiquitin positive/tau negative inclusions. In both
fALS and sporadic types of ALS-FTD, UBI are found in cortical frontal and temporal lobe
neurons.
2.1.1.1. TAR DNA binding Protein 43 (TDP-43)
TDP-43 is a major component of ubiquinated inclusions in sALS, FTD with ubiquitin-positive
but tau-negative inclusions (non-tau FTD), FTD-ALS, and non-SOD1 fALS. TDP-43 inclusions
are practically not present in mSOD1-related fALS.
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2.1.1.2. Fused in Sarcoma protein (FUS)
Recently, mutations in the gene codifying for the fused in sarcoma protein (FUS) have been
linked to fALS. Indeed, spinal cord LMNs in fALS and sALS but not in mSOD1-fALS are
immunoreactive for FUS inclusions. These inclusions also present immunoreactivity for
TDP-43 and ubiquitin (Chaudhuri et al., 1995).
2.1.2. Bunina bodies
Bunina bodies are eosinophilic paracrystalline bodies present in the LMNs of many cases of
ALS (Piao et al., 2003). They are immunoreactive for a cysteine protease inhibitor called cystatin
C (Okamoto et al., 1993).
2.1.3. Hyaline Conglomerate Inclusions (HCI)
HCI consist of intracellular accumulation of intermediate filament proteins, especially
hyperphosphorylated neurofilament subunits and peripherin (Corbo and Hays, 2002), and are
found in the motor cortex neurons (Troost et al., 1992). HCI are much less frequently encoun‐
tered in spinal motor neurons than UBI and they are mainly associated with some types of
mSOD1 fALS. They form a larger conglomeration than UBI and are positive for silver staining,
contrary of UBI. (Ince PG and Wharton S, 2007).
3. Oxidative stress
Mutations in the gene of copper/zinc superoxide dismutase type 1 (SOD1) are the most
common cause of fALS (Rothstein, 2009; Boillee and Cleveland, 2008; Robberecht and Phillips,
2013). Recent reports indicate that SOD1 mutations may also be the cause of between 0.7 - 4%
cases of sporadic ALS (sALS) (Robberecht and Phillips, 2013). SOD1 is primarily an antioxidant
metalloenzyme that catalyzes the conversion of superoxide radical (O2.-) to oxygen (O2) and
hydrogen peroxide (H2O2). However, SOD1-linked fALS is most likely not caused by loss of
the normal SOD1 activity, but rather by a gain of a toxic function. One of the hypotheses for
mutant SOD-linked fALS toxicity proposes that an aberrant SOD1 chemistry is responsible for
the toxic gain-of-function, which allows small molecules such us peroxynitrite or hydrogen
peroxide to produce damaging free radicals. Other hypotheses for mutant SOD1 neurotoxicity
include inhibition of the proteasome activity, mitochondrial damage, and formation of
intracellular aggregates. SOD1 aggregation is an early event in ALS and could mediate motor
neuron degeneration via sequestration of cellular components, decreasing chaperone activity
and the ubiquitin proteasome pathway. Also, SOD1 mutations seem to disrupt RNA process‐
ing in the cells.
Defining the role of oxidative stress, and particularly nitrative stress in neurodegeneration has
been extremely difficult because of the multiplicity of potential targets that can be damaged
by oxidation and nitration. Certain proteins are particularly susceptible to tyrosine nitration
by the oxidant peroxynitrite (ONOO-). Tyrosine nitration is a well-established, early biomarker
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in ALS and it has been proposed that in fALS mutant SOD1 produces motor neuron death by
allowing peroxynitrite formation and catalyzing tyrosine nitration, which in turn inhibits
trophic signals (Estevez et al., 1999; Beckman et al., 1993; Crow et al., 1997; Ischiropoulos et al.,
1992; Franco and Estevez, 2011). Motor neurons are highly dependent on a continuous supply
of trophic factors to survive both in vivo and in vitro. Deprivation of trophic support in vivo by
ventral root avulsion in adult animals and axotomy in newborns, but not in adults, triggers
apoptosis (Li et al, 1994; Oppenheim, 1997; Gould and Oppenheim, 2011). Induction of
apoptosis in these conditions is preceded by induction of neuronal nitric oxide synthase
(nNOS) and nitric oxide production. Motor neuron death induced by trophic factor deprivation
requires protein synthesis and caspase activation both in vivo and in vitro (Milligan et al.,
1994; Li et al, 1998; Yaginuma et al, 2001). Cultured motor neurons deprived of trophic factors
induce nNOS expression, production of nitric oxide and peroxynitrite formation that is
followed by tyrosine nitration, which precedes motor neuron death (Estevez et al., 1998).
Inhibition of nitric oxide production and peroxynitrite formation prevents rather than delays
motor neuron death, suggesting that peroxynitrite is acting at decision-making points in the
apoptotic cascade. Deprivation of trophic factors activates the Fas pathway in motor neurons,
and inhibition of the Fas pathway prevents motor neuron death. Fas activation in motor
neurons triggers two parallel pathways: the classical extrinsic pathway recruiting FADD and
Caspase 8; and a seemingly motor neuron specific pathway, that activates DAXX/ASK1/p38
and the induction of neuronal NOS, increasing production of nitric oxide, peroxynitrite
formation and tyrosine nitration (Raoul et al, 2002).
4. Excitotoxicity
4.1. Glutamate
A dominant hypothesis of ALS pathogenesis is glutamate excitotoxicity. Glutamate is the
major excitatory neurotransmitter found in mammalian central nervous system (CNS)
however, in high concentrations is toxic to motor neurons. Some of the evidence supporting
glutamate excitotoxicity was based on the observation that exposure of neuronal cell cultures
to excess glutamate leads to cell death (Choi et al 1988). A similar observation was made in
anterior horn cells in tissue cultures of rat spinal cord where incubation with high concentra‐
tions of glutamate is associated with cell loss (Silani et al 2000). In addition, defects in glutamate
transport leading to elevated glutamate levels have been reported in mSOD1 mice and
significant number of patients with sALS (Dunlop et al., Lin et al., Rothstein et al.,). Elevated
glutamate levels were found in serum and spinal fluid of patients with sALS (Al-Chalabi, et
al 2000; Rothstein et al., 1990; Shaw, et al, 1995). Another study showed that 40% of about 400
patients with sALS have an elevation in glutamate levels that correlates with the severity of
the disease (Spreux-Varoquax et al., 2002)
The mechanism of glutamate neurotoxicity remains elusive. Excessive glutamate levels lead
to activation of glutamate ionotropic AMPA receptors in neurons and glial cells. AMPA
receptor activation triggers mitochondrial changes such as reduction in ATP synthesis,
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decreased cellular oxygen consumption, oxydative phosphorylation uncoupling, and increase
in mitochondrial reactive oxygen species (ROS) production, causing a loss in the mitochondrial
calcium buffer properties and apotosis (Heath and Shaw 2002) (Fig. 1). Rapid clearance of
glutamate at the synapsis cleft is an essential step in the prevention of motor neuron excito‐
toxicity. This step accomplished by the astrocyte glutamate transporter excitatory amino acid-2
(EAAT2) (Rothstein et,al 1996). In transgenic mice, depletion of EAAT2 has been implicated
with neuronal death (Rothstein et,al 1996). Abnormalities in EAAT2 expression were identified
in two rodent models of fALS. In the SOD1G85R transgenic mice a ~ 50% decrease in EAAT2
expression was observed in the spinal cord at the end of the disease (Bruijin et al., 1997), while
in the spinal cord ventral horn of transgenic SOD1G93A rats EAAT2 expression was decreased
before the symptomatic stage of the disease and was almost undetectable at the end of the
disease (Howland et al., 2002). Reduction in the expression of EAAT2 was found in motor
neuron disease (Fray et al 1998) and decreased glutamate transport was identified in motor
cortex and spinal cord in ALS (Rothstein et al., 1992) (Fig. 1).
4.2. Glutamate receptor
An alteration in the expression of the glutamate receptor was found in motor neurons
expressing mutant SOD1, suggesting that excitotoxicity is not only induced by increased
glutamate levels but also by alterations in the glutamate signaling pathway (Spalloni et al.,
2004). In oocytes co-expressing A4V or I113T-SOD1 with EAAT2, the mutants but not the wild
type SOD1 selectively inactivated the glial glutamate transporter in the presence of hydrogen
peroxide. This suggests that EAAT2 may be a target for mutant SOD1 toxicity (Trotti et al.,
1999). On the other hand, overexpression of EAAT2 in mutant SOD1 expressing mice delayed
the onset of motor neuron disease and decreased caspase 3 activation, the final step of the
apoptotic pathway (Guo et al 2003). In motor cortex and spinal cord extracts from ALS patients,
25% of the patients showed almost complete loss of EAAT2 protein, and 80% of the patients
showed some sort of protein abnormality (Rothstein et al., 1995) (Fig.1).
Glutamate receptor dysfunction is other possible route of excitotoxicity. Glutamate toxicity in
motor neurons is primarily mediated via alpha-amino-3-hydroxy-5-methyl-4 isoxazole
propionic acid (AMPA) receptors (Van Den Bosch et al., 2000). In patients with ALS, a
deficiency in the AMPA receptor mRNA expression was found in spinal motor neurons
(Kawahara, et al., 2004). This defect results in an increase in calcium influx through the receptor
leading to cell damaged. The increased entry in calcium in addition to the reduction in the
calcium buffer capacity due to abnormal mitochondria result in an increase in free intracellular
calcium levels, leading to motor neuron death (Bogaert et al., 2010) (Fig.1). Additionally, the
expression of the glutamate receptor subunits is reduced in ALS motor neurons (Williams et
al 1997). Another pathway leading to excitotoxicity is via deficiency in glutamate dehydro‐
genase activity (Pioro et al., 1999).
The modest protection conferred by the antigluaminergic drug riluzole in ALS patients as well
as in mutant SOD1 mice seems to support the effect of glutamate toxicity in the pathogenesis
of ALS (Lacomblez et al., 1996; Gurney et al., 1996). However, whether riluzole protects by a
mechanism related to its antiglutaminergic properties needs to be established.
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in ALS and it has been proposed that in fALS mutant SOD1 produces motor neuron death by
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and inhibition of the Fas pathway prevents motor neuron death. Fas activation in motor
neurons triggers two parallel pathways: the classical extrinsic pathway recruiting FADD and
Caspase 8; and a seemingly motor neuron specific pathway, that activates DAXX/ASK1/p38
and the induction of neuronal NOS, increasing production of nitric oxide, peroxynitrite
formation and tyrosine nitration (Raoul et al, 2002).
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4.1. Glutamate
A dominant hypothesis of ALS pathogenesis is glutamate excitotoxicity. Glutamate is the
major excitatory neurotransmitter found in mammalian central nervous system (CNS)
however, in high concentrations is toxic to motor neurons. Some of the evidence supporting
glutamate excitotoxicity was based on the observation that exposure of neuronal cell cultures
to excess glutamate leads to cell death (Choi et al 1988). A similar observation was made in
anterior horn cells in tissue cultures of rat spinal cord where incubation with high concentra‐
tions of glutamate is associated with cell loss (Silani et al 2000). In addition, defects in glutamate
transport leading to elevated glutamate levels have been reported in mSOD1 mice and
significant number of patients with sALS (Dunlop et al., Lin et al., Rothstein et al.,). Elevated
glutamate levels were found in serum and spinal fluid of patients with sALS (Al-Chalabi, et
al 2000; Rothstein et al., 1990; Shaw, et al, 1995). Another study showed that 40% of about 400
patients with sALS have an elevation in glutamate levels that correlates with the severity of
the disease (Spreux-Varoquax et al., 2002)
The mechanism of glutamate neurotoxicity remains elusive. Excessive glutamate levels lead
to activation of glutamate ionotropic AMPA receptors in neurons and glial cells. AMPA
receptor activation triggers mitochondrial changes such as reduction in ATP synthesis,
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decreased cellular oxygen consumption, oxydative phosphorylation uncoupling, and increase
in mitochondrial reactive oxygen species (ROS) production, causing a loss in the mitochondrial
calcium buffer properties and apotosis (Heath and Shaw 2002) (Fig. 1). Rapid clearance of
glutamate at the synapsis cleft is an essential step in the prevention of motor neuron excito‐
toxicity. This step accomplished by the astrocyte glutamate transporter excitatory amino acid-2
(EAAT2) (Rothstein et,al 1996). In transgenic mice, depletion of EAAT2 has been implicated
with neuronal death (Rothstein et,al 1996). Abnormalities in EAAT2 expression were identified
in two rodent models of fALS. In the SOD1G85R transgenic mice a ~ 50% decrease in EAAT2
expression was observed in the spinal cord at the end of the disease (Bruijin et al., 1997), while
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before the symptomatic stage of the disease and was almost undetectable at the end of the
disease (Howland et al., 2002). Reduction in the expression of EAAT2 was found in motor
neuron disease (Fray et al 1998) and decreased glutamate transport was identified in motor
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An alteration in the expression of the glutamate receptor was found in motor neurons
expressing mutant SOD1, suggesting that excitotoxicity is not only induced by increased
glutamate levels but also by alterations in the glutamate signaling pathway (Spalloni et al.,
2004). In oocytes co-expressing A4V or I113T-SOD1 with EAAT2, the mutants but not the wild
type SOD1 selectively inactivated the glial glutamate transporter in the presence of hydrogen
peroxide. This suggests that EAAT2 may be a target for mutant SOD1 toxicity (Trotti et al.,
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25% of the patients showed almost complete loss of EAAT2 protein, and 80% of the patients
showed some sort of protein abnormality (Rothstein et al., 1995) (Fig.1).
Glutamate receptor dysfunction is other possible route of excitotoxicity. Glutamate toxicity in
motor neurons is primarily mediated via alpha-amino-3-hydroxy-5-methyl-4 isoxazole
propionic acid (AMPA) receptors (Van Den Bosch et al., 2000). In patients with ALS, a
deficiency in the AMPA receptor mRNA expression was found in spinal motor neurons
(Kawahara, et al., 2004). This defect results in an increase in calcium influx through the receptor
leading to cell damaged. The increased entry in calcium in addition to the reduction in the
calcium buffer capacity due to abnormal mitochondria result in an increase in free intracellular
calcium levels, leading to motor neuron death (Bogaert et al., 2010) (Fig.1). Additionally, the
expression of the glutamate receptor subunits is reduced in ALS motor neurons (Williams et
al 1997). Another pathway leading to excitotoxicity is via deficiency in glutamate dehydro‐
genase activity (Pioro et al., 1999).
The modest protection conferred by the antigluaminergic drug riluzole in ALS patients as well
as in mutant SOD1 mice seems to support the effect of glutamate toxicity in the pathogenesis
of ALS (Lacomblez et al., 1996; Gurney et al., 1996). However, whether riluzole protects by a
mechanism related to its antiglutaminergic properties needs to be established.
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5. Mitochondrial abnormalities
The mitochondrion is a vital organelle with multiple functions within cells. Mitochondria are
the main source of ATP, maintain calcium homeostasis and participate in calcium signaling,
and play a key role in the intrinsic apoptotic pathway. Mitochondrial malfunction turns motor
neuron more vulnerable to damage, especially in aging and stress neurons. Mitochondrial
malfunction is an important hypothesis in ALS pathogenesis (Bruijn et al., 2004; Manfredi et
al., 2005).
5.1. Mitochondrial morphology
Indeed, mitochon ria m rphol gical and ultrastructural changes as well as bio nergetic
malfunction have been reported in ALS. SOD1 is localized mainly in the cytoplasm, but has
been found also in the mitochondria and other organelles (Okado et al., 2001; Sturtz et al.,
2001). Mutant SOD1 protein is present in the mitochondrial intermembrane space, matrix and
outer membrane of mitochondria (Higgins, et al, 2002; Vijayvergiya et al., 2005; Vande Velde
et al., 2008; Kawamata et al., 2008). This abnormal SOD1 protein may fail to fold properly
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resulting in mitochondrial protein retention and mitochondrial dysfunction with damaged of
the mitochondrial membrane and loss of mitochondrial membrane potential and swelling
(Wong et al., 1995; Kong et al., 1998). Severe mitochondrial morphological changes were found
in NSC34 cells overexpressing mutant SOD1 (Raimondi et al., 2006; Menzies et al., 2002). In
addition, mitochondrial swelling and vacuolization in motor neuron axons and dendrites were
reported in mSOD1 mice even before disease onset (Wong et al., 1995; Kong et al., 1998;
Borthwick et al., 1999). The presence of abnormal mitochondrial clusters was also described
in mutant SOD1 rat motor axons (Sotelo-Silveira et al., 2009) as well as in lumbar spinal cord
motor neurons and proximal axons of sALS patients (Sasaki et al., 1996; Hirano et al., 1984).
5.2. Electron transport chain
Abnormal respiratory complex activities, disrupted redox homeostasis and decreased ATP
production were described in ALS (Borthwick et al., 1999; Jung et al., 2002; Bowling et al.,
1993; Ferri et al., 2006). Biochemical studies showed several abnormalities in mitochondrial
electron transport chain. The enzymatic activity of the electron transport chain complexes I,
II, IV was reduced in mSOD1 mice and cell cultures from patients with fALS (Jung et al.,
2002; Mattiazzi et al., 2002). The interaction between cytochrome c and the inner mitochondrial
membrane in addition to the activity of complex IV were reduced in the SOD1G93A transgenic
mice (Kirkinezos et al., 2005). Decreased oxygen consumption, lack of ADP-dependent
respiratory control, and decreased membrane potential were also reported in mutant SOD1
rat spinal astrocytes (Cassina et al., 2008) (Fig. 2).
5.3. Calcium homeostasis
Mitochondria play an important role in the intracellular calcium homeostasis as a calcium
buffer, accumulating or releasing calcium depending on the cytosolic levels. Abnormalities in
mitochondrial calcium homeostasis were reported in ALS patients and in mutant SOD1
animals (Kruman et al., 1999; Carri et al., 1997; Reiner et al, 1995; Jaiswal et al., 2009). The release
of calcium from the mitochondria leads to excessive intracellular calcium levels. This abnormal
calcium homeostasis induces motor neuron death through several mechanisms including: 1)
toxic generation of reactive oxygen species (ROS), as reported in SOD1G93A transgenic mice
(Kruman et al., 1999); 2) release of cytochrome c from the mitochondria (Martin et al., 2009);
3) glutamate excitotoxicity (Nicholls et al., 2003), and others. All these mechanisms may have
a special role in motor neurons because these cells contain less mitochondrial density per
volume compared to non-neuronal cells, thus making neurons more deficient in mitochondrial
calcium buffering properties (Grosskreutz et al., 2007) (Fig. 2). In addition, ALS patients show
a deficiency in calcium binding proteins calbidin and paralbumin in cortical motor and spinal
motor neurons. These two proteins regulate intracellular calcium levels and their deficiency
may result in neuronal loss. On the contrary, oculomotor neurons or neuron from the Onuff’s
nuclei contains normal levels of calbidin and paralbumin levels and they are preserved despite
ALS progression (Alexianu, et al. 1994; Celio, 1990; Ince et al., 1993, Palecek et al., 1999).
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the main source of ATP, maintain calcium homeostasis and participate in calcium signaling,
and play a key role in the intrinsic apoptotic pathway. Mitochondrial malfunction turns motor
neuron more vulnerable to damage, especially in aging and stress neurons. Mitochondrial
malfunction is an important hypothesis in ALS pathogenesis (Bruijn et al., 2004; Manfredi et
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resulting in mitochondrial protein retention and mitochondrial dysfunction with damaged of
the mitochondrial membrane and loss of mitochondrial membrane potential and swelling
(Wong et al., 1995; Kong et al., 1998). Severe mitochondrial morphological changes were found
in NSC34 cells overexpressing mutant SOD1 (Raimondi et al., 2006; Menzies et al., 2002). In
addition, mitochondrial swelling and vacuolization in motor neuron axons and dendrites were
reported in mSOD1 mice even before disease onset (Wong et al., 1995; Kong et al., 1998;
Borthwick et al., 1999). The presence of abnormal mitochondrial clusters was also described
in mutant SOD1 rat motor axons (Sotelo-Silveira et al., 2009) as well as in lumbar spinal cord
motor neurons and proximal axons of sALS patients (Sasaki et al., 1996; Hirano et al., 1984).
5.2. Electron transport chain
Abnormal respiratory complex activities, disrupted redox homeostasis and decreased ATP
production were described in ALS (Borthwick et al., 1999; Jung et al., 2002; Bowling et al.,
1993; Ferri et al., 2006). Biochemical studies showed several abnormalities in mitochondrial
electron transport chain. The enzymatic activity of the electron transport chain complexes I,
II, IV was reduced in mSOD1 mice and cell cultures from patients with fALS (Jung et al.,
2002; Mattiazzi et al., 2002). The interaction between cytochrome c and the inner mitochondrial
membrane in addition to the activity of complex IV were reduced in the SOD1G93A transgenic
mice (Kirkinezos et al., 2005). Decreased oxygen consumption, lack of ADP-dependent
respiratory control, and decreased membrane potential were also reported in mutant SOD1
rat spinal astrocytes (Cassina et al., 2008) (Fig. 2).
5.3. Calcium homeostasis
Mitochondria play an important role in the intracellular calcium homeostasis as a calcium
buffer, accumulating or releasing calcium depending on the cytosolic levels. Abnormalities in
mitochondrial calcium homeostasis were reported in ALS patients and in mutant SOD1
animals (Kruman et al., 1999; Carri et al., 1997; Reiner et al, 1995; Jaiswal et al., 2009). The release
of calcium from the mitochondria leads to excessive intracellular calcium levels. This abnormal
calcium homeostasis induces motor neuron death through several mechanisms including: 1)
toxic generation of reactive oxygen species (ROS), as reported in SOD1G93A transgenic mice
(Kruman et al., 1999); 2) release of cytochrome c from the mitochondria (Martin et al., 2009);
3) glutamate excitotoxicity (Nicholls et al., 2003), and others. All these mechanisms may have
a special role in motor neurons because these cells contain less mitochondrial density per
volume compared to non-neuronal cells, thus making neurons more deficient in mitochondrial
calcium buffering properties (Grosskreutz et al., 2007) (Fig. 2). In addition, ALS patients show
a deficiency in calcium binding proteins calbidin and paralbumin in cortical motor and spinal
motor neurons. These two proteins regulate intracellular calcium levels and their deficiency
may result in neuronal loss. On the contrary, oculomotor neurons or neuron from the Onuff’s
nuclei contains normal levels of calbidin and paralbumin levels and they are preserved despite
ALS progression (Alexianu, et al. 1994; Celio, 1990; Ince et al., 1993, Palecek et al., 1999).
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Figure 2. Mitochondrial abnormalities associated with mutant SOD1 (mSOD1). Mutant SOD1 translocates to mitochondrial intermembrane 
space and matrix, and is associated with the mitochondrial outer membrane. The expression of mutant SOD1 is linked to decrease of mitochondrial 
membrane potential and electron transport chain activity. The release of calcium and cytochrome c to the cytosol, and the production of ROS lead to 
cell death in ALS. 
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Transport of proteins, vesicles, and organelles between cell body and terminal axons is a vital process in neuronal development, 
function and survival. Cytoskeletal proteins such as neurofilament (NFs) confer structure and shape to motor neurons, and are 
involved in axonal anterograde and retrograde transport between soma and motor axons. NFs are intermediate filaments made 
from the assembly of light, medium, and heavy subunits (Maragakis and Galvez-Jimenez, 2012). Disorganization of NFs affects 
axonal transport resulting in axonal strangulation and accumulation of axonal cargo (Collard et al., 1995). A hallmark of ALS 
pathology is the abnormal accumulation of NFs in the neuronal cell bodies and proximal axons. Animal models and patients with 
ALS show that axonal transport is a critical component in ALS pathogenesis (Morrison et al., 1998; Lin et al., 2006).  Transgenic 
models of fALS and sALS are associated with mutations of the heavy NF subunits (Figlewicz et al., 1994; Al-Chalabi et al., 1999). In 
addition, reduction in light subunit mRNA levels was found in motor neurons from the spinal cord of patients with ALS (Wong et 
al., 2000). Abnormal axonal transport, vacuolization and degeneration of axons and motor neurons have been reported in 
transgenic mice overexpressing or with reduced expression of NF subunits (Collard et al., 1995; Cote et al., 1993). In neurons, 
mitochondria are frequently found in axon terminals due to the high demand of ATP and calcium handling at the synapses 
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6. Axonal transpor  abnormalities
Transport of proteins, vesicles, and organelles between cell body and terminal axons is a vital
process in neuro al developme t, function and survival. Cyt skeletal proteins such as
neurofilament (NFs) confer structure and shape to motor neurons, and are involved in axonal
anterograde and retrograde transport between soma and motor axons. NFs are intermediate
filaments made from the assembly of light, medium, nd he vy subuni s (Maragakis and
Galvez-Jimenez, 2012). Disorganization of NFs affects axonal transport resulting in axonal
strangulation and accumulation of axonal cargo (Collard et al., 1995). A hallmark of ALS
pathology is the abnormal accumulation of NFs in the neuronal cell bodies and proximal axons.
Animal models and patients with ALS show that axonal transport is a critical component in
ALS pathogenesis (Morrison et al., 1998; Lin et al., 2006). Transgenic models of fALS and sALS
are associated with mutations of the heavy NF subunits (Figlewicz et al., 1994; Al-Chalabi et
al., 1999). In addition, reduction in light subunit mRNA levels was found in motor neurons
from the spinal cord of patients with ALS (Wong et al., 2000). Abnormal axonal transport,
vacuolization and degeneration of axons and motor neurons have been reported in transgenic
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mice overexpressing or with reduced expression of NF subunits (Collard et al., 1995; Cote et
al., 1993). In neurons, mitochondria are frequently found in axon terminals due to the high
demand of ATP and calcium handling at the synapses (Shepherd et al., 1998; Rowland et al.,
2000). Mitochondria are transported in both anterograde and retrograde directions via kinesin
and dynein motor complexes (Nangaku et al., 1994; Zhang, et al 2004; Varadi et al., 2004). The
disruption of the mitochondrial axonal transport has been implicated in neurodegenerative
diseases including ALS (Hollenbeck et al., 2005; De Vos et al., 2007; Magrane et al. 2009).
Mitochondria display saltatory movement along microtubules. In SOD1G93A transgenic mice
and cortical neurons transfected with G93A-SOD1, mitochondrial transport was selectively
reduced in the anterograde direction (De Vos et al., 2007). In addition, in NSC34 cells overex‐
pressing mutant SOD1 mitochondrial transport was altered in both anterograde and retro‐
grade directions (Magrane et al., 2009). Abnormalities in axonal transport cause abnormal
renewal of mitochondria and autophagosomes at distal motor axons resulting in mitochondrial
accumulation, deficit in energy production, accumulation of ROS, and released of pro-
apoptotic agents leading to neuronal death. Slow axonal transport impairment has been
described as one of the earliest pathological events in mSOD1 mice (Williamson et al., 1999;
Zhang et al. 1997). Fast axonal transport is mediated by kinesin while dynein motor complexes
mediate the transport of membrane-bound organelles necessary for axonal and synaptic
functions. In patients and transgenic rodent models of ALS there are impairments in the
kinesin-mediated anterograde transport and dynein-mediated retrograde axonal transport
(Williamson et al., 1999; Breuer et al 1987; Breuer et al., 1988; Collard et al., 1995; Sasaki et al.,
1996; Ligon et al., 2005; Parkhouse et al., 2008). Disruption of kinesin heavy chain KIF5B causes
perinuclear clustering of mitochondria in mice neurons, indicating that KIF5B is essential for
mitochondrial dispersion (Tanaka et al., 1998). Abnormalities in the transport of other proteins
such as dynactin, myosin and actine were also identified in transgenic mutant SOD1 models
(LaMonte et al., 2002). Dynactin mutations have been associated with autosomal familiar motor
neuron disease (Puls et al 2003; Puls et al 2005). Peripherin, another intermediate transport
filament was found in neuronal inclusions of sALS (Corbo et al., 1992). Overexpression of
peripherin in transgenic mice is associated with axonal degeneration. Inflammatory cytokines
increased peripherin levels, suggesting an association between inflammation and axonal
transport disorders (Sterneck, et al 1996).
7. Growth factors
Several growth factors (GFs) has been investigated and potentially implicated in the patho‐
gensis of ALS. One of the most studied GFs is the vascular endothelial growth factor (VEGF),
a protein involved in vasculogenesis and angiogenesis, and in restoration of oxygen supply
upon limited blood circulation. Animal data suggest that VEGF may be neuroprotector.
Overexpression of VEGF delayed onset and progression motor neuron disease, as shown in a
double transgenic mice generated by crossing mice expressing human mutant SOD1 with mice
overexpressing neuronal VEGF (mSOD1/VEGF). The mSOD1/VEGF transgenic mice showed
a delayed in motor neuron loss, motor impairment, and a prolonged survival compared with
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5.3. Calcium homeostasis 
Mitochondria play an important role in the intracellular calcium homeostasis as a calcium buffer, accumulating or releasing 
calcium depending on the cytosolic levels. Abnormalities in mitochondrial calcium homeostasis were reported in ALS patients and 
in mutant SOD1 animals (Kruman et al., 1999; Carri et al., 1997; Reiner et al, 1995; Jaiswal et al., 2009).  The release of calcium from 
the mitochondria leads to excessive intracellular calcium levels. This abnormal calcium homeostasis induces motor neuron death 
through several mechanisms including: 1) toxic generation of reactive oxygen species (ROS), as reported in SOD1G93A transgenic 
mice (Kruman et al., 1999); 2) release of cytochrome c from the mitochondria (Martin et al., 2009); 3) glutamate excitotoxicity 
(Nicholls et al., 2003), and others. All these mechanisms may have a special role in motor neurons because these cells contain less 
mitochondrial density per volume compared to non-neuronal cells, thus making neurons more deficient in mitochondrial calcium 
buffering properties (Grosskreutz et al., 2007) (Fig. 2). In addition, ALS patients show a deficiency in calcium binding proteins 
calbidin and paralbumin in cortical motor and spinal motor neurons. These two proteins regulate intracellular calcium levels and 
their deficiency may result in neuronal loss. On the contrary, oculomotor neurons or neuron from the Onuff’s nuclei contains 
normal levels of calbidin and paralbumin levels and they are preserved despite ALS progression  (Alexianu, et al. 1994; Celio, 1990; 
Ince et al., 1993, Palecek et al., 1999). 
 
Figure 2. Mitochondrial abnormalities associated with mutant SOD1 (mSOD1). Mutant SOD1 translocates to mitochondrial intermembrane 
space and matrix, and is associated with the mitochondrial outer membrane. The expression of mutant SOD1 is linked to decrease of mitochondrial 
membrane potential and electron transport chain activity. The release of calcium and cytochrome c to the cytosol, and the production of ROS lead to 
cell death in ALS. 
6. Axonal transport abnormalities 
Transport of proteins, vesicles, and organelles between cell body and terminal axons is a vital process in neuronal development, 
function and survival. Cytoskeletal proteins such as neurofilament (NFs) confer structure and shape to motor neurons, and are 
involved in axonal anterograde and retrograde transport between soma and motor axons. NFs are intermediate filaments made 
from the assembly of light, medium, and heavy subunits (Maragakis and Galvez-Jimenez, 2012). Disorganization of NFs affects 
axonal transport resulting in axonal strangulation and accumulation of axonal cargo (Collard et al., 1995). A hallmark of ALS 
pathology is the abnormal accumulation of NFs in the neuronal cell bodies and proximal axons. Animal models and patients with 
ALS show that axonal transport is a critical component in ALS pathogenesis (Morrison et al., 1998; Lin et al., 2006).  Transgenic 
models of fALS and sALS are associated with mutations of the heavy NF subunits (Figlewicz et al., 1994; Al-Chalabi et al., 1999). In 
addition, reduction in light subunit mRNA levels was found in motor neurons from the spinal cord of patients with ALS (Wong et 
al., 2000). Abnormal axonal transport, vacuolization and degeneration of axons and motor neurons have been reported in 
transgenic mice overexpressing or with reduced expression of NF subunits (Collard et al., 1995; Cote et al., 1993). In neurons, 
mitochondria are frequently found in axon terminals due to the high demand of ATP and calcium handling at the synapses 
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Transport of proteins, vesicles, and organelles between cell body and terminal axons is a vital
process in neuro al developme t, function and survival. Cyt skeletal proteins such as
neurofilament (NFs) confer structure and shape to motor neurons, and are involved in axonal
anterograde and retrograde transport between soma and motor axons. NFs are intermediate
filaments made from the assembly of light, medium, nd he vy subuni s (Maragakis and
Galvez-Jimenez, 2012). Disorganization of NFs affects axonal transport resulting in axonal
strangulation and accumulation of axonal cargo (Collard et al., 1995). A hallmark of ALS
pathology is the abnormal accumulation of NFs in the neuronal cell bodies and proximal axons.
Animal models and patients with ALS show that axonal transport is a critical component in
ALS pathogenesis (Morrison et al., 1998; Lin et al., 2006). Transgenic models of fALS and sALS
are associated with mutations of the heavy NF subunits (Figlewicz et al., 1994; Al-Chalabi et
al., 1999). In addition, reduction in light subunit mRNA levels was found in motor neurons
from the spinal cord of patients with ALS (Wong et al., 2000). Abnormal axonal transport,
vacuolization and degeneration of axons and motor neurons have been reported in transgenic
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mice overexpressing or with reduced expression of NF subunits (Collard et al., 1995; Cote et
al., 1993). In neurons, mitochondria are frequently found in axon terminals due to the high
demand of ATP and calcium handling at the synapses (Shepherd et al., 1998; Rowland et al.,
2000). Mitochondria are transported in both anterograde and retrograde directions via kinesin
and dynein motor complexes (Nangaku et al., 1994; Zhang, et al 2004; Varadi et al., 2004). The
disruption of the mitochondrial axonal transport has been implicated in neurodegenerative
diseases including ALS (Hollenbeck et al., 2005; De Vos et al., 2007; Magrane et al. 2009).
Mitochondria display saltatory movement along microtubules. In SOD1G93A transgenic mice
and cortical neurons transfected with G93A-SOD1, mitochondrial transport was selectively
reduced in the anterograde direction (De Vos et al., 2007). In addition, in NSC34 cells overex‐
pressing mutant SOD1 mitochondrial transport was altered in both anterograde and retro‐
grade directions (Magrane et al., 2009). Abnormalities in axonal transport cause abnormal
renewal of mitochondria and autophagosomes at distal motor axons resulting in mitochondrial
accumulation, deficit in energy production, accumulation of ROS, and released of pro-
apoptotic agents leading to neuronal death. Slow axonal transport impairment has been
described as one of the earliest pathological events in mSOD1 mice (Williamson et al., 1999;
Zhang et al. 1997). Fast axonal transport is mediated by kinesin while dynein motor complexes
mediate the transport of membrane-bound organelles necessary for axonal and synaptic
functions. In patients and transgenic rodent models of ALS there are impairments in the
kinesin-mediated anterograde transport and dynein-mediated retrograde axonal transport
(Williamson et al., 1999; Breuer et al 1987; Breuer et al., 1988; Collard et al., 1995; Sasaki et al.,
1996; Ligon et al., 2005; Parkhouse et al., 2008). Disruption of kinesin heavy chain KIF5B causes
perinuclear clustering of mitochondria in mice neurons, indicating that KIF5B is essential for
mitochondrial dispersion (Tanaka et al., 1998). Abnormalities in the transport of other proteins
such as dynactin, myosin and actine were also identified in transgenic mutant SOD1 models
(LaMonte et al., 2002). Dynactin mutations have been associated with autosomal familiar motor
neuron disease (Puls et al 2003; Puls et al 2005). Peripherin, another intermediate transport
filament was found in neuronal inclusions of sALS (Corbo et al., 1992). Overexpression of
peripherin in transgenic mice is associated with axonal degeneration. Inflammatory cytokines
increased peripherin levels, suggesting an association between inflammation and axonal
transport disorders (Sterneck, et al 1996).
7. Growth factors
Several growth factors (GFs) has been investigated and potentially implicated in the patho‐
gensis of ALS. One of the most studied GFs is the vascular endothelial growth factor (VEGF),
a protein involved in vasculogenesis and angiogenesis, and in restoration of oxygen supply
upon limited blood circulation. Animal data suggest that VEGF may be neuroprotector.
Overexpression of VEGF delayed onset and progression motor neuron disease, as shown in a
double transgenic mice generated by crossing mice expressing human mutant SOD1 with mice
overexpressing neuronal VEGF (mSOD1/VEGF). The mSOD1/VEGF transgenic mice showed
a delayed in motor neuron loss, motor impairment, and a prolonged survival compared with
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mutant SOD1 transgenic mice (Wang et al., 2007). Intracerebroventricular administration of
VEGF in a SOD1G93A rat model of ALS delayed motor neuron degeneration and onset of
paralysis, improved motor performance, preserved neuromuscular junction, and extended
survival (Storkebaum et al., 2005). This study also showed that in SOD1G93A mice, neurons
expressing a transgenic VEGF receptor prolonged mice survival. Also supporting the VEGF
neuroprotective role, a single injection of a VEGF-expressing lentiviral vector into several
muscles of SOD1G93A mice delayed the onset as well as the progression of the disease even at
onset of paralysis (Azzouz et al., 2004). Interestingly, mouse models in which the hypoxia-
response element in the VEGF gene was deleted showed a decrease in VEGF expression in
normoxia and under hypoxic conditions. This model resulted in a progressive motor neuron
degeneration disease that resembles ALS (Oosthuyse, et al., 2001). A meta-analysis of over 900
individuals from Sweden and over 1,000 individuals from Belgium and England with a specific
haplotype for VEGF associated with reduced circulating VEGF and VEGF gene transciption
showed a two-fold increase in the risk of developing ALS for these individuals (Lambrechts
et al., 2003). In another study, SOD1G93A mice crossed with VEGF haplotype mice showed a
much more severe motor neuron degeneration. VEGF probably has neuronal direct and
indirect neuroprotective effects preventing ischemic changes while regulating vascular
perfusion.
Additionally, VEGF-B, a homolog of VEGF with minimal angiogenetic activity, was shown to
be protective for cultured primary motor neurons. In addition, transgenic mice with deletion
of the VEGF-B gene were implicated in an ALS-like pathogenesis, as shown crossing a VEGF-
B knockout mouse with transgenic mice expressing human mutant SOD1 (mSOD1/VEGF-B-/-)
(Poesen et al., 2008). mSOD1/VEGF-B-/- mice showed an earlier death and more severe motor
neuron degeneration compared with mutant SOD1 transgenic mice. Intracerebroventricular
administration of VEGF-B in a SOD1G93A rat model of ALS prolonged the survival of mutant
SOD-expressing rats, suggesting that VEGF is neuroprotective by a mechanism independent
of angiogenesis (Poesen et al., 2008).
Other beneficial growth factors are innsuline growth factor-1, glial cell line –derived neuro‐
trophic factor, and brain derived neurotrophic factor.
8. RNA metabolism disorders
Ubiquinated intracytoplamsmatic inclusions containing trans-activation response DNA-
binding protein of 43 KDa (TDP-43), encoded by the TARDBP gene in chromosome-1, had
been identified in motor neurons of patients with sALS and frontal lobar degeneration (FTLD)
linked to TDP-43 pathology (FTLD-TDP) (Neumann et al., 2006). TDP-43 positive inclusions
were also identified in patients with non-SOD1 fALS. Gene mutations of the TDP-43 gene
probably accounts for 5% of patients with fALS. All the cases of sALS and SOD1 negative fALS
have neural and glial inclusions immunoreactive to both ubiquitin and TDP-43 whereas
positive SOD1 mutations in fALS were absent of TDP-43 immunoreactivity. (MacKenzie et al.,
2007; Tran et al., 2007). TDP-43 inclusions were also identified in patients with Guamanian
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parkinsonism-dementia complex, and familial British dementia (Sreedharan et al., 2008;
Kabashi et al., 2008; Van Deerlin et al., 2008; Yokoseki et al., 2008; Rutherford et al., 2008; Del
Bo et al., 2009; Hasegawa et al., 2007; Schwab et al., 2009). TDP-43 is a nuclear protein expressed
in almost all tissues that binds to mRNA and DNA and regulates mRNA processing processes
such as splicing, translation, and gene transcription. TDP-43 structure consists of two RNA
recognition motifs (RRMs) that bind to nucleic acids, and a glycine rich domain containing the
majority of ALS associated mutations (Cohen et al., 2012; Buratti et al., 2001). Genetic mutation
of another RNA processing protein, fused in sarcoma /translated in liposarcoma (FUS/TLS),
has been also associated with ALS (Kwiatkowski et al., 2009; Vance et al., 2009). The FUS/TLS
has a similar structure to TDP-43 with RRM and glycin rich domains. FUS/TLS, also a nuclear
protein, accumulates in intracytoplasmatic tau- and TDP-43 negative inclusions in patients
with fALS, sALS, and frontal lobar degeneration FTLD-FUS (Mackenzie et al., 2010). TDP-43
and FUS/TLS stabilized mRNA encoding histone deacetylase 6 (HDAC6) involved in clearance
of misfolded protein aggregates (Kim et.al, 2010, Fiesel, et al., 2010; Lee et al., 2010; Kawaguchi
et al., 2003). TDP-43 binds to a wide range of RNA targets and promotes the synthesis of several
proteins implicated in the neuronal development and integrity (Tollervey et al., 2011). TDP-43
expression is carefully controlled by a tightly autoregulated mechanism (Winton et al., 2008).
Thus, TDP-43 abnormalities in RNA binding and autoregulation, and FUS/TLS may have a
essential role in neuronal integrity. TDP-43 also has a protective effect on mitochondrial
function; abnormal expression of mitochondrial fission/fusion proteins in transgenic mice
expressing human wild-type TDP-43 transgene driven by mouse prion promoter had been
reported (Xu et al., 2010). In cultured cells, exposure to stress caused TDP-43 to be relocated
into stress granules (SGs). This abnormal localization of TDP-43 could start a pathological
TDP-43 aggregation or TDP-43 interaction with other SGs-proteins. A similar process may
occur with FUS/TLS protein (Bosco et al., 2010; Dormann et al., 2010). The formation of SGs
may lead to pathological inclusion aggregations resulting in neuronal and glial cell damage.
Hyperphosphorilated TDP-43 aggregates were identified in ALS spinal cord and FTLP-TDP
brain tissue. TDP-43 glycin-rich domain, where most of the mutations had been identified,
seems to be required for TDP-43 association with SGs. Expression of insoluble aggregates of
TDP-43 terminal fragment was implicated in the generation of SGs (Liu-Yesucevitz et al.,
2010). In addition, TDP-43 interacts with cytoplasmatic Ataxin-2 protein resulting in TDP-43
accumulation in misfolded aggregates. Mutant polyglutamine expansions within ataxin-2
enhanced the binding to TDP-43 facilitating the formation of aggregates in ALS patients
(Elden,AC et al., 2010). The formation of these aggregates seems to be implicated in neuronal
death, but the mechanism remains elusive.
9. Non-cell autonomous mechanisms
Evidence is accumulating indicating that motor neuron degeneration in ALS is not only
restricted to neuronal autonomous cell death but it is rather a more complex process involving
inflammatory neurotoxicity from non-neuronal glial cells such as astrocytes and microglia
(Phani et al., 2012). Support for non-autonomous evidence comes from several studies in
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mutant SOD1 transgenic mice (Wang et al., 2007). Intracerebroventricular administration of
VEGF in a SOD1G93A rat model of ALS delayed motor neuron degeneration and onset of
paralysis, improved motor performance, preserved neuromuscular junction, and extended
survival (Storkebaum et al., 2005). This study also showed that in SOD1G93A mice, neurons
expressing a transgenic VEGF receptor prolonged mice survival. Also supporting the VEGF
neuroprotective role, a single injection of a VEGF-expressing lentiviral vector into several
muscles of SOD1G93A mice delayed the onset as well as the progression of the disease even at
onset of paralysis (Azzouz et al., 2004). Interestingly, mouse models in which the hypoxia-
response element in the VEGF gene was deleted showed a decrease in VEGF expression in
normoxia and under hypoxic conditions. This model resulted in a progressive motor neuron
degeneration disease that resembles ALS (Oosthuyse, et al., 2001). A meta-analysis of over 900
individuals from Sweden and over 1,000 individuals from Belgium and England with a specific
haplotype for VEGF associated with reduced circulating VEGF and VEGF gene transciption
showed a two-fold increase in the risk of developing ALS for these individuals (Lambrechts
et al., 2003). In another study, SOD1G93A mice crossed with VEGF haplotype mice showed a
much more severe motor neuron degeneration. VEGF probably has neuronal direct and
indirect neuroprotective effects preventing ischemic changes while regulating vascular
perfusion.
Additionally, VEGF-B, a homolog of VEGF with minimal angiogenetic activity, was shown to
be protective for cultured primary motor neurons. In addition, transgenic mice with deletion
of the VEGF-B gene were implicated in an ALS-like pathogenesis, as shown crossing a VEGF-
B knockout mouse with transgenic mice expressing human mutant SOD1 (mSOD1/VEGF-B-/-)
(Poesen et al., 2008). mSOD1/VEGF-B-/- mice showed an earlier death and more severe motor
neuron degeneration compared with mutant SOD1 transgenic mice. Intracerebroventricular
administration of VEGF-B in a SOD1G93A rat model of ALS prolonged the survival of mutant
SOD-expressing rats, suggesting that VEGF is neuroprotective by a mechanism independent
of angiogenesis (Poesen et al., 2008).
Other beneficial growth factors are innsuline growth factor-1, glial cell line –derived neuro‐
trophic factor, and brain derived neurotrophic factor.
8. RNA metabolism disorders
Ubiquinated intracytoplamsmatic inclusions containing trans-activation response DNA-
binding protein of 43 KDa (TDP-43), encoded by the TARDBP gene in chromosome-1, had
been identified in motor neurons of patients with sALS and frontal lobar degeneration (FTLD)
linked to TDP-43 pathology (FTLD-TDP) (Neumann et al., 2006). TDP-43 positive inclusions
were also identified in patients with non-SOD1 fALS. Gene mutations of the TDP-43 gene
probably accounts for 5% of patients with fALS. All the cases of sALS and SOD1 negative fALS
have neural and glial inclusions immunoreactive to both ubiquitin and TDP-43 whereas
positive SOD1 mutations in fALS were absent of TDP-43 immunoreactivity. (MacKenzie et al.,
2007; Tran et al., 2007). TDP-43 inclusions were also identified in patients with Guamanian
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parkinsonism-dementia complex, and familial British dementia (Sreedharan et al., 2008;
Kabashi et al., 2008; Van Deerlin et al., 2008; Yokoseki et al., 2008; Rutherford et al., 2008; Del
Bo et al., 2009; Hasegawa et al., 2007; Schwab et al., 2009). TDP-43 is a nuclear protein expressed
in almost all tissues that binds to mRNA and DNA and regulates mRNA processing processes
such as splicing, translation, and gene transcription. TDP-43 structure consists of two RNA
recognition motifs (RRMs) that bind to nucleic acids, and a glycine rich domain containing the
majority of ALS associated mutations (Cohen et al., 2012; Buratti et al., 2001). Genetic mutation
of another RNA processing protein, fused in sarcoma /translated in liposarcoma (FUS/TLS),
has been also associated with ALS (Kwiatkowski et al., 2009; Vance et al., 2009). The FUS/TLS
has a similar structure to TDP-43 with RRM and glycin rich domains. FUS/TLS, also a nuclear
protein, accumulates in intracytoplasmatic tau- and TDP-43 negative inclusions in patients
with fALS, sALS, and frontal lobar degeneration FTLD-FUS (Mackenzie et al., 2010). TDP-43
and FUS/TLS stabilized mRNA encoding histone deacetylase 6 (HDAC6) involved in clearance
of misfolded protein aggregates (Kim et.al, 2010, Fiesel, et al., 2010; Lee et al., 2010; Kawaguchi
et al., 2003). TDP-43 binds to a wide range of RNA targets and promotes the synthesis of several
proteins implicated in the neuronal development and integrity (Tollervey et al., 2011). TDP-43
expression is carefully controlled by a tightly autoregulated mechanism (Winton et al., 2008).
Thus, TDP-43 abnormalities in RNA binding and autoregulation, and FUS/TLS may have a
essential role in neuronal integrity. TDP-43 also has a protective effect on mitochondrial
function; abnormal expression of mitochondrial fission/fusion proteins in transgenic mice
expressing human wild-type TDP-43 transgene driven by mouse prion promoter had been
reported (Xu et al., 2010). In cultured cells, exposure to stress caused TDP-43 to be relocated
into stress granules (SGs). This abnormal localization of TDP-43 could start a pathological
TDP-43 aggregation or TDP-43 interaction with other SGs-proteins. A similar process may
occur with FUS/TLS protein (Bosco et al., 2010; Dormann et al., 2010). The formation of SGs
may lead to pathological inclusion aggregations resulting in neuronal and glial cell damage.
Hyperphosphorilated TDP-43 aggregates were identified in ALS spinal cord and FTLP-TDP
brain tissue. TDP-43 glycin-rich domain, where most of the mutations had been identified,
seems to be required for TDP-43 association with SGs. Expression of insoluble aggregates of
TDP-43 terminal fragment was implicated in the generation of SGs (Liu-Yesucevitz et al.,
2010). In addition, TDP-43 interacts with cytoplasmatic Ataxin-2 protein resulting in TDP-43
accumulation in misfolded aggregates. Mutant polyglutamine expansions within ataxin-2
enhanced the binding to TDP-43 facilitating the formation of aggregates in ALS patients
(Elden,AC et al., 2010). The formation of these aggregates seems to be implicated in neuronal
death, but the mechanism remains elusive.
9. Non-cell autonomous mechanisms
Evidence is accumulating indicating that motor neuron degeneration in ALS is not only
restricted to neuronal autonomous cell death but it is rather a more complex process involving
inflammatory neurotoxicity from non-neuronal glial cells such as astrocytes and microglia
(Phani et al., 2012). Support for non-autonomous evidence comes from several studies in
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transgenic mutant SOD1 mice. The expression of mutant SOD1 restricted to motor neurons in
vivo was not enough or caused a mild neurodegeneration (Jaarsma et. al.; 2008). Indeed, when
mutant SOD1 expression was reduced in microglia and macrophages there was a reduction
in motor neuron degeneration (Boillee 2006, Wang 2009). In addition, mutant SOD1 expression
in astrocytes is required to cause neurodegeneration by release of toxic factors (Gong et. al.,
2000; Nagai et al. 2007). Co-cultures of healthy motor neurons with astrocytes expressing
mutant SOD1 resulted in more than 50% motor neuron death (Marchetto et al, 2008), while
astrocytes obtained from postmortem tissue from patients with fALS and sALS were both toxic
to motor neurons (Haidet-Phillips et al., 2011). In agreement, mutant SOD1 knockdown in
astrocytes attenuated toxicity towards motor neurons, suggesting that the mutant enzyme
plays a role in both fALS and sALS (Phillips et al., 2011). SOD1G93A glial-restricted precursor
cells transpanted into the cervical spinal cord of wild type rats survived and differentiated
efficiently into astrocytes. These graft-derived SOD1G93A astrocytes induced host ubiquitina‐
tion and death of motor neurons, reactive astrocytosis, and reduction of the glial glutamate
transporter GLT-1 expression that was associated with animal limb weakness and respiratory
dysfunction (Papadeas et al., 2011). The SOD1G93A astrocyte-induced motor neuron death may
be madiated by host microglial activation (Papadeas et al., 2011).
Abnormalities in the immune system have also been observed in ALS patients. Blood samples
of ALS patients have increased levels of CD4+ cells and reduced levels of CD8+ T lymphocytes.
However, early in the disease when motor features are still mild there is a reduction in CD4+/
CD25+ T-regulatory cells (T-reg) and CD14+ monocytes. These observations suggest that the
reduction in circulating T-reg cells could be due to the relocation of the cells into the central
nervous system. Upon relocation, the T-reg cells would activate the innate immune cells like
microglia, leading to the release of anti-inflammatory cytokines such as interleukin-10 and
transforming growth factor-β to protect the affected area (Kipnis et al., 2004 and Mantonavi,
et al., 2009). Indeed, immunostaining for the astrocytic marker glial fibrillary acid protein
(GFAP) showed a significantly increased presence of astrocytes in the precentral gyrus of
patients with both fALS and sALS. In addition, staining for activated microglia and macro‐
phages markers such as leukocyte common antigen (LCA), lymphocytes function associate
molecule (LFA-1), complementary receptors CR3 (CD11b), and CR4 (CD11c) was also in‐
creased in motor cortex, brainstem, and corticospinal tract (Kawamata, et al., 1992; Papidimi‐
triou et al., 2010). Samples from brain and spinal cord from animal models and patient with
ALS also showed a significant increase in activated or reactive astrocytes, an indication of
neuroinflammation (Sta et al., 2011).
Astrocytes and microglia play an essential role in immune surveillance and response in the
central nervous system. Reactive astrocytes recruited to the injured area reestablish the blood-
brain-barrier (BBB), release neurotrophins and growth factors (IGF-1), clear debri, and isolate
the injured region through the formation of a glial scar (Papadimitriou et al 2010; Dong and
Benviste 2001). Microglia are also activated in the presence of antigens exposed during
neurodegeneration leading to the phagocytosis of cellular debri and the secretion of several
neurotrophic factors, neurotrophins, and cytokines. However, a poor regulation of these
factors could be harmful to motor neurons. Microglia seems to protect motor neurons from
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neurodegeneration, but is activated in the first steps of neurodegeneration. An increase in the
immunostaining for GFAP and CD11 suggests the presence of reactive astrocytes and micro‐
glia in SOD1 transgenic mice (Fischer et. al, 2004). Increase in NGF, a sign of reactive atrocytes,
leads to aptoptosis in ALS through a pathway involving activation of p75 (Pehar et al., 2004).
Additionally, in ALS animal models mutant SOD1-expressing astrocytes are neurotoxic to
motor neurons, and reducing mutant SOD1 expression decreases motor neuron degeneration
and increases animal life span (Lepore at al., 2008, Barbeito et al., 2010). The release of pro-
inflammatory cytokines, oxidative stressors such as prostanglandins, leukotrienes, and
reactive nitrogen species (RNS) is toxic to motor neurons (Henkel, et al., 2009). In in vitro
studies, normal motor neurons die through a pro-apoptotic Bax pathway when co-cultured
with astrocytes expressing mutant SOD1 (Nagai at al., 2007). In in vivo studies, microglia
releases pro-inflammatory cytokines such us TNF-α and IL-1β as well as ROS (Henkel 2009)
whereas in ALS patients, there is an increase of pro-inflammatory cytokines and prostran‐
glandin E2 (Papadimitou, 2010). Media obtained from activated microglia causes motor
neuron death by activation of TNF-α and NMDA receptors (Moisee and Strong 2006). In mouse
model of ALS, a reduction in the expression of mutant SOD1 by microglia does not change age
of symptoms onset, but slowed down disease progression (Boillee et al. 2006b). Motor neurons
expressing mutant SOD1 are more susceptible to Fas ligand and NO-triggered cell death
(Raoul et al., 2002), suggesting that in the context of ALS progression, motor neurons express‐
ing mutant SOD1 are more vulnerable to external stimuli such as ROS, RNS and toxic factors
release by surrounding cells.
10. Apoptosis
Apoptosis is a programmed cell death cascade involved in several physiological processes
during development and aging. Cell death by apoptosis sustains the homeostasis of cell
population in tissues including cell turnover, hormone dependent- and chemical induced-cell
death, and immune system development. The programmed cell death also functions as a
defense when cells are damaged by disease or noxious stimuli (Elmore, S; 2007). Thereby,
inappropriate apoptosis is a potential mechanism implicated in the pathogenesis of several
neurodegenerative disorders, including ALS (Elmore, S; 2007). There are two main apoptotic
pathways, the extrinsic or death receptor pathway and the intrinsic or mitochondrial pathway
(Igney and Krammer, 2002). The extrinsic pathway involves transmembrane receptor-
mediated interactions between ligands and death receptors resulting in transmission of death
signals from cell surface to the intracellular signaling pathways (Locksley et al., 2001). The
most studied ligand and death receptor association are Fas ligand and Fas receptor (FasL/FasR)
and tumor necrosis factor (TNF) and its receptor (TNFL/TNFR) (Hsu et al 1995; Wajant, 2002).
The intrinsic pathway consists of non-receptor-mediated stimuli that cause changes in the
inner mitochondrial membrane. These changes include the opening of mitochondrial mem‐
brane pores leading to loss of transmembrane potential and released of pro-apoptotic proteins
such as cytochrome c, Smac/DIABLO, HtrA2/Omi, and others ending with the activation of
caspases (Sealens, et al., 2004; Du et al., 2000; Van Loo et al., 2002; Garrido at al., 2005). The
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transgenic mutant SOD1 mice. The expression of mutant SOD1 restricted to motor neurons in
vivo was not enough or caused a mild neurodegeneration (Jaarsma et. al.; 2008). Indeed, when
mutant SOD1 expression was reduced in microglia and macrophages there was a reduction
in motor neuron degeneration (Boillee 2006, Wang 2009). In addition, mutant SOD1 expression
in astrocytes is required to cause neurodegeneration by release of toxic factors (Gong et. al.,
2000; Nagai et al. 2007). Co-cultures of healthy motor neurons with astrocytes expressing
mutant SOD1 resulted in more than 50% motor neuron death (Marchetto et al, 2008), while
astrocytes obtained from postmortem tissue from patients with fALS and sALS were both toxic
to motor neurons (Haidet-Phillips et al., 2011). In agreement, mutant SOD1 knockdown in
astrocytes attenuated toxicity towards motor neurons, suggesting that the mutant enzyme
plays a role in both fALS and sALS (Phillips et al., 2011). SOD1G93A glial-restricted precursor
cells transpanted into the cervical spinal cord of wild type rats survived and differentiated
efficiently into astrocytes. These graft-derived SOD1G93A astrocytes induced host ubiquitina‐
tion and death of motor neurons, reactive astrocytosis, and reduction of the glial glutamate
transporter GLT-1 expression that was associated with animal limb weakness and respiratory
dysfunction (Papadeas et al., 2011). The SOD1G93A astrocyte-induced motor neuron death may
be madiated by host microglial activation (Papadeas et al., 2011).
Abnormalities in the immune system have also been observed in ALS patients. Blood samples
of ALS patients have increased levels of CD4+ cells and reduced levels of CD8+ T lymphocytes.
However, early in the disease when motor features are still mild there is a reduction in CD4+/
CD25+ T-regulatory cells (T-reg) and CD14+ monocytes. These observations suggest that the
reduction in circulating T-reg cells could be due to the relocation of the cells into the central
nervous system. Upon relocation, the T-reg cells would activate the innate immune cells like
microglia, leading to the release of anti-inflammatory cytokines such as interleukin-10 and
transforming growth factor-β to protect the affected area (Kipnis et al., 2004 and Mantonavi,
et al., 2009). Indeed, immunostaining for the astrocytic marker glial fibrillary acid protein
(GFAP) showed a significantly increased presence of astrocytes in the precentral gyrus of
patients with both fALS and sALS. In addition, staining for activated microglia and macro‐
phages markers such as leukocyte common antigen (LCA), lymphocytes function associate
molecule (LFA-1), complementary receptors CR3 (CD11b), and CR4 (CD11c) was also in‐
creased in motor cortex, brainstem, and corticospinal tract (Kawamata, et al., 1992; Papidimi‐
triou et al., 2010). Samples from brain and spinal cord from animal models and patient with
ALS also showed a significant increase in activated or reactive astrocytes, an indication of
neuroinflammation (Sta et al., 2011).
Astrocytes and microglia play an essential role in immune surveillance and response in the
central nervous system. Reactive astrocytes recruited to the injured area reestablish the blood-
brain-barrier (BBB), release neurotrophins and growth factors (IGF-1), clear debri, and isolate
the injured region through the formation of a glial scar (Papadimitriou et al 2010; Dong and
Benviste 2001). Microglia are also activated in the presence of antigens exposed during
neurodegeneration leading to the phagocytosis of cellular debri and the secretion of several
neurotrophic factors, neurotrophins, and cytokines. However, a poor regulation of these
factors could be harmful to motor neurons. Microglia seems to protect motor neurons from
Current Advances in Amyotrophic Lateral Sclerosis12
neurodegeneration, but is activated in the first steps of neurodegeneration. An increase in the
immunostaining for GFAP and CD11 suggests the presence of reactive astrocytes and micro‐
glia in SOD1 transgenic mice (Fischer et. al, 2004). Increase in NGF, a sign of reactive atrocytes,
leads to aptoptosis in ALS through a pathway involving activation of p75 (Pehar et al., 2004).
Additionally, in ALS animal models mutant SOD1-expressing astrocytes are neurotoxic to
motor neurons, and reducing mutant SOD1 expression decreases motor neuron degeneration
and increases animal life span (Lepore at al., 2008, Barbeito et al., 2010). The release of pro-
inflammatory cytokines, oxidative stressors such as prostanglandins, leukotrienes, and
reactive nitrogen species (RNS) is toxic to motor neurons (Henkel, et al., 2009). In in vitro
studies, normal motor neurons die through a pro-apoptotic Bax pathway when co-cultured
with astrocytes expressing mutant SOD1 (Nagai at al., 2007). In in vivo studies, microglia
releases pro-inflammatory cytokines such us TNF-α and IL-1β as well as ROS (Henkel 2009)
whereas in ALS patients, there is an increase of pro-inflammatory cytokines and prostran‐
glandin E2 (Papadimitou, 2010). Media obtained from activated microglia causes motor
neuron death by activation of TNF-α and NMDA receptors (Moisee and Strong 2006). In mouse
model of ALS, a reduction in the expression of mutant SOD1 by microglia does not change age
of symptoms onset, but slowed down disease progression (Boillee et al. 2006b). Motor neurons
expressing mutant SOD1 are more susceptible to Fas ligand and NO-triggered cell death
(Raoul et al., 2002), suggesting that in the context of ALS progression, motor neurons express‐
ing mutant SOD1 are more vulnerable to external stimuli such as ROS, RNS and toxic factors
release by surrounding cells.
10. Apoptosis
Apoptosis is a programmed cell death cascade involved in several physiological processes
during development and aging. Cell death by apoptosis sustains the homeostasis of cell
population in tissues including cell turnover, hormone dependent- and chemical induced-cell
death, and immune system development. The programmed cell death also functions as a
defense when cells are damaged by disease or noxious stimuli (Elmore, S; 2007). Thereby,
inappropriate apoptosis is a potential mechanism implicated in the pathogenesis of several
neurodegenerative disorders, including ALS (Elmore, S; 2007). There are two main apoptotic
pathways, the extrinsic or death receptor pathway and the intrinsic or mitochondrial pathway
(Igney and Krammer, 2002). The extrinsic pathway involves transmembrane receptor-
mediated interactions between ligands and death receptors resulting in transmission of death
signals from cell surface to the intracellular signaling pathways (Locksley et al., 2001). The
most studied ligand and death receptor association are Fas ligand and Fas receptor (FasL/FasR)
and tumor necrosis factor (TNF) and its receptor (TNFL/TNFR) (Hsu et al 1995; Wajant, 2002).
The intrinsic pathway consists of non-receptor-mediated stimuli that cause changes in the
inner mitochondrial membrane. These changes include the opening of mitochondrial mem‐
brane pores leading to loss of transmembrane potential and released of pro-apoptotic proteins
such as cytochrome c, Smac/DIABLO, HtrA2/Omi, and others ending with the activation of
caspases (Sealens, et al., 2004; Du et al., 2000; Van Loo et al., 2002; Garrido at al., 2005). The
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Bcl-2 family of proteins regulates the intrinsic apoptotic pathway (Cory and Adams 2002) and
these proteins in turn are regulated by the tumor suppressor protein p53 (Schuler and Green,
2001). The Bcl-2 family includes pro-apoptotic and anti-apoptotic proteins. Some of the anti-
apoptotic proteins comprise Bcl2, Bcl-x, Bcl XL, Bcl-XS, Bcl-w, BAG, whereas the pro-apoptotic
proteins include Bcl-10, BAX, Balk, Bid, Bad, Bim, Bik, and Blk. Both the intrinsic and extrinsic
pathways require a specific stimuli to activate its own caspase initiator (caspase -2,-8,-9,-10).
These two pathways, once activated, convey in the activation of a final execution pathway with
cleavage of caspase-3, resulting in DNA fragmentation, cytoskeletal and nuclear protein
cleavage, protein cross-linking, apoptotic bodies formation, expression of ligands for phago‐
cytic recognizion, and final uptake by phagocytic cells (Martinvalet, et al, 2005). There is
compelling evidence in ALS, at least in mutant SOD1-ALS, that toxicity is mediated by
apoptosis. In transgenic SOD1 mice there are numerous apoptotic findings such as DNA
fragmentation, caspase activation, and altered expression of the anti-apoptotic protein Bcl-2
(Durham HD, et al. 1997; Spooren WP et al. 2000). Motor neuron degeneration in ALS struc‐
turally resembles apoptosis. The neuronal death progression is divided in 3 sequential stages:
chromatolysis, somatodendritic attrition, and apoptosis. In ALS, in the spinal cord anterior
horn and motor cortex there is DNA fragmentation and increased in caspase-3 activity.
Vulnerable central nervous system regions affected by ALS show elevation of pro-apoptotic
proteins Bax and Bak and reduction of the antiapoptotic protein Bcl-2 in mitochondrial-
enriched membrane compartment. Co-immunoprecipitation experiments show greater Bax-
Bax interactions and lower Bax-Bcl-2 interactions in the mitochondrial-enriched membrane
compartment of ALS motor cortex compared with controls, (Martin LJ, 1999). In mutant SOD1
mice apoptotic signals are activated in sequence, caspase 1, an inflammatory caspase, is
activated at disease onset while activated caspase-3 is detected later in the curse of the disease
(Pasinelli, P, et al. 2000). In SOD1 mice, intracerebroventricular injection of a broad caspase-
inhibitor reduces caspase 1 and caspase 3 mRNA levels resulting in spear motor neurons at
the spinal cord and delay in disease onset and progression compared with vehicle-infused
mice (Li M, et al.; 2000). Overexpression of the antiapoptotic protein Bcl-2 and deletion of the
pro-apoptotic protein Bax preserve motor function and prolong life in a SOD1G93A model.
Genetic deletion of mitochondrial pro-apoptotic Bak and Bax proteins in a mouse model of
ALS prevent neuronal loss and axonal degeneration, and delayed onset of disease (Reyes et
al., 2012).
In SOD1G93A transgenic mice, cytosolic release of cytochrome c was observed (Pasinelli, et al.,
2004; Kirkinezos et al., 2005; Takeuchi et al., 2002), and levels of pro-apoptotic proteins Bad
and Bax were increased while those of anti-apoptotic proteins Bcl2, Bcl-xL and XIAP were
decreased (Guegan et al., 2001; Vukosavic et al., 1999; Ishigaki et al., 2002). Caspase 1 and
caspase 3 were also sequentially activated in motor neurons and astrocytes in SOD1G93A,
SOD1G37R, and SOD1G85R mice (Li et al., 2000; Pasinelli et al., 1998; Pasinelli et al., 2000).
Intraventricular administration of minocycline, which inhibits cytochrome c release from
mitochondria, was shown to delay disease onset and extend survival (Zhu et al., 2002).
However minocycline failed in human ALS patients (Gordon et al, 2007). Similar results were
observed upon intraventricular administration of the broad-spectrum caspase inhibitor zVAD-
fmk (Li et al., 2000). Additionally, over-expression of anti-apoptotic protein Bcl-2 delayed
Current Advances in Amyotrophic Lateral Sclerosis14
activation of the caspases, attenuated neuron degeneration and delayed disease onset and
mortality (Vukosavic et al., 1999, Kostic et al., 1997).
11. Conclusion
The research in the ALS field encounters many limitations, what is clearly reflected in the little
progress accomplished in the therapy of this neurodegenerative disorder. Most of the studies
describe the mechanisms involved in the pathogenesis of the familial form of ALS, which
accounts for a minority of all the ALS cases. However, some of the hypothesis currently under
investigation may also explain how the pathology develops in the sporadic forms of ALS. In
the last two decades several experimental models in vitro and in vivo have shaded light into
the pathogenesis of the disease. Several potential mechanisms have been implicated in ALS
onset and progression including oxidative stress, excitotoxicity, mitochondrial dysfunction,
glial activation, RNA-processing, and growth factor abnormalities. Whether these mechanisms
intertwine, work in parallel or in sequence to cause neuronal death remains to be investigated.
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Bcl-2 family of proteins regulates the intrinsic apoptotic pathway (Cory and Adams 2002) and
these proteins in turn are regulated by the tumor suppressor protein p53 (Schuler and Green,
2001). The Bcl-2 family includes pro-apoptotic and anti-apoptotic proteins. Some of the anti-
apoptotic proteins comprise Bcl2, Bcl-x, Bcl XL, Bcl-XS, Bcl-w, BAG, whereas the pro-apoptotic
proteins include Bcl-10, BAX, Balk, Bid, Bad, Bim, Bik, and Blk. Both the intrinsic and extrinsic
pathways require a specific stimuli to activate its own caspase initiator (caspase -2,-8,-9,-10).
These two pathways, once activated, convey in the activation of a final execution pathway with
cleavage of caspase-3, resulting in DNA fragmentation, cytoskeletal and nuclear protein
cleavage, protein cross-linking, apoptotic bodies formation, expression of ligands for phago‐
cytic recognizion, and final uptake by phagocytic cells (Martinvalet, et al, 2005). There is
compelling evidence in ALS, at least in mutant SOD1-ALS, that toxicity is mediated by
apoptosis. In transgenic SOD1 mice there are numerous apoptotic findings such as DNA
fragmentation, caspase activation, and altered expression of the anti-apoptotic protein Bcl-2
(Durham HD, et al. 1997; Spooren WP et al. 2000). Motor neuron degeneration in ALS struc‐
turally resembles apoptosis. The neuronal death progression is divided in 3 sequential stages:
chromatolysis, somatodendritic attrition, and apoptosis. In ALS, in the spinal cord anterior
horn and motor cortex there is DNA fragmentation and increased in caspase-3 activity.
Vulnerable central nervous system regions affected by ALS show elevation of pro-apoptotic
proteins Bax and Bak and reduction of the antiapoptotic protein Bcl-2 in mitochondrial-
enriched membrane compartment. Co-immunoprecipitation experiments show greater Bax-
Bax interactions and lower Bax-Bcl-2 interactions in the mitochondrial-enriched membrane
compartment of ALS motor cortex compared with controls, (Martin LJ, 1999). In mutant SOD1
mice apoptotic signals are activated in sequence, caspase 1, an inflammatory caspase, is
activated at disease onset while activated caspase-3 is detected later in the curse of the disease
(Pasinelli, P, et al. 2000). In SOD1 mice, intracerebroventricular injection of a broad caspase-
inhibitor reduces caspase 1 and caspase 3 mRNA levels resulting in spear motor neurons at
the spinal cord and delay in disease onset and progression compared with vehicle-infused
mice (Li M, et al.; 2000). Overexpression of the antiapoptotic protein Bcl-2 and deletion of the
pro-apoptotic protein Bax preserve motor function and prolong life in a SOD1G93A model.
Genetic deletion of mitochondrial pro-apoptotic Bak and Bax proteins in a mouse model of
ALS prevent neuronal loss and axonal degeneration, and delayed onset of disease (Reyes et
al., 2012).
In SOD1G93A transgenic mice, cytosolic release of cytochrome c was observed (Pasinelli, et al.,
2004; Kirkinezos et al., 2005; Takeuchi et al., 2002), and levels of pro-apoptotic proteins Bad
and Bax were increased while those of anti-apoptotic proteins Bcl2, Bcl-xL and XIAP were
decreased (Guegan et al., 2001; Vukosavic et al., 1999; Ishigaki et al., 2002). Caspase 1 and
caspase 3 were also sequentially activated in motor neurons and astrocytes in SOD1G93A,
SOD1G37R, and SOD1G85R mice (Li et al., 2000; Pasinelli et al., 1998; Pasinelli et al., 2000).
Intraventricular administration of minocycline, which inhibits cytochrome c release from
mitochondria, was shown to delay disease onset and extend survival (Zhu et al., 2002).
However minocycline failed in human ALS patients (Gordon et al, 2007). Similar results were
observed upon intraventricular administration of the broad-spectrum caspase inhibitor zVAD-
fmk (Li et al., 2000). Additionally, over-expression of anti-apoptotic protein Bcl-2 delayed
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activation of the caspases, attenuated neuron degeneration and delayed disease onset and
mortality (Vukosavic et al., 1999, Kostic et al., 1997).
11. Conclusion
The research in the ALS field encounters many limitations, what is clearly reflected in the little
progress accomplished in the therapy of this neurodegenerative disorder. Most of the studies
describe the mechanisms involved in the pathogenesis of the familial form of ALS, which
accounts for a minority of all the ALS cases. However, some of the hypothesis currently under
investigation may also explain how the pathology develops in the sporadic forms of ALS. In
the last two decades several experimental models in vitro and in vivo have shaded light into
the pathogenesis of the disease. Several potential mechanisms have been implicated in ALS
onset and progression including oxidative stress, excitotoxicity, mitochondrial dysfunction,
glial activation, RNA-processing, and growth factor abnormalities. Whether these mechanisms
intertwine, work in parallel or in sequence to cause neuronal death remains to be investigated.
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1. Introduction
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurological disorder with higher
selectivity in the degeneration of the upper and lower motor neurons, which leads to progres‐
sive paralysis of voluntary muscles. Although most cases fall under sporadic ALS (sALS), 10%
of cases are inherited and known as familial ALS (fALS). The etiology of most ALS cases
remains unknown, but mutations of ALS-linked Cu/Zn superoxide dismutase 1 (SOD1) are
the most common causes of fALS and are responsible for its neurotoxicity and disease
propagation due to the acquired toxic gain-of-function [1-2]. Studies in both human ALS
patients and the transgenic ALS mouse model have delineated multiple pathological mecha‐
nisms of neuronal death that include genetic mutations, excitotoxicity, free radicals, apoptosis,
inflammation, and protein aggregation. Targeting the multiple routes of the motor neuron
degeneration is likely to contribute to the development of novel therapeutics for ALS patients.
2. Excitotoxicity
2.1. Glutamate neurotoxicity
Glutamate mediates excitatory synaptic transmission by activating the ionotropic glutamate
receptors that are sensitive to N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-meth‐
yl-4-isoxazolepropionic acid (AMPA), or kainate. While the ionotropic glutamate receptors
constitute fast excitatory synapses in the brain and the spinal cord, the glutamate receptors are
excessively activated under pathological conditions such as hypoxic ischemia, trauma, and
epilepsy, which triggers degeneration of neurons and oligodendrocytes. Extensive evidence
supports the causative role of Ca2+-permeable ionotropic glutamate receptors in motor neuron
degeneration in ALS patients. Intracellular Ca2+ overload causes catastrophic neuronal death
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1. Introduction
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurological disorder with higher
selectivity in the degeneration of the upper and lower motor neurons, which leads to progres‐
sive paralysis of voluntary muscles. Although most cases fall under sporadic ALS (sALS), 10%
of cases are inherited and known as familial ALS (fALS). The etiology of most ALS cases
remains unknown, but mutations of ALS-linked Cu/Zn superoxide dismutase 1 (SOD1) are
the most common causes of fALS and are responsible for its neurotoxicity and disease
propagation due to the acquired toxic gain-of-function [1-2]. Studies in both human ALS
patients and the transgenic ALS mouse model have delineated multiple pathological mecha‐
nisms of neuronal death that include genetic mutations, excitotoxicity, free radicals, apoptosis,
inflammation, and protein aggregation. Targeting the multiple routes of the motor neuron
degeneration is likely to contribute to the development of novel therapeutics for ALS patients.
2. Excitotoxicity
2.1. Glutamate neurotoxicity
Glutamate mediates excitatory synaptic transmission by activating the ionotropic glutamate
receptors that are sensitive to N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-meth‐
yl-4-isoxazolepropionic acid (AMPA), or kainate. While the ionotropic glutamate receptors
constitute fast excitatory synapses in the brain and the spinal cord, the glutamate receptors are
excessively activated under pathological conditions such as hypoxic ischemia, trauma, and
epilepsy, which triggers degeneration of neurons and oligodendrocytes. Extensive evidence
supports the causative role of Ca2+-permeable ionotropic glutamate receptors in motor neuron
degeneration in ALS patients. Intracellular Ca2+ overload causes catastrophic neuronal death
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by impairing mitochondria or activating proteases, cytosolic phospholipase A2, kinases,
endonucleases, and nuclear factor kappa B [3].
2.1.1. Abnormal glutamate re-uptake in ALS
Glutamate transporter 1 (GLT-1), also known as excitatory amino acid transporter 2 (EAAT2),
and glutamate-aspartate transporter (GLAST), the primary transporters of glutamate into
astrocytes, plays a central role in regulating the extracellular levels of glutamate [4-5]. The
expression of GLT-1 was markedly reduced in the motor cortex and the spinal cord of sporadic
and familial ALS patients [6]. In mutant SOD1 mice, the levels and the activity of EAAT2 were
reduced in the spinal cord [7-8]. The levels of extracellular glutanmate increased in the plasma
and the cerebrospinal fluid of ALS patients [9-10] and of mutant SOD1-expressing rodent
models [7,11-12]. Reducing the expression of EAAT2 with antisense oligonucleotide reduced
transporter activity induces neuronal death in vitro and in vivo [13]. Crossing transgenic mice
that overexpress EAAT2 with SOD1G93A mice caused delayed motor deficit [14]. In addition,
increasing the expression of GLT-1 significantly extended the survival of mutant SOD1 mice
[15]. More recently, a sumoylated fragment of EAAT2 cleaved to by activating caspase-3 was
shown to cause motor neuron death [16]. This implies that reduced glutamate uptake into
astrocytes mediates degeneration of spinal motor neurons in ALS.
2.1.2. Mediation of motor neuron degeneration by the Ca2+ permeability of AMPA receptors
Ca2+-permeable AMPA glutamate receptors appear to mediate chronic motor neuron degen‐
eration in ALS. AMPA receptors consist of heteromeric combinations of four sub-units,
GluR1-4 [17]. The glutamate (Q)/arginine (R)-editing of the GluR2 mRNA provides a positively
charged form of GluR2 protein with arginine, which is responsible for Ca2+ impermeability
[18]. When AMPA receptors contain reduced levels of Q/R-edited GluR2, the AMPA receptor
complex becomes more permeable to Ca2+ [18]. The motor neuron of ALS patients showed
evidence of defective editing of the pre-mRNA of GluR2 [19]. While lack of GluR2 accelerated
motor neuron degeneration and shortened the life span of the SOD1 mice, overexpression of
GluR2 delayed the disease onset and reduced the mortality of mutant SOD1 mice [20-21].
Moreover, the GluR2-N transgenic mice that expressed GluR2 gene encoding a asparagine at
the Q/R site showed late-onset degeneration of the spinal motor neurons and motor function
deficit [22]. Crossbreeding GluR2-N mice with mutant SOD1 mice aggravated motor neuron
degeneration and shortened the survival time.
2.1.3. Therapies related to glutamate-mediated excitotoxicity
Although riluzole, the only approved disease-modifying therapy available to ALS patients
since 1995, has been shown to inhibit glutamate release, subsequent studies demonstrated that
riluzole inhibited AMPA receptors and presynaptic NMDA receptors [23-24]. Administration
of riluzole significantly improved the motor neuron survival, motor function, and life expect‐
ancy of mutant SOD1 mice [25]. Similar beneficial effects of AMPA receptor antagonists such
as memantine, 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide
(NBQX), and talampanel have been verified in mutant SOD1 mice [26-28]. The B-lactam
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antibiotic cefriaxone increased GLT-1 expression in spinal cord culture and in normal rats. The
cefriaxone treatment delayed motor deficits with marginal survival in SOD1G93A mice [15].
An adaptive design Phase II/III study revealed good tolerability over 20 weeks [29]. The
extened phase III of this study is ongoing.
3. Oxidative stress
3.1. Homeostasis and generation of free radicals in cells
Free radicals, including reactive oxygen species (ROS) and reactive nitrogen species (RNS), are
characterized by unpaired electrons in their outer orbit. The most common cellular free radicals
are hydroxyl (OH ) radicals, superoxide (O2- ) anions, and nitric monoxide (NO ). Although
hydrogen peroxide (H2O2) and peroxynitrite (ONOO-) are literally not free radicals, they are
deemed to generate free radicals through various chemical reactions in many cases. Free
radicals are cleared through several defense mechanisms, as follows: (1) catalytic removal of
reactive species by enzymes such as superoxide dismutase, catalase, and peroxidase; (2)
scavenging of reactive species by low-molecular-weight agents that were either synthesized
in vivo (including glutathione, α-keto acids, lipoic acid, and coenzyme Q) or obtained from
the diet [including ascorbate (vitamin C) and α-tocopherol (vitamin E)]; and (3) minimization
of the availability of pro-oxidants such as transition metals [30]. CNS, which is mainly
composed of polyunsaturated fatty acids (PUFAs), is readily susceptible to oxidative damage
because the system demands a high metabolic oxidative rate with limited anti-oxidants and
has a high transition metal content that acts as a potent pro-oxidant through the Haber-Weiss
reaction or the Fenton reaction [51]. Upon shifting to pro-oxidants, CNS is promptly attacked
by ROS that includes H2O2, NO, O2- , and highly reactive OH and NO and undergoes serious
functional abnormality that is directly related to the demise of the course of neurons.
3.2. Evidence of oxidative stress in ALS
There is extensive evidence of the causative role of oxidative stress in motor neuron degener‐
ation in ALS. The 3-nitrotyrosine(3-NT) level was elevated in subjects with both sporadic and
familial cases of ALS, and the immunoreactivity of 3-NT became more evident within large
motor neurons in the ventral horn of the lumbar spinal cord [31-32]. Higher carbonylation of
proteins with the use of 2,4-dinitrophenylhydrazine (DNPH) was detected in the spinal cord
in sporadic ALS [33]. Elevation of 8-hydroxy-2-deoxyguanosine (8-OHdG) was found in the
CSF, serum, and urine of ALS patients [34]. The 4-hydroxynonenal level increased in the serum
of ALS patients [35]. Transgenic ALS mice overexpression of the human mutant SOD1 revealed
oxidative damage to proteins, lipids, and DNA [36-37].
3.2.1. Role of mitochondria in oxidative stress
Mitochondria produce ATP using about 90% of the O2 that is taken up by neurons. During
electron transfer in the inner membrane of the organelle, electrons spontaneously leak from
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by impairing mitochondria or activating proteases, cytosolic phospholipase A2, kinases,
endonucleases, and nuclear factor kappa B [3].
2.1.1. Abnormal glutamate re-uptake in ALS
Glutamate transporter 1 (GLT-1), also known as excitatory amino acid transporter 2 (EAAT2),
and glutamate-aspartate transporter (GLAST), the primary transporters of glutamate into
astrocytes, plays a central role in regulating the extracellular levels of glutamate [4-5]. The
expression of GLT-1 was markedly reduced in the motor cortex and the spinal cord of sporadic
and familial ALS patients [6]. In mutant SOD1 mice, the levels and the activity of EAAT2 were
reduced in the spinal cord [7-8]. The levels of extracellular glutanmate increased in the plasma
and the cerebrospinal fluid of ALS patients [9-10] and of mutant SOD1-expressing rodent
models [7,11-12]. Reducing the expression of EAAT2 with antisense oligonucleotide reduced
transporter activity induces neuronal death in vitro and in vivo [13]. Crossing transgenic mice
that overexpress EAAT2 with SOD1G93A mice caused delayed motor deficit [14]. In addition,
increasing the expression of GLT-1 significantly extended the survival of mutant SOD1 mice
[15]. More recently, a sumoylated fragment of EAAT2 cleaved to by activating caspase-3 was
shown to cause motor neuron death [16]. This implies that reduced glutamate uptake into
astrocytes mediates degeneration of spinal motor neurons in ALS.
2.1.2. Mediation of motor neuron degeneration by the Ca2+ permeability of AMPA receptors
Ca2+-permeable AMPA glutamate receptors appear to mediate chronic motor neuron degen‐
eration in ALS. AMPA receptors consist of heteromeric combinations of four sub-units,
GluR1-4 [17]. The glutamate (Q)/arginine (R)-editing of the GluR2 mRNA provides a positively
charged form of GluR2 protein with arginine, which is responsible for Ca2+ impermeability
[18]. When AMPA receptors contain reduced levels of Q/R-edited GluR2, the AMPA receptor
complex becomes more permeable to Ca2+ [18]. The motor neuron of ALS patients showed
evidence of defective editing of the pre-mRNA of GluR2 [19]. While lack of GluR2 accelerated
motor neuron degeneration and shortened the life span of the SOD1 mice, overexpression of
GluR2 delayed the disease onset and reduced the mortality of mutant SOD1 mice [20-21].
Moreover, the GluR2-N transgenic mice that expressed GluR2 gene encoding a asparagine at
the Q/R site showed late-onset degeneration of the spinal motor neurons and motor function
deficit [22]. Crossbreeding GluR2-N mice with mutant SOD1 mice aggravated motor neuron
degeneration and shortened the survival time.
2.1.3. Therapies related to glutamate-mediated excitotoxicity
Although riluzole, the only approved disease-modifying therapy available to ALS patients
since 1995, has been shown to inhibit glutamate release, subsequent studies demonstrated that
riluzole inhibited AMPA receptors and presynaptic NMDA receptors [23-24]. Administration
of riluzole significantly improved the motor neuron survival, motor function, and life expect‐
ancy of mutant SOD1 mice [25]. Similar beneficial effects of AMPA receptor antagonists such
as memantine, 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide
(NBQX), and talampanel have been verified in mutant SOD1 mice [26-28]. The B-lactam
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antibiotic cefriaxone increased GLT-1 expression in spinal cord culture and in normal rats. The
cefriaxone treatment delayed motor deficits with marginal survival in SOD1G93A mice [15].
An adaptive design Phase II/III study revealed good tolerability over 20 weeks [29]. The
extened phase III of this study is ongoing.
3. Oxidative stress
3.1. Homeostasis and generation of free radicals in cells
Free radicals, including reactive oxygen species (ROS) and reactive nitrogen species (RNS), are
characterized by unpaired electrons in their outer orbit. The most common cellular free radicals
are hydroxyl (OH ) radicals, superoxide (O2- ) anions, and nitric monoxide (NO ). Although
hydrogen peroxide (H2O2) and peroxynitrite (ONOO-) are literally not free radicals, they are
deemed to generate free radicals through various chemical reactions in many cases. Free
radicals are cleared through several defense mechanisms, as follows: (1) catalytic removal of
reactive species by enzymes such as superoxide dismutase, catalase, and peroxidase; (2)
scavenging of reactive species by low-molecular-weight agents that were either synthesized
in vivo (including glutathione, α-keto acids, lipoic acid, and coenzyme Q) or obtained from
the diet [including ascorbate (vitamin C) and α-tocopherol (vitamin E)]; and (3) minimization
of the availability of pro-oxidants such as transition metals [30]. CNS, which is mainly
composed of polyunsaturated fatty acids (PUFAs), is readily susceptible to oxidative damage
because the system demands a high metabolic oxidative rate with limited anti-oxidants and
has a high transition metal content that acts as a potent pro-oxidant through the Haber-Weiss
reaction or the Fenton reaction [51]. Upon shifting to pro-oxidants, CNS is promptly attacked
by ROS that includes H2O2, NO, O2- , and highly reactive OH and NO and undergoes serious
functional abnormality that is directly related to the demise of the course of neurons.
3.2. Evidence of oxidative stress in ALS
There is extensive evidence of the causative role of oxidative stress in motor neuron degener‐
ation in ALS. The 3-nitrotyrosine(3-NT) level was elevated in subjects with both sporadic and
familial cases of ALS, and the immunoreactivity of 3-NT became more evident within large
motor neurons in the ventral horn of the lumbar spinal cord [31-32]. Higher carbonylation of
proteins with the use of 2,4-dinitrophenylhydrazine (DNPH) was detected in the spinal cord
in sporadic ALS [33]. Elevation of 8-hydroxy-2-deoxyguanosine (8-OHdG) was found in the
CSF, serum, and urine of ALS patients [34]. The 4-hydroxynonenal level increased in the serum
of ALS patients [35]. Transgenic ALS mice overexpression of the human mutant SOD1 revealed
oxidative damage to proteins, lipids, and DNA [36-37].
3.2.1. Role of mitochondria in oxidative stress
Mitochondria produce ATP using about 90% of the O2 that is taken up by neurons. During
electron transfer in the inner membrane of the organelle, electrons spontaneously leak from
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the electron transport chain and react with available O2 to produce superoxide, which makes
mitochondria the major cellular sources of ROS. Mitochondria exist in the motor neurons due
to the high rate of metabolic demand, which makes motor neurons more vulnerable to
cumulative oxidative stress. Free radicals that accumulate over time decrease mitochondrial
efficacy and increase the production of mutated mitochondrial DNA related to the aging
process, although mitochondria have their own specific anti-oxidants that consist of SOD1,
SOD2, glutathioneperoxidase, and peroxiredoxin 3 and can usually combat the high rate of
ROS production [38]. Morphological abnormality in the organelle, which includes a fragment‐
ed network and swelling, and increased cristae have been observed in the soma and proximal
axons of ventral motor neurons of sporadic ALS (sALS) patients [39]. In the axon and soma of
motor neurons of mice that expressed SOD1G93A and SOD1G37R [40-41], membrane vacuoles
derived from degenerating mitochondria were reported. Morphological alteration in mito‐
chondria was also illustrated in NSC34 motor-neuron-like cells that expressed SOD1G93A
[42-43]. Mutant SOD1 that was localized in mitochondria was associated with increased
oxidative damage, decreased respiratory activity of the mitochondria, and architectural
change. The interaction of mutant SOD1 and mitochondria was enough to result in motor
neuron death in neuroblastoma cells [44]. Mitochondrial SOD1 and its chaperone protein
named copper chaperone for SOD1 (CCS) are co-localized in the mitochondrial inter-mem‐
brane space [45]. The aggregates of mutant SOD1 were shown within the mitochondria in the
spinal cord of SOD1G93A mice before the onset of the symptoms [46-47] and were implicated in
increased oxidative damage, decreased respiratory activity of mitochondria [48], and mito‐
chondrial swelling and vacuolization [47].
3.2.2. Role of transition metals in oxidative stress
Redox-active transition metals are useful but harmful trace elements. Copper and iron are
abundant (~0.1-0.5 mM) in the brain and have been implicated in the generation of ROS in
various neurodegenerative diseases that include Alzheimer’s disease and Parkinson’s disease
[49-50]. These transition metals mediate the formation of a hydroxyl radical through the iron-
catalyzed or copper-catalyzed Haber-Weiss reactions [51]. Once copper ions are transported
into the cell, they must be delivered to specific targets (e.g., SOD1 and cytochrome c oxidase)
or stored in copper scavenging systems (e.g., GSH and metallothioneins) [52-53]. When these
events are out of control, the cells have an uncomfortable abundance of toxic and radical-
generating metal ions. FALS-linked SOD1 mutation has weaker binding affinity to copper ions,
which are readily libertated to increase oxidative stress in cells expressed with fALS-SOD1 [54].
The detrimental role of copper in fALS pathogenesis was supported by several experiments
that used copper chelators, which delayed the disease onset and prolonged the survival of
fALS-G93A mice [55], prevented peroxidase activity by expressing fALS-SOD1 A4V and G93A
in vitro [56], and reduced elevated ROS production in the lymphoblasts of fALS patients [57].
Iron is vital for all living organisms because it has an essential role in oxygen transport and
electron transfer, and is a cofactor in many enzyme systems that include DNA synthesis. Iron
homeostasis and its regulatory system [58] was readily disrupted in the development and
progress of neurodegenerative diseases such as AD or PD [59-60]. Recently, several pieces of
evidence supported the concept that iron is dysregulated in ALS. An increased ferritin level
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was observed in the serum of sporadic ALS patients, which suggests a possible risk factor and
the disturbance of iron homeostasis [61-62]. Ferritin was upregulated just prior to the end-
stage disease in SOD1-G93A mice, which supports increased Fe levels [63]. In the same animal
model, increased iron was evident in the spinal cord at the ages of 90 and 120 days, with the
onset of the symptoms and in the late stage, due to the disease progress. The increased iron
levels were attenuated by iron chelators, which improved the motor function and the survival
[64]. mRNAs associated with iron homeostasis (e.g., DMT1, TfR1, the iron exporter Fpn, and
CP) also increased with a caudal-to-rostral gradient, with the highest levels rostrally in the
cervical region in SOD1G37R [65]. HFE protein is a membrane protein that can influence
cellular iron uptake, and mutated HFE is well recognized in haemochromatosis, a genetic
disorder due to the irregular accumulation of free forms of Fe in parenchymal tissue. In studies
of sporadic ALS patients, both the prevalence of HFE mutation and its polymorphisms (e.g.,
H63D) were evident [66-67]. Therefore, HFE polymorphisms in ALS may be associated with
the altered Fe homeostasis and oxidative stress in this disease. Although abnormal iron
homeostasis was evident, the iron regulation mechanisms for motor neuron death must be
explained.
3.2.3. Possible mechanisms related to oxidative stress in ALS
Human SOD1 mutation has a toxic gain-of-function that may be due to loss of the active site
of copper binding that converts the SOD1 itself to pro-oxidant proteins and participates in ROS
generation [68]. Several pieces of evidence have been suggested to show that higher interaction
of mutant SOD1 with mitochondria may induce mitochondrial dysfunction and selectively
lead to excessive oxidative stress in motor neurons [46]. Reduced transcription factor nuclear
erythroid 2-related factor 2 (Nrf2) mRNA and protein expression has been reported in the
spinal cord of ALS patients [69]. Crossbreeding SOD1G93A mice with overexpressed Nrf2
extended their survival [70], which suggests that increasing the Nef2 activity may be a novel
therapeutic target. Nrf2 activation increases the expression of anti-oxidant proteins due to its
interaction with the anti-oxidant-response element (ARE) after its translocation to the nucleus.
In another reported mechanism of oxidative stress, the activity of NADPH oxidase (Nox)
increased in both sALS patients and mutant SOD1 mice. Expressed Nox in activated microglia
may influence motor neuron death. Deletion of either Nox1 or Nox2 prolonged the survival
of mutant SOD1G93A mice [71-72]. Protein aggregation is a common pathological feature in
ALS patients and animal ALS models. TAR DNA-binding protein-43 (TDP-43) or mutant SOD1
is a constituent of inclusions in ALS patients and mutant SOD1 mice [73-74]. Mutant SOD1
itself caused oxidative damage of proteins in mutant SOD1 mice [37].
3.2.4. Therapeutic drugs for oxidative stress in ALS
Several anti-oxidants have been tested using animal ALS models (Table 1). Completed,
ongoing, or planned trials explored, are exploring, or will explore the value of anti-oxidants.
Vitamin E, the most potent natural scavenger of ROS and RNS, delayed their clinical onset and
slowed the disease progression in mutant SOD1 mice [25]. Long-term vitamin E supplements
reduced the risk of death from ALS in ALS-free subjects [75-76]. Unfortunately, two vitamin
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the electron transport chain and react with available O2 to produce superoxide, which makes
mitochondria the major cellular sources of ROS. Mitochondria exist in the motor neurons due
to the high rate of metabolic demand, which makes motor neurons more vulnerable to
cumulative oxidative stress. Free radicals that accumulate over time decrease mitochondrial
efficacy and increase the production of mutated mitochondrial DNA related to the aging
process, although mitochondria have their own specific anti-oxidants that consist of SOD1,
SOD2, glutathioneperoxidase, and peroxiredoxin 3 and can usually combat the high rate of
ROS production [38]. Morphological abnormality in the organelle, which includes a fragment‐
ed network and swelling, and increased cristae have been observed in the soma and proximal
axons of ventral motor neurons of sporadic ALS (sALS) patients [39]. In the axon and soma of
motor neurons of mice that expressed SOD1G93A and SOD1G37R [40-41], membrane vacuoles
derived from degenerating mitochondria were reported. Morphological alteration in mito‐
chondria was also illustrated in NSC34 motor-neuron-like cells that expressed SOD1G93A
[42-43]. Mutant SOD1 that was localized in mitochondria was associated with increased
oxidative damage, decreased respiratory activity of the mitochondria, and architectural
change. The interaction of mutant SOD1 and mitochondria was enough to result in motor
neuron death in neuroblastoma cells [44]. Mitochondrial SOD1 and its chaperone protein
named copper chaperone for SOD1 (CCS) are co-localized in the mitochondrial inter-mem‐
brane space [45]. The aggregates of mutant SOD1 were shown within the mitochondria in the
spinal cord of SOD1G93A mice before the onset of the symptoms [46-47] and were implicated in
increased oxidative damage, decreased respiratory activity of mitochondria [48], and mito‐
chondrial swelling and vacuolization [47].
3.2.2. Role of transition metals in oxidative stress
Redox-active transition metals are useful but harmful trace elements. Copper and iron are
abundant (~0.1-0.5 mM) in the brain and have been implicated in the generation of ROS in
various neurodegenerative diseases that include Alzheimer’s disease and Parkinson’s disease
[49-50]. These transition metals mediate the formation of a hydroxyl radical through the iron-
catalyzed or copper-catalyzed Haber-Weiss reactions [51]. Once copper ions are transported
into the cell, they must be delivered to specific targets (e.g., SOD1 and cytochrome c oxidase)
or stored in copper scavenging systems (e.g., GSH and metallothioneins) [52-53]. When these
events are out of control, the cells have an uncomfortable abundance of toxic and radical-
generating metal ions. FALS-linked SOD1 mutation has weaker binding affinity to copper ions,
which are readily libertated to increase oxidative stress in cells expressed with fALS-SOD1 [54].
The detrimental role of copper in fALS pathogenesis was supported by several experiments
that used copper chelators, which delayed the disease onset and prolonged the survival of
fALS-G93A mice [55], prevented peroxidase activity by expressing fALS-SOD1 A4V and G93A
in vitro [56], and reduced elevated ROS production in the lymphoblasts of fALS patients [57].
Iron is vital for all living organisms because it has an essential role in oxygen transport and
electron transfer, and is a cofactor in many enzyme systems that include DNA synthesis. Iron
homeostasis and its regulatory system [58] was readily disrupted in the development and
progress of neurodegenerative diseases such as AD or PD [59-60]. Recently, several pieces of
evidence supported the concept that iron is dysregulated in ALS. An increased ferritin level
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was observed in the serum of sporadic ALS patients, which suggests a possible risk factor and
the disturbance of iron homeostasis [61-62]. Ferritin was upregulated just prior to the end-
stage disease in SOD1-G93A mice, which supports increased Fe levels [63]. In the same animal
model, increased iron was evident in the spinal cord at the ages of 90 and 120 days, with the
onset of the symptoms and in the late stage, due to the disease progress. The increased iron
levels were attenuated by iron chelators, which improved the motor function and the survival
[64]. mRNAs associated with iron homeostasis (e.g., DMT1, TfR1, the iron exporter Fpn, and
CP) also increased with a caudal-to-rostral gradient, with the highest levels rostrally in the
cervical region in SOD1G37R [65]. HFE protein is a membrane protein that can influence
cellular iron uptake, and mutated HFE is well recognized in haemochromatosis, a genetic
disorder due to the irregular accumulation of free forms of Fe in parenchymal tissue. In studies
of sporadic ALS patients, both the prevalence of HFE mutation and its polymorphisms (e.g.,
H63D) were evident [66-67]. Therefore, HFE polymorphisms in ALS may be associated with
the altered Fe homeostasis and oxidative stress in this disease. Although abnormal iron
homeostasis was evident, the iron regulation mechanisms for motor neuron death must be
explained.
3.2.3. Possible mechanisms related to oxidative stress in ALS
Human SOD1 mutation has a toxic gain-of-function that may be due to loss of the active site
of copper binding that converts the SOD1 itself to pro-oxidant proteins and participates in ROS
generation [68]. Several pieces of evidence have been suggested to show that higher interaction
of mutant SOD1 with mitochondria may induce mitochondrial dysfunction and selectively
lead to excessive oxidative stress in motor neurons [46]. Reduced transcription factor nuclear
erythroid 2-related factor 2 (Nrf2) mRNA and protein expression has been reported in the
spinal cord of ALS patients [69]. Crossbreeding SOD1G93A mice with overexpressed Nrf2
extended their survival [70], which suggests that increasing the Nef2 activity may be a novel
therapeutic target. Nrf2 activation increases the expression of anti-oxidant proteins due to its
interaction with the anti-oxidant-response element (ARE) after its translocation to the nucleus.
In another reported mechanism of oxidative stress, the activity of NADPH oxidase (Nox)
increased in both sALS patients and mutant SOD1 mice. Expressed Nox in activated microglia
may influence motor neuron death. Deletion of either Nox1 or Nox2 prolonged the survival
of mutant SOD1G93A mice [71-72]. Protein aggregation is a common pathological feature in
ALS patients and animal ALS models. TAR DNA-binding protein-43 (TDP-43) or mutant SOD1
is a constituent of inclusions in ALS patients and mutant SOD1 mice [73-74]. Mutant SOD1
itself caused oxidative damage of proteins in mutant SOD1 mice [37].
3.2.4. Therapeutic drugs for oxidative stress in ALS
Several anti-oxidants have been tested using animal ALS models (Table 1). Completed,
ongoing, or planned trials explored, are exploring, or will explore the value of anti-oxidants.
Vitamin E, the most potent natural scavenger of ROS and RNS, delayed their clinical onset and
slowed the disease progression in mutant SOD1 mice [25]. Long-term vitamin E supplements
reduced the risk of death from ALS in ALS-free subjects [75-76]. Unfortunately, two vitamin
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E clinical trials failed to show the vitamin’s efficacy in ALS patients due to impermeable BBB
penetration [77]. Creatine, N-acetylcysteine, AEOL-10150, and edarabone have successfully
improved the motor function and survival of mutant SOD1 mice [78-81]. Creatine and N-
acetylcystein were not effective in the clinical trial phase II.
4. Apoptosis
4.1. Evidence of apoptosis in ALS
Kerr et al. (1972)[82] reported electron microscopic features of shrinkage necrosis or apoptosis
that are expected to play a role in the regulation of the number of cells under physiological
and pathological conditions. The apoptotic cells were accompanied by condensation of the
nucleus and the cytoplasm, nuclear fragmentation, and aggregated condensation of nuclear
chromatin. Interestingly, apoptosis is prevented by inhibitors of protein and mRNA synthesis,
and thus, appears to require the expression and activation of death-regulating proteins in
neurons and non-neuronal cells [83-84]. The morphological and molecular features of apop‐
tosis have been reported in the nervous system during the development of various neurolog‐
ical diseases. Apoptosis is probably correlated with the demise of motor neurons in ALS.
Degenerating motor neurons in the spinal cord and the motor cortex are illustrated by the dark
and shrunken cytoplasm and nuclei, chromatin condensation, and apoptotic bodies in the cells.
Various pro-apoptosis proteins are activated in the ALS-injured area, and protein synthesis
inhibitors attenuate ALS-related neuronal death.
4.1.1. Death receptor Fas
The death receptor Fas (CD95 or APO-1) belongs to the tumor necrosis factor (TNF) receptor
superfamily and functions as a key determinant of cell fate under physiological and patho‐
logical conditions [86-87]. The Fas ligand (Fas-L) activates Fas in an autocrine or paracrine
manner, which leads to the trimerization of Fas with Fas-associating protein within the death
domain (FADD) and procaspase-8. Fas activation has been shown as an obligatory step in
apoptosis in neurons deprived of trophic factors [88-90]. Fas antibodies were more frequently
found in the serum of sporadic or familial ALS patients than in that of the normal controls [91],
which also induced apoptosis in the human neuroblastoma cell line and in neuron-glia co-
cultured cells of the spinal cord of rat embryos [92]. Primary motor neurons of mouse embryos
that expressed mutant SOD1 were susceptible to Fas-induced death [93]. Continuous silencing
of the Fas receptor on the motor-neuron-ameliorated motor function and survival of
SOD1G93A mice using small interfering RNA-mediated interference supported the role of Fas-
linked motor neuron degeneration in ALS [94]. In SOD1G93A mice, a Fas pathway is required
to allow Fas interaction with FADD, which in turn recruits caspase-8 as one of the downstream
effectors. In addition, TIMP-3 controls Fas-mediated apoptosis by inhibiting the MMP-3-
mediated shedding activity in the Fas ligand on the cell surface [95]. The FASS/FADD-
mediated motor neuron degeneration was attenuated by Lithium treatment in SOD1G93A
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mice [96]. A Fas/NO feedback loop with downstream Daxx and P38 was proposed as another
Fas pathway of motor neuron death in mutant SOD1 mice [97].
4.1.2. Pro-apoptotic family of Bcl-2
The physiological and pathological roles of the Bcl-2 family have been extensively reviewed
[98-99]. The physical balance between anti-apoptotic and pro-apoptotic members of the Bcl-2
family generally appears to determine the fate of developing and mature cells. Anti- and pro-
apoptotic proteins are separated by the presence or absence of Bcl-2 homology (BH) domains.
There are four domains: BH1-BH4. Bcl-2 and Bcl-xL contain all four domains and are anti-
apoptotic. The pro-apoptotic Bcl-2 family includes Bax, Bcl-xs, Bak, Bad, and Bid and partici‐
pates in the neuronal death process. Unbalanced pro- or anti-apoptotic proteins activate
caspase-realted apoptosis by releasing cytochrome c into cytosol. Bax is oligomerized, inserted
into the outer membrane of mitochondria, and shown to induce cytochrome c release [100-101].
The ratio of the apoptotic cell death genes Bax to Bcl-2 increases at both the mRNA and protein
levels in the spinal motor neurons of ALS patients and SOD1G93A mice [102-104]. Interest‐
ingly, mutant SOD1 was highly associated with Bcl-2 in the mitochondria, which resulted in
conformational or phenotypic change of Bcl-2 that weakened the mitochondria in the spinal
cord [105]. Blunt Bcl-2 may contribute to the activation of the mitochondrial apoptosis
machinery such as caspase-9, caspase 3, and cytochrome c in the spinal motor neurons of ALS
transgenic mice and humans with ALS [106-107]. To support this idea, Bcl-2 overexpression
or Bax depletion crossbred with SOD1G93A mice delayed the onset of symptoms and extended
the life expectancy [108-109].
4.1.3. Caspase cascade
Caspases, a family of cysteine-dependent aspartate-directed proteases, mediate the propaga‐
tion and execution of apoptosis. They can be classified into initiator caspases and effector
caspases [110]. Caspase-9 is an initiator caspase and is proteolytically activated by apaf-1, a
cytoplasmic protein that is homologous to ced-4, and by cytochrome c. The latter is located in
the intermembrane space of the mitochondria and released into the cytoplasm by the pro-
apoptotic Bcl-2 (e.g., Bax) that is transported from the cytoplasm into the mitochondria in the
early phase of apoptosis. Caspase-8, which is known as another initiator caspase, is activated
through the interaction of procaspase-9 with the Fas receptor and the FADD adapter. Activated
caspase-8 and caspase-9 can activate downstream caspases such as caspase-3, 6, and 7 that can
cleave to a number of proteins that are essential to the structure, signal transduction, and cell
cycle and terminate the overall apoptosis process. Under the ER (endoplasmic reticulum)
stress, caspase-12 is activated with the cleavage (activation) of caspase-9 and caspase-3,
regardless of the release of cytochrome c. Marginally, ER stress triggers caspase-8 activation,
which results in a mitochondria-mediated pathway via Bid cleavage. The caspase-1, -3, and -9
activities were higher in the motor neurons of the spinal cord or the motor cortex of ALS
patients than in those of the control [107,111]. Caspase-1 truncated Bid to be highly reactive
[106]. The orderly activation of caspase-1 and -3 was evident, and their mRNAs were abundant
in animal ALS models [111-112]. The sequential activation of caspase-9 to caspase-7 was
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E clinical trials failed to show the vitamin’s efficacy in ALS patients due to impermeable BBB
penetration [77]. Creatine, N-acetylcysteine, AEOL-10150, and edarabone have successfully
improved the motor function and survival of mutant SOD1 mice [78-81]. Creatine and N-
acetylcystein were not effective in the clinical trial phase II.
4. Apoptosis
4.1. Evidence of apoptosis in ALS
Kerr et al. (1972)[82] reported electron microscopic features of shrinkage necrosis or apoptosis
that are expected to play a role in the regulation of the number of cells under physiological
and pathological conditions. The apoptotic cells were accompanied by condensation of the
nucleus and the cytoplasm, nuclear fragmentation, and aggregated condensation of nuclear
chromatin. Interestingly, apoptosis is prevented by inhibitors of protein and mRNA synthesis,
and thus, appears to require the expression and activation of death-regulating proteins in
neurons and non-neuronal cells [83-84]. The morphological and molecular features of apop‐
tosis have been reported in the nervous system during the development of various neurolog‐
ical diseases. Apoptosis is probably correlated with the demise of motor neurons in ALS.
Degenerating motor neurons in the spinal cord and the motor cortex are illustrated by the dark
and shrunken cytoplasm and nuclei, chromatin condensation, and apoptotic bodies in the cells.
Various pro-apoptosis proteins are activated in the ALS-injured area, and protein synthesis
inhibitors attenuate ALS-related neuronal death.
4.1.1. Death receptor Fas
The death receptor Fas (CD95 or APO-1) belongs to the tumor necrosis factor (TNF) receptor
superfamily and functions as a key determinant of cell fate under physiological and patho‐
logical conditions [86-87]. The Fas ligand (Fas-L) activates Fas in an autocrine or paracrine
manner, which leads to the trimerization of Fas with Fas-associating protein within the death
domain (FADD) and procaspase-8. Fas activation has been shown as an obligatory step in
apoptosis in neurons deprived of trophic factors [88-90]. Fas antibodies were more frequently
found in the serum of sporadic or familial ALS patients than in that of the normal controls [91],
which also induced apoptosis in the human neuroblastoma cell line and in neuron-glia co-
cultured cells of the spinal cord of rat embryos [92]. Primary motor neurons of mouse embryos
that expressed mutant SOD1 were susceptible to Fas-induced death [93]. Continuous silencing
of the Fas receptor on the motor-neuron-ameliorated motor function and survival of
SOD1G93A mice using small interfering RNA-mediated interference supported the role of Fas-
linked motor neuron degeneration in ALS [94]. In SOD1G93A mice, a Fas pathway is required
to allow Fas interaction with FADD, which in turn recruits caspase-8 as one of the downstream
effectors. In addition, TIMP-3 controls Fas-mediated apoptosis by inhibiting the MMP-3-
mediated shedding activity in the Fas ligand on the cell surface [95]. The FASS/FADD-
mediated motor neuron degeneration was attenuated by Lithium treatment in SOD1G93A
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mice [96]. A Fas/NO feedback loop with downstream Daxx and P38 was proposed as another
Fas pathway of motor neuron death in mutant SOD1 mice [97].
4.1.2. Pro-apoptotic family of Bcl-2
The physiological and pathological roles of the Bcl-2 family have been extensively reviewed
[98-99]. The physical balance between anti-apoptotic and pro-apoptotic members of the Bcl-2
family generally appears to determine the fate of developing and mature cells. Anti- and pro-
apoptotic proteins are separated by the presence or absence of Bcl-2 homology (BH) domains.
There are four domains: BH1-BH4. Bcl-2 and Bcl-xL contain all four domains and are anti-
apoptotic. The pro-apoptotic Bcl-2 family includes Bax, Bcl-xs, Bak, Bad, and Bid and partici‐
pates in the neuronal death process. Unbalanced pro- or anti-apoptotic proteins activate
caspase-realted apoptosis by releasing cytochrome c into cytosol. Bax is oligomerized, inserted
into the outer membrane of mitochondria, and shown to induce cytochrome c release [100-101].
The ratio of the apoptotic cell death genes Bax to Bcl-2 increases at both the mRNA and protein
levels in the spinal motor neurons of ALS patients and SOD1G93A mice [102-104]. Interest‐
ingly, mutant SOD1 was highly associated with Bcl-2 in the mitochondria, which resulted in
conformational or phenotypic change of Bcl-2 that weakened the mitochondria in the spinal
cord [105]. Blunt Bcl-2 may contribute to the activation of the mitochondrial apoptosis
machinery such as caspase-9, caspase 3, and cytochrome c in the spinal motor neurons of ALS
transgenic mice and humans with ALS [106-107]. To support this idea, Bcl-2 overexpression
or Bax depletion crossbred with SOD1G93A mice delayed the onset of symptoms and extended
the life expectancy [108-109].
4.1.3. Caspase cascade
Caspases, a family of cysteine-dependent aspartate-directed proteases, mediate the propaga‐
tion and execution of apoptosis. They can be classified into initiator caspases and effector
caspases [110]. Caspase-9 is an initiator caspase and is proteolytically activated by apaf-1, a
cytoplasmic protein that is homologous to ced-4, and by cytochrome c. The latter is located in
the intermembrane space of the mitochondria and released into the cytoplasm by the pro-
apoptotic Bcl-2 (e.g., Bax) that is transported from the cytoplasm into the mitochondria in the
early phase of apoptosis. Caspase-8, which is known as another initiator caspase, is activated
through the interaction of procaspase-9 with the Fas receptor and the FADD adapter. Activated
caspase-8 and caspase-9 can activate downstream caspases such as caspase-3, 6, and 7 that can
cleave to a number of proteins that are essential to the structure, signal transduction, and cell
cycle and terminate the overall apoptosis process. Under the ER (endoplasmic reticulum)
stress, caspase-12 is activated with the cleavage (activation) of caspase-9 and caspase-3,
regardless of the release of cytochrome c. Marginally, ER stress triggers caspase-8 activation,
which results in a mitochondria-mediated pathway via Bid cleavage. The caspase-1, -3, and -9
activities were higher in the motor neurons of the spinal cord or the motor cortex of ALS
patients than in those of the control [107,111]. Caspase-1 truncated Bid to be highly reactive
[106]. The orderly activation of caspase-1 and -3 was evident, and their mRNAs were abundant
in animal ALS models [111-112]. The sequential activation of caspase-9 to caspase-7 was
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required for the mitochondria-dependent apoptosis pathway in a rodent ALS model [107].
Moreover, caspase-9 was simultaneously activated with a death receptor pathway that
contained Fas, FADD, caspase-8, and caspase-3 in the ALS mice after their motor neuron death
began [95-96]. Cleaved forms of caspase-12 were expressed presymptomatically in animal
models, which shows evidence of ER stress [113]. A more advanced mechanism than that with
caspases revealed that caspases such as caspase-3 or caspase-7 mediated TDP-43 cleavage
[114], which was observed immunologically in an aggregated form in the cytoplasmic
inclusions in ALS. Intraventricular administration of zVAD-fmk, a broad-spectrum caspase
inhibitor, prolonged the survival of G93ASOD1 mice [111], which supports the causative role
of caspase cascade in motor neuron death.
4.1.4. Anti-apoptotic drugs served as therapy for ALS
Even though minocycline has anti-inflammatory effects that prevent microglia proliferation,
the drug prevented apoptotic motor neuron death by inhibiting cytochrome c release in mutant
SOD1 mice [115]. The beneficial effects were proven in several studies to prolong survival and
ameliorate the motor function [115-117]. Minocycline accelerated disease progression in a
clinical trial, though [118]. TCH-346, a molecule that binds to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), was used in small samples in a Phase II/III randomized trial, but it
did not show beneficial effects [119].
5. Inflammation
5.1. Microglia and astrocyte
Microglia activation is an early event in all forms of pathology. Thus, activated microglia was
initially considered a sensitive marker to identify sites that were predestined for tissue. The
classical bone-marrow-derived microglial cells dwell in the gray matter and have ramified
(highly branched) structures with a small portion of perinuclear cytoplasm and a small, dense,
and heterochromatic nucleus. In many CNS pathologies, the cells increase, and this may arise
from either local proliferation or recruitment from the blood, or both. The morphology of
microglia becomes reactive under pathological conditions that were determined as infiltration
of blood-derived cells, local BBB [120], or presence of damaged neurons. Microglia near areas
of neuronal injury tend to have more amoeboid features with intense cell bodies and reduced
numbers of shortened and thick processes [121] that lead to a structural morphology similar
to that of macrophages. A shift in the active style of microglia affects neural, vascular, and
blood-borne cells due to several secretions that include pro-inflammatory cytokines and
chemokines, nitric oxide, and reactive oxygen intermediates. Astrocytes have many essential
physiological functions in the CNS such as provision of trophic support for neurons, conduct
of synaptic formation and plasticity, and regulation of the cerebral blood flow. Due to their
strategic structure, they are in close contact with CNS resident cells and blood vessels
[122-123]. An inflammatory insult causes proliferation of astrocytes and morphological
changes. Astroglial activation is recognized via increased expression of the intermediate
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filament glial fibrillary acidic protein (GFAP) and the marker aldehyde dehydrogenase 1
family, member L1 (ALDH1L1). Although astrocytes are not immune cells, they can contribute
to the immune response in pathological conditions. Microgliosis and astrocytosis are promient
features of neurodegenerative diseases that include AD, PD, and ALS.
5.2. Evidence of inflammation in ALS
Several studies have shown the possibility that glial cells adjacent to degenerating motor
neurons, mainly primed microglia and astrocytes, have causative roles in the course of disease
propagation in ALS. Massive gliosis is apparent in pathologically vulnerable departments of
CNS in both human ALS patients and ALS animal models [124-125]. Microglia antibodies have
also been found in the CSF of an ALS patient [126]. Recently, the presence of activated microglia
was visualized via positron emission tomography (PET), using [11C](R)-PK11195, in the motor
cortex, dorsolateral prefrontal cortex, thalamus, and pos of living patients [127]. In the
presymptomatic stage of the disease, TNF-α and M-CSF expression increased in a transgenic
ALS model. Interestingly, the increase in the expressed TNF-α was found to be correlated to
the severity of motor neuron loss [128]. The elevation of TNF-α and of its two receptors [TNFRI
(p55TNF) and TNFRII ( p75TNF)] was observed in the serum of ALS patients, unlike in those
of healthy controls [129]. To date, primed microglia-sensitive intracellular signaling that
affectas ALS is authorized by the activation of p38 mitogen-activated protein kinase
(p38MAPK), the translocation of the transcription factor NF-κB into the nucleus, and the
upregulation of COX-2. The activation of NF-κB regulates the transcription of a wide range of
inflammation-related genes that include inducible nitric oxide synthesis (iNOS), COX-2,
MCP-1, MMP-9, IL-2, IL-6, IL-8, IL-12p40, IL-2 receptor, ICAM-1, TNF-α, and IFN-γ [130],
which leads to the secretion of many inflammatory mediators. The aforementioned genes were
shown to have changed in the tissues of ALS patients and hSOD1 transgenic mice
[128,131-133]. COX-2 is inducible and is a rate-limiting enzyme of the synthesis pathways of
the prostaglandins (PG) PGD2, PGE2, PGF2a, and PGI2 and thromboxane (TXA2). Prostaglan‐
dins play a role in various cellular effectors that include the instigation of inflammatory
responses, the re-arrangement of cytoskeletons, and gene transcription changes [134]. COX-2
expression was significantly elevated in motor neuron and glial cells in the spinal cord of ALS
patients [135-136], and the COX-2 activity increased in the spinal cord of ALS patients [137].
In addition, the PGE2 levels jumped up in the CSF of ALS patients by two to 10 times, compared
with the controls [137]. The deletion of the prostaglandin E(2) EP2 receptor in SOD1G93A mice
improved their motor function and prolonged their survival, which suggests that PGE2
signalling via the EP2 receptor acts as an inflammatory mediator in motor neuron degeneration
[138].
5.2.1. Non-cell-autonomous neurotoxicity in ALS
Aside from degenerating motor neurons, microglia and astrocytes concomitantly play a role
in disease progression in ALS model mice. Recent reports emphasized the potential role of
non-cell-autonomous mechanisms, which are harmonious with and critical in SOD1G93A-
induced cell-autonomous death signals [139-140]. Either neuron-specific or glia-specific
Multiple Routes of Motor Neuron Degeneration in ALS
http://dx.doi.org/10.5772/56625
43
required for the mitochondria-dependent apoptosis pathway in a rodent ALS model [107].
Moreover, caspase-9 was simultaneously activated with a death receptor pathway that
contained Fas, FADD, caspase-8, and caspase-3 in the ALS mice after their motor neuron death
began [95-96]. Cleaved forms of caspase-12 were expressed presymptomatically in animal
models, which shows evidence of ER stress [113]. A more advanced mechanism than that with
caspases revealed that caspases such as caspase-3 or caspase-7 mediated TDP-43 cleavage
[114], which was observed immunologically in an aggregated form in the cytoplasmic
inclusions in ALS. Intraventricular administration of zVAD-fmk, a broad-spectrum caspase
inhibitor, prolonged the survival of G93ASOD1 mice [111], which supports the causative role
of caspase cascade in motor neuron death.
4.1.4. Anti-apoptotic drugs served as therapy for ALS
Even though minocycline has anti-inflammatory effects that prevent microglia proliferation,
the drug prevented apoptotic motor neuron death by inhibiting cytochrome c release in mutant
SOD1 mice [115]. The beneficial effects were proven in several studies to prolong survival and
ameliorate the motor function [115-117]. Minocycline accelerated disease progression in a
clinical trial, though [118]. TCH-346, a molecule that binds to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), was used in small samples in a Phase II/III randomized trial, but it
did not show beneficial effects [119].
5. Inflammation
5.1. Microglia and astrocyte
Microglia activation is an early event in all forms of pathology. Thus, activated microglia was
initially considered a sensitive marker to identify sites that were predestined for tissue. The
classical bone-marrow-derived microglial cells dwell in the gray matter and have ramified
(highly branched) structures with a small portion of perinuclear cytoplasm and a small, dense,
and heterochromatic nucleus. In many CNS pathologies, the cells increase, and this may arise
from either local proliferation or recruitment from the blood, or both. The morphology of
microglia becomes reactive under pathological conditions that were determined as infiltration
of blood-derived cells, local BBB [120], or presence of damaged neurons. Microglia near areas
of neuronal injury tend to have more amoeboid features with intense cell bodies and reduced
numbers of shortened and thick processes [121] that lead to a structural morphology similar
to that of macrophages. A shift in the active style of microglia affects neural, vascular, and
blood-borne cells due to several secretions that include pro-inflammatory cytokines and
chemokines, nitric oxide, and reactive oxygen intermediates. Astrocytes have many essential
physiological functions in the CNS such as provision of trophic support for neurons, conduct
of synaptic formation and plasticity, and regulation of the cerebral blood flow. Due to their
strategic structure, they are in close contact with CNS resident cells and blood vessels
[122-123]. An inflammatory insult causes proliferation of astrocytes and morphological
changes. Astroglial activation is recognized via increased expression of the intermediate
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filament glial fibrillary acidic protein (GFAP) and the marker aldehyde dehydrogenase 1
family, member L1 (ALDH1L1). Although astrocytes are not immune cells, they can contribute
to the immune response in pathological conditions. Microgliosis and astrocytosis are promient
features of neurodegenerative diseases that include AD, PD, and ALS.
5.2. Evidence of inflammation in ALS
Several studies have shown the possibility that glial cells adjacent to degenerating motor
neurons, mainly primed microglia and astrocytes, have causative roles in the course of disease
propagation in ALS. Massive gliosis is apparent in pathologically vulnerable departments of
CNS in both human ALS patients and ALS animal models [124-125]. Microglia antibodies have
also been found in the CSF of an ALS patient [126]. Recently, the presence of activated microglia
was visualized via positron emission tomography (PET), using [11C](R)-PK11195, in the motor
cortex, dorsolateral prefrontal cortex, thalamus, and pos of living patients [127]. In the
presymptomatic stage of the disease, TNF-α and M-CSF expression increased in a transgenic
ALS model. Interestingly, the increase in the expressed TNF-α was found to be correlated to
the severity of motor neuron loss [128]. The elevation of TNF-α and of its two receptors [TNFRI
(p55TNF) and TNFRII ( p75TNF)] was observed in the serum of ALS patients, unlike in those
of healthy controls [129]. To date, primed microglia-sensitive intracellular signaling that
affectas ALS is authorized by the activation of p38 mitogen-activated protein kinase
(p38MAPK), the translocation of the transcription factor NF-κB into the nucleus, and the
upregulation of COX-2. The activation of NF-κB regulates the transcription of a wide range of
inflammation-related genes that include inducible nitric oxide synthesis (iNOS), COX-2,
MCP-1, MMP-9, IL-2, IL-6, IL-8, IL-12p40, IL-2 receptor, ICAM-1, TNF-α, and IFN-γ [130],
which leads to the secretion of many inflammatory mediators. The aforementioned genes were
shown to have changed in the tissues of ALS patients and hSOD1 transgenic mice
[128,131-133]. COX-2 is inducible and is a rate-limiting enzyme of the synthesis pathways of
the prostaglandins (PG) PGD2, PGE2, PGF2a, and PGI2 and thromboxane (TXA2). Prostaglan‐
dins play a role in various cellular effectors that include the instigation of inflammatory
responses, the re-arrangement of cytoskeletons, and gene transcription changes [134]. COX-2
expression was significantly elevated in motor neuron and glial cells in the spinal cord of ALS
patients [135-136], and the COX-2 activity increased in the spinal cord of ALS patients [137].
In addition, the PGE2 levels jumped up in the CSF of ALS patients by two to 10 times, compared
with the controls [137]. The deletion of the prostaglandin E(2) EP2 receptor in SOD1G93A mice
improved their motor function and prolonged their survival, which suggests that PGE2
signalling via the EP2 receptor acts as an inflammatory mediator in motor neuron degeneration
[138].
5.2.1. Non-cell-autonomous neurotoxicity in ALS
Aside from degenerating motor neurons, microglia and astrocytes concomitantly play a role
in disease progression in ALS model mice. Recent reports emphasized the potential role of
non-cell-autonomous mechanisms, which are harmonious with and critical in SOD1G93A-
induced cell-autonomous death signals [139-140]. Either neuron-specific or glia-specific
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expression of SOD1 mutation in mice led to the ALS phenotype, with marginal effects
[141-142]. Specific expression of mutant SOD1 within neurons using Nefl (neurofilament light
chain) promoters did not cause motor neuron degeneration in transgenic mice [142]. Consis‐
tently, selective expression of mutant SOD1 in microglia or astrocytes did not kill motor
neurons [141,143].These non-cell-autonomous deaths of motor neurons were supported by an
analysis of chimeric mice that had mixed populations of normal cells and cells that expressed
mutant SOD1 [144]. Conditional knockout of mutant SOD1 in motor neurons using an Isl1
promoter-driven Cre transgene that is expressed in the spinal cord delayed the disease onset
in and prolonged the survival of mutant SOD1 transgenic mice. On the other hand, however,
selective removal from cells of the myeloid lineage that included microglia using a Cd11b
promoter-driven Cre transgene did not delay the disease onset but extended its progress [139].
In the same lineages, selective viral vector-mediated delivery of small interfering RNAs against
human SOD1 in motor neurons delayed the disease onset but did not modify the disease
progression once it started [145], whereas silencing of mutant SOD1 within myeloid cells or
astrocytes slowed the disease progression rather than the disease onset [139-140]. After all the
bone marrow of mutant-SOD1-expressing PU-/- mice, which lacked myeloid and lymphoid
cells, were replaced with wild-type-SOD1 bone marrow, their disease progression and survival
improved [143], which suggests that microglia and astrocytes were not sufficient for the
initiation of motor neuron death, but hastened the disease progression.
5.2.2. Systemic inflammation
Damaged or aged brains continuously suffer from systemic inflammation connected with
peripheral factors, regardless of the presence of innate inflammation in the CNS [146-147].
Three critical components are directly correlated with the synthesis of cytokines and inflam‐
matory mediators in the brain parenchyma to communicate an inflammatory signal to the
brain and to trigger tissue injury. First, inflammatory responses in the thoracic-abdominal
cavity are transduced into the brain via vagal-nerve sensory afferents, and then the outflow of
a vagal efferent seems to manipulate these events through acetylcholine secretion, which acts
on alpha 7 nicotinic receptors of macrophages [148]. Second, cytokines and inflammatory
mediators from the specific area of the inflammation are put into the blood and communicate
with macrophages and other cells in the circumventricular organs, which lack a patent blood-
brain barrier [149]. Third, the cytokines or inflammatory mediators themselves might directly
communicate with the brain endothelium via receptors expressed on the endothelium [150].
Several pieces of evidence showed that a systemic immune response is related to a clinically
symptomatic feature of a neurodegenerative disease such as AD. In accordance with frequently
circulating cytokines in the blood or CSF of AD patients, the abundance of pro-inflammatory
factors preceded the clinical onset of dementia in the subjects [151]. Aged people with systemic
infections have a double risk of developing AD. Similarly, the correlation of clinical events
with systemic immunity was experimentally evaluated in an animal that was challenged with
systemic stimulation. Infection of aged rats with LPS revealed neuronal loss in the brain and
the memory deficits [152]. Thus, it can be said that systemic inflammation contributes to the
onset and progression of neurodegenerative diseases. In recent clinical and pathological
studies, ALS patients revealed dysregulation of their systemic inflammatory components,
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which belonged to alterations in their microglia/macrophage activation profiles [153]; elevated
levels of complementary proteins in their sera [154]; increased IL-13-producing T cells and
circulating neutrophils [155-156]; and higher production of CD8+ T cells in the lymphocytes
[157]. Monocyte chemoattractant protein (MCP)-1 and RANTES were abundant in the
cerebrospinal fluid and sera of ALS patients [158-161]. Increased MCP-1 was shown in the
microglia of mutant SOD1 mice [162-163]. Moreover, the higher LPS level in the plasma of ALS
patients was proportional to the total abnormally activated monocyte/macrophage contents
of the peripheral blood [164]. Long-term exposure to LPS also furthered the disease progres‐
sion in animal ALS models, which implies that systemic inflammation connected to peripheral
factors and innate immunity in the CNS concurrently influences the disease course [165]. With
aging, the blood-brain barrier (BBB) is less tight and thus, more vulnerable to systemic
inflammation. The collapse of BBB or of the blood-spinal cord barrier (BSCB) was shown in
animal ALS models or human ALS patients using evans blue leakage and immunohistochem‐
istry against the anti-CD44 antibody, respectively [166-167]. Under these conditions, periph‐
eral-inflammation-inducing factors were very apparent in the CNS and thereby affected the
neurodegeneration.
5.2.3. Therapies for inflammation in ALS
Minocycline, which is believed to attenuate microglia activation, or celecoxib, a cox-2 inhibitor,
showed beneficial effects in mutant SOD1 mice [115-117,168-169]. Clinical studies on the two
drugs did not disprove, however, their therapeutic property in ALS patients. Thalidomide,
glatiramer acetate, and ONO-2506 also supported the causative role of the inflammation in the
pathology in ALS mice that showed improved motor function and survival [170-171], but their
beneficial effects were not linked to the ALS patients.
6. Mitochondrial pathology in ALS
Mitochondria constitute approximately 25% of the cytoplasmic volume in most eukaryotic
cells and produce cellular energy in the form of ATP via electron transport and oxidative
phosphorylation. During electron transfer in the inner membrane of the organelle, electrons
spontaneously leak from the electron transport chain and react with available O2 to produce
superoxide, which makes mitochondria the major cellular sources of ROS. Mitochondria have
been recognized as target organelles for the regulation and execution of cell death under
pathological conditions [172-173]. There are many mitochondria in the motor neurons because
of the high rate of metabolic demand therein, which implies that motor neurons are susceptible
to functional or morphological alteration in mitochondria. Mtochondrial abnormality may
play a crucial role in the pathologic mechanism of motor neuron diseases and of ALS. Studies
with ALS patients and animal ALS models have been performed to examine both the mor‐
phologic and functional abnormalities of the mitochondria [174]. Morphological abnormality
in the organelle that includes a fragmented network, swelling, and increased cristae has been
observed in the soma and proximal axons of ventral motor neurons of sporadic ALS (sALS)
patients [39]. In ALS patients, a reduction in complex IV of the electron transport chain activity
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expression of SOD1 mutation in mice led to the ALS phenotype, with marginal effects
[141-142]. Specific expression of mutant SOD1 within neurons using Nefl (neurofilament light
chain) promoters did not cause motor neuron degeneration in transgenic mice [142]. Consis‐
tently, selective expression of mutant SOD1 in microglia or astrocytes did not kill motor
neurons [141,143].These non-cell-autonomous deaths of motor neurons were supported by an
analysis of chimeric mice that had mixed populations of normal cells and cells that expressed
mutant SOD1 [144]. Conditional knockout of mutant SOD1 in motor neurons using an Isl1
promoter-driven Cre transgene that is expressed in the spinal cord delayed the disease onset
in and prolonged the survival of mutant SOD1 transgenic mice. On the other hand, however,
selective removal from cells of the myeloid lineage that included microglia using a Cd11b
promoter-driven Cre transgene did not delay the disease onset but extended its progress [139].
In the same lineages, selective viral vector-mediated delivery of small interfering RNAs against
human SOD1 in motor neurons delayed the disease onset but did not modify the disease
progression once it started [145], whereas silencing of mutant SOD1 within myeloid cells or
astrocytes slowed the disease progression rather than the disease onset [139-140]. After all the
bone marrow of mutant-SOD1-expressing PU-/- mice, which lacked myeloid and lymphoid
cells, were replaced with wild-type-SOD1 bone marrow, their disease progression and survival
improved [143], which suggests that microglia and astrocytes were not sufficient for the
initiation of motor neuron death, but hastened the disease progression.
5.2.2. Systemic inflammation
Damaged or aged brains continuously suffer from systemic inflammation connected with
peripheral factors, regardless of the presence of innate inflammation in the CNS [146-147].
Three critical components are directly correlated with the synthesis of cytokines and inflam‐
matory mediators in the brain parenchyma to communicate an inflammatory signal to the
brain and to trigger tissue injury. First, inflammatory responses in the thoracic-abdominal
cavity are transduced into the brain via vagal-nerve sensory afferents, and then the outflow of
a vagal efferent seems to manipulate these events through acetylcholine secretion, which acts
on alpha 7 nicotinic receptors of macrophages [148]. Second, cytokines and inflammatory
mediators from the specific area of the inflammation are put into the blood and communicate
with macrophages and other cells in the circumventricular organs, which lack a patent blood-
brain barrier [149]. Third, the cytokines or inflammatory mediators themselves might directly
communicate with the brain endothelium via receptors expressed on the endothelium [150].
Several pieces of evidence showed that a systemic immune response is related to a clinically
symptomatic feature of a neurodegenerative disease such as AD. In accordance with frequently
circulating cytokines in the blood or CSF of AD patients, the abundance of pro-inflammatory
factors preceded the clinical onset of dementia in the subjects [151]. Aged people with systemic
infections have a double risk of developing AD. Similarly, the correlation of clinical events
with systemic immunity was experimentally evaluated in an animal that was challenged with
systemic stimulation. Infection of aged rats with LPS revealed neuronal loss in the brain and
the memory deficits [152]. Thus, it can be said that systemic inflammation contributes to the
onset and progression of neurodegenerative diseases. In recent clinical and pathological
studies, ALS patients revealed dysregulation of their systemic inflammatory components,
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which belonged to alterations in their microglia/macrophage activation profiles [153]; elevated
levels of complementary proteins in their sera [154]; increased IL-13-producing T cells and
circulating neutrophils [155-156]; and higher production of CD8+ T cells in the lymphocytes
[157]. Monocyte chemoattractant protein (MCP)-1 and RANTES were abundant in the
cerebrospinal fluid and sera of ALS patients [158-161]. Increased MCP-1 was shown in the
microglia of mutant SOD1 mice [162-163]. Moreover, the higher LPS level in the plasma of ALS
patients was proportional to the total abnormally activated monocyte/macrophage contents
of the peripheral blood [164]. Long-term exposure to LPS also furthered the disease progres‐
sion in animal ALS models, which implies that systemic inflammation connected to peripheral
factors and innate immunity in the CNS concurrently influences the disease course [165]. With
aging, the blood-brain barrier (BBB) is less tight and thus, more vulnerable to systemic
inflammation. The collapse of BBB or of the blood-spinal cord barrier (BSCB) was shown in
animal ALS models or human ALS patients using evans blue leakage and immunohistochem‐
istry against the anti-CD44 antibody, respectively [166-167]. Under these conditions, periph‐
eral-inflammation-inducing factors were very apparent in the CNS and thereby affected the
neurodegeneration.
5.2.3. Therapies for inflammation in ALS
Minocycline, which is believed to attenuate microglia activation, or celecoxib, a cox-2 inhibitor,
showed beneficial effects in mutant SOD1 mice [115-117,168-169]. Clinical studies on the two
drugs did not disprove, however, their therapeutic property in ALS patients. Thalidomide,
glatiramer acetate, and ONO-2506 also supported the causative role of the inflammation in the
pathology in ALS mice that showed improved motor function and survival [170-171], but their
beneficial effects were not linked to the ALS patients.
6. Mitochondrial pathology in ALS
Mitochondria constitute approximately 25% of the cytoplasmic volume in most eukaryotic
cells and produce cellular energy in the form of ATP via electron transport and oxidative
phosphorylation. During electron transfer in the inner membrane of the organelle, electrons
spontaneously leak from the electron transport chain and react with available O2 to produce
superoxide, which makes mitochondria the major cellular sources of ROS. Mitochondria have
been recognized as target organelles for the regulation and execution of cell death under
pathological conditions [172-173]. There are many mitochondria in the motor neurons because
of the high rate of metabolic demand therein, which implies that motor neurons are susceptible
to functional or morphological alteration in mitochondria. Mtochondrial abnormality may
play a crucial role in the pathologic mechanism of motor neuron diseases and of ALS. Studies
with ALS patients and animal ALS models have been performed to examine both the mor‐
phologic and functional abnormalities of the mitochondria [174]. Morphological abnormality
in the organelle that includes a fragmented network, swelling, and increased cristae has been
observed in the soma and proximal axons of ventral motor neurons of sporadic ALS (sALS)
patients [39]. In ALS patients, a reduction in complex IV of the electron transport chain activity
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was evident and has been associated with mutations in mitochondrial DNA [175-176].
Although SOD1 is mainly localized in cytosols, it is also resilient in other subcellular com‐
partments such as the mitochondria [45,177-178] and even the endoplasmic reticulum [182].
The aggregates of mutant SOD1 were shown within the mitochondria of the spinal cord of
SOD1G93A mice before the onset of symptoms [46-47] and were implicated in increased
oxidative damage, decreased respiratory activity of mitochondria [48], and the appearance of
mitochondrial swelling and vacuolization [47]. Dissociated cytochrome c from the interaction
of mitochondria with mutant SOD1 activates apoptosis [44]. Mitochondria function as
reservoirs of intracellular Ca2+, as ER. Once overloaded in cytosol, the accumulated Ca2+ in the
mitochondria prepares the organelle to undergo permeability transition, and then swells and
ruptures in their outermembrane, which in turn produces free radicals from them and oxidizes
their lipids and DNA [179-180]. Ca2+-induced mitochondrial damage can also result in
mitochondrial release of cytotoxic substances such as cytochrome c [181] and can affect caspase
cascade. The homeostasis at the intracellular Ca2+ level was also disturbed in motor neurons
of SOD1G93A mice [182]. Moreover, increased Ca2+ uptake into the mitochondria of motor
neurons easily occurred after exposure to the glutamate agonist AMPA or kinate, and triggered
increased ROS generation [183]. ALS-linked SOD1 has been shown to slow down fast axonal
transport of mitochondria. The axonal mitochondria transport was primarily reduced in the
anterograde direction, which suggests that the energy supply in the presynaptic terminals of
the motor endplates is compromised [184]. Multiple functions of the mitochondria over cellular
injury and the apearance of mitochondrial dysfunction in the presymptomatic stage may
contribute to various routes of neuronal death in ALS. More recently, in mice that expressed
human TDP-43 only in neurons that included motor neurons, massive accumulation of
mitochondria in TDP-43-negative cytoplasmic inclusions in the motor neurons were reported
and the lack of mitochondria in the motor axon terminal was observed [185]. In addition, the
transgenic mice that overexpressed human TDP-43 driven by the mouse prion promoter
demonstrated motor deficits, early mortality, and mitochondrial aggregation [186]. These
results imply that TDP-43 is indirectly involved in mitochondrial dysfunction in neurodege‐
nerative diseases such as ALS.
7. Autophagy in ALS
Autophagy is a degradative mechanism that is involved in the recycling and turnover of long-
life proteins and organelles [187]. Autophagy is basically induced by lack of nutrients and
energy or by various toxicants. Although its primary role is adaptation to scarcity, this
degradative process is also critical for the normal turnover of cytoplasmic contents that include
neurons. Genetic ablation of autophagy-related genes provokes neurodeneration even with
lack of disease-like mutant proteins [188]. Recent studies verified the importance of the
autophagy pathway in various pathological conditions that include neurodegenerative
diseases [189]. Interestingly, the catabolic process is both beneficial and detrimental to cells,
depending on its context and specific stimuli. The lethality of mutated SOD1 is the result of
abnormal protein aggregates, which impair the degradation machinery such as the ubiqutin-
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proteasome system and the autophay-lysosome pathway [190-191]. Enhancing the latter with
physiological characteristics prevents motor neuron dysfunction in vivo [192-193]. Defects in
the autophagy pathway have a principal disease-causing role in human pathologies that
include neurodegeneration [189,194]. Studies of the spinal motor neurons of ALS patients [195]
and ALS transgenic mice [196] have delineated the abnormality in autophagy, which is
probably correlated with the pathogenesis of the disease [192-193,197]. A growing number of
studies support the concept that autophagy makes diseased motor neurons healthy by clearing
the aggregated mutant SOD1, which was accomplished by inducing autophagy, as illustrated
by the increased number of autophagosomes and the higher level of autophagy markers such
as Beclin-1, ATG5-ATG12 complex, and LC3-II [192-193]. It is also possible, however, that blunt
autophagy in neurodegenerative conditions was accompanied by the abnormal accumulation
of autophagosomes and excessive markers, which might have killed the neurons [197-198] and
which indicates the compensatory role of autophagy in inherited ALS. Thus, the detailed
molecular mechanism of the development of autophagy-mediated diseases must be explained.
8. Therapeutic strategy for ALS
8.1. Separate routes of motor neuron degeneration in ALS
The parallel pathway of oxidative stress and Fas-mediated apoptosis in motor neuron death
in SOD1G93A mice was previously focused on [96]. This study provided the first evidence that
combination therapy that targets oxidative stress and apoptosis together also delays the onset
and progression of motor dysfunction and extends the survival time of ALS transgenic mice.
Evidence was accumulated that shows that oxidative stress and apoptotic insults cause
neuronal death through distinctive pathways and with unique morphological changes. The
neurotrophins’ nerve growth factor, the brain-derived neurotrophic factor (BDNF), neurotro‐
phin 3 (NT-3), and NT-4/5, and the insulin-like growth factors IGF-I and IGF-II, promote
neuronal survival by preventing programmed cell death or apoptosis, but they significantly
enhance necrotic degeneration of neurons exposed to oxidative stress or deprived of oxygen
and glucose [199-200]. Neurotrophins can induce oxidative stress by upregulating NADPH
oxidase, which leads to neuronal cell necrosis [201]. Surprisingly, the insulin-like growth factor
1 (IGF-1) prevented neuronal cell apoptosis and protected spinal motor neurons in ALS mice
[199,202], but markedly potentiated neuronal cell necrosis induced by hydroxyl radicals or
glutathione depletion [203]. Given that oxidative stress and apoptosis play a central role in
motor neuron degeneration and can contribute to neuronal death through distinctive routes
in ALS, it was hypothesized that a therapeutic approach that targets both oxidative stress and
apoptosis would have additive effects on neuronal survival and the motor function. To
pharmacologically prevent oxidative stress and apoptosis, Neu2000, a novel anti-oxidant, and
Li+, a well-known anti-apoptosis agent, were used. The former, a chemical derivative of aspirin
and sulfasalazine, was developed to protect neurons from oxidative stress with greater potency
and safety, and has been shown to be a potent and secure anti-oxidant in vitro and in animal
models of hypoxic ischemia [204]. Li+ has been shown to prevent apoptosis through mecha‐
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and the lack of mitochondria in the motor axon terminal was observed [185]. In addition, the
transgenic mice that overexpressed human TDP-43 driven by the mouse prion promoter
demonstrated motor deficits, early mortality, and mitochondrial aggregation [186]. These
results imply that TDP-43 is indirectly involved in mitochondrial dysfunction in neurodege‐
nerative diseases such as ALS.
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Autophagy is a degradative mechanism that is involved in the recycling and turnover of long-
life proteins and organelles [187]. Autophagy is basically induced by lack of nutrients and
energy or by various toxicants. Although its primary role is adaptation to scarcity, this
degradative process is also critical for the normal turnover of cytoplasmic contents that include
neurons. Genetic ablation of autophagy-related genes provokes neurodeneration even with
lack of disease-like mutant proteins [188]. Recent studies verified the importance of the
autophagy pathway in various pathological conditions that include neurodegenerative
diseases [189]. Interestingly, the catabolic process is both beneficial and detrimental to cells,
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and ALS transgenic mice [196] have delineated the abnormality in autophagy, which is
probably correlated with the pathogenesis of the disease [192-193,197]. A growing number of
studies support the concept that autophagy makes diseased motor neurons healthy by clearing
the aggregated mutant SOD1, which was accomplished by inducing autophagy, as illustrated
by the increased number of autophagosomes and the higher level of autophagy markers such
as Beclin-1, ATG5-ATG12 complex, and LC3-II [192-193]. It is also possible, however, that blunt
autophagy in neurodegenerative conditions was accompanied by the abnormal accumulation
of autophagosomes and excessive markers, which might have killed the neurons [197-198] and
which indicates the compensatory role of autophagy in inherited ALS. Thus, the detailed
molecular mechanism of the development of autophagy-mediated diseases must be explained.
8. Therapeutic strategy for ALS
8.1. Separate routes of motor neuron degeneration in ALS
The parallel pathway of oxidative stress and Fas-mediated apoptosis in motor neuron death
in SOD1G93A mice was previously focused on [96]. This study provided the first evidence that
combination therapy that targets oxidative stress and apoptosis together also delays the onset
and progression of motor dysfunction and extends the survival time of ALS transgenic mice.
Evidence was accumulated that shows that oxidative stress and apoptotic insults cause
neuronal death through distinctive pathways and with unique morphological changes. The
neurotrophins’ nerve growth factor, the brain-derived neurotrophic factor (BDNF), neurotro‐
phin 3 (NT-3), and NT-4/5, and the insulin-like growth factors IGF-I and IGF-II, promote
neuronal survival by preventing programmed cell death or apoptosis, but they significantly
enhance necrotic degeneration of neurons exposed to oxidative stress or deprived of oxygen
and glucose [199-200]. Neurotrophins can induce oxidative stress by upregulating NADPH
oxidase, which leads to neuronal cell necrosis [201]. Surprisingly, the insulin-like growth factor
1 (IGF-1) prevented neuronal cell apoptosis and protected spinal motor neurons in ALS mice
[199,202], but markedly potentiated neuronal cell necrosis induced by hydroxyl radicals or
glutathione depletion [203]. Given that oxidative stress and apoptosis play a central role in
motor neuron degeneration and can contribute to neuronal death through distinctive routes
in ALS, it was hypothesized that a therapeutic approach that targets both oxidative stress and
apoptosis would have additive effects on neuronal survival and the motor function. To
pharmacologically prevent oxidative stress and apoptosis, Neu2000, a novel anti-oxidant, and
Li+, a well-known anti-apoptosis agent, were used. The former, a chemical derivative of aspirin
and sulfasalazine, was developed to protect neurons from oxidative stress with greater potency
and safety, and has been shown to be a potent and secure anti-oxidant in vitro and in animal
models of hypoxic ischemia [204]. Li+ has been shown to prevent apoptosis through mecha‐
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nisms that involve Bcl-2 upregulation, glycogen synthase kinase-3 beta inhibition, and
activation of phosphatidylinositol 3-kinase that activates serine/threonine kinase Akt-1 and
phospholipase C gamma [205-206]. An additional benefit of Li+ was recently demonstrated
the induction of an autophagy pathway at a low dose, clears altered mitochondria and protein
aggregates [192]. In the results of this study, the concurrent administration of Neu2000 and Li
+, which block free-radical-mediated necrosis and Fas-mediated apoptosis, respectively,
significantly delayed the onset and progression of motor neuron degeneration and motor
function deficits. Thus, targeting both oxidative stress and the Fas apoptosis pathway with
concurrent treatment with Neu2000 and Li+ may further improve the neurological function
Figure 1. Multiple pathways of motor neuron degeneration and their therapeutic drugs in ALS: (1) increased Ca2+ in
the motor neuron: dysfunction or downregulation of glutamate transporters such as GLT1 on the astrocytes, elevation
of the Ca2+ permeable AMPA receptor via downregulation of or a deficit in the post-transcriptional edition of GluR2
sub-units, and mitochondrial dysfunction; (2) oxidative damage of the motor neuron: increased intracellular Ca2+ con‐
tents, high levels of mitochondria due to high energy demand, and increase in free metal ions such as copper and
iron; (3) apoptosis in the motor neuron: activation of the Fas-mediated pathway, alteration of Bcl-2 family proteins via
mitochondrial interaction with mSOD1, and initiation, propagation, or execution of caspase cascade; (4) inflamma‐
tion: non-cell-autonomous motor neuron death (the disease progression is coordinated by mSOD1 expression in all
neuronal and non-neuronal cells) and concurrent activation of the innate immune system and systemic inflammation
(BBB breakdown may induce a vicious cycle of inflammation); and (5) autophagy: increased autophagosome forma‐
tion.Current therapeutic drugs were developed basically against a specific route of ALS disease progression.
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and neuronal survival in ALS and possibly other neurological diseases such as stroke,
Alzheimer’s disease, and Parkinson’s disease. The authors’ hypothesis was supported by other
experiments in which a cocktail of neuroprotective drugs with different modes of action more
significantly improved survival and the motor function than did monotherapy in transgenic
mouse ALS models [117,207].
8.2. Current treatment and new approach of ALS medications
Riluzole, the only therapeutic drug approved for ALS, extends life expectancy to up to 3
months in human patients. The symptomatic drug potentially targets gluatamate- or oxidative-
stress-induced neurodegeneration with marginal apoptosis effects [25]. As mentioned,
Compound Dose Administrationroute Hypothetical mechanism Survival Reference
Creatine 1% diet Antioxidant 9% Klivenyi P et al., 1999 [78]
2% diet Antioxidant 17%
Creatine 2% diet Antioxidant 20% Klivenyi P et al., 2004 [169]
creatine 2% diet Antioxidant 12% Zhang W et al., 2003 [117]
Vitamin E 200 IU chow Antioxidant No effect Gurney ME et al., 1996 [125]
Edaravone 5 mg/kg ip Antioxidant 12.4% Ito H et al., 2008 [81]
15 mg/kg ip 17%
AEOL-10150 2.5 mg/kg ip Antioxidant 26% Crow JP et al., 2005 [80]
2.5 mg/kg sc 22%
N-acetylcysteine 2 mg/kg/d drinking water Antioxidant 7% Andreassen OA et al., 2000 [79]
TRO19622 (Olesoxime) 3 mg/kg sc Antioxidant 10% Bordet T et al., 2007 [209]
30 mg/kg sc 8%
Ammonium tetrathiomolybdate 5 mg/kg not described Antioxidant 25% Tokuda E et al., 2008 [210]
Neu2000 30 mg/kg diet Antioxidant 15% Shin et al., 2007 [96]
zVAD Antiapoptotic 22% Li et al., 2000 [111]
Cyclosporin A 18mg/kg intrathecal Antiapoptotic 12% Keep M et al., 2001 [211]
Minocycline 25 mg/kg ip Antiapoptotic/Anti-inflammatory 10%  Van Den Bosch L et al., 2002 [116]
50 mg/kg ip 15.8%
Minocycline 11 mg/kg Antiapoptotic/Anti-inflammatory 9% Zhu S et al., 2002 [115]
Minocycline 22mg/kg/d ip Antiapoptotic/Anti-inflammatory 13% Zhang W et al., 2003 [117]
Lithium 1 mEq/kg ip Antiapoptotic/Autophagy inducer 36% Fornai F et al., 2007 [192]
Lithium 60 mg/kg ip Antiapoptotic/Autophagy inducer 8% Feng H et al., 2008 [212]
Lithium 2% diet Antiapoptotic/Autophagy inducer 10% Shin et al., 2007 [96]
Celecoxib 1500ppm chow Anti-inflammatory 25% Drachman DB et al., 2002 [168]
Celecoxib 0.012% diet Anti-inflammatory 21% Klivenyi P et al., 2004 [169]
Thalidomide 50 mg/kg Anti-inflammatory 12% Kiaei M et al., 2006 [213]
100 mg/kg 16%
Glatiramer acetate 7ug/0.1 ml PBS immunization Anti-inflammatory 1.4% Banerjee R et al., 2008 [171]
AM1241 1 mg/kg ip Anti-inflammatory 3%
Celastrol 8 mg/kg diet Anti-inflammatory 13% Kiaei M et al., 2005 [213]
2 mg/kg 9.4%
Nordihydroguaiaretic acid 2500ppm po Anti-inflammatory 10% West M et al., 2004 [214]
RO-28-2653 100 mg/kg po Anti-inflammatory 11% Lorenzl S et al., 2006 [215]
Riluzole 100ug/ml drinking water Antiglutamatergic 10% Gurney ME et al., 1996 [117]
Riluzol 30 mg/kg drinking water Antiglutamatergic 11% Waibel et al., 2004 [224]
Gabapentin 3% chow Antiglutamatergic 5% Gurney ME et al., 1996 [117]
Memantine 10 mg/kg subcutaneus Antiglutamatergic 7% Wang et al., 2005 [216]
Memantine 30 mg/kg drinking water Antiglutamatergic 5% Joo IS et al., 2007 [26]
90 mg/kg drinking water 1%
vegf 1.0 ug/kg ip Antiglutamatergic 8% Zheng C et al., 2004 [217]
Lentiviral vecor Antiglutamatergic 30% Azzouz M et al., 2004 [218]
Ceftriaxone 200 mg/kg ip Antiglutamatergic 10% Rothstein JD et al., 2005 [219]
L-Arginine 6% drinking water Antiglutamatergic 20% Lee J et al., 2009 [220]
N-acetylated a-linked
acidic dipetidase
30 mg/kg po Antiglutamatergic 15% Ghadge GD et al., [221]
Table 1. List of drugs tested with ALS mice
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nisms that involve Bcl-2 upregulation, glycogen synthase kinase-3 beta inhibition, and
activation of phosphatidylinositol 3-kinase that activates serine/threonine kinase Akt-1 and
phospholipase C gamma [205-206]. An additional benefit of Li+ was recently demonstrated
the induction of an autophagy pathway at a low dose, clears altered mitochondria and protein
aggregates [192]. In the results of this study, the concurrent administration of Neu2000 and Li
+, which block free-radical-mediated necrosis and Fas-mediated apoptosis, respectively,
significantly delayed the onset and progression of motor neuron degeneration and motor
function deficits. Thus, targeting both oxidative stress and the Fas apoptosis pathway with
concurrent treatment with Neu2000 and Li+ may further improve the neurological function
Figure 1. Multiple pathways of motor neuron degeneration and their therapeutic drugs in ALS: (1) increased Ca2+ in
the motor neuron: dysfunction or downregulation of glutamate transporters such as GLT1 on the astrocytes, elevation
of the Ca2+ permeable AMPA receptor via downregulation of or a deficit in the post-transcriptional edition of GluR2
sub-units, and mitochondrial dysfunction; (2) oxidative damage of the motor neuron: increased intracellular Ca2+ con‐
tents, high levels of mitochondria due to high energy demand, and increase in free metal ions such as copper and
iron; (3) apoptosis in the motor neuron: activation of the Fas-mediated pathway, alteration of Bcl-2 family proteins via
mitochondrial interaction with mSOD1, and initiation, propagation, or execution of caspase cascade; (4) inflamma‐
tion: non-cell-autonomous motor neuron death (the disease progression is coordinated by mSOD1 expression in all
neuronal and non-neuronal cells) and concurrent activation of the innate immune system and systemic inflammation
(BBB breakdown may induce a vicious cycle of inflammation); and (5) autophagy: increased autophagosome forma‐
tion.Current therapeutic drugs were developed basically against a specific route of ALS disease progression.
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and neuronal survival in ALS and possibly other neurological diseases such as stroke,
Alzheimer’s disease, and Parkinson’s disease. The authors’ hypothesis was supported by other
experiments in which a cocktail of neuroprotective drugs with different modes of action more
significantly improved survival and the motor function than did monotherapy in transgenic
mouse ALS models [117,207].
8.2. Current treatment and new approach of ALS medications
Riluzole, the only therapeutic drug approved for ALS, extends life expectancy to up to 3
months in human patients. The symptomatic drug potentially targets gluatamate- or oxidative-
stress-induced neurodegeneration with marginal apoptosis effects [25]. As mentioned,
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therapeutic strategies and drugs developed based on them, as shown in Figure 1, explain the
multiple-disease-causing process of ALS. As shown in Table 1, many drugs were evaluated in
mice that expressed mutant SOD1. Most of the drugs were beneficial to the motor function
and survival in the tests with the mice. Several drugs (such as creatine, celecoxib, gabapentin,
topiramate, lamotrigine, minocycline, thalidomide, valproate, vitamin E, and even lithium)
showed beneficial effects in animal ALS models, but none of them significantly prolonged the
survival or improved the quality of life of human ALS patients. The therapeutic effects on the
animal models and the human patients significantly differed due to the following translational
mismatch issues: first, the methological inappropriateness of the drug screening with the use
of animals that had biological confounding variables such as sex and differences in the
treatment initiation time point; second, the lack of correct pharmacokinetics, which were
considered in a dose-ranging study of safety/toxicity and BBB penetration; and finally, the
methodological pitfall of ALS clinical trials due to the insufficiency of the number of patients,
the inclusion of heterogeneous populations, the short duration of the trial, and the inadequate
analysis of the efficacy. It should be noted that the combination of creatine and celecoxib
improved the motor function in a randomized clinical phase II trial of ALS patients and
SOD1G93A mice, although single treatment with either creatine or celecoxib failed to show
beneficial effects in human ALS trials [208], which suggests the greater efficacy of combined
anti-oxidant and NSAID therapy than those of monotherapy. Several pieces of evidence
support the notion that therapeutic combinations are more effective than individual agents in
animal ALS models (Table2). More recently, the authors reported that a single agent named
Compound Dose Survival Reference
Creatine 2% 12% Zhang W et al., 2003 [117]
Minocycline 22mg/kg 13%
Creatine/Minocycline 25%





Rasagiline 2 mg/kg 14% Waibel et al., 2004 [224]
Riluzol 30 mg/kg 11%
Rasagiline/Riluzol 20%
Neu2000 30 mg/kg 15% Shin et al., 2007 [96]
Lithium 2% 10%
Neu2000/Lithium 2% 22%
Lithium 60 mg/kg 8% Feng H et al., 2008 [212]
Valproic acid 300 mg/kg 10%
Lithium/ VPA 15%
Riluzole 7.5% Del Signore Sj et al., 2009 [222]
Sodium phenylbutyrate 12.8%
Riluzole/Sodium phenylbutyrate 21.5%
 Minocycline/ Riluzole/ Nimodipine 80 + 40 +30 (mg/kg) 13% Kriz et al., 2003 [223]
Table 2. Additive effect of combination therapy in ALS mice
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AAD-2004, which has a dual mode of action as an anti-oxidant and an mPGES-1 inhibitor, had
better efficacy on the motor function and survival than those of riluzole and ibuprofen.
In support of such a notion, a phase II clinical trial was recently conducted, which showed that
the suggested strategy may be feasible and efficient.
9. Conclusion
In ALS, knowledge of the contribution of multiple pathways to the degeneration of motor
neurons has expanded greatly and has challenged clinical trials of drugs that target the
processes. Better understanding of the detrimental processes that cause neurodegeneration
will help define its medical importance and clarify the therapeutic potential of interfering with
them.
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therapeutic strategies and drugs developed based on them, as shown in Figure 1, explain the
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and survival in the tests with the mice. Several drugs (such as creatine, celecoxib, gabapentin,
topiramate, lamotrigine, minocycline, thalidomide, valproate, vitamin E, and even lithium)
showed beneficial effects in animal ALS models, but none of them significantly prolonged the
survival or improved the quality of life of human ALS patients. The therapeutic effects on the
animal models and the human patients significantly differed due to the following translational
mismatch issues: first, the methological inappropriateness of the drug screening with the use
of animals that had biological confounding variables such as sex and differences in the
treatment initiation time point; second, the lack of correct pharmacokinetics, which were
considered in a dose-ranging study of safety/toxicity and BBB penetration; and finally, the
methodological pitfall of ALS clinical trials due to the insufficiency of the number of patients,
the inclusion of heterogeneous populations, the short duration of the trial, and the inadequate
analysis of the efficacy. It should be noted that the combination of creatine and celecoxib
improved the motor function in a randomized clinical phase II trial of ALS patients and
SOD1G93A mice, although single treatment with either creatine or celecoxib failed to show
beneficial effects in human ALS trials [208], which suggests the greater efficacy of combined
anti-oxidant and NSAID therapy than those of monotherapy. Several pieces of evidence
support the notion that therapeutic combinations are more effective than individual agents in
animal ALS models (Table2). More recently, the authors reported that a single agent named
Compound Dose Survival Reference
Creatine 2% 12% Zhang W et al., 2003 [117]
Minocycline 22mg/kg 13%
Creatine/Minocycline 25%





Rasagiline 2 mg/kg 14% Waibel et al., 2004 [224]
Riluzol 30 mg/kg 11%
Rasagiline/Riluzol 20%
Neu2000 30 mg/kg 15% Shin et al., 2007 [96]
Lithium 2% 10%
Neu2000/Lithium 2% 22%
Lithium 60 mg/kg 8% Feng H et al., 2008 [212]
Valproic acid 300 mg/kg 10%
Lithium/ VPA 15%
Riluzole 7.5% Del Signore Sj et al., 2009 [222]
Sodium phenylbutyrate 12.8%
Riluzole/Sodium phenylbutyrate 21.5%
 Minocycline/ Riluzole/ Nimodipine 80 + 40 +30 (mg/kg) 13% Kriz et al., 2003 [223]
Table 2. Additive effect of combination therapy in ALS mice
Current Advances in Amyotrophic Lateral Sclerosis50
AAD-2004, which has a dual mode of action as an anti-oxidant and an mPGES-1 inhibitor, had
better efficacy on the motor function and survival than those of riluzole and ibuprofen.
In support of such a notion, a phase II clinical trial was recently conducted, which showed that
the suggested strategy may be feasible and efficient.
9. Conclusion
In ALS, knowledge of the contribution of multiple pathways to the degeneration of motor
neurons has expanded greatly and has challenged clinical trials of drugs that target the
processes. Better understanding of the detrimental processes that cause neurodegeneration
will help define its medical importance and clarify the therapeutic potential of interfering with
them.
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1. Introduction
Amyotrophic Lateral Sclerosis, generally known as ALS, is a lethal neurodegenerative disease
that gradually affects the motor neurons (nerve cells) which control muscle movement. The
causes of the disease are as yet unknown and the substantial amount of research currently
under way has found that the causes of ALS are multifactorial, such as genetic predisposition.
In fact, about the involvement of genetic, ALS is a multigenic disease result from mutations in
more than one gene (Table 1). The annual incidence of ALS is 0,4-1,76 per 100000 [1]. The
majority of cases of ALS are sporadic (90-95%), called SALS. Around 5-10% of cases are
considered to be familial (FALS), where the disease is present in both a proband and first-
degree or second-degree relative [2-3]. FALS is usually inherited in an autosomal dominant
manner, though there are rare cases of autosomal recessive disease. FALS is genetically
heterogeneous, including 15 mapped loci, of which the causative genes are identified for 11.
Mutations in several of the known FALS genes have also been described in apparently sporadic
cases of ALS at low frequencies. Genetic changes detected in sporadic cases arise both from
new mutations and also lack of evidence of inheritance due to the difficulty in recognizing a
genetic component to rapidly lethal late-onset disease. The systematic, detailed diagnosis of
neurological disease in older people is a modern, and still incomplete, medical phenomenon.
For any late-onset disorder both incomplete penetrance and premature death of earlier
generations due to other causes attenuates the expression of disease within a family so that in
many examples where apparently sporadic ALS is associated with genetic mutation there is
limited information about the family rather than a clear demonstration of unequivocally de
novo genetic change [4].
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ALS type Onset Inheritance Locus Gene Protein
ALS1 Adult AD 21q22.1 SOD1 Cu/Zn superoxide dismutase
ALS2 Juvenile AR 2q33-35 ALS2 Alsin
ALS3 Adult AD 18q21 Unknown
ALS4 Juvenile AD 9q34 SETX Senataxin
ALS5 Juvenile AR 15q15-21 SPG11 Spatacsin
ALS6 Adult AD 16p11.2 FUS Fused in sarcoma
ALS7 Adult AD 20p13 Unknown
ALS8 Adult AD 20q13.33 VAPB VAMP-associated protein B
ALS9 Adult AD 14q11 ANG Angiogenin
ALS10 Adult AD 1q36 TARDBP TAR DNA-binding protein
ALS11 Adult AD 6q21 FIG4 PI(3,5)P(2)5-phosphatase
ALS12 Adult AR/AD 10p15p14 OPTN Optineurin
ALS-FTD1 Adult AD 9q21-22 Unknown
ALS-FTD2 Juvenile AD 9p13.2-21.3 Unknown
ALS-FTD3 Adult AD 9p21 C9Orf72 C9Orf72
Table 1. Genes and loci associated with ALS.
Discoveries in the clinical genetics of ALS in particular offer opportunities to deepen under‐
standing of various disease phenotypes that appear to share aspects of pathogenesis, confirm
previous hypothesis around the concept of disease spectra, in terms of linkage to a specific
proteinopathy, and increase the scope of pathological studies of human motor system disease.
Genetic factors may play a role in determining the range of ALS phenotypes although to date
no genes have been shown to have a definite effect on phenotype [4]. In fact the genetic
alteration is not the only factor that determines the clinical course of the disease, other factors
must also contribute to phenotype and it is not yet possible to predict the evolution of patients
based solely on presence of the mutation or rate of progression in other family members.
The diagnosis of ALS is based on the original El Escorial diagnostic criteria, revised from 2000
[5-6].
It is a generally accepted notion that the clinical spectrum of ALS includes different phenotypes
marked by a varying involvement of spinal and bulbar upper and lower motor neurons.
Accordingly, eight distinctive clinical phenotypes are recognised in the literature: classic,
bulbar, flail arm, flail leg, pyramidal, respiratory, pure lower motor neuron, pure upper motor
neuron.
a. Classic ALS phenotype is characterised by onset of symptomps in the upper or lower
limbs, with clear but not predominant pyramidal signs. It is the commonest phenotype in
men and the second in women, with a peak of incidence rate in the seventh decade in both
Current Advances in Amyotrophic Lateral Sclerosis74
genders. 0-5% of cases have frontotemporal dementia. Median survival time is 2,5 years
[4].
b. Bulbar phenotype starts with dysarthria, dysphagia, tongue wasting, fasciculation and no
peripheral spinal involvement for the first 6 months after symptomps onset; pyramidal
signs aren’t required to be evident in the first period but needs to be evident therafter.
This subtype has the same incidence in the two genders, with peak of incidence in the
eighth decade. It is the commonest phenotype associated with frontotemporal dementia
(10%). Median survival time is 2 years [4]. It is now accepted that FTD and MND are part
of the same clinicopathological spectrum. Frontotemporal dementia is characterised
clinically by progressive behavioural changes and frontal executive deficits and/or
selective language difficulties. The presence of FTD is determined using a screening test,
such as FAB (frontal assessment battery), and is based on Neary criteria [7-8]. Frontotem‐
poral dementia is present in about 5-10% of patients, however many ALS patients have
evidence of FTD behavioural dysfunction that may not satisfy Neary criteria for FTD.
Patients often have bulbar phenotype with muscle atrophy, weakness and fasciculations
prominent in the tongue and also in the upper extremities.
c. Flail arm phenotype is characterised by progressive, predominantly proximal, weakness
and wasting in the upper limbs and functional involvement has to be confined in this parts
for at least 12 months after symptomps onset. This phenotype is relatively rare and more
common in men, often benign with a median survival time of 4 years. Frontotemporal
dementia is rare in this phenotype [4].
d. Flail leg begins with progressive distal onset of symptomps in lower limbs. Patients with
symptomps beginning proximally in the legs without distal involvement at onset are
classified as classic ALS. This type of disease has the same incidence in two genders. Mean
age of onset is about 65 years and the peak of incidence rate is in the eighth decade. Median
survival time is 3 years [4].
In two last categories there are forms with pathological deep tendon reflexes or Hoffmann and
Babinski sign but without hypertonia or clonus.
e. Patients with pyramidal phenotype have manifestations dominated by severe spastic
para/tertaparesis associated with Babinski or Hoffmann sign, hyperactive reflexes, clonic
jaw jerk, dysarthric speech and pseudobulbar affect. Spastic paresis could be present at
the beginning or in the fully developed stage of the disease. These patients show at the
same time clear-cut signs of lower motor neuron impairment from onset of the disease,
as indicated by muscle weakness and wasting and by the presence of chronic and active
denervation at the EMG examination in at least two different sites. Patients have a quite
young age at onset, under 60 years. Both genders are equally represented. FTD is uncom‐
mon and median survival time is 6 years [4].
f. There is a particular and the rarest phenotype with respiratory impairment at onset,
defined as orthopnoea or dyspnoea at rest or during exertion, with only mild spinal or
bulbar signs in the fisrt 6 months after onset. These patients show signs of upper motor
neuron involvement. Median survival time is 1,5 years, with the worst prognosis [4].
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Accordingly, eight distinctive clinical phenotypes are recognised in the literature: classic,
bulbar, flail arm, flail leg, pyramidal, respiratory, pure lower motor neuron, pure upper motor
neuron.
a. Classic ALS phenotype is characterised by onset of symptomps in the upper or lower
limbs, with clear but not predominant pyramidal signs. It is the commonest phenotype in
men and the second in women, with a peak of incidence rate in the seventh decade in both
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genders. 0-5% of cases have frontotemporal dementia. Median survival time is 2,5 years
[4].
b. Bulbar phenotype starts with dysarthria, dysphagia, tongue wasting, fasciculation and no
peripheral spinal involvement for the first 6 months after symptomps onset; pyramidal
signs aren’t required to be evident in the first period but needs to be evident therafter.
This subtype has the same incidence in the two genders, with peak of incidence in the
eighth decade. It is the commonest phenotype associated with frontotemporal dementia
(10%). Median survival time is 2 years [4]. It is now accepted that FTD and MND are part
of the same clinicopathological spectrum. Frontotemporal dementia is characterised
clinically by progressive behavioural changes and frontal executive deficits and/or
selective language difficulties. The presence of FTD is determined using a screening test,
such as FAB (frontal assessment battery), and is based on Neary criteria [7-8]. Frontotem‐
poral dementia is present in about 5-10% of patients, however many ALS patients have
evidence of FTD behavioural dysfunction that may not satisfy Neary criteria for FTD.
Patients often have bulbar phenotype with muscle atrophy, weakness and fasciculations
prominent in the tongue and also in the upper extremities.
c. Flail arm phenotype is characterised by progressive, predominantly proximal, weakness
and wasting in the upper limbs and functional involvement has to be confined in this parts
for at least 12 months after symptomps onset. This phenotype is relatively rare and more
common in men, often benign with a median survival time of 4 years. Frontotemporal
dementia is rare in this phenotype [4].
d. Flail leg begins with progressive distal onset of symptomps in lower limbs. Patients with
symptomps beginning proximally in the legs without distal involvement at onset are
classified as classic ALS. This type of disease has the same incidence in two genders. Mean
age of onset is about 65 years and the peak of incidence rate is in the eighth decade. Median
survival time is 3 years [4].
In two last categories there are forms with pathological deep tendon reflexes or Hoffmann and
Babinski sign but without hypertonia or clonus.
e. Patients with pyramidal phenotype have manifestations dominated by severe spastic
para/tertaparesis associated with Babinski or Hoffmann sign, hyperactive reflexes, clonic
jaw jerk, dysarthric speech and pseudobulbar affect. Spastic paresis could be present at
the beginning or in the fully developed stage of the disease. These patients show at the
same time clear-cut signs of lower motor neuron impairment from onset of the disease,
as indicated by muscle weakness and wasting and by the presence of chronic and active
denervation at the EMG examination in at least two different sites. Patients have a quite
young age at onset, under 60 years. Both genders are equally represented. FTD is uncom‐
mon and median survival time is 6 years [4].
f. There is a particular and the rarest phenotype with respiratory impairment at onset,
defined as orthopnoea or dyspnoea at rest or during exertion, with only mild spinal or
bulbar signs in the fisrt 6 months after onset. These patients show signs of upper motor
neuron involvement. Median survival time is 1,5 years, with the worst prognosis [4].
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g. Pure lower motor neuron phenotype is characterised by clinical and electrophysiological
evidence of progressive LMN involvement. Patients with family history of inherited
spinal muscular atrophy are excluded. It has a low incidence rate and is twice as frequent
in men. Patients with this form are younger than those with any other ALS phenotype,
with a peak of incidence rate in the seventh decade among men and in the sixth decade
among women. Nobody has FTD and mean survival is the longest (7 years) [4].
h. Patients with pure upper motor neuron have signs of UMN involvement (severe spastic
para/tertaparesis associated with Babinski or Hoffmann sign, hyperactive reflexes, clonic
jaw jerk, dysarthric speech and pseudobulbar affect). Patients with clinical or EMG signs
of LMN involvement or with history of spastic para/tetraparesis in family such as
hereditary spastic paraplegia are excluded. It has a low incidence rate with peak in the
sixth decade in both genders, Median survival time is the longest among ALS phenotype
(more than 10 years) [4].
Table 2. Mean age at onset, mean time delay from onset to diagnosis and frequency of frontotemporal dementia [4].
Table 3. Amyotrophic lateral sclerosis phenotypes. Overall and men versus women mean annual crude incidence
raters (/100000 population), 95% CIs and gender incidence rate ratios [4].
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In this chapter we would deep investigate the correlation between genetic and clinical features
in the ALS population that we better know, the Italian one. However, heterogeneity between
and among families implies that other environmental and genetic influences contribute to not
only the rate of evolution and which signs predominate but also whether the disease will
appear at all during life. Considerable work lies ahead in determining the genetic and
environmental factors that most contribute to ALS. Altogether one determinant of ALS
phenotype is the underlying causative mutation.
We will focus this book section on the correlation between genotype and phenotype in Italian
ALS disease population. This chapter will be organized in different paragraphs about the genes
mostly mutated in Italian ALS patients, SOD1, FUS, TARDBP, ANG, C9orf72 and OPTN genes
(Table 2), and each paragraphs will be subdivided in two parts about genotype and phenotype.
Moreover we will try to define and understand particular connection between phenotype and
genotype in Italian population and in our experience in Pavia to characterize the Italian ALS
population in relation to the genetic aspects.
Obviously in literature different mutations are known for every genes and many other ones
will be discovered in future.
In this chapter we cannot deepen the importance of every mutation in relation to the pheno‐
typic characteristic of ALS patients.
For this reason in this book section we will develop speech on more frequent alterations and
on which we have met during our daily activity in Pavia or in our collaborations with other
groups.
2. Cu/Zn Superoxide Dismutase (SOD1 gene)
Superoxide dismutase [Cu-Zn] also known as superoxide dismutase 1 or SOD1 is a soluble
protein acting as a 32 kDa homodimeric enzyme. SOD1 is one of three human superoxide
dismutases.
Its main function is the conversion, naturally occurring, but harmful, superoxide radicals to
molecular oxygen and hydrogen peroxide.
SOD1 binds copper and zinc ions and is one of three superoxide dismutases responsible for
destroying free superoxide radicals in the body. The encoded isozyme is a soluble cytoplasmic
and mitochondrial inter-membrane space protein, acting as a homodimer to convert naturally
occurring, but harmful, superoxide radicals to molecular oxygen and hydrogen peroxide
2.1. Genotype
The human SOD1 gene (Entrez Gene ID 6647) is located on chromosome 21q22.11, and it codes
for the monomeric SOD1 polypeptide (153 amino acids, molecular weight 16 kDa).
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In 1991, Siddique and collaborators [15] identified a linkage between familial ALS and the
SOD1 locus on chromosome 21q22 and demonstrated genetic locus heterogeneity in FALS
studying 23 ALS families.
In 1993, Rosen and collaborators [16] have reported tight genetic linkage between ALS and
SOD1 gene, establishing SOD1 as the first causative gene for ALS. More than 150 SOD1
mutations have been reported in 68 of the 153 codons, spread over all five exons (ALS Online

















SOD1 FUS TARDBP ANG C9orf72 OPTN non-mutated Other genes (VAPB, FIG4, SPG11, PFN1)
Figure 1. Summarize the percentage of mutations in Italian ALS patients, (a) SALS, (b) FALS [2, 9, 10, 11, 12, 13, 14].
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The vast majority of which are missense substitutions distributed throughout the five exons
of the gene. Also frame-shift deletions and insertions, all clustered in exons 4 and 5, which lead
to a premature truncation of the protein have been described (Figure 2).
Collectively,  SOD1  mutations  are  found  in  ~20%  of  all  FALS  patients,  and  in  ~3%  of
SALS cases [17].
In Italian ALS population, different screening have been performed [2, 18] and both confirmed
that the percentage of mutation in SOD1 gene in Italian SALS was 4.5%.
About FALS the percentage of SOD1-mutated FALS patients was 14.7% [18]. In the most recent
screening of 480 SALS patients in 48 FALS has been found that the percentage of mutations
was totally 2.1% [19].
Novel mutations are continuous discovered, the last one in Italian patient has been described
in January 2012 [20].
Figure 2. Distribution of SOD1 mutations detected in sporadic ALS patients.
2.2. Phenotype
Patients with SOD1 mutations, FALS and SALS, show a phenotypic heterogeneity even within
the same mutation although some sporadic missense mutations carry a consistently worse or
better prognosis. A lot of mutations have been described during the time, we have focused in
this paragraph on the most interesting in the Italian population for eventually presence of
correlation between genotype and phenotype, both for FALS and SALS.
Patients with FALS and G41S mutations have similar clinical phenotype with early upper and
lower motor neuron involvement in one or both lower limbs, rapidly spreading to upper limbs,
appearance of bulbar signs within 1 years and death a few months later [21].
In 2010 Battistini et al. [22] described a family with 9 members ALS affected, in which there
was evidence of a missense mutation in exon 4 (L106F) in SOD1 gene. In this family there was
autosomal dominant inheritance. The clinical presentation was characterized by relatively
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early age of onset, spinal onset with proximal distribution weakness, bulbar involvement and
a rapid disease course about two years.
Another mutation, L106P, has been found in a patient who presented similar clinical pattern
with spinal onset with weakness mainly in proximal areas; however in this patient, 30 months
after disease onset, weakness remained restricted to the upper limbs without pyramidal signs
and it was consistent with brachial amyotrophic diplegia, a relatively slowly progressive
variant of motor neuron disease [23].
Corrado et al. [2] suggested that the nonsense mutation in exon 5 was present in SALS patients
with severe and rapid clinical course, analogous to what found for most SOD1 mutations
leading to a truncated protein. Conversely, N65S and A95T are both associated to a slowly
progressive course of the disease, similarly to other mutations (H46R, D76V, H13T, L144P,
G93V, I151T, D90A, A89T) detected in patients with a disease duration >10 years. In addition
N65S seems to be strictly correlated to a prevalent involvement of the lower motor neurons
and only at the spinal cord.
In 2011 in their article, Del Grande et al. [3] showed a similar phenotype in three unrelated
patients with sporadic SOD1 mutation D11Y: slow progression, initial distal limbs muscles
involvement and predominant lower motor neurons signs. The topographic distribution in
distal muscles was a constant feature over many years, with only late impairment of proximal
or bulbar muscles (respiratory muscles involvement after 7-10 years). All three patients had
slight pyramidal signs (hyperactive reflexes, Babinski sign without increase of muscular tone).
In 2011 Luigetti et al. [24] described a strange case report of a sporadic patient with SOD1 G93D
mutation disclosing a rapid progression of the disease. The beginning of symptoms was
weakness in upper limbs, without involvement of lower limbs or bulbar functions. Over a 2-
year-follow up the patient showed a rapidly progressive course with involvement of lower
limbs, bulbar and respiratory muscles and the patient died after 30 months since the onset.
This case is in contrast with literature data [25-27]: other patients with SOD1 mutation (FALS)
presented a slowly progressive diseas with a long-lasting paucisymptomatic phase. The
authors discovered a novel heterozygous ANG missense mutation (c. 433 C>T, p.R145C), so
they hypothesised a role in pathogenesis and clinical phenotype [24].
Penco et al. [28] described a family with same mutation of SOD1, in which there was wide
variability of disease expression among family members. The ANG IVS1+27 variant in the
heterozygous state was found in the proband that disclosed an aggressive clinical course.
Though this variant occurred in noncoding region and no prediction of splicing alteration was
made, the authors speculated that this variant contributed to the clinical phenotype.
These findings support a possible pathogenetic role of ANG mutation with influence on clinical
manifestations in patient with SOD1 mutation.
Often bulbar onset is associated with older age of disease presentation without significant
difference of distribution between FALS and SALS [21].
These data are confirmed by international literature [29-32].
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3. TAR DNA-Binding Protein 43 (TARDBP gene)
TAR DNA-binding protein 43 is homologous to the heterogeneous nuclear ribonucleoproteins
(hnRNPs) [33], which are involved in RNA processing, and its abnormal cellular distribution
is one of the key feature of ALS and frontotemporal lobar degeneration (FTLD) [34].
The protein is highly conserved, widely expressed and predominantly localized to the nucleus
with a very small amount being present in the cytoplasm [34-35].
3.1. Genotype
The human TARDBP gene (Entrez Gene ID 23435) is located on chromosome 1p36.22, and it
codes for a protein of 414 amino acids.
Mutations in TARDBP gene associated with ALS disease have been discovered fro the first
time in 2008 [34, 36].
The proposed mutational frequency is ~5% for FALS and 0.5-2% for SALS. To date, more than
30 different TARDBP mutations have been described, all of which are missense substitutions.
With a single exception, all of them are clustered in the C-terminal glycine-rich region encoded
by exon 6. The most common mutation is A382T.
Mutations in TARDBP gene associated with ALS disease have been discovered fro the first
time in 2009 and in the same year a Italian screening has been performed [9]. The Italian results
showed a higher frequency of TARDBP mutations in SALS Italian patients compared to
individuals of mainly Northern European origin (2.7% vs. 1%).
The frequency of mutations in TARDBP gene in Italian patients (4.4%) are similar to other
population studies (about 3 to 4% of FALS cases) [37, 38].
Most TARDBP mutations are missense changes in exon 6, encoding for Gly-rich C-terminal
region that allows to bind single-stranded DNA, RNA and proteins [39, 40] (Figure 3).
Figure 3. Distribution of TDP-43 mutations detected in sporadic ALS patients [41].
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Many individuals who present with a pure ALS phenotype also develop pathological features
of FTD and vice versa. Recently TDP-43 is identified as the major protein of inclusions in FTD
and ALS brain tissues, suggesting that both degenerative diseases belong to a clinio-patho‐
logical spectrum of overlapping central nervous system disorders. Dominant mutations in the
gene encoding the deposited protein account for at least some cases of these diseases.
Corrado et al. [9] described 12 different missense mutations in TARDBP, all located in exon 6,
in 18 patients with ALS, both FALS and SALS. Patients don’t share a homogeneous clinical
phenotype: the average age at onset is 53,2 +/- 14,5 years, the site of onset is mainly spinal
(88%), disease duration varies from 17 to 87 months. But in contrast to what is expected from
the similarity of TDP-43 pathological deposits in ALS and FTD, none of patients tested
worldwide with FTD carried TARDBP mutations. On the contrary, a TARDBP mutation
(p.G294V) is discovered in patients with ALS and dementia of Alzheimer type. He developed
dementia 3 years before the onset of MND. It is possible that the concurrence of the two diseases
is only by chance.
Piaceri et al. [42] described clinical heterogeneity in patients with ALS and mutations in
TARDBP. Age at onset is between 49 and 62 years, site of onset is both spinal and bulbar with
different involvement of upper or lower motor neuron, disease duration varies from 9 to 85
years. Nobody has FTD. One patient has p.ALA382Thr mutation in exon 6.
In literature also [9, 36] this mutation is associated with some differences in phenotype, that
are in site of onset (bulbar-spinal in France and spinal in Italy), disease duration (28-73 months
in France, 17-60 months in Italy) and age at onset (50 years in France, 32-69 years in Italy).
Italian and French patients shared a common haplotype with allele D1S2667 and D1S489, so
there was a common founder for the mutation.
Literature datas [43] suggested that in TARDBP patients site of onset is in the upper limbs,
with both upper and lower motor neuron signs but with disease progression lower signs
became predominant. Age at onset is mean of 54 years, disease duration mean of 58 months.
Some patients presented cognitive impairment that met criteria for FTD.
4. Fused in Sarcoma, Translocated in LipoSarcoma (FUS/TLS gene)
Fused in Sarcoma, Translocated in LipoSarcoma (FUS/TLS) is a heterogeneous ribonucleo‐
protein (hnRNP) that is involved, as TARDBP, in RNA splicing, transportation and stabiliza‐
tion [38, 44]. FUS/TLS (fused in sarcoma/translocated in liposarcoma) was initially identified
by investigators as a component of fusion proteins found in a variety of cancers such as myxoid
liposarcoma, acute myeloid leukemia, and Ewing’s tumour. More recently, researchers have
found several mutations of FUS/TLS in ALS and FTLD (frontotemporal lobar degeneration)
patients that causes cytoplasmic mislocalization of FUS/TLS.
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4.1. Genotype
The human FUS/TLS gene (Entrez Gene ID 2521) is located on chromosome 16p11.2, and it
codes for a protein of 525 amino acids.
Mutations in FUS/TLS gene in ALS patients have been discovered for the first time in 2009 [37,
45], as TARDBP.
Following the original reports [37, 45], several other groups identified additional variants in
ALS cohorts of different ethnicities, proposing an overall mutational frequency of ~4% in FALS
and ~1% in SALS [46, 47, 48].
To date more than 30 different mutations have been described, the vast majority of which are
missense substitutions and the rest are frameshift or nonsense mutations (Figure 3).
In the next year a Italian screening has been performed [10]. The results of the Italian screening
are in accord with the interanation screening. The Italian data showed that the percentage of
FUS missense mutations is 0.7% of Italian SALS cases, 4.4% in FALS.
Figure 4. Distribution of FUS mutations detected in sporadic ALS patients [41].
4.2. Phenotype
In 2010 Corrado et al. [10] identified 9 SALS or FALS patients carrying FUS missense mutations.
Site of onset was both in upper and lower limbs, age at onset was lower (median 50 years).
One of these patients with sporadic ALS and FUS mutation presented, at the age of 34, bilateral
scapular girdle muscle weakness with unusual neck flexor/extensor muscle weakness with
cramps and fasciculations, no weakness in the lower limbs has been demonstrated. Another
patient with FALS and FUS mutation, at the age of 54, slowly developed weakness of the neck
flexor/extensor muscles and bilateral scapular girdle and proximal upper limb muscle
weakness, with subsequent impairment of the pelvic girdle, no bulbar involvement has been
shown but slight proximal weakness in the lower limbs; one year after onset, the symptoms
extended to the bulbar region. So these two patients developed an unusual proximal sym‐
metrical upper limbs onset and axial involvement.
Ticozzi N et al. in 2009 [49] described two patients with FALS and mutation of FUS that
presented the same clinical phenotype.




Many individuals who present with a pure ALS phenotype also develop pathological features
of FTD and vice versa. Recently TDP-43 is identified as the major protein of inclusions in FTD
and ALS brain tissues, suggesting that both degenerative diseases belong to a clinio-patho‐
logical spectrum of overlapping central nervous system disorders. Dominant mutations in the
gene encoding the deposited protein account for at least some cases of these diseases.
Corrado et al. [9] described 12 different missense mutations in TARDBP, all located in exon 6,
in 18 patients with ALS, both FALS and SALS. Patients don’t share a homogeneous clinical
phenotype: the average age at onset is 53,2 +/- 14,5 years, the site of onset is mainly spinal
(88%), disease duration varies from 17 to 87 months. But in contrast to what is expected from
the similarity of TDP-43 pathological deposits in ALS and FTD, none of patients tested
worldwide with FTD carried TARDBP mutations. On the contrary, a TARDBP mutation
(p.G294V) is discovered in patients with ALS and dementia of Alzheimer type. He developed
dementia 3 years before the onset of MND. It is possible that the concurrence of the two diseases
is only by chance.
Piaceri et al. [42] described clinical heterogeneity in patients with ALS and mutations in
TARDBP. Age at onset is between 49 and 62 years, site of onset is both spinal and bulbar with
different involvement of upper or lower motor neuron, disease duration varies from 9 to 85
years. Nobody has FTD. One patient has p.ALA382Thr mutation in exon 6.
In literature also [9, 36] this mutation is associated with some differences in phenotype, that
are in site of onset (bulbar-spinal in France and spinal in Italy), disease duration (28-73 months
in France, 17-60 months in Italy) and age at onset (50 years in France, 32-69 years in Italy).
Italian and French patients shared a common haplotype with allele D1S2667 and D1S489, so
there was a common founder for the mutation.
Literature datas [43] suggested that in TARDBP patients site of onset is in the upper limbs,
with both upper and lower motor neuron signs but with disease progression lower signs
became predominant. Age at onset is mean of 54 years, disease duration mean of 58 months.
Some patients presented cognitive impairment that met criteria for FTD.
4. Fused in Sarcoma, Translocated in LipoSarcoma (FUS/TLS gene)
Fused in Sarcoma, Translocated in LipoSarcoma (FUS/TLS) is a heterogeneous ribonucleo‐
protein (hnRNP) that is involved, as TARDBP, in RNA splicing, transportation and stabiliza‐
tion [38, 44]. FUS/TLS (fused in sarcoma/translocated in liposarcoma) was initially identified
by investigators as a component of fusion proteins found in a variety of cancers such as myxoid
liposarcoma, acute myeloid leukemia, and Ewing’s tumour. More recently, researchers have
found several mutations of FUS/TLS in ALS and FTLD (frontotemporal lobar degeneration)
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4.1. Genotype
The human FUS/TLS gene (Entrez Gene ID 2521) is located on chromosome 16p11.2, and it
codes for a protein of 525 amino acids.
Mutations in FUS/TLS gene in ALS patients have been discovered for the first time in 2009 [37,
45], as TARDBP.
Following the original reports [37, 45], several other groups identified additional variants in
ALS cohorts of different ethnicities, proposing an overall mutational frequency of ~4% in FALS
and ~1% in SALS [46, 47, 48].
To date more than 30 different mutations have been described, the vast majority of which are
missense substitutions and the rest are frameshift or nonsense mutations (Figure 3).
In the next year a Italian screening has been performed [10]. The results of the Italian screening
are in accord with the interanation screening. The Italian data showed that the percentage of
FUS missense mutations is 0.7% of Italian SALS cases, 4.4% in FALS.
Figure 4. Distribution of FUS mutations detected in sporadic ALS patients [41].
4.2. Phenotype
In 2010 Corrado et al. [10] identified 9 SALS or FALS patients carrying FUS missense mutations.
Site of onset was both in upper and lower limbs, age at onset was lower (median 50 years).
One of these patients with sporadic ALS and FUS mutation presented, at the age of 34, bilateral
scapular girdle muscle weakness with unusual neck flexor/extensor muscle weakness with
cramps and fasciculations, no weakness in the lower limbs has been demonstrated. Another
patient with FALS and FUS mutation, at the age of 54, slowly developed weakness of the neck
flexor/extensor muscles and bilateral scapular girdle and proximal upper limb muscle
weakness, with subsequent impairment of the pelvic girdle, no bulbar involvement has been
shown but slight proximal weakness in the lower limbs; one year after onset, the symptoms
extended to the bulbar region. So these two patients developed an unusual proximal sym‐
metrical upper limbs onset and axial involvement.
Ticozzi N et al. in 2009 [49] described two patients with FALS and mutation of FUS that
presented the same clinical phenotype.
Genetics of ALS and Correlations Between Genotype and Phenotype in ALS — A Focus on Italian Population
http://dx.doi.org/10.5772/56547
83
In 2011 Lai SL et al. [50] described 4 Italian patients with sporadic ALS and FUS mutations
(p.Y66Y, p.G507D, p.R521C, p.R521H). All of these cases initially manifested limb weakness
and symptoms onset was before 50 years of age in more cases.
In 2009 Chiò et al. [51] described a patient with mutation in FUS and a very young age at onset
(<30 years) with a bulbar presentation and a short duration.
In literature [37, 45] confirmed this correlations between genotype and phenotype in FUS
mutations in ALS both FALS and SALS patients.
Millecamps S et al. [43] suggested that FUS patients had a shorter lifespan, more rapid disease,
younger onset than other mutations.
5. Angiogenin (ANG)
Angiogenin is a angiogenic ribonuclease whose activity is related to its ability in regulating
ribosomal RNA (rRNA) transcription. ANG induces angiogenesis by activating vessel
endothelial and smooth muscle cells and triggering a number of biological processes, including
cell migration, invasion, proliferation, and formation of tubular structures [52].
5.1. Genotype
The human ANG gene (Entrez Gene ID 283) is located on chromosome 14q11.1-q11.2, and it
codes for a protein of 147 amino acids.
ANG, encoding a 14 kDa angiogenic ribonuclease, is the first loss-of-function gene identified
in ALS. Since original discovery of ANG as an ALS candidate gene, a total of 15 missense
mutations in the coding region of ANG have been identified in 37 of the 4,193 ALS patients.
Among them, 10 have been characterized in detail and shown to be loss-of-function mutations.
ANG gene has been found mutated in 2.3% of FALS and 1% of SALS patients [53].
The percentage of ANG gene mutations has been confirmed in the Italian ALS population [11].
5.2. Phenotype
Gellera et al. [11] identified 9 patients with new ANG mutation, 6 SALS and 3 FALS. Two
patients presented bulbar onset, while 7 patients spinal onset. Patients with P-4S mutation
presented signs of LMN involvement in both legs at age of 55 years and subsequently a rapidly
progressive course with signs of UMN and LMN involvement. Two patients had G20G
mutation but two different clinical course: first patient had slowly progressive lower limb onset
MND at age 62 with prevalence of LMN signs and 3 years later manifested cognitive dysfunc‐
tion of frontal lobe type, second patient presented distal weakness of upper limb at age 21 with
a slowly progressive course characterized by prevalence of LMN signs. SALS Patient with
V113I mutation developed spasticity of the right arm and atrophy of the right hand muscles
at age 51, one year later the same symptoms appeared in the controlateral upper limb with
prevalence of UMN signs. Patient with H114R mutation started with bulbar signs at age of 68.
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Patients with previously described I46V mutation presented distal weakness of lower limbs,
predominance of LMN signs, slow course of disease (only in one case more rapid with bulbar
involvement). Age at onset was between 50-60 years.
So there was a wide phenotypic variability in these patients, for both district of onset and
involvemenent of UMN/LMN.
Greenway et al. [53] reported that bulbar onset was more frequent in patients with ANG
mutations.
6. Chromosome 9 open reading frame 72 (C9orf72)
Chromosome 9 open reading frame 72 is a protein localized on plasma membrane and
cytoskeleton. There are two isoforms of C9orf72 that are produced as a result of alternative
splicing events and the molecular weight of C9orf72 isoforms is 54/25 kDa. Normally, it is
nuclear protein, even if the mutated form has been described in the cytoplasm [54].
6.1. Genotype
The human C9orf72 gene (Entrez Gene ID 203228) is located on chromosome 9p21.2, and it
codes for a protein of 481 amino acids.
Recently, a hexanucleotide repeat expansion within the C9orf72 gene was identified as the
cause of chromosome 9p21-linked ALS-FTD [54, 55].
About the Italian population, a screening C9orf72 in a large cohort of 259 familial ALS, 1275
sporadic ALS, and 862 control individuals has been performed [12]. It has been found RE in
23.9% familial ALS, 5.1% sporadic ALS, and 0.2% controls. Two cases carried the RE together
with mutations in other ALS-associated genes.
Genotype data revealed that 95% of RE carriers shared a restricted 10-single nucleotide
polymorphism haplotype within the previously reported 20-single nucleotide polymorphism
risk haplotype, detectable in only 27% of nonexpanded ALS cases and in 28% of controls,
suggesting a common founder with cohorts of North European ancestry. Although C9orf72 RE
segregates with disease, the identification of RE both in controls and in patients carrying
additional pathogenic mutations suggests that penetrance and phenotypic expression of
C9orf72 RE may depend on additional genetic risk factors.
6.2. Phenotype
Ratti et al. [12] observed that the phenotype of RE carriers was characterized in higher
proportion by bulbar-onset compared with nonexpanded patients, while in individuals with
spinal onset expanded patients displayed an early involvement of the upper limbs less
frequently than other patients, with predominance of upper motor neuron signs. RE carriers
had a shorter survival compared with noncarriers. There was a correlation between more
frequent bulbar onset in expanded patients and shorter survival time. The concurrence of FTD
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was significantly higher in expanded cases compared with wild type individuals and also ALS-
FTD patients with RE manifested cognitive behaviour before the onset of motor symptoms. In
most cases the phenotype was compatible with a behavioural variant of FTD and frequently
dominated by psychiatric symptoms, such as visual hallucination, paranoid behaviour with
persecutory delusions, aggressive behaviour and/or suicidal thoughts.
Reports in literature were in according [56-59].
Extrapyramidal and cerebellar signs were also observed in two patients, while a patients
presented continuous lingual myclonus at disease onset. These cases suggested that clinical
phenotype associated with RE in C9orf72 may be broader than originally thought, possibly
involving extramotoneuronal structures such as the basal ganglia, cerebellum, brainstem
nuclei.
Sabatelli et al. and Chiò et al. [60, 61, 62] studied clinical phenotype of patients with repeat
expansion in large population and also two Sardinian families with neurodegenerative
diseases (FTD-ALS) in which mutations in different genes (TARDBP p.A382T mutation and
repeat expansion GGGGCC C9orf72) co-existed as pathogenetic causes, giving varied pheno‐
types.
7. Optineurin
Optineurin is an inhibitor protein that play an important role in the maintenance of the Golgi
complex, in membrane trafficking and in exocytosis. Alternative splicing results in multiple
transcript variants encoding the same protein., three different isoforms are known.
7.1. Genotype
The human OPTN gene (Entrez Gene ID 10133) is located on chromosome 10p13, and it codes
for a protein of 577 amino acids. In 2010 OPTN mutations have been described, for the first
time, in ALS patients [63]. In the first paper about OPTN mutation three type of mutation have
been found, two point mutation and one deletion. In 2011, a screening in the Caucasian
population in SALS and FALS patients showed that OPTN mutations causing ALS are rare,
especially in mainly Caucasian ALS subjects [64]. About Italian population, Del Bo and
collaborators screened 274 ALS patients, 161 FALS and 113 SALS and the results showed six
novel variants in both FALS and SALS patients, all occurring in an heterozygous state [13].
This data support the involvement of OPTN in ALS, especially in FALS patients, due to the
1.2% cases found mutated [13].
7.2. Phenotype
Del Bo et al. [13] suggested that ALS patients carrying OPTN mutations showed a prevalent
lower-limb onset, with large variable age of onset (from 24 to 71 years of age) and progression
(very aggressive forms with survival time < 1 year and very slow disease course over 10 years)
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with no differencies between SALS and FALS patients. Many patients were characterized by
a prevalence of upper motor neuron signs.
8. Conclusions
Amyotrophic Lateral Sclerosis is a multifactorial and multigenic disease with still unknown
aetiology and pathogenesis. We know many causative mutations in particular genes, both in
familial and sporadic patients, and different clinical presentation of ALS. Genetic factors may
play a role in determining the range of ALS phenotypes although in this moment no genes
have been demonstrated to have a definite effect on phenotype (Chiò et al., 2011) [4]. Hetero‐
geneity between and among families and patients with same mutation suggests that environ‐
mental and other influences contribute to not only the rate of evolution and which signs
predominate but also whether the disease will appear at all during life.
In this chapter we have identified cases in which connection between phenotype and genotype
is possible and relevant.
We started from the ALS patients part of the recruitment of our Institute to define the possible
clinical features that may be related to specific genes alteration.
For ALS patients with mutations in some genes, such as SOD1, there are an important clinical
phenotypic heterogeneity at onset and during evolution of disease, different time of survival
and velocity of progression with rapidly or slowly involvement of bulbar functions.
TARDBP is involved both in pathogenesis of frontotemporal dementia and ALS, but it’s not
sure that all patients with ALS will develop FTD and they don’t demonstrated an homogenous
clinical pattern.
In particular we will focus attention on connection between FUS mutations, and clinical
presentation with upper limbs onset, developed weakness of the neck flexor/extensor muscles
and bilateral scapular girdle and proximal muscle. In many cases this phenotype is correlated
with rapidly bulbar evolution and frontotemporal behaviour alterations, with negative
prognosis in short time. This focus is in particular due to the presence of FUS mutated patients
in our cohort and the “poverty” of the literature about FUS and clinical features.
Another interesting suggestion is that sometimes mutated patients (i.e. SOD1) can have
particular clinical course modulated by other causative or associated modified genes (ANG).
It is an important issue that maybe indicates a central role of genotype in developing pheno‐
type.
For other genes it’s difficult discovering association between genotype and phenotype for
rarity of manifestation compared with more frequent mutations.
In conclusion, at this time, in front of a patient with ALS, a neurologist should has some
“milestones” considering clinical phenotype:
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• if patient’s history suggests a familial form, it is important to perform a screening of four
principal genes (SOD1, TARDBP, FUS, C9ORF) because they cover more than 50% of FALS;
• if onset of disease is in early age, the probability of a mutation is high and four principal
genes are still first candidates in SALS;
• if patient presents frontotemporal characters or premature respiratory involvement,
TARDBP, FUS, C9ORF are essential in screening;
• if clinical phenotype is characterized by proximal muscles involvement in upper and/or
lower limbs, FUS has to be suspected.
Our idea is that a specific mutation can cause a particular clinical onset, involvement and
evolution of ALS, with a pathogenetic mechanism still unknown.
On the other side, now we have some ideas for type of disease correlated with particular
mutations (i.e. FUS and TARDBP give a early onset, short duration of disease for early bulbar
involvement) but it’s impossible predict exactly what kind of phenotype can be developed by
patient.
Different genes are involved in ALS disease, the importance of a good clinical characterization
may help in choosing the genetic approach. We hypothesized that in the future, the symptoms
observation may became more specific to indicate which gene is the most probably mutated.
This idea may proceed in the same time of a better collaboration between clinicians and
biologist to create a direct link from bed to bench.
This approach may be relevant for diagnostic use, so starting from neurological exam, that
remains the essential element, and we can formulate diagnostic hypothesis that it can be surely
confirmed by genetic test.
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1. Introduction
Neuroinflammation is an inflammatory response that takes place within the central nervous
system (CNS) during a neurodegenerative process or following a neuronal injury. The main
effectors of neuroinflammation, which are astrocytes, microglia and immune cells can confer
in a context- and time-dependent manner both neuroprotective and neurotoxic effects. It has
now become evident that neuroinflammation is a prominent pathological hallmark of several
neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and Amyotro‐
phic Lateral Sclerosis (ALS)(reviewed in [1, 2]). Indeed, reactive astrocytes and microglia as
well as infiltrating T lymphocytes have been identified in ALS experimental models and
patients. In the present chapter, we will describe the neuroinflammatory phenotype that
characterizes ALS and discuss how the aberrant astrocytes, microglia and immune cells may
actively participate in the neurodegenerative process. Further, we will examine the therapeutic
potential of targeting neuroinflammation in both pre-clinical disease models and ALS patients.
2. The contribution of astrocytes in the neuroinflammatory response
2.1. Activation profile of astrocytes in human and animal models of ALS
Under normal and healthy conditions, astrocytes, which are the most abundant cell type within
the CNS, are typically found in a resting state. Activation of astrocytes follows an acute or
chronic injury, where the cells adopt a different morphology, become proliferative, express
the intermediate filament glial fibrillary acidic protein (GFAP) release pro-inflammatory
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cytokines and growth factors as well as produce nitric oxide (NO)(reviewed in [3]). The
phenomenon of astrocytosis has been well characterized in both ALS patients and animal
models. Analysis of human ALS brains reveals the presence of reactive astrocytes within the
subcortical white matter in a widespread fashion [4]. Importantly, the same brain regions from
patients with non-ALS neurological disorders display a distinct histopathology, suggesting
that the ALS astrocytosis is not simply an indirect result of the ongoing neurodegenerative
process [4]. Similarly, the cortical gray matter tissue and the primary motor area from both
sporadic and familial ALS patients are characterized by the omnipresence of reactive astrocytes
[5, 6]. Studies performed on spinal cords from ALS patients show the occurrence of astrocytosis
in both the ventral and dorsal horn region of the spinal cord [7, 8]. In addition to the above-
mentioned post-mortem observations, in vivo brain imaging of ALS patients using deuterium-
substituted [11C](L)-deprenyl positron emission tomography has allowed the visualization of
astrocytosis in live patients [9]. Hence, a thorough analysis of the CNS of ALS patients has
uncovered and highlighted astrocytosis as a bona fide feature of ALS pathology, whether
sporadic or inherited. While human ALS tissue represents most accurately the hallmarks that
typify the disease, the caveat is that it limits our knowledge of the cellular events that occur
prior to disease onset.
The generation of both mouse and rat models of ALS has helped elucidate more precisely the
contributory role of astrocytosis during the neurodegenerative process. Analysis of different
superoxide dismutase 1 (SOD1) mutant mouse models identifies astrocytic alterations such as
reactive morphological changes, proliferation as well as the presence of SOD1- and ubiquitin-
positive inclusions, as occurring prior or close-to axonal degeneration and neuronal loss
[10-13]. Furthermore, the process of astrocytosis significantly intensifies as the disease
progresses [10, 11]. Three-dimensional reconstruction of SOD1G93A spinal cord sections shows
that astrocytic processes actually target and envelop pathological vacuoles within the degen‐
erating neurons [11]. Similarly to the murine models, the transgenic SOD1G93A rats also display
signs of astrocytosis prior to significant motoneuron loss. As the disease progresses, there is
an increase of astrocytic hypertrophy and proliferation as well as an accumulation of ubiquitin
and tau-positive aggregates [14, 15]. Thus, while the human data provided the first insights
into astrocytosis as a pathological hallmark of ALS, the observation in pre-clinical models of
astrocytic inflammation prior to neurodegeneration strengthened the proposed contributory
role of astrocytes in ALS pathogenesis.
2.2. A role for astrocytes in ALS pathogenesis
Once the astrocytic histopathology was thoroughly characterized in both human and animal
ALS models, a comprehensive assessment of its functional influence on motoneuron loss thus
ensued. One of the first indications of astrocyte-dependent neurodegeneration in ALS comes
from the generation of chimeric mice, composed of both normal cells and SOD1 mutant-
expressing cells [16]. This study demonstrates that mutant SOD1-positive motoneurons
surrounded by wildtype non-neuronal cells have a better survival rate than those enclosed by
mutant SOD1-positive non-neuronal cells [16]. A complementary approach consisting in
deleting the human mutant SOD1 specifically within astrocytes of the SOD1G37R mice suggests
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that mutant astrocytes contribute to progression, but not onset of the disease [17]. However,
knocking down the mutant SOD1 in astrocytes of the SOD1G85R mouse model results in
increased survival by delaying disease onset as well as the early stage of the disease [18].
Despite minor differences between the targeted disease stages in both models, the key finding
is that mutant SOD1-expressing astrocytes regulate the disease progression of murine ALS.
Another approach used to address the astrocytic-induced motoneuron loss in ALS is the in
vitro co-culture of both cell types. Indeed, when cultured alone, primary SOD1G93A astrocytes
express high levels of pro-inflammatory effectors such as tumor necrosis factor alpha (TNFα),
interferon gamma (IFNγ), interleukins (IL)-1 beta (IL-1β) and -18 (IL-18), 5-lipoxygenase (5-
LOX), leukotriene B4, cyclooxygenase (COX-2) and prostaglandin E2 (PGE2), thus displaying
an inflammatory phenotype with potential neurotoxic effects [19]. Consequently, primary
wildtype and mutant motoneurons or motoneurons derived from murine or human embry‐
onic stem cells show decreased survival when cultured in the presence of astrocytes expressing
different mutated forms of SOD1 [20-24]. While the above-mentioned in vivo and in vitro studies
suggest a contributory role for astrocytes in ALS pathogenesis, the targeted ablation of GFAP-
expressing proliferating astrocytes in SOD1G93A mice has no effect on the onset or the progres‐
sion of the neurodegenerative process [25]. Recently, a subtype of astrocytes from spinal cord
cultures of SOD1G93A rats that displayed an aberrant phenotype has been isolated (termed Aba
cells). Aba cells, that highly express S100β and connexin-43, but weakly express GFAP, are
distinguished by their increased proliferative abilities and the absence of replicative senes‐
cence. Specifically, they are localized in proximity of motoneurons in vivo, increase drastically
upon disease onset and demonstrate a greater neurotoxicity compared to non-Aba astrocytes
isolated from SOD1G93A rats [26]. Combined, these studies suggest that different subpopula‐
tions of astrocytes with different functional features and different cellular origin coexist during
the pathological processes.
An additional important feature of the astrocytic contribution in ALS relates to the observation
that the expression of SOD1G85R solely in astrocytes does not give rise to motoneuron loss
despite the fact that astrocytosis occurs prominently [27]. Likewise, the specific expression of
SOD1G37R in spinal cord motoneurons or the accumulation of SOD1G93A in postnatal motoneur‐
ons does not impact motor function, neurodegeneration or disease onset and progression [28,
29]. Together, these observations therefore point to the critical communication that takes place
between astrocytes and motoneurons, which might in turn lead to the initiation of neuronal
death pathways.
2.3. Misregulation of neuronal transmission by astrocytes
The glutamate hypothesis proposes that a glutamate imbalance, leading to a calcium (Ca2+)-
mediated excitotoxic insult, represents a major mechanism of motoneuron injury [30].
Astrocytes actively participate in modulating neuronal excitability and neurotransmission by
controlling the extracellular levels of ions and neurotransmitters. The astroglial glutamate
transporter excitatory amino-acid transporter 2 (EAAT2) in humans or glutamate transporter
1 (GLT-1) in rodents is the primary means of maintaining low extracellular glutamate levels.
EAAT2/GLT-1 rapidly removes glutamate from the extracellular milieu and thereby prevents
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cytokines and growth factors as well as produce nitric oxide (NO)(reviewed in [3]). The
phenomenon of astrocytosis has been well characterized in both ALS patients and animal
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an increase of astrocytic hypertrophy and proliferation as well as an accumulation of ubiquitin
and tau-positive aggregates [14, 15]. Thus, while the human data provided the first insights
into astrocytosis as a pathological hallmark of ALS, the observation in pre-clinical models of
astrocytic inflammation prior to neurodegeneration strengthened the proposed contributory
role of astrocytes in ALS pathogenesis.
2.2. A role for astrocytes in ALS pathogenesis
Once the astrocytic histopathology was thoroughly characterized in both human and animal
ALS models, a comprehensive assessment of its functional influence on motoneuron loss thus
ensued. One of the first indications of astrocyte-dependent neurodegeneration in ALS comes
from the generation of chimeric mice, composed of both normal cells and SOD1 mutant-
expressing cells [16]. This study demonstrates that mutant SOD1-positive motoneurons
surrounded by wildtype non-neuronal cells have a better survival rate than those enclosed by
mutant SOD1-positive non-neuronal cells [16]. A complementary approach consisting in
deleting the human mutant SOD1 specifically within astrocytes of the SOD1G37R mice suggests
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expressing proliferating astrocytes in SOD1G93A mice has no effect on the onset or the progres‐
sion of the neurodegenerative process [25]. Recently, a subtype of astrocytes from spinal cord
cultures of SOD1G93A rats that displayed an aberrant phenotype has been isolated (termed Aba
cells). Aba cells, that highly express S100β and connexin-43, but weakly express GFAP, are
distinguished by their increased proliferative abilities and the absence of replicative senes‐
cence. Specifically, they are localized in proximity of motoneurons in vivo, increase drastically
upon disease onset and demonstrate a greater neurotoxicity compared to non-Aba astrocytes
isolated from SOD1G93A rats [26]. Combined, these studies suggest that different subpopula‐
tions of astrocytes with different functional features and different cellular origin coexist during
the pathological processes.
An additional important feature of the astrocytic contribution in ALS relates to the observation
that the expression of SOD1G85R solely in astrocytes does not give rise to motoneuron loss
despite the fact that astrocytosis occurs prominently [27]. Likewise, the specific expression of
SOD1G37R in spinal cord motoneurons or the accumulation of SOD1G93A in postnatal motoneur‐
ons does not impact motor function, neurodegeneration or disease onset and progression [28,
29]. Together, these observations therefore point to the critical communication that takes place
between astrocytes and motoneurons, which might in turn lead to the initiation of neuronal
death pathways.
2.3. Misregulation of neuronal transmission by astrocytes
The glutamate hypothesis proposes that a glutamate imbalance, leading to a calcium (Ca2+)-
mediated excitotoxic insult, represents a major mechanism of motoneuron injury [30].
Astrocytes actively participate in modulating neuronal excitability and neurotransmission by
controlling the extracellular levels of ions and neurotransmitters. The astroglial glutamate
transporter excitatory amino-acid transporter 2 (EAAT2) in humans or glutamate transporter
1 (GLT-1) in rodents is the primary means of maintaining low extracellular glutamate levels.
EAAT2/GLT-1 rapidly removes glutamate from the extracellular milieu and thereby prevents
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excitotoxic injury to neurons that occurs by overstimulation of the post-synaptic N-methyl-D-
aspartic acid (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/
kainate ionotropic glutamate receptors [31, 32]. Decreased expression of EAAT2/GLT-1, which
leads to elevated levels of extracellular glutamate, has been found in a vast majority of sporadic
and familial ALS patients as well as ALS mice and rats [10, 33-35], suggesting the participation
of astrocytes in glutamate-induced excitotoxicity.
In addition to the relationship between glutamate excitotoxicity and glutamate transporter
loss, other glutamatergic pathways have been implicated in motoneuron degeneration.
Functional AMPA receptors consist of various combinations of four subunits (designated
glutamate receptor (GluR)1-4) and are involved in fast excitatory synaptic transmission in the
CNS [36]. The GluR2 subunit is functionally dominant and renders AMPA receptors imper‐
meable to Ca2+, preventing Ca2+ influx-induced toxicity. Thus, high levels of GluR2 in neuronal
tissues might confer neuroprotection against glutamate-induced excitotoxicity. Within normal
human spinal motoneurons, there is a low relative abundance of the GluR2 subunit mRNA
compared to other GluR subunits and to other neuronal tissues, which may make them unduly
susceptible to Ca2+-mediated toxic events following glutamate receptor activation [37].
However, work from another group does not observe any significant quantitative changes in
GluR2 mRNA within spinal cord motoneurons, suggesting that a selective decrease of the
GluR2 subunit might not be the only mechanism mediating the AMPA receptor-dependent
neurotoxicity in ALS [38]. Indeed, it has been demonstrated that RNA editing of GluR2 mRNA
at the glutamine/arginine (Q/R) site is decreased in autopsy-obtained spinal motoneurons from
patients with sporadic ALS [39], a molecular event that confers Ca2+ permeability to the GluR2
receptor [40]. Therefore, reductions in both GluR2 expression and GluR2 Q/R site editing may
contribute to increased Ca2+ influx and neurotoxicity through AMPA receptors in ALS.
The molecular basis for lower GluR2 abundance in motoneurons compared to other CNS
neurons has been investigated using two different rat strains that show differential vulnera‐
bility to AMPA-mediated excitotoxicity [41]. It has thus been demonstrated that astrocytes
derived from the ventral spinal cord, but not those derived from the dorsal spinal cord,
cerebellum, or the cortex, have the ability to regulate GluR2 expression in motoneurons.
Interestingly, expression of mutant SOD1 abolishes their GluR2-regulating capacity. Al‐
though, the astrocytic factor responsible for GluR2 regulation in motoneurons remains to be
identified, the regulation of motoneuron electrical activity through neuronal GluR2 expression
and the uptake of glutamate by the glial transporter EAAT2/GLT-1 are major mechanisms by
which astrocytes may mediate excitotoxic neurodegeneration in ALS.
2.4. Additional mechanisms of astrocytic neurotoxicity
While the astrocytic influence on neuronal excitability is seldom disputed, various reports
suggest that they may also participate in the neurodegenerative process via the release of
neurotoxic factors. Typically, the activation and/or reaction of astrocytes that characterize
neuroinflammation occurs following a CNS injury, including chronic neurodegenerative
diseases (reviewed in [42]). In experiments where the spinal cords of neonatal rats were injected
with cerebrospinal fluid (CSF) from ALS patients, there is an increased GFAP immunoreac‐
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tivity within the grey and white matter [43], suggesting that the astrocytosis in ALS might in
fact be a responsive phenomenon. Conversely, many research groups have identified specific
factors that are abnormally regulated in ALS astrocytes that could potentially trigger the
motoneuron loss that typifies the disease.
2.4.1. The interferon response
Type I, II and III IFNs are an important family of immunomodulatory cytokines (reviewed in
[44]). Elevated levels of IFNγ, a potent pro-inflammatory mediator, are found in the CSF of
ALS patients, in the serum as the disease progresses and in spinal cord of sporadic ALS patients
[45-47]. Further, the analysis of spinal cord sections from ALS patients shows that IFNγ is
detected in ventral horn neurons, glial cells and plausibly immune cells [47]. In addition, the
IFNγ-inducible protein, IP-30 and the interferon-stimulated gene 15 (ISG15) are significantly
upregulated in human ALS spinal cord [48, 49]. In spinal cord extracts and serum of ALS mice,
elevated levels of IFNγ mRNA and protein are also documented [24, 50, 51]. The expression
of IFNγ is found within motoneurons and astrocytes of SOD1G93A and SOD1G85R spinal cords
at both disease onset and symptomatic stages [24]. Similarly, a gene expression array analysis
of pre-symptomatic SOD1G93A spinal cord reveals an induction of several genes regulated by
type I IFNα, IFNβ and type II IFNγ, with specifically an increased expression of ISG15 in spinal
cord astrocytes. Further, the phosphorylation of signal transducer and activator of transcrip‐
tion (STAT) 1 and 2, downstream effectors of IFNs [52], and STAT4, an inducer of IFNγ, is also
elevated in SOD1G93A spinal cords [51]. Functionally, the genetic deletion of Ifnα/β receptor 1 in
SOD1G93A mice significantly prolongs life expectancy [49]. Importantly, astrocytic IFNγ triggers
a motoneuron-selective death pathway via the activation of lymphotoxin beta receptor (LT-
βR) by LIGHT. LIGHT is also upregulated in sporadic ALS spinal cords and the genetic
ablation of Light in SOD1G93A mice delays disease progression [24]. Combined, these observa‐
tions in rodent and human models of the disease suggest that the neuroinflammatory role of
IFNs may contribute to the neurodegenerative process in ALS.
2.4.2. The contribution of nerve growth factor
The low affinity p75 neurotrophin receptor (p75NTR) has a well-described role in mediating
neuronal death signaling (reviewed in [53]). In symptomatic SOD1G93A mice and in ALS
patients, p75NTR is overexpressed within spinal motoneurons [54]. Correspondingly, the
immunoreactivity of nerve growth factor (NGF), a p75NTR ligand [55], is increased in spinal
cord astrocytes of symptomatic SOD1G93A mice and in primary SOD1G93A astrocyte cultures [56,
57]. Further, the excessive expression of fibroblast growth factor 1 (FGF-1) by SOD1G93A
motoneurons stimulates the nuclear accumulation of FGF receptor 1 (FGFR1) in astrocytes,
consequently triggering astrocytic NGF production [58]. Importantly, primary SOD1G93A
motoneuron cultures are hypersensitive to the NGF-p75NTR apoptotic signaling [59]. Thus, the
astrocyte-dependent activation of the neurotoxic NGF-p75NTR pathway might participate to
the neurodegeneration that typifies ALS.
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GluR2 subunit might not be the only mechanism mediating the AMPA receptor-dependent
neurotoxicity in ALS [38]. Indeed, it has been demonstrated that RNA editing of GluR2 mRNA
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receptor [40]. Therefore, reductions in both GluR2 expression and GluR2 Q/R site editing may
contribute to increased Ca2+ influx and neurotoxicity through AMPA receptors in ALS.
The molecular basis for lower GluR2 abundance in motoneurons compared to other CNS
neurons has been investigated using two different rat strains that show differential vulnera‐
bility to AMPA-mediated excitotoxicity [41]. It has thus been demonstrated that astrocytes
derived from the ventral spinal cord, but not those derived from the dorsal spinal cord,
cerebellum, or the cortex, have the ability to regulate GluR2 expression in motoneurons.
Interestingly, expression of mutant SOD1 abolishes their GluR2-regulating capacity. Al‐
though, the astrocytic factor responsible for GluR2 regulation in motoneurons remains to be
identified, the regulation of motoneuron electrical activity through neuronal GluR2 expression
and the uptake of glutamate by the glial transporter EAAT2/GLT-1 are major mechanisms by
which astrocytes may mediate excitotoxic neurodegeneration in ALS.
2.4. Additional mechanisms of astrocytic neurotoxicity
While the astrocytic influence on neuronal excitability is seldom disputed, various reports
suggest that they may also participate in the neurodegenerative process via the release of
neurotoxic factors. Typically, the activation and/or reaction of astrocytes that characterize
neuroinflammation occurs following a CNS injury, including chronic neurodegenerative
diseases (reviewed in [42]). In experiments where the spinal cords of neonatal rats were injected
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[44]). Elevated levels of IFNγ, a potent pro-inflammatory mediator, are found in the CSF of
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[45-47]. Further, the analysis of spinal cord sections from ALS patients shows that IFNγ is
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IFNγ-inducible protein, IP-30 and the interferon-stimulated gene 15 (ISG15) are significantly
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tion (STAT) 1 and 2, downstream effectors of IFNs [52], and STAT4, an inducer of IFNγ, is also
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SOD1G93A mice significantly prolongs life expectancy [49]. Importantly, astrocytic IFNγ triggers
a motoneuron-selective death pathway via the activation of lymphotoxin beta receptor (LT-
βR) by LIGHT. LIGHT is also upregulated in sporadic ALS spinal cords and the genetic
ablation of Light in SOD1G93A mice delays disease progression [24]. Combined, these observa‐
tions in rodent and human models of the disease suggest that the neuroinflammatory role of
IFNs may contribute to the neurodegenerative process in ALS.
2.4.2. The contribution of nerve growth factor
The low affinity p75 neurotrophin receptor (p75NTR) has a well-described role in mediating
neuronal death signaling (reviewed in [53]). In symptomatic SOD1G93A mice and in ALS
patients, p75NTR is overexpressed within spinal motoneurons [54]. Correspondingly, the
immunoreactivity of nerve growth factor (NGF), a p75NTR ligand [55], is increased in spinal
cord astrocytes of symptomatic SOD1G93A mice and in primary SOD1G93A astrocyte cultures [56,
57]. Further, the excessive expression of fibroblast growth factor 1 (FGF-1) by SOD1G93A
motoneurons stimulates the nuclear accumulation of FGF receptor 1 (FGFR1) in astrocytes,
consequently triggering astrocytic NGF production [58]. Importantly, primary SOD1G93A
motoneuron cultures are hypersensitive to the NGF-p75NTR apoptotic signaling [59]. Thus, the
astrocyte-dependent activation of the neurotoxic NGF-p75NTR pathway might participate to
the neurodegeneration that typifies ALS.




COX-2 is a pro-inflammatory enzyme that converts arachidonic acid into prostanoids such as
PGE2, a potent inflammatory mediator (reviewed in [60]). In the anterior horn region of the
spinal cord of SOD1G93A mice, at both the early and end stage of the disease, COX-2 immunor‐
eactivity is elevated in astrocytes [61]. Similarly, spinal cord astrocytes from sporadic ALS
patients also display increased COX-2 expression [61, 62]. The expression of COX-2 can be
modulated by the binding of CD40, a member of the TNF family (reviewed in [63]), with its
ligand CD40L [64]. Interestingly, spinal cord astrocytes of symptomatic SOD1G39A mice show
an upregulation of CD40, concomitant with COX-2 astrocytic expression. Moreover, the
activation of COX-2 in astrocytes upon CD40 stimulation leads to motoneuron death in vitro
[65], suggesting that an astrocytic CD40-COX-2 pathway could also participate in ALS
pathogenesis. The contribution of the CD40/CD40L pathway has recently been proposed in
ALS mice, though its role in astrocytic neurotoxicity role has not been established [66]. Finally,
another facet of the COX-2 pathway relates to the ability of PGE2 to promote glutamate release
from astrocytes, emphasizing further the complex multimodality of neuroinflammatory
signals [67].
2.4.4. The Wnt/β-catenin signaling pathway
The canonical Wnt/β-catenin transduction pathway, which comprises multiple Wnt genes,
regulates many biological functions (reviewed in [68]), including neuronal survival, as
demonstrated by its involvement in other neurodegenerative disease such as Alzheimer’s
disease and Parkinson’s disease [69, 70]. In the ventral region of symptomatic SOD1G93A spinal
cords, there is an increase in the number of Wnt3a- and β-catenin-positive astrocytes [71]. An
upregulation of Wnt2 and Wnt7 within astrocytes of symptomatic SOD1G93A spinal cords is
also reported [72]. Among its biological functions, the Wnt/β-catenin pathway mediates the
activity of cyclin D1 [73], a nuclear transcription factor important for cell cycle regulation
(reviewed in [74]). The upregulation of cyclin D1 in SOD1G93A astrocytes suggests that the
increased activation of the Wnt/β-catenin/cyclin D1 may plausibly direct astrocytosis [71].
Interestingly, a study performed in colorectal cancer cell lines uncovers the possible regulation
of COX-2 by the Wnt/β-catenin pathway [75]. Thus, an astrocytic increased activation of Wnt
and β-catenin may not only impact cyclin D1 expression but potentially that of COX-2, for
which a possible role in ALS neurodegeneration has been described above.
2.4.5. Monoamine oxidase-B
Monoamine oxidase-B (MAO-B) is an outer mitochondrial membrane-bound enzyme that
catalyzes the oxidative deamination of biogenic amines, thus producing reactive oxygen
species (ROS). MAO-B is primarily found in the CNS where it localizes mainly in astrocytes
and radial glial [76]. The spinal cord lumbar region from symptomatic ALS patients displays
more MAO-B, due to the general astrocyte proliferation and to a cell-intrinsic increased
expression [77]. Using 3H-L deprenyl in vitro autoradiography, a more in-depth follow-up
study in the post-mortem ALS CNS reveals an increased expression in the corticospinal tract,
the ventral white matter and in the vicinity of motoneurons. Further, reactive astrocytes
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displayed a higher content of MAO-B compared to microglial cells [8, 78]. Finally, an epide‐
miological analysis has uncovered that the MAO-B allelic phenotype influences the age of ALS
onset [79]. Excessive astrocytic MAO-B expression, which results in elevations of extracellular
ROS levels, may have damaging effects on neighboring motoneurons. Additional mechanisms
could also involve mitochondrial dysfunction by the selective inhibition of respiratory
complex I, which further leads to increased production of superoxide as well as microglial
activation [80].
2.4.6. Mitochondrial dysfunctions
While there is a vast amount of research on the mitochondrial dysfunction in ALS motoneurons
(reviewed in [81]), not much is known about the impact of toxic genetic mutations on the
mitochondria of astrocytes. There is evidence however, that ALS astrocytes do in fact display
pathological mitochondrial dysfunction that subsequently leads to oxidative damage, sus‐
taining their reactive status. Indeed, primary astrocytes isolated from the cerebral cortex of
neonatal rats and overexpressing SOD1G93A display a decreased mitochondrial respiration rate,
an increased superoxide formation and a decreased membrane potential [82]. In co-culture
experiments, modulating the mitochondrial defects of SOD1G93A-expressing astrocytes via
small chemical compounds improves astrocytic-dependent motoneuron survival. Conversely,
induction of mitochondrial damage to wildtype astrocytes increases motoneuron death [82].
Thus, organelle dysfunction within ALS astrocytes may be an important contributor to the
neurodegenerative process. In addition, a positive amplification system could take place
during the degenerative process, since the inflammatory mediator NO, mainly produced by
the inducible form of nitric oxide synthase (iNOS) in reactive astrocytes, can in turn induce
mitochondrial dysfunction in astrocytes [83].
2.4.7. Activation of microglial cells
A fundamental role for astrocytes in the neuroinflammation process is the recruitment of
microglia [84], the resident macrophages of the CNS (reviewed in [85]). In SOD1G37R mice where
the mutant SOD1 gene is specifically deleted in astrocytes, the delay in the progression of the
later stages of disease is accompanied with an inhibition of microglial activation and microglia-
dependent detrimental NO production [17]. Thus, astrocytosis in ALS may promote neuroin‐
flammation events through microglial recruitment, which in turn may participate directly or
indirectly to the motoneuron loss in ALS. Several pro-inflammatory contributors including
TNFα, IFNγ, IL-1β and NO, which are aberrantly produced by mutant astrocytes can indeed
enhance the activation of microglia. The specific role of microglia in the neuroinflammatory
aspects of ALS will therefore be discussed below.
Figure 1 illustrates the potential non-cell-autonomous mechanisms implicating reactive
astrocytes in the selective death of motoneurons in ALS.
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more MAO-B, due to the general astrocyte proliferation and to a cell-intrinsic increased
expression [77]. Using 3H-L deprenyl in vitro autoradiography, a more in-depth follow-up
study in the post-mortem ALS CNS reveals an increased expression in the corticospinal tract,
the ventral white matter and in the vicinity of motoneurons. Further, reactive astrocytes
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displayed a higher content of MAO-B compared to microglial cells [8, 78]. Finally, an epide‐
miological analysis has uncovered that the MAO-B allelic phenotype influences the age of ALS
onset [79]. Excessive astrocytic MAO-B expression, which results in elevations of extracellular
ROS levels, may have damaging effects on neighboring motoneurons. Additional mechanisms
could also involve mitochondrial dysfunction by the selective inhibition of respiratory
complex I, which further leads to increased production of superoxide as well as microglial
activation [80].
2.4.6. Mitochondrial dysfunctions
While there is a vast amount of research on the mitochondrial dysfunction in ALS motoneurons
(reviewed in [81]), not much is known about the impact of toxic genetic mutations on the
mitochondria of astrocytes. There is evidence however, that ALS astrocytes do in fact display
pathological mitochondrial dysfunction that subsequently leads to oxidative damage, sus‐
taining their reactive status. Indeed, primary astrocytes isolated from the cerebral cortex of
neonatal rats and overexpressing SOD1G93A display a decreased mitochondrial respiration rate,
an increased superoxide formation and a decreased membrane potential [82]. In co-culture
experiments, modulating the mitochondrial defects of SOD1G93A-expressing astrocytes via
small chemical compounds improves astrocytic-dependent motoneuron survival. Conversely,
induction of mitochondrial damage to wildtype astrocytes increases motoneuron death [82].
Thus, organelle dysfunction within ALS astrocytes may be an important contributor to the
neurodegenerative process. In addition, a positive amplification system could take place
during the degenerative process, since the inflammatory mediator NO, mainly produced by
the inducible form of nitric oxide synthase (iNOS) in reactive astrocytes, can in turn induce
mitochondrial dysfunction in astrocytes [83].
2.4.7. Activation of microglial cells
A fundamental role for astrocytes in the neuroinflammation process is the recruitment of
microglia [84], the resident macrophages of the CNS (reviewed in [85]). In SOD1G37R mice where
the mutant SOD1 gene is specifically deleted in astrocytes, the delay in the progression of the
later stages of disease is accompanied with an inhibition of microglial activation and microglia-
dependent detrimental NO production [17]. Thus, astrocytosis in ALS may promote neuroin‐
flammation events through microglial recruitment, which in turn may participate directly or
indirectly to the motoneuron loss in ALS. Several pro-inflammatory contributors including
TNFα, IFNγ, IL-1β and NO, which are aberrantly produced by mutant astrocytes can indeed
enhance the activation of microglia. The specific role of microglia in the neuroinflammatory
aspects of ALS will therefore be discussed below.
Figure 1 illustrates the potential non-cell-autonomous mechanisms implicating reactive
astrocytes in the selective death of motoneurons in ALS.


















































Figure 1. Proposed mechanisms for astrocytic-mediated neuroinflammation and toxicity towards motoneurons. Reac‐
tive astrocytes contribute to the degenerative process by influencing the activity of microglial and immune cells as
well as by releasing soluble factors that are toxic to motoneurons (as described in section 2).
3. A role for microglia in neuroinflammation
3.1. Activation profile in human and animal models of ALS
Microglia are often termed the immune cells of the CNS as they constantly monitor the
neuronal environment in a resting state and become activated upon acute or chronic neuronal
damage, eliciting a strong pro-inflammatory response (reviewed in [86]). In ALS patients,
reactive microglia are observed in the motor cortex, the motor nuclei of the brainstem, the
ventral horn of the spinal cord, along the entire corticospinal tract and within the CSF [87-89].
Given the relationship between astrocytes and microglia [17, 84] and the importance of
astrocytosis in ALS, it has been hypothesized that microgliosis may also participate in ALS
pathogenesis.
To better understand at which developmental point of the disease reactive microglia appear,
microgliosis has been characterized in rodent ALS models at various stages of the disease.
Microgliosis occurs in pre-symptomatic and symptomatic SOD1G93A spinal cords as well as
within various CNS compartments [90-93]. Similarly, SOD1G37R mice display microgliosis at
both onset and early-stage of the disease [94]. An in-depth characterization of microgliosis in
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SOD1G93A mice via in vivo imaging by two-photon laser-scanning microscopy shows that
microglia are highly reactive in pre-symptomatic stages while they lose their ability to respond
to injury and to monitor the environment as the disease progresses [95]. Indeed, comparison
of microglia populations during disease progression reveals that microglia isolated from either
neonatal or early onset SOD1G93A mice display an alternatively activated M2 phenotype and
enhance motoneuron survival while microglia isolated from either adult or endstage SOD1G93A
mice have a classically activated M1 phenotype and induce motoneuron death [96, 97]. In the
pre-symptomatic and symptomatic SOD1G93A rat model, microglia aggregates are detected in
both the spinal cord and brainstem [98, 99]. Interestingly, the microglia in endstage SOD1G93A
rats display a degenerative and apoptotic phenotype [98]. Further, in the lumbar spinal cord
of pre-symptomatic SOD1H46R rats, the microglia express the proliferating marker Ki67 and the
phagocytic markers ED1 and major histocompatibility complex (MHC) class II [100, 101]. The
thorough investigation of microglial events in rodents therefore suggests that microgliosis not
only typifies ALS but that the function of microglia changes during disease progression, thus
exerting differential effects on the degenerating motoneurons.
3.2. A role for microglia in ALS pathogenesis
Experimental endeavors have been undertaken to better understand the precise contribution
of microglia in the neurodegenerative process. A key finding in support of the proposed direct
contribution of microglia to ALS pathogenesis is in ALS mice where the mutant SOD1 (G37R
or G85R) is specifically deleted from macrophages and microglial lineages [94, 102]. This
results in a delay in the progression but not onset of the disease and a significant extension in
lifespan. The importance of microgliosis in ALS pathology was also ascertained in SOD1G93A
mice bred with PU.1-/- mice that lack CNS microglia at birth [103, 104]. While the bone marrow
transplantation of SOD1G93A microglia into PU.1-/- mice did not induce neurodegeneration, the
bone marrow transplantation of wildtype microglia into SOD1G93A;PU.1-/- mice improved
survival compared to the bone marrow transplantation of SOD1G93A microglia [103]. Further,
administration of extracellular murine SOD1G93A to primary cultures of microglia activates
these cells and renders them neurotoxic [105]. However, phenotypical analysis of microglia in
different regions of SOD1G93A spinal cord suggests that both neuroprotective and neurotoxic
population of microglial cells may coexist during the disease [106]. In fact, the depletion of
proliferative microglia does not prevent motoneuron degeneration [107]. Together, these
studies suggest that microglia participate, through a complex balance between neuroprotec‐
tive and neurotoxic signals, in the course of the disease.
3.3. Proposed mechanisms of microglial-derived neurotoxicity
While the injection of motoneuron-directed or ALS patient-derived immunoglobulin G into
the spinal cord of mice initiates the recruitment of reactive microglia [108], a study looking at
cerebral cortex of ALS patients shows that the phagocytosis of degenerating neurons is
mediated by perivascular macrophages and not microglia [109]. This finding already suggest‐
ed that reactive microglia might play a more complex function in ALS than simply eliminating


















































Figure 1. Proposed mechanisms for astrocytic-mediated neuroinflammation and toxicity towards motoneurons. Reac‐
tive astrocytes contribute to the degenerative process by influencing the activity of microglial and immune cells as
well as by releasing soluble factors that are toxic to motoneurons (as described in section 2).
3. A role for microglia in neuroinflammation
3.1. Activation profile in human and animal models of ALS
Microglia are often termed the immune cells of the CNS as they constantly monitor the
neuronal environment in a resting state and become activated upon acute or chronic neuronal
damage, eliciting a strong pro-inflammatory response (reviewed in [86]). In ALS patients,
reactive microglia are observed in the motor cortex, the motor nuclei of the brainstem, the
ventral horn of the spinal cord, along the entire corticospinal tract and within the CSF [87-89].
Given the relationship between astrocytes and microglia [17, 84] and the importance of
astrocytosis in ALS, it has been hypothesized that microgliosis may also participate in ALS
pathogenesis.
To better understand at which developmental point of the disease reactive microglia appear,
microgliosis has been characterized in rodent ALS models at various stages of the disease.
Microgliosis occurs in pre-symptomatic and symptomatic SOD1G93A spinal cords as well as
within various CNS compartments [90-93]. Similarly, SOD1G37R mice display microgliosis at
both onset and early-stage of the disease [94]. An in-depth characterization of microgliosis in
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SOD1G93A mice via in vivo imaging by two-photon laser-scanning microscopy shows that
microglia are highly reactive in pre-symptomatic stages while they lose their ability to respond
to injury and to monitor the environment as the disease progresses [95]. Indeed, comparison
of microglia populations during disease progression reveals that microglia isolated from either
neonatal or early onset SOD1G93A mice display an alternatively activated M2 phenotype and
enhance motoneuron survival while microglia isolated from either adult or endstage SOD1G93A
mice have a classically activated M1 phenotype and induce motoneuron death [96, 97]. In the
pre-symptomatic and symptomatic SOD1G93A rat model, microglia aggregates are detected in
both the spinal cord and brainstem [98, 99]. Interestingly, the microglia in endstage SOD1G93A
rats display a degenerative and apoptotic phenotype [98]. Further, in the lumbar spinal cord
of pre-symptomatic SOD1H46R rats, the microglia express the proliferating marker Ki67 and the
phagocytic markers ED1 and major histocompatibility complex (MHC) class II [100, 101]. The
thorough investigation of microglial events in rodents therefore suggests that microgliosis not
only typifies ALS but that the function of microglia changes during disease progression, thus
exerting differential effects on the degenerating motoneurons.
3.2. A role for microglia in ALS pathogenesis
Experimental endeavors have been undertaken to better understand the precise contribution
of microglia in the neurodegenerative process. A key finding in support of the proposed direct
contribution of microglia to ALS pathogenesis is in ALS mice where the mutant SOD1 (G37R
or G85R) is specifically deleted from macrophages and microglial lineages [94, 102]. This
results in a delay in the progression but not onset of the disease and a significant extension in
lifespan. The importance of microgliosis in ALS pathology was also ascertained in SOD1G93A
mice bred with PU.1-/- mice that lack CNS microglia at birth [103, 104]. While the bone marrow
transplantation of SOD1G93A microglia into PU.1-/- mice did not induce neurodegeneration, the
bone marrow transplantation of wildtype microglia into SOD1G93A;PU.1-/- mice improved
survival compared to the bone marrow transplantation of SOD1G93A microglia [103]. Further,
administration of extracellular murine SOD1G93A to primary cultures of microglia activates
these cells and renders them neurotoxic [105]. However, phenotypical analysis of microglia in
different regions of SOD1G93A spinal cord suggests that both neuroprotective and neurotoxic
population of microglial cells may coexist during the disease [106]. In fact, the depletion of
proliferative microglia does not prevent motoneuron degeneration [107]. Together, these
studies suggest that microglia participate, through a complex balance between neuroprotec‐
tive and neurotoxic signals, in the course of the disease.
3.3. Proposed mechanisms of microglial-derived neurotoxicity
While the injection of motoneuron-directed or ALS patient-derived immunoglobulin G into
the spinal cord of mice initiates the recruitment of reactive microglia [108], a study looking at
cerebral cortex of ALS patients shows that the phagocytosis of degenerating neurons is
mediated by perivascular macrophages and not microglia [109]. This finding already suggest‐
ed that reactive microglia might play a more complex function in ALS than simply eliminating
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dying motoneurons. Indeed, various misregulated pathways within ALS microglia have been
identified that may influence motoneuron survival.
3.3.1. Endoplasmic reticulum stress
When a cell starts to excessively accumulate misfolded or unfolded proteins, the over-activated
endoplasmic reticulum (ER) stress induces apoptosis (reviewed in [110]). Importantly, ER
stress is an established characteristic of ALS pathogenesis (reviewed in [111]). In spinal cord
microglia of both sporadic ALS patients and symptomatic SOD1G93A mice, there is an increased
expression of C/EBP homologous protein (CHOP) [112], a member of the apoptotic ER stress
pathway (reviewed in [113]). It remains unclear however if the aberrant levels of CHOP reflect
an upstream defect in protein folding or if they directly participate in microglial neurotoxicity.
It is noteworthy that the exposure of microglial cells to IFNγ induces iNOS expression, and
the subsequent increased NO production can cause an ER stress response involving CHOP
[114]. Interestingly, the analysis of selectively vulnerable motoneurons from low-expression
SOD1G93A, high-expression SOD1G93A and SOD1G85R mice shows the initiation of a specific ER
stress response accompanied by microglial activation [115]. Thus, the interaction between ALS
motoneurons and microglia may be important in the modulation of the neurodegenerative
process.
3.3.2. CD14-toll-like receptor signaling
Once the ligand-dependent CD14 lipopolysaccharide (LPS) receptor located at the microglial
surface [116] is activated, it initiates a pro-inflammatory signaling cascade dependent on Toll-
like receptors (TLRs), specifically TLR2 and TLR4 [117, 118]. Interestingly, the neurotoxic
activation of microglia by extracellular SOD1G93A is mediated by the CD14-TLR pathway [105,
119]. Indeed, immortalized microglia cells expressing mutant SOD1 display an increased TLR2
stimulation and subsequent release of pro-inflammatory cytokines, including TNFα and
IL-1β. Importantly, an analysis of spinal cord microglia from sporadic ALS patients shows an
enhanced TLR2 immunoreactivity [120]. Recently, it has been shown that the endocytosis of
extracellular mutant SOD1 by microglia is required for the activation of caspase-1, which is
required for the maturation of IL-1β [121]. This can be paralleled with the finding that the
microgliosis caused by fibrillar amyloid beta (Aβ), the main component of the aggregates that
are a pathological signature of Alzheimer’s disease, also requires CD14, TLR2 and TLR4 [122].
All together, these studies suggest that microglia may participate in motoneuron loss following
the specific activation of the CD14-TLR pathway by secreted SOD1 mutant, therefore propa‐
gating pro-inflammatory stimuli.
3.3.3. Purinergic signaling
The release of extracellular nucleoside di- and tri-phosphates by degenerating neurons can
elicit the activation of microglia through the ionotropic P2X and metabotropic P2Y purinergic
receptors. A general alarm signal for microglia is ATP, which can subsequently elicit a pro-
inflammatory response, chemotaxis and phagocytosis (reviewed in [123, 124]). Embryonic
immortalized microglia and neonatal primary microglial cultures isolated from mutant SOD1
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mice display an upregulation of P2X4, P2X7 and P2Y6 receptors [125]. Notably, the immunor‐
eactivity of P2X is increased within spinal cord microglia of ALS patients [126]. Activation of
P2X7 in SOD1G93A microglial cells produces significantly higher levels of TNFα, which has a
neurotoxic effect on motoneuron cultures [127], and of COX-2, compared to non-mutant
microglia [125]. In addition, a reduced ATP hydrolysis activity, possibly implicating the ecto-
NTPDase CD39, is observed in mutant SOD1 microglia, suggesting that a potentiation of a
purinergic-mediated inflammation can participate to the neuroinflammatory state of micro‐
glial cells. Since ATP induces an astrocytic neurotoxic phenotype through P2X7 [128], it is thus
feasible to hypothesize that increased extracellular ATP in ALS, whether exacerbated by
motoneurons and/or microglia contributes to the pathogenic microgliosis.
3.4. The potential influence of microglia on neuronal excitability
To our knowledge, there is presently no direct assessment of the influence of microglia on
motoneuron electrophysiology. However, studies on peripheral nerve injury or spinal cord
injury show that microglia activation has prominent effects on neuronal inhibitory control.
Importantly, loss of inhibitory control is a contributing mechanism to the motoneuron
hyperexcitability that typifies ALS pathogenesis in humans [129].
Loss of neuronal inhibitory control occurs by several means including decrease in gamma-
aminobutyric acid (GABA)ergic interneurons [130] combined with changes in the expression
of the GABAA receptor mRNA subunit [131]. GABAA and glycine receptors are chloride (Cl-)
channels and the expression of cation-chloride co-transporter contributes to inhibitory effects
of these Cl- currents [132]. Indeed, the entry of Cl- following the opening of GABAA and glycine
receptor-gated Cl- channels inhibits neuron excitability by hyperpolarizing membrane
potential. Under physiological condition, low [Cl-]i is maintained by the potassium (K+)-
chloride co-transporter KCC2 that extrudes Cl- from mature neurons [133]. Stimulation of
spinal microglia following peripheral nerve injury induces a decrease in KCC2 expression
among dorsal horn nociceptive neurons [134]. KCC2 decrease is induced by the brain-derived
neurotrophic factor (BDNF) and this is consistent with the previous observation that BDNF
can be produced by non-neuronal cells involved in immune responses, including T and B
lymphocytes, monocytes and microglia [135, 136]. BDNF produces a depolarizing shift in the
anion reversal potential of dorsal horn lamina I neurons due to an increase in [Cl-]i. This shift
prompts an inversion of inhibitory GABA currents that contributes to neuropathic pain
following nerve injury [135]. Decrease in KCC2 expression is thus responsible for the excitatory
effects of GABA on neurons. Microglia activation and BDNF secretion are mediated through
ATP activation of microglial P2X receptors. As described earlier, P2X receptors might be
involved in ALS pathology since a higher density of P2X7-immunoreactive microglial cells/
macrophages are found in affected regions of spinal cords from ALS patients [126]. Levels of
BDNF have been found to be increased in microglial cells isolated from ALS mice at the onset
of disease and KCC2 is decreased in vulnerable motoneurons in SOD1G93A mice [96, 137].
Additionally, BDNF might play a role in the microglia’s influence on motoneuron electric
activity as suggested by work on spasticity. Spasticity is characterized by a velocity-dependent
increase in muscle tone resulting from hyperexcitable stretch reflexes, spasms and hypersen‐
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dying motoneurons. Indeed, various misregulated pathways within ALS microglia have been
identified that may influence motoneuron survival.
3.3.1. Endoplasmic reticulum stress
When a cell starts to excessively accumulate misfolded or unfolded proteins, the over-activated
endoplasmic reticulum (ER) stress induces apoptosis (reviewed in [110]). Importantly, ER
stress is an established characteristic of ALS pathogenesis (reviewed in [111]). In spinal cord
microglia of both sporadic ALS patients and symptomatic SOD1G93A mice, there is an increased
expression of C/EBP homologous protein (CHOP) [112], a member of the apoptotic ER stress
pathway (reviewed in [113]). It remains unclear however if the aberrant levels of CHOP reflect
an upstream defect in protein folding or if they directly participate in microglial neurotoxicity.
It is noteworthy that the exposure of microglial cells to IFNγ induces iNOS expression, and
the subsequent increased NO production can cause an ER stress response involving CHOP
[114]. Interestingly, the analysis of selectively vulnerable motoneurons from low-expression
SOD1G93A, high-expression SOD1G93A and SOD1G85R mice shows the initiation of a specific ER
stress response accompanied by microglial activation [115]. Thus, the interaction between ALS
motoneurons and microglia may be important in the modulation of the neurodegenerative
process.
3.3.2. CD14-toll-like receptor signaling
Once the ligand-dependent CD14 lipopolysaccharide (LPS) receptor located at the microglial
surface [116] is activated, it initiates a pro-inflammatory signaling cascade dependent on Toll-
like receptors (TLRs), specifically TLR2 and TLR4 [117, 118]. Interestingly, the neurotoxic
activation of microglia by extracellular SOD1G93A is mediated by the CD14-TLR pathway [105,
119]. Indeed, immortalized microglia cells expressing mutant SOD1 display an increased TLR2
stimulation and subsequent release of pro-inflammatory cytokines, including TNFα and
IL-1β. Importantly, an analysis of spinal cord microglia from sporadic ALS patients shows an
enhanced TLR2 immunoreactivity [120]. Recently, it has been shown that the endocytosis of
extracellular mutant SOD1 by microglia is required for the activation of caspase-1, which is
required for the maturation of IL-1β [121]. This can be paralleled with the finding that the
microgliosis caused by fibrillar amyloid beta (Aβ), the main component of the aggregates that
are a pathological signature of Alzheimer’s disease, also requires CD14, TLR2 and TLR4 [122].
All together, these studies suggest that microglia may participate in motoneuron loss following
the specific activation of the CD14-TLR pathway by secreted SOD1 mutant, therefore propa‐
gating pro-inflammatory stimuli.
3.3.3. Purinergic signaling
The release of extracellular nucleoside di- and tri-phosphates by degenerating neurons can
elicit the activation of microglia through the ionotropic P2X and metabotropic P2Y purinergic
receptors. A general alarm signal for microglia is ATP, which can subsequently elicit a pro-
inflammatory response, chemotaxis and phagocytosis (reviewed in [123, 124]). Embryonic
immortalized microglia and neonatal primary microglial cultures isolated from mutant SOD1
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mice display an upregulation of P2X4, P2X7 and P2Y6 receptors [125]. Notably, the immunor‐
eactivity of P2X is increased within spinal cord microglia of ALS patients [126]. Activation of
P2X7 in SOD1G93A microglial cells produces significantly higher levels of TNFα, which has a
neurotoxic effect on motoneuron cultures [127], and of COX-2, compared to non-mutant
microglia [125]. In addition, a reduced ATP hydrolysis activity, possibly implicating the ecto-
NTPDase CD39, is observed in mutant SOD1 microglia, suggesting that a potentiation of a
purinergic-mediated inflammation can participate to the neuroinflammatory state of micro‐
glial cells. Since ATP induces an astrocytic neurotoxic phenotype through P2X7 [128], it is thus
feasible to hypothesize that increased extracellular ATP in ALS, whether exacerbated by
motoneurons and/or microglia contributes to the pathogenic microgliosis.
3.4. The potential influence of microglia on neuronal excitability
To our knowledge, there is presently no direct assessment of the influence of microglia on
motoneuron electrophysiology. However, studies on peripheral nerve injury or spinal cord
injury show that microglia activation has prominent effects on neuronal inhibitory control.
Importantly, loss of inhibitory control is a contributing mechanism to the motoneuron
hyperexcitability that typifies ALS pathogenesis in humans [129].
Loss of neuronal inhibitory control occurs by several means including decrease in gamma-
aminobutyric acid (GABA)ergic interneurons [130] combined with changes in the expression
of the GABAA receptor mRNA subunit [131]. GABAA and glycine receptors are chloride (Cl-)
channels and the expression of cation-chloride co-transporter contributes to inhibitory effects
of these Cl- currents [132]. Indeed, the entry of Cl- following the opening of GABAA and glycine
receptor-gated Cl- channels inhibits neuron excitability by hyperpolarizing membrane
potential. Under physiological condition, low [Cl-]i is maintained by the potassium (K+)-
chloride co-transporter KCC2 that extrudes Cl- from mature neurons [133]. Stimulation of
spinal microglia following peripheral nerve injury induces a decrease in KCC2 expression
among dorsal horn nociceptive neurons [134]. KCC2 decrease is induced by the brain-derived
neurotrophic factor (BDNF) and this is consistent with the previous observation that BDNF
can be produced by non-neuronal cells involved in immune responses, including T and B
lymphocytes, monocytes and microglia [135, 136]. BDNF produces a depolarizing shift in the
anion reversal potential of dorsal horn lamina I neurons due to an increase in [Cl-]i. This shift
prompts an inversion of inhibitory GABA currents that contributes to neuropathic pain
following nerve injury [135]. Decrease in KCC2 expression is thus responsible for the excitatory
effects of GABA on neurons. Microglia activation and BDNF secretion are mediated through
ATP activation of microglial P2X receptors. As described earlier, P2X receptors might be
involved in ALS pathology since a higher density of P2X7-immunoreactive microglial cells/
macrophages are found in affected regions of spinal cords from ALS patients [126]. Levels of
BDNF have been found to be increased in microglial cells isolated from ALS mice at the onset
of disease and KCC2 is decreased in vulnerable motoneurons in SOD1G93A mice [96, 137].
Additionally, BDNF might play a role in the microglia’s influence on motoneuron electric
activity as suggested by work on spasticity. Spasticity is characterized by a velocity-dependent
increase in muscle tone resulting from hyperexcitable stretch reflexes, spasms and hypersen‐
The Neuroinflammation in the Physiopathology of Amyotrophic Lateral Sclerosis
http://dx.doi.org/10.5772/56489
107
sitivity to normally innocuous sensory stimulations. Spasticity develops following spinal cord
injury and is also regarded as an ALS clinical symptom [138]. The main mechanisms hypothe‐
sized to be responsible for spasticity are increased motoneuron excitability and increased
synaptic inputs in response to muscle stretch due to reduced inhibitory mechanisms. Recently,
it has been demonstrated that, following spinal cord injury, increased levels of BDNF mediated
spasticity, due to post-transcriptional down regulation of KCC2 [139]. Together, these studies
suggest that reactive microglia in ALS may exert an aberrant effect on the electrical activity of
motoneurons and highlight the importance of furthering our understanding of this functional
interaction.
Lastly, a hypothetical scenario relates to the defect in astrocytic glutamate transporter and the
neurotoxic accumulation of the excitatory amino acid that we have mentioned above. It has
been demonstrated that TNFα promotes the release of glutamate by activated microglia
through the cystine/glutamate exchanger (Xc)[140]. Though the implication of the Xc system
in ALS has not yet been investigated, it is intriguing that the Aβ peptide induces a neurotoxic
phenotype in microglia through the Xc-mediated release of glutamate Therefore, system Xc
represents a potential mechanism of microglia-mediated excitotoxicity that warrants further
study [141].
The potential non-cell-autonomous mechanisms involving microglial cells in the selective
degeneration of motoneurons in ALS are illustrated in Figure 2.
4. Involvement of neuroimmunity in motoneuron degeneration
4.1. Pathological phenotype of the immune system in ALS
In addition to astrocytes and microglia, immune cells may also play synergistic and critical
roles in ALS neuroinflammation and disease progression. Presence of a systemic immune
activation is suggested by abnormalities observed in the blood and CSF of ALS patients such
as increased numbers of circulating lymphocytes (CD4+ helper T cells, CD8+ cytotoxic T
lymphocytes (CTL) and natural killer (NK) cells), increased expression of MHC class II
molecules on monocytes as well as higher levels of inflammatory chemokines and cytokines
(regulated on activation normal T cell expressed and secreted (RANTES), monocyte chemo‐
tactic protein (MCP-1), IL-12, IL-15, IL-17 and IL-23)[142-146]. Further, post-mortem studies of
brain and spinal cord from ALS patients show that the activation and proliferation of microglia
is associated with an infiltration of activated macrophages, mast cells and T lymphocytes
which are found in close proximity to degenerating tissues [147-149]. An in-depth autopsy of
six ALS patients reveals an enrichment of T-cell receptor Vβ2 positive T cells in the spinal cord
and CSF, suggesting an antigen-driven T cell selection [150]. Finally, ALS patients with a more
rapidly progressing pathology show decreased numbers of regulatory T lymphocytes (Tregs),
suggesting that the numbers of Tregs are inversely correlated with disease progression [144,
151]. Tregs secrete anti-inflammatory cytokines such as IL-4, IL-10 and transforming growth
factor beta (TGF-β) as well as the neurotrophic growth factors glial-derived neurotrophic factor
(GDNF) and BDNF. Tregs are also able to dampen a Th1 pro-inflammatory response and
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attenuate toxic microglial responses. Contribution of the innate immune system is also
suggested by the presence of immunoglobulins and complement deposition as well as a
significant increase of NK cells in the blood of ALS patients [87, 144, 152]. While these
investigations of ALS samples and tissues do not assess the contributory role of the immune
system to the disease pathogenesis, they do highlight its active presence.
In support of what is observed in humans, ALS rodent models also display a particular
immunological phenotype. Indeed, SOD1G93A mice demonstrate that the inflammatory cell
subtypes are phenotypicaly and functionally different depending upon the disease stage
[96]. During the initial stages, infiltrating CD4+ T cells are almost mainly Th2 (IL-4+) while
as the disease progresses there is a skew toward Th1 (IFNγ+) cells and CD8+ T cells (both
IL-17A  positive  and  negative)[106,  153].  Alteration  in  inflammatory  cell  subtypes  is
associated with, and maybe driven by, differences in Tregs. Interestingly, early symptomat‐
ic SOD1G93A mice have increased numbers of Tregs and a decreased proliferation of effectors
T lymphocytes (Teffs), whereas decreased numbers of Tregs and increased proliferation of
Teffs is found in end-stage animals [151, 154]. The innate immune system is also affected
in ALS rodents, displayed by the substantial increase of NK and NKT in the spinal cord














































Figure 2. Proposed mechanisms by which microglial activation and inflammation contribute to the neurodegenera‐
tive process in ALS. Microglia can influence astrocytes and immune cells as well as directly impact motoneuron viability
via several mechanisms.
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sitivity to normally innocuous sensory stimulations. Spasticity develops following spinal cord
injury and is also regarded as an ALS clinical symptom [138]. The main mechanisms hypothe‐
sized to be responsible for spasticity are increased motoneuron excitability and increased
synaptic inputs in response to muscle stretch due to reduced inhibitory mechanisms. Recently,
it has been demonstrated that, following spinal cord injury, increased levels of BDNF mediated
spasticity, due to post-transcriptional down regulation of KCC2 [139]. Together, these studies
suggest that reactive microglia in ALS may exert an aberrant effect on the electrical activity of
motoneurons and highlight the importance of furthering our understanding of this functional
interaction.
Lastly, a hypothetical scenario relates to the defect in astrocytic glutamate transporter and the
neurotoxic accumulation of the excitatory amino acid that we have mentioned above. It has
been demonstrated that TNFα promotes the release of glutamate by activated microglia
through the cystine/glutamate exchanger (Xc)[140]. Though the implication of the Xc system
in ALS has not yet been investigated, it is intriguing that the Aβ peptide induces a neurotoxic
phenotype in microglia through the Xc-mediated release of glutamate Therefore, system Xc
represents a potential mechanism of microglia-mediated excitotoxicity that warrants further
study [141].
The potential non-cell-autonomous mechanisms involving microglial cells in the selective
degeneration of motoneurons in ALS are illustrated in Figure 2.
4. Involvement of neuroimmunity in motoneuron degeneration
4.1. Pathological phenotype of the immune system in ALS
In addition to astrocytes and microglia, immune cells may also play synergistic and critical
roles in ALS neuroinflammation and disease progression. Presence of a systemic immune
activation is suggested by abnormalities observed in the blood and CSF of ALS patients such
as increased numbers of circulating lymphocytes (CD4+ helper T cells, CD8+ cytotoxic T
lymphocytes (CTL) and natural killer (NK) cells), increased expression of MHC class II
molecules on monocytes as well as higher levels of inflammatory chemokines and cytokines
(regulated on activation normal T cell expressed and secreted (RANTES), monocyte chemo‐
tactic protein (MCP-1), IL-12, IL-15, IL-17 and IL-23)[142-146]. Further, post-mortem studies of
brain and spinal cord from ALS patients show that the activation and proliferation of microglia
is associated with an infiltration of activated macrophages, mast cells and T lymphocytes
which are found in close proximity to degenerating tissues [147-149]. An in-depth autopsy of
six ALS patients reveals an enrichment of T-cell receptor Vβ2 positive T cells in the spinal cord
and CSF, suggesting an antigen-driven T cell selection [150]. Finally, ALS patients with a more
rapidly progressing pathology show decreased numbers of regulatory T lymphocytes (Tregs),
suggesting that the numbers of Tregs are inversely correlated with disease progression [144,
151]. Tregs secrete anti-inflammatory cytokines such as IL-4, IL-10 and transforming growth
factor beta (TGF-β) as well as the neurotrophic growth factors glial-derived neurotrophic factor
(GDNF) and BDNF. Tregs are also able to dampen a Th1 pro-inflammatory response and
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attenuate toxic microglial responses. Contribution of the innate immune system is also
suggested by the presence of immunoglobulins and complement deposition as well as a
significant increase of NK cells in the blood of ALS patients [87, 144, 152]. While these
investigations of ALS samples and tissues do not assess the contributory role of the immune
system to the disease pathogenesis, they do highlight its active presence.
In support of what is observed in humans, ALS rodent models also display a particular
immunological phenotype. Indeed, SOD1G93A mice demonstrate that the inflammatory cell
subtypes are phenotypicaly and functionally different depending upon the disease stage
[96]. During the initial stages, infiltrating CD4+ T cells are almost mainly Th2 (IL-4+) while
as the disease progresses there is a skew toward Th1 (IFNγ+) cells and CD8+ T cells (both
IL-17A  positive  and  negative)[106,  153].  Alteration  in  inflammatory  cell  subtypes  is
associated with, and maybe driven by, differences in Tregs. Interestingly, early symptomat‐
ic SOD1G93A mice have increased numbers of Tregs and a decreased proliferation of effectors
T lymphocytes (Teffs), whereas decreased numbers of Tregs and increased proliferation of
Teffs is found in end-stage animals [151, 154]. The innate immune system is also affected
in ALS rodents, displayed by the substantial increase of NK and NKT in the spinal cord














































Figure 2. Proposed mechanisms by which microglial activation and inflammation contribute to the neurodegenera‐
tive process in ALS. Microglia can influence astrocytes and immune cells as well as directly impact motoneuron viability
via several mechanisms.
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Whether neuroinflammation is a cause or a consequence of motoneuron death is still debated.
It is interesting to note that inflammation is not limited to the CNS but systemic with increased
levels of plasma LPS associated with increased numbers of activated circulating monocytes
and T lymphocytes that correlate with disease evolution [142, 157]. A thymic dysfunction is
also observed in parallel to the neurodegenerative process in mutant SOD1 mice and ALS
patient [158]. In the CNS of ALS patients, TAR DNA-binding protein 43 (TDP-43) increased
and interacts with nuclear factor kappa B (NF-κB) in glial and neuronal cells. LPS-activation
of NF-κB in microglial cells expressing the TDP-43 mutant is associated with the production
of pro-inflammatory cytokines, including TNFα, IL-1β, IL-6 and IFNγ [159]. The central role
of inflammation and NF-κB in ALS was recently confirmed by the description in familial ALS
of mutations in the gene encoding optineurin, a negative regulator of TNF-induced NF-κB
activation [160].
Altogether, the information from pre-clinical models and ALS patients suggest that systemic
immune activation (innate and adaptive) might play a key role in ALS pathogenesis and may
represent an interesting target for the development of novel treatments. However, a better
understanding of the specific roles played by the different subtypes of immune cells is of
utmost necessity. Indeed, accumulative evidence suggests that inflammatory cells mediate
both protective and deleterious effects on motoneuron survival and that these functions vary
during disease progression.
4.2. The protective function of the immune response in ALS
Protective immunity, a homeostatic phenomenon important in the repair of damaged tissues,
results from both the clearance of debris and the effects of cytokines and growth factors
delivered by inflammatory T-cells to the site of injury [161, 162]. The neuroprotective ability
of immune cells is also evident in ALS. Indeed, when SOD1G93A mice are bred with mice lacking
functional T cells or CD4+ T cells, microglia skew towards an M1 inflammatory phenotype
and disease progression accelerates, suggesting that CD4+ T cells provide neuroprotection by
suppressing the cytotoxic activation of microglia. Accordingly, reconstitution of T cells
following bone marrow transplantation of SOD1G93A mice lacking functional T and B cells
prolonged their survival and suppressed the activation of M1 microglia [163]. Further analysis
shows that the increased numbers of CD4+/CD25+/Foxp3+ Tregs during early symptomatic
stages secrete IL-4, thus promoting the M2 protective microglia while inhibiting the neurotoxic
Th1 response and IFNγ secretion. As described above, these neuroprotective Tregs are
decreased as the disease progression accelerates. Co-culture experiments show that Tregs
suppress the expression of cytotoxic factors Nox2 and iNOS from SOD1G93A microglia through
IL-4. Tregs also inhibit the proliferation of SOD1G93A Teffs via the combined secretion of IL-4,
IL-10 and TGF-β[154]. The neuroprotective properties of Tregs are also reinforced by their
ability to secrete GDNF and BDNF, thus attenuating toxic microglial responses [164]. Impor‐
tantly, the passive transfer of endogenous Tregs into SOD1G93A mice lengthens disease duration
and prolongs survival, suggesting that Tregs is likely the neuroprotective subpopulation
among CD4+ T lymphocytes. Therefore, a subtype of immune cells appear to have a beneficial
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role in ALS and targeting the Tregs/M2 signaling pathway may be an attractive therapeutic
strategy for this neurodegenerative disease.
4.3. The neurotoxic function of the immune response in ALS
T lymphocytes could mediate motoneuron damage either directly through cell-cell contact,
secretion of cytokines or indirectly through activation of microglia and macrophages [165]. As
mentioned above, the effect of the immune system varies during disease progression from a
protective role at early stages to a neurotoxic activity when disease accelerates [151]. Neuro‐
protective activity has been associated with a Tregs/M2 response and expression of trophic
and anti-inflammatory factors such as BDNF, GDNF and IL-4 whereas neurotoxic effects are
associated with an M1/Th1/CTL pro-inflammatory immune response [106]. Accordingly,
mutated SOD1 Teffs proliferate to a greater extend and produce more IFNγ (Th1-driven)
during the rapidly progressing phase than Teffs isolated during slowly progressing phase
[154]. Different death pathways can be induced by Th1/CTL lymphocytes and promote
motoneuron loss in ALS. For instance, activation of Fas (CD95) has been demonstrated to
trigger a motoneuron-restricted death pathway. Motoneurons expressing ALS-linked SOD1
mutants showed an increased susceptibility to Fas-mediated death through activation of an
amplification loop [166-168]. Accordingly, mutant SOD1 mice with homozygous FasL
mutation present a reduced loss of motoneurons and a prolonged life expectancy [169].
Likewise, the RNA interference-mediated silencing of Fas following intrathecal delivery of
Fas-specific small interfering RNA improves motor function and survival in ALS mice [170].
While it remains unclear if T lymphocytes contribute to Fas-induced motoneuron degenera‐
tion, these studies suggest the possibility of their direct participation in the degenerative
process.
T lymphocytes could also amplify the neuroinflammation in ALS via glial cells. Upon activa‐
tion, microglia cells increase membrane expression of MHC class II molecules, becoming
efficient antigen presenting cells able to actively drive T cell activation and differentiation. In
turn, cytokines secreted by T cells modulate microglia phenotype and function. For instance,
TNFα and IFNγ, two major pro-inflammatory cytokines produced by Th1 lymphocytes induce
and activate M1 microglial cells and cause neurotoxicity toward motoneurons. Experimental
studies in ALS mice demonstrated that inflammatory cell subtypes were phenotypicaly and
functionally different depending upon the disease stage [96]. At initial stages, microglia
exhibits anti-inflammatory M2 phenotype (Ym1+, CD163+) and infiltrating T cells are almost
exclusively CD4+ while end-stage disease is associated with a skew of microglia toward a pro-
inflammatory M1 phenotype (Nox2+) and T lymphocytes are mainly Th1 cells [106].
The neurotoxic effect of NK cells is suggested by the neuroprotective effect of the immuno‐
modulation of NK cells, which increases lifespan of ALS mice and is accompanied by a reduced
astrocytosis. While the pathological modalities of NK cells in ALS remain elusive, several
hypothetical mechanisms can be raised. Indeed, activated NK (and to a lesser extent CD8+ T
cells) inhibit neurite outgrowth of cerebellar neurons in a cell contact-dependent manner in
vitro [171]. In sensory neurons, IL-2-activated NK cells have a killing activity that requires
cellular contact and perforin [172]. Further, the production of IFNγ by activated NK cells might
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of inflammation and NF-κB in ALS was recently confirmed by the description in familial ALS
of mutations in the gene encoding optineurin, a negative regulator of TNF-induced NF-κB
activation [160].
Altogether, the information from pre-clinical models and ALS patients suggest that systemic
immune activation (innate and adaptive) might play a key role in ALS pathogenesis and may
represent an interesting target for the development of novel treatments. However, a better
understanding of the specific roles played by the different subtypes of immune cells is of
utmost necessity. Indeed, accumulative evidence suggests that inflammatory cells mediate
both protective and deleterious effects on motoneuron survival and that these functions vary
during disease progression.
4.2. The protective function of the immune response in ALS
Protective immunity, a homeostatic phenomenon important in the repair of damaged tissues,
results from both the clearance of debris and the effects of cytokines and growth factors
delivered by inflammatory T-cells to the site of injury [161, 162]. The neuroprotective ability
of immune cells is also evident in ALS. Indeed, when SOD1G93A mice are bred with mice lacking
functional T cells or CD4+ T cells, microglia skew towards an M1 inflammatory phenotype
and disease progression accelerates, suggesting that CD4+ T cells provide neuroprotection by
suppressing the cytotoxic activation of microglia. Accordingly, reconstitution of T cells
following bone marrow transplantation of SOD1G93A mice lacking functional T and B cells
prolonged their survival and suppressed the activation of M1 microglia [163]. Further analysis
shows that the increased numbers of CD4+/CD25+/Foxp3+ Tregs during early symptomatic
stages secrete IL-4, thus promoting the M2 protective microglia while inhibiting the neurotoxic
Th1 response and IFNγ secretion. As described above, these neuroprotective Tregs are
decreased as the disease progression accelerates. Co-culture experiments show that Tregs
suppress the expression of cytotoxic factors Nox2 and iNOS from SOD1G93A microglia through
IL-4. Tregs also inhibit the proliferation of SOD1G93A Teffs via the combined secretion of IL-4,
IL-10 and TGF-β[154]. The neuroprotective properties of Tregs are also reinforced by their
ability to secrete GDNF and BDNF, thus attenuating toxic microglial responses [164]. Impor‐
tantly, the passive transfer of endogenous Tregs into SOD1G93A mice lengthens disease duration
and prolongs survival, suggesting that Tregs is likely the neuroprotective subpopulation
among CD4+ T lymphocytes. Therefore, a subtype of immune cells appear to have a beneficial
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role in ALS and targeting the Tregs/M2 signaling pathway may be an attractive therapeutic
strategy for this neurodegenerative disease.
4.3. The neurotoxic function of the immune response in ALS
T lymphocytes could mediate motoneuron damage either directly through cell-cell contact,
secretion of cytokines or indirectly through activation of microglia and macrophages [165]. As
mentioned above, the effect of the immune system varies during disease progression from a
protective role at early stages to a neurotoxic activity when disease accelerates [151]. Neuro‐
protective activity has been associated with a Tregs/M2 response and expression of trophic
and anti-inflammatory factors such as BDNF, GDNF and IL-4 whereas neurotoxic effects are
associated with an M1/Th1/CTL pro-inflammatory immune response [106]. Accordingly,
mutated SOD1 Teffs proliferate to a greater extend and produce more IFNγ (Th1-driven)
during the rapidly progressing phase than Teffs isolated during slowly progressing phase
[154]. Different death pathways can be induced by Th1/CTL lymphocytes and promote
motoneuron loss in ALS. For instance, activation of Fas (CD95) has been demonstrated to
trigger a motoneuron-restricted death pathway. Motoneurons expressing ALS-linked SOD1
mutants showed an increased susceptibility to Fas-mediated death through activation of an
amplification loop [166-168]. Accordingly, mutant SOD1 mice with homozygous FasL
mutation present a reduced loss of motoneurons and a prolonged life expectancy [169].
Likewise, the RNA interference-mediated silencing of Fas following intrathecal delivery of
Fas-specific small interfering RNA improves motor function and survival in ALS mice [170].
While it remains unclear if T lymphocytes contribute to Fas-induced motoneuron degenera‐
tion, these studies suggest the possibility of their direct participation in the degenerative
process.
T lymphocytes could also amplify the neuroinflammation in ALS via glial cells. Upon activa‐
tion, microglia cells increase membrane expression of MHC class II molecules, becoming
efficient antigen presenting cells able to actively drive T cell activation and differentiation. In
turn, cytokines secreted by T cells modulate microglia phenotype and function. For instance,
TNFα and IFNγ, two major pro-inflammatory cytokines produced by Th1 lymphocytes induce
and activate M1 microglial cells and cause neurotoxicity toward motoneurons. Experimental
studies in ALS mice demonstrated that inflammatory cell subtypes were phenotypicaly and
functionally different depending upon the disease stage [96]. At initial stages, microglia
exhibits anti-inflammatory M2 phenotype (Ym1+, CD163+) and infiltrating T cells are almost
exclusively CD4+ while end-stage disease is associated with a skew of microglia toward a pro-
inflammatory M1 phenotype (Nox2+) and T lymphocytes are mainly Th1 cells [106].
The neurotoxic effect of NK cells is suggested by the neuroprotective effect of the immuno‐
modulation of NK cells, which increases lifespan of ALS mice and is accompanied by a reduced
astrocytosis. While the pathological modalities of NK cells in ALS remain elusive, several
hypothetical mechanisms can be raised. Indeed, activated NK (and to a lesser extent CD8+ T
cells) inhibit neurite outgrowth of cerebellar neurons in a cell contact-dependent manner in
vitro [171]. In sensory neurons, IL-2-activated NK cells have a killing activity that requires
cellular contact and perforin [172]. Further, the production of IFNγ by activated NK cells might
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directly trigger motoneuron death through the LIGHT/LT-βR pathway or potentiate a
cytotoxic Th1/CTL response via the combined action of other NK-related cytokines such as
IL-17 or IL-22 [173]. Of note, NK cells also produce IL-4 upon activation, which as described
earlier, mediates a neuroprotective effect. Therefore, NK cells represent an appealing branch
of the immunopathology that could be considered as a therapeutic target for ALS.
In addition to the adaptive immune system, several studies suggest that humoral immunity
and immunoglobulins could also contribute to the disease. Autoantibodies to voltage-gated
Ca2+ or K+ channels have been described in ALS patients, which induce specific motoneuron
alterations both in vitro and in vivo after passive transfer in mice [174-178]. Accordingly, C5a
and other complement activation products released after activation of the classical comple‐
ment pathway by antibodies are elevated in the CSF and spinal cord of ALS mice and patients
and specific inhibition of C5a receptor ameliorates disease in SOD1G93A mice [179, 180].
Additionally, abnormal levels of anti-Fas antibodies, able to induce neuronal apoptosis in
vitro, have been detected in the serum of patients with ALS [181, 182]. Thus, both the innate
and adaptive immune system appear to have deleterious consequences on the survival and
maintenance of motoneurons in ALS.
Figure 3 illustrates the potential mechanisms implicating different populations of immune cells
in ALS pathogenesis.
5. Pre-clinical therapies targeting neuroinflammation
5.1. Pharmacological targeting of the neuroinflammatory response
In light of the salient evidence supporting the contribution of neuroinflammation in ALS,
several drug- or cell-based therapeutic approaches have been evaluated in ALS mice for their
ability to modulate the pathologic process. Those that have shown a positive effect on
astrocytosis and microgliosis are described below and have been categorized based on their
desired functional target.
In order to mitigate the detrimental effects of the overactive p75NTR pathway in ALS, an
antagonist that mimics the short NGF β loop region that binds the p75NTR has been utilized
[183]. Unfortunately, the intraperitoneal (i.p.) delivery of the p75NTR antagonist from asymp‐
tomatic stage up until the endpoint of the disease does not improve the phenotype or survival
of SOD1G93A mice [183]. However, antisense peptide nucleic acid-based silencing of p75NTR
following early systemic i.p. administration delays by about 10% both onset and progression
of the disease [184]. Although, alternative route of administration or development of more
efficient molecules should be assessed, p75NTR represents a therapeutic target that needs to be
further explored.
COX-2 appears as an appealing therapeutic target for ALS as it promotes both pro-inflamma‐
tory events and astrocytic glutamate release [60, 67]. Celecoxib, a COX-2 inhibitor, fed to
SOD1G93A mice from asymptomatic to end-stage results in a delayed onset and an increased
lifespan of approximately 25%. Celecoxib treatment prevents loss of spinal motoneurons and
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reduces astrocytosis [185]. Importantly, celecoxib-treated SOD1G93A spinal cords display
reduced levels of PGE2, a potent pro-inflammatory mediator as well as a signal for glutamate
release from astrocytes [67].
Lenalidomide, an immunomodulatory drug with pleiotropic properties derived from thali‐
domide, has been evaluated in mutant SOD1 mice due to its inhibitory effect on TNFα
production by monocytes [186]. A lenalidomide-diet given to SOD1G93A mice retards disease
onset, ameliorates motoneuron survival and extends survival by 18%. A significant decrease
in IL-1α and TNFα as well as an increase in IL-1 receptor antagonist (IL-1RA) and TGF-β1 is
observed in the spinal cord of Lenalidomide-treated mice [187]. In a similar study, the lifespan
of ALS mice treated with lenalidomide at onset of symptoms is increased by 12%. Concomi‐
tantly, there is an improved survival of motoneurons, decreased levels of the pro-inflammatory
cytokines TNFα and Fas associated Factor as well as an increased expression of the anti-
inflammatory cytokines TGF-β3 and IL-1RA [188].
Epigallocathecin gallate (EGCG) is a green tea polyphenol that can prevent microglial
neurotoxicity through the modulation of TNFα mRNA transcription and release as well as
iNOS production [189]. The daily oral administration of EGCG to SOD1G93A mice daily from



































Figure 3. Potential Mechanisms by which peripheral and central immunity might contribute to the neurodegenerative
process in ALS. Both neuroprotective and neurotoxic functions can be proposed for the involvement of lymphocytes in
ALS pathogenesis (as described in section 3).
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and other complement activation products released after activation of the classical comple‐
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and specific inhibition of C5a receptor ameliorates disease in SOD1G93A mice [179, 180].
Additionally, abnormal levels of anti-Fas antibodies, able to induce neuronal apoptosis in
vitro, have been detected in the serum of patients with ALS [181, 182]. Thus, both the innate
and adaptive immune system appear to have deleterious consequences on the survival and
maintenance of motoneurons in ALS.
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in ALS pathogenesis.
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ability to modulate the pathologic process. Those that have shown a positive effect on
astrocytosis and microgliosis are described below and have been categorized based on their
desired functional target.
In order to mitigate the detrimental effects of the overactive p75NTR pathway in ALS, an
antagonist that mimics the short NGF β loop region that binds the p75NTR has been utilized
[183]. Unfortunately, the intraperitoneal (i.p.) delivery of the p75NTR antagonist from asymp‐
tomatic stage up until the endpoint of the disease does not improve the phenotype or survival
of SOD1G93A mice [183]. However, antisense peptide nucleic acid-based silencing of p75NTR
following early systemic i.p. administration delays by about 10% both onset and progression
of the disease [184]. Although, alternative route of administration or development of more
efficient molecules should be assessed, p75NTR represents a therapeutic target that needs to be
further explored.
COX-2 appears as an appealing therapeutic target for ALS as it promotes both pro-inflamma‐
tory events and astrocytic glutamate release [60, 67]. Celecoxib, a COX-2 inhibitor, fed to
SOD1G93A mice from asymptomatic to end-stage results in a delayed onset and an increased
lifespan of approximately 25%. Celecoxib treatment prevents loss of spinal motoneurons and
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reduces astrocytosis [185]. Importantly, celecoxib-treated SOD1G93A spinal cords display
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respectively. EGCG also moderately mitigates motoneuron loss and reduces microglia
activation [190].
Pioglitazone is a drug that was initially developed to treat type II diabetes patients that also
exerts ant-inflammatory and neuroprotective activities (reviewed in [191]). For these reasons,
it has been hypothesized that it may improve ALS pathology. Indeed, pioglitazone-fed
SOD1G93A mice have a delayed onset of 10% and a prolonged lifespan of about 8% [192].
Pioglitazone significantly reduces microgliosis and astrocytosis in SOD1G93A mice as well as
alters the expression profile of spinal cord lysates from pro-inflammatory to anti-inflammatory
[192, 193]. Further analysis of spinal cords reveals that pioglitazone may act through the
inhibition of the p38 kinase, NF-κB and STAT3 pathways [167, 193, 194].
Olesoxime has previously been selected as a neuroprotective agent via a motoneuron survival-
based screen [195]. Interestingly, SOD1G93A mice fed an olesoxime diet from asymptomatic
stage to end-stage survive 10% longer than non-treated mice and also demonstrate a reduction
in both astrocytosis and microgliosis [195, 196].
Dicatechol nordihydroguaiaretic acid (NDGA) is a selective inhibitor of 5-LOX that presents
TNFα antagonizing activity in microglial cells. SOD1G93A mice on an NDGA-diet from pre‐
symptomatic stage to end-point have a 32% increase in median lifespan as well as a reduced
motoneuron loss and astrocytosis [197].
Minocycline is a member of the tetracycline molecules that can enter the CNS and mediates
inflammation and microgliosis (reviewed in [198]). Asymptomatic SOD1G93A mice that received
daily minocycline by i.p. injection have a delayed disease onset, a 16% increase in lifespan as
well as a preservation of spinal motoneurons [199]. Similarly, minocycline-fed late pre-
symptomatic SOD1G37R mice display a 6% longer survival, an increased number of spinal cord
motoneurons and a reduced microgliosis [200]. However, a minocycline diet in symptomatic
SOD1G93A has no effect on survival while amplifying both astrocytosis and microgliosis [201].
These results strikingly illustrate the time-dependent dynamics of the neuroinflammation
response, highlighting not only the requirement to target the most pertinent therapeutic
molecular and cellular effectors but to also do so at the proper stage of the disease.
5.2. Advances and possible applications of protein therapy
In addition to chemical compounds, the therapeutic delivery of proteins has also been assessed
as a potential modulator of neuroinflammation in ALS. Indeed, the granulocyte-colony
stimulating factor (G-CSF), a hematopoietic growth factor, has been delivered to SOD1G93A mice
by osmotic pump starting at asymptomatic stage for a continuance of 8 weeks [202]. G-CSF-
recipient ALS mice display a delay in disease onset as well as an increased motoneuron
survival. The time to clinical endstage is increased by 10% in SOD1G93A mice receiving G-CSF.
Importantly, while G-CSF was initially used for its neuroprotective effects and its ability to
readily cross the blood-brain barrier [203, 204], further characterization of treated SOD1G93A
mice shows a reduced spinal cord astrocytosis and microgliosis as well as an increased
availability of migratory healing monocytes, suggesting that G-CSF may be beneficial in ALS
via its modulation of neuroinflammation [205].
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Another potential protein therapy is the administration of the activated protein C (APC), a
plasma protease with anti-coagulant, neuroprotective and anti-inflammatory functions
(reviewed in [206]). A daily i.p. injection of APC to symptomatic SOD1G93A mice until death
slows disease progression, leading to a 25% increase in lifespan [207]. Further, APC appears
to exert its beneficial effects via a downregulation of mutant SOD1 expression in both moto‐
neurons and microglia, thus resulting in delayed neuroinflammatory events [207].
Anakinra (Kineret), a recombinant form of human IL-1RA, that inhibits the pro-inflammatory
activity of both IL-1α and IL-1β, is approved by the U.S food and drug administration for
rheumatoid arthritis [208]. When administrated by i.p. daily to asymptomatic stage to
SOD1G93A mice, it ameliorates motor function and prolongs lifespan by approximately 4% [121].
The CD40 costimulatory pathway, which plays an important role in B and T cell activation
[209], has been proposed to contribute to ALS pathogenesis. The weekly delivery of a blocking
anti-CD40L antibody by i.p. injection starting at an asymptomatic stage delays onset and
prolongs survival by approximately 7%. Consistently, anti-CD40L delivery reduces signifi‐
cantly the percentage of peripheral CD8+ T cells as well as GFAP+ astrocytes and Mac2+
microglia in the spinal cord [66], suggesting that the CD40 pathway, an integral component of
neuroimmunity, is a potential therapeutic target in ALS.
5.3. Cell therapy perspectives
While drugs and protein therapy target the misregulated pathways within astrocytes and
microglia, the aim of cell therapy is to replace these aberrantly functional cells by healthy ones
or use implanted cells as a therapeutic platform to deliver neurotrophic support, thus hope‐
fully alleviating neuroinflammation in ALS.
5.3.1. Glial precursor cells
Glial cell therapy has indeed been evaluated by isolating human neural progenitor cells
(hNPCs) and genetically modifying them to express GDNF [210, 211]. Prior to direct injection
in the spinal cord of SOD1G93A rats, hNPCs were pre-differentiated into astrocytes [210]. Despite
the fact that the hNPC injection did not increase the lifespan of SOD1G93A rats, they do localize
within both the grey and white matter of the spinal cord and survive until the death of the
animal. Further investigation of this method reveals that hNPCs preserve dying motoneuron
cell bodies in SOD1G93A rats without improving their innervations at the neuromuscular
junction [212]. In SOD1G93A mice, GDNF-expressing hNPCs also migrate to the spinal cord
where a subset of them differentiates into astrocytes, again without improving survival or
neurodegeneration [213]. However, the lack of beneficial outcome is most likely due to the
regional specificity of GDNF’s biological activity, as intramuscular but not intraspinal delivery
of GDNF exerts its neuroprotective effect [214, 215]. Another astrocyte precursor with potential
benefits is the glial-restricted progenitors (GRPs), isolated from the spinal cord of embryonic
rats [216]. The transplantation of GRPs in the ventral horn of SOD1G93A rats shows that these
cells differentiate into astrocytes and can survive and migrate along the spinal cord [217].
Importantly, GRP-recipient ALS rats survive longer as well as show a slower cervical neuro‐
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respectively. EGCG also moderately mitigates motoneuron loss and reduces microglia
activation [190].
Pioglitazone is a drug that was initially developed to treat type II diabetes patients that also
exerts ant-inflammatory and neuroprotective activities (reviewed in [191]). For these reasons,
it has been hypothesized that it may improve ALS pathology. Indeed, pioglitazone-fed
SOD1G93A mice have a delayed onset of 10% and a prolonged lifespan of about 8% [192].
Pioglitazone significantly reduces microgliosis and astrocytosis in SOD1G93A mice as well as
alters the expression profile of spinal cord lysates from pro-inflammatory to anti-inflammatory
[192, 193]. Further analysis of spinal cords reveals that pioglitazone may act through the
inhibition of the p38 kinase, NF-κB and STAT3 pathways [167, 193, 194].
Olesoxime has previously been selected as a neuroprotective agent via a motoneuron survival-
based screen [195]. Interestingly, SOD1G93A mice fed an olesoxime diet from asymptomatic
stage to end-stage survive 10% longer than non-treated mice and also demonstrate a reduction
in both astrocytosis and microgliosis [195, 196].
Dicatechol nordihydroguaiaretic acid (NDGA) is a selective inhibitor of 5-LOX that presents
TNFα antagonizing activity in microglial cells. SOD1G93A mice on an NDGA-diet from pre‐
symptomatic stage to end-point have a 32% increase in median lifespan as well as a reduced
motoneuron loss and astrocytosis [197].
Minocycline is a member of the tetracycline molecules that can enter the CNS and mediates
inflammation and microgliosis (reviewed in [198]). Asymptomatic SOD1G93A mice that received
daily minocycline by i.p. injection have a delayed disease onset, a 16% increase in lifespan as
well as a preservation of spinal motoneurons [199]. Similarly, minocycline-fed late pre-
symptomatic SOD1G37R mice display a 6% longer survival, an increased number of spinal cord
motoneurons and a reduced microgliosis [200]. However, a minocycline diet in symptomatic
SOD1G93A has no effect on survival while amplifying both astrocytosis and microgliosis [201].
These results strikingly illustrate the time-dependent dynamics of the neuroinflammation
response, highlighting not only the requirement to target the most pertinent therapeutic
molecular and cellular effectors but to also do so at the proper stage of the disease.
5.2. Advances and possible applications of protein therapy
In addition to chemical compounds, the therapeutic delivery of proteins has also been assessed
as a potential modulator of neuroinflammation in ALS. Indeed, the granulocyte-colony
stimulating factor (G-CSF), a hematopoietic growth factor, has been delivered to SOD1G93A mice
by osmotic pump starting at asymptomatic stage for a continuance of 8 weeks [202]. G-CSF-
recipient ALS mice display a delay in disease onset as well as an increased motoneuron
survival. The time to clinical endstage is increased by 10% in SOD1G93A mice receiving G-CSF.
Importantly, while G-CSF was initially used for its neuroprotective effects and its ability to
readily cross the blood-brain barrier [203, 204], further characterization of treated SOD1G93A
mice shows a reduced spinal cord astrocytosis and microgliosis as well as an increased
availability of migratory healing monocytes, suggesting that G-CSF may be beneficial in ALS
via its modulation of neuroinflammation [205].
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Another potential protein therapy is the administration of the activated protein C (APC), a
plasma protease with anti-coagulant, neuroprotective and anti-inflammatory functions
(reviewed in [206]). A daily i.p. injection of APC to symptomatic SOD1G93A mice until death
slows disease progression, leading to a 25% increase in lifespan [207]. Further, APC appears
to exert its beneficial effects via a downregulation of mutant SOD1 expression in both moto‐
neurons and microglia, thus resulting in delayed neuroinflammatory events [207].
Anakinra (Kineret), a recombinant form of human IL-1RA, that inhibits the pro-inflammatory
activity of both IL-1α and IL-1β, is approved by the U.S food and drug administration for
rheumatoid arthritis [208]. When administrated by i.p. daily to asymptomatic stage to
SOD1G93A mice, it ameliorates motor function and prolongs lifespan by approximately 4% [121].
The CD40 costimulatory pathway, which plays an important role in B and T cell activation
[209], has been proposed to contribute to ALS pathogenesis. The weekly delivery of a blocking
anti-CD40L antibody by i.p. injection starting at an asymptomatic stage delays onset and
prolongs survival by approximately 7%. Consistently, anti-CD40L delivery reduces signifi‐
cantly the percentage of peripheral CD8+ T cells as well as GFAP+ astrocytes and Mac2+
microglia in the spinal cord [66], suggesting that the CD40 pathway, an integral component of
neuroimmunity, is a potential therapeutic target in ALS.
5.3. Cell therapy perspectives
While drugs and protein therapy target the misregulated pathways within astrocytes and
microglia, the aim of cell therapy is to replace these aberrantly functional cells by healthy ones
or use implanted cells as a therapeutic platform to deliver neurotrophic support, thus hope‐
fully alleviating neuroinflammation in ALS.
5.3.1. Glial precursor cells
Glial cell therapy has indeed been evaluated by isolating human neural progenitor cells
(hNPCs) and genetically modifying them to express GDNF [210, 211]. Prior to direct injection
in the spinal cord of SOD1G93A rats, hNPCs were pre-differentiated into astrocytes [210]. Despite
the fact that the hNPC injection did not increase the lifespan of SOD1G93A rats, they do localize
within both the grey and white matter of the spinal cord and survive until the death of the
animal. Further investigation of this method reveals that hNPCs preserve dying motoneuron
cell bodies in SOD1G93A rats without improving their innervations at the neuromuscular
junction [212]. In SOD1G93A mice, GDNF-expressing hNPCs also migrate to the spinal cord
where a subset of them differentiates into astrocytes, again without improving survival or
neurodegeneration [213]. However, the lack of beneficial outcome is most likely due to the
regional specificity of GDNF’s biological activity, as intramuscular but not intraspinal delivery
of GDNF exerts its neuroprotective effect [214, 215]. Another astrocyte precursor with potential
benefits is the glial-restricted progenitors (GRPs), isolated from the spinal cord of embryonic
rats [216]. The transplantation of GRPs in the ventral horn of SOD1G93A rats shows that these
cells differentiate into astrocytes and can survive and migrate along the spinal cord [217].
Importantly, GRP-recipient ALS rats survive longer as well as show a slower cervical neuro‐
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degeneration and a reduced spinal cord microgliosis. In SOD1G93A mice however, while the
GRPs efficiently differentiate into astrocytes, survive, and locate to both grey and white matter
of the spinal cord, they do not influence lifespan and do not prevent motoneuron loss [218].
Human umbilical cord blood cells (hUCBCs) also have the potential to differentiate into glial
cells (reviewed in [219]). Pre-symptomatic SOD1G93A mice received either native hUCBCs or
cells engineered to overexpress vascular endothelial growth factor (VEGF) and/or FGF [220].
Two weeks following the orbital injection, analysis of the spinal cords reveals the presence of
the transplanted hUCBCs with the non-modified cells preferentially differentiating into
microglia while the cells expressing the growth factors became astrocytes [220]. Importantly,
the administration of hUCBCs to pre-symptomatic and symptomatic SOD1G93A mice via
intravenous injections delays disease progression, increases lifespan by approximately 8%,
prevents motoneuron loss and reduces both astrocytosis and microgliosis [221].
5.3.2. Mesenchymal stem cells
Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate in a broad
variety of cells and instigate a reparative environment. MSCs have been therapeutically
assessed in light of their immunosuppressive capacities, limiting inflammatory responses in
their surroundings [222]. MSCs isolated from rat muscle injected into the CSF of SOD1G93A rats
subsequently localize to the spinal cord and adopt astrocytic characteristics [223]. The injected
ALS rats display motor deficits at the same age than vehicle-injected animals. However, the
MSC-injected SOD1G93A rats show an increased survival of approximately 11%, an increased
number of motoneurons as well as a reduced neuroinflammation [223]. Similarly, the intra‐
venous injection of MSCs after the onset of disease in SOD1G93A mice increases lifespan by 13%
and reduces both astrocytosis and microgliosis [224]. Alternatively, a combination of intra‐
spinal and intravenous transplantation of MSCs has been evaluated in SOD1G93A rats at disease
onset and leads to a 6% increased in survival [225]. Similarly, the intracisternal delivery at
asymptomatic stage of human MSCs derived from ALS patients also prolongs survival ALS
mice by about 6% [226]. Further, intramuscular administration of MSCs genetically engineered
to produce GDNF in asymptomatic SOD1G93A rats does not influence the time of disease onset
but prolongs survival of implanted ALS rats. However, the beneficial effect of MSCs trans‐
plantation was not correlated with decreased astrocytosis or microgliosis [227]. Although this
pre-clinical evidence proposes MSC-based therapy as a potential means to intervene in the
course of disease, the neuroprotective mechanisms involved remain elusive, especially
regarding the immunosuppressive abilities of MSCs.
6. Clinical aspects
As discussed in the present book and chapter, the molecular pathways and cellular effectors
responsible for ALS are numerous and their precise contributions to disease pathogenesis are
still debated. While this has made translational therapy a challenge, it has shifted the devel‐
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opment of neuronal-specific therapies toward those targeting more general phenomena
characterizing ALS, including neuroinflammation.
The pattern of neurodegeneration in ALS has been described as overall linear, albeit with some
variations [228, 229]. One of the biggest discrepancies between individuals is the evolution of
the disease, which ranges from death in less than 6 months to a limited handicap after more
than 10 years following the initial diagnosis. Either rapid or slow, the topography of neuro‐
degenerative events is rather reproducible, usually spreading from one limb to the opposite
one and then to another level. Thus, from the moment a patient presents himself at the clinic
with symptoms, there is a progressive extension and diffusion of the pathological process. This
spreading of neurodegeneration over time may result from the infiltration and migration of
non-neuronal cells or by the exchange of molecules from one cell to another. This hypothesis,
based on pre-clinical and clinical observations, highlights the importance of developing
therapies that modulate immunity and/or neuroinflammation.
As described in section 2.3, the excitotoxic theory suggests that glutamate accumulates within
the intercellular space and induce a pathological synaptic excitotoxic transmission, leading to
motoneuron death [230]. This hypothesis motivated a series of clinical trials with riluzole, a
potent glutamate antagonist, culminating in the demonstration that riluzole is efficient in
slowing down disease progression [231]. To date, only riluzole is marketed as a bona fide
treatment for ALS. While riluzole is thought to reduce glutamate release in neurons via the
inhibition of voltage-gated sodium channels [232], riluzole may also have some important anti-
inflammatory functions. Indeed, riluzole significantly decreases IL-1β, TNFα and iNOS levels
as well as increases IL-10 levels in LPS-activated microglial cells [233]. Another neuroprotective
mechanism mediated by riluzole may include the production of BDNF and GDNF by astro‐
cytes, as demonstrated in cultures [234]. In experimental autoimmune encephalomyelitis
(EAE), a commonly used murine model of multiple sclerosis, riluzole administration signifi‐
cantly ameliorates motor functions. Importantly, the decrease in the clinical severity of
riluzole-treated EAE mice is associated with a diminished inflammatory response and a
marked reduction in lymphocytes infiltrating the spinal cord [235]. Together, these results
suggest a more complex mode of action for riluzole where a modulation of inflammation
should be acknowledged as one of its therapeutic activity.
Other immunomodulatory agents have also been tested in ALS clinical trials, but their
therapeutic benefits have not been as promising as those demonstrated by riluzole [236].
Indeed, immunosuppressants such as cyclosporine or cyclophosphamide as well as the more
aggressive total lymphoid irradiation were not successful. The intravenous immunoglobulin
G (IVIg) treatment has been proposed to suppress inflammatory responses by inducing an
IFNγ-refractory state in macrophages [237]. Interestingly, an open-label pilot study of IVIg
administration in ALS patients led to a transient clinical improvement in subjects with bulbar-
ALS but not in patients with lower signs, suggesting that immunomodulation may have
therapeutic potential [238]. Nevertheless, the combined administration of cyclophosphamide
and IVIg in another cohort of 7 patients with upper and lower signs did not lead to clinical
improvement [239]. These studies highlight the importance of a better identification of targets
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degeneration and a reduced spinal cord microgliosis. In SOD1G93A mice however, while the
GRPs efficiently differentiate into astrocytes, survive, and locate to both grey and white matter
of the spinal cord, they do not influence lifespan and do not prevent motoneuron loss [218].
Human umbilical cord blood cells (hUCBCs) also have the potential to differentiate into glial
cells (reviewed in [219]). Pre-symptomatic SOD1G93A mice received either native hUCBCs or
cells engineered to overexpress vascular endothelial growth factor (VEGF) and/or FGF [220].
Two weeks following the orbital injection, analysis of the spinal cords reveals the presence of
the transplanted hUCBCs with the non-modified cells preferentially differentiating into
microglia while the cells expressing the growth factors became astrocytes [220]. Importantly,
the administration of hUCBCs to pre-symptomatic and symptomatic SOD1G93A mice via
intravenous injections delays disease progression, increases lifespan by approximately 8%,
prevents motoneuron loss and reduces both astrocytosis and microgliosis [221].
5.3.2. Mesenchymal stem cells
Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate in a broad
variety of cells and instigate a reparative environment. MSCs have been therapeutically
assessed in light of their immunosuppressive capacities, limiting inflammatory responses in
their surroundings [222]. MSCs isolated from rat muscle injected into the CSF of SOD1G93A rats
subsequently localize to the spinal cord and adopt astrocytic characteristics [223]. The injected
ALS rats display motor deficits at the same age than vehicle-injected animals. However, the
MSC-injected SOD1G93A rats show an increased survival of approximately 11%, an increased
number of motoneurons as well as a reduced neuroinflammation [223]. Similarly, the intra‐
venous injection of MSCs after the onset of disease in SOD1G93A mice increases lifespan by 13%
and reduces both astrocytosis and microgliosis [224]. Alternatively, a combination of intra‐
spinal and intravenous transplantation of MSCs has been evaluated in SOD1G93A rats at disease
onset and leads to a 6% increased in survival [225]. Similarly, the intracisternal delivery at
asymptomatic stage of human MSCs derived from ALS patients also prolongs survival ALS
mice by about 6% [226]. Further, intramuscular administration of MSCs genetically engineered
to produce GDNF in asymptomatic SOD1G93A rats does not influence the time of disease onset
but prolongs survival of implanted ALS rats. However, the beneficial effect of MSCs trans‐
plantation was not correlated with decreased astrocytosis or microgliosis [227]. Although this
pre-clinical evidence proposes MSC-based therapy as a potential means to intervene in the
course of disease, the neuroprotective mechanisms involved remain elusive, especially
regarding the immunosuppressive abilities of MSCs.
6. Clinical aspects
As discussed in the present book and chapter, the molecular pathways and cellular effectors
responsible for ALS are numerous and their precise contributions to disease pathogenesis are
still debated. While this has made translational therapy a challenge, it has shifted the devel‐
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opment of neuronal-specific therapies toward those targeting more general phenomena
characterizing ALS, including neuroinflammation.
The pattern of neurodegeneration in ALS has been described as overall linear, albeit with some
variations [228, 229]. One of the biggest discrepancies between individuals is the evolution of
the disease, which ranges from death in less than 6 months to a limited handicap after more
than 10 years following the initial diagnosis. Either rapid or slow, the topography of neuro‐
degenerative events is rather reproducible, usually spreading from one limb to the opposite
one and then to another level. Thus, from the moment a patient presents himself at the clinic
with symptoms, there is a progressive extension and diffusion of the pathological process. This
spreading of neurodegeneration over time may result from the infiltration and migration of
non-neuronal cells or by the exchange of molecules from one cell to another. This hypothesis,
based on pre-clinical and clinical observations, highlights the importance of developing
therapies that modulate immunity and/or neuroinflammation.
As described in section 2.3, the excitotoxic theory suggests that glutamate accumulates within
the intercellular space and induce a pathological synaptic excitotoxic transmission, leading to
motoneuron death [230]. This hypothesis motivated a series of clinical trials with riluzole, a
potent glutamate antagonist, culminating in the demonstration that riluzole is efficient in
slowing down disease progression [231]. To date, only riluzole is marketed as a bona fide
treatment for ALS. While riluzole is thought to reduce glutamate release in neurons via the
inhibition of voltage-gated sodium channels [232], riluzole may also have some important anti-
inflammatory functions. Indeed, riluzole significantly decreases IL-1β, TNFα and iNOS levels
as well as increases IL-10 levels in LPS-activated microglial cells [233]. Another neuroprotective
mechanism mediated by riluzole may include the production of BDNF and GDNF by astro‐
cytes, as demonstrated in cultures [234]. In experimental autoimmune encephalomyelitis
(EAE), a commonly used murine model of multiple sclerosis, riluzole administration signifi‐
cantly ameliorates motor functions. Importantly, the decrease in the clinical severity of
riluzole-treated EAE mice is associated with a diminished inflammatory response and a
marked reduction in lymphocytes infiltrating the spinal cord [235]. Together, these results
suggest a more complex mode of action for riluzole where a modulation of inflammation
should be acknowledged as one of its therapeutic activity.
Other immunomodulatory agents have also been tested in ALS clinical trials, but their
therapeutic benefits have not been as promising as those demonstrated by riluzole [236].
Indeed, immunosuppressants such as cyclosporine or cyclophosphamide as well as the more
aggressive total lymphoid irradiation were not successful. The intravenous immunoglobulin
G (IVIg) treatment has been proposed to suppress inflammatory responses by inducing an
IFNγ-refractory state in macrophages [237]. Interestingly, an open-label pilot study of IVIg
administration in ALS patients led to a transient clinical improvement in subjects with bulbar-
ALS but not in patients with lower signs, suggesting that immunomodulation may have
therapeutic potential [238]. Nevertheless, the combined administration of cyclophosphamide
and IVIg in another cohort of 7 patients with upper and lower signs did not lead to clinical
improvement [239]. These studies highlight the importance of a better identification of targets
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as well as a more efficient and specific design of therapies by specifically taking into account
the clinical heterogeneity of the disease.
Among the drugs mentioned that have been evaluated in pre-clinical models, celecoxib and
pioglitazone were both assessed in a randomized, double-blind, placebo-controlled trial, but
gave disappointing results as there were no effects on motor function and survival rate [240,
241]. When minocycline was tested in a randomized placebo-controlled phase III trial, it not
only did not show any benefits, it in fact displayed serious harmful effect in patients [242].
Thalidomide, an analogue of lenalidomide, which showed therapeutic potential in SOD1
mutant mice, was used in a single arm, open label phase II study. Unfortunately, similar to
minocycline, thalidomide led to undesirable side effects, without any positive effects [243]. A
pilot trial (double-blind, placebo-controlled, randomized) where G-CSF was administered to
ALS patients for over 25 days does however show encouraging results on the prevention of
degeneration of several white matter tracts [244]. This study supports a larger scale trial in
which the immunomodulatory aspect of G-CSF should be further explored.
The translational therapy of neuroinflammatory and immunomodulatory effectors has thus
shown both exciting and disappointing outcomes. There are many factors that could help
explain the discrepancy between pre-clinical and clinical evaluations of potential therapies.
Firstly, most drugs are typically assessed in the mutant SOD1 animal models. This poses an
important caveat, as not only there exists an obvious difference between humans and animals,
but SOD1 models also represent hereditary ALS, which account for only 4% of ALS cases. Thus,
a drug may show a positive influence on an inherited disease model without having any effect
on sporadic cases. There is therefore the risk of wrongly eliminating or pushing forward an
ALS treatment due to the lack of diverse familial and sporadic pre-clinical models. Secondly,
the exact timing of a specific treatment could also impact its efficiency. Indeed, as described
in the present chapters, neuroinflammation consists of dynamic mechanisms, combining over
time and space, different cell types with opposing neuroprotective and neurotoxic functions.
Thus, depending on the desired target, the therapeutic window of various drugs may differ
one from another. Thirdly, while establishing a dosage regimen (concentration of drug and
treatment length) is amenable in pre-clinical models, determining the exact dose and duration
of a therapy in human patients is somewhat more complex. Further, it remains unclear if the
treatment of ALS patients should take place daily for several months or periodically in pulses.
It thus becomes imperative to develop new analytical methods to adequately extract from pre-
clinical studies the equivalent doses for humans as well as the optimal treatment protocol.
Finally, in light of the high heterogeneity of ALS forms, it is possible that not all patients will
respond equally to a particular therapy. Therefore, all of these parameters, including addi‐
tional ones not mentioned herein, have to be thoroughly considered and analyzed to ensure
that we do not wrongly disregard or promote a drug.
When dealing with neuroinflammation in ALS, the therapeutic intervention is of a different
kind than the previous major clinical trials. It is not compulsorily a matter of influencing the
disease process, that is the motoneuron death itself, but a matter of stopping a potential
amplification and/or diffusion phenomenon. In animal models, this strategy has given
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interesting results but there still remains a lot of work before a successful therapy targeting
neuroinflammation is translated into humans.
7. Future directions
In the present chapter, we have described the cellular and molecular events characterizing the
neuroinflammation in ALS. We have also highlighted the beneficial potential of various
therapeutic approaches specifically targeting these neuroinflammatory effectors. While the
reports discussed herein support a role for astrocytes, microglia and immune cells in ALS, it
remains unclear how they influence disease onset, progression or both. Hence, a thorough
investigation of the neuroinflammatory pathways that impact neurodegeneration will
ultimately enhance our understanding of how and when to therapeutically modulate this
pathological process. Further, it is important to remember that the astrocytosis and microglio‐
sis that typify ALS stem from the chronicity of this neurodegenerative disorder and thus, there
is an active communication with the neurotoxic environment that is composed of neurons,
glial cells and immune cells. Therefore, it is with caution that we should proceed with defining
a causal or consequential role for neuroinflammation in ALS, but instead, our focus should be
on identifying its exact pathological contribution.
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as well as a more efficient and specific design of therapies by specifically taking into account
the clinical heterogeneity of the disease.
Among the drugs mentioned that have been evaluated in pre-clinical models, celecoxib and
pioglitazone were both assessed in a randomized, double-blind, placebo-controlled trial, but
gave disappointing results as there were no effects on motor function and survival rate [240,
241]. When minocycline was tested in a randomized placebo-controlled phase III trial, it not
only did not show any benefits, it in fact displayed serious harmful effect in patients [242].
Thalidomide, an analogue of lenalidomide, which showed therapeutic potential in SOD1
mutant mice, was used in a single arm, open label phase II study. Unfortunately, similar to
minocycline, thalidomide led to undesirable side effects, without any positive effects [243]. A
pilot trial (double-blind, placebo-controlled, randomized) where G-CSF was administered to
ALS patients for over 25 days does however show encouraging results on the prevention of
degeneration of several white matter tracts [244]. This study supports a larger scale trial in
which the immunomodulatory aspect of G-CSF should be further explored.
The translational therapy of neuroinflammatory and immunomodulatory effectors has thus
shown both exciting and disappointing outcomes. There are many factors that could help
explain the discrepancy between pre-clinical and clinical evaluations of potential therapies.
Firstly, most drugs are typically assessed in the mutant SOD1 animal models. This poses an
important caveat, as not only there exists an obvious difference between humans and animals,
but SOD1 models also represent hereditary ALS, which account for only 4% of ALS cases. Thus,
a drug may show a positive influence on an inherited disease model without having any effect
on sporadic cases. There is therefore the risk of wrongly eliminating or pushing forward an
ALS treatment due to the lack of diverse familial and sporadic pre-clinical models. Secondly,
the exact timing of a specific treatment could also impact its efficiency. Indeed, as described
in the present chapters, neuroinflammation consists of dynamic mechanisms, combining over
time and space, different cell types with opposing neuroprotective and neurotoxic functions.
Thus, depending on the desired target, the therapeutic window of various drugs may differ
one from another. Thirdly, while establishing a dosage regimen (concentration of drug and
treatment length) is amenable in pre-clinical models, determining the exact dose and duration
of a therapy in human patients is somewhat more complex. Further, it remains unclear if the
treatment of ALS patients should take place daily for several months or periodically in pulses.
It thus becomes imperative to develop new analytical methods to adequately extract from pre-
clinical studies the equivalent doses for humans as well as the optimal treatment protocol.
Finally, in light of the high heterogeneity of ALS forms, it is possible that not all patients will
respond equally to a particular therapy. Therefore, all of these parameters, including addi‐
tional ones not mentioned herein, have to be thoroughly considered and analyzed to ensure
that we do not wrongly disregard or promote a drug.
When dealing with neuroinflammation in ALS, the therapeutic intervention is of a different
kind than the previous major clinical trials. It is not compulsorily a matter of influencing the
disease process, that is the motoneuron death itself, but a matter of stopping a potential
amplification and/or diffusion phenomenon. In animal models, this strategy has given
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interesting results but there still remains a lot of work before a successful therapy targeting
neuroinflammation is translated into humans.
7. Future directions
In the present chapter, we have described the cellular and molecular events characterizing the
neuroinflammation in ALS. We have also highlighted the beneficial potential of various
therapeutic approaches specifically targeting these neuroinflammatory effectors. While the
reports discussed herein support a role for astrocytes, microglia and immune cells in ALS, it
remains unclear how they influence disease onset, progression or both. Hence, a thorough
investigation of the neuroinflammatory pathways that impact neurodegeneration will
ultimately enhance our understanding of how and when to therapeutically modulate this
pathological process. Further, it is important to remember that the astrocytosis and microglio‐
sis that typify ALS stem from the chronicity of this neurodegenerative disorder and thus, there
is an active communication with the neurotoxic environment that is composed of neurons,
glial cells and immune cells. Therefore, it is with caution that we should proceed with defining
a causal or consequential role for neuroinflammation in ALS, but instead, our focus should be
on identifying its exact pathological contribution.
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1. Introduction
Oxidative stress is defined as the imbalance between reactive species such as free radicals and
oxidants and the antioxidant defenses. Free radicals are molecules with one or more unpaired
electrons, while oxidants are molecules with a high potential for taking electrons from other
molecules. The more recognized reactive species are the reactive oxygen species (ROS), which
include oxygen and its reduction products superoxide, hydrogen peroxide and hydroxyl
radical, and the reactive nitrogen species (RNS) such as the free radical nitric oxide and its by-
products, including the powerful oxidant peroxynitrite and the sub-product of peroxynitrite
decomposition nitrogen dioxide.
As part of the antioxidant defense system, superoxide dismutase 1 (SOD1) is an abundant and
highly conserved cytosolic enzyme responsible for the disproportionation of superoxide to
molecular oxygen and hydrogen peroxide (McCord and Fridovich, 1969). SOD1 is a relatively
small protein of 153 amino acids that works as a tight homodimer and requires a high stability
for fast catalysis (Perry et al., 2010; Trumbull and Beckman, 2009). The stability is conferred by
the quaternary structure of the protein, an eight-strand beta-barrel, as well as the binding of
Cu and Zn, two metal ions with catalytic roles positioned in the active site channel (Perry et
al., 2010; Trumbull and Beckman, 2009). The disproportionation of superoxide is a two-step
oxidation-reduction reaction that involves the cycling of the copper atom in SOD1 from Cu2+
to Cu+ and back to Cu+2.
The zinc does not participate in this reaction but is essential for the structure of the active site.
In addition, the formation of an intrasubunit disulfide bridge stabilizes the enzyme and plays
an important role in preventing aggregation of metal-deficient SOD (Getzoff et al., 1989).
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Mutations in the gene codifying for SOD1 were linked to familial ALS almost 20 years ago.
Currently, over 130 point mutations on more than 70 sites on SOD1 have been described, most
of these being missense single residue mutations located in critical positions that affect the
stability and folding of the enzyme (Beckman et al., 2001; Perry et al., 2010; Roberts et al.,
2007). The goal of this chapter is to review recent advances in our understanding of the role of
oxidative stress on the gain of a toxic function associated with mutations in the gene of the
copper/zinc superoxide dismutase.
2. Zn-deficient SOD1
The first proposed mechanisms linking mutations of SOD1 with ALS were based on the loss
of dismutase activity (Beckman et al., 1993; Deng et al., 1993a). However, the SOD1 mutants
G37R and G93A remain fully active and were linked to familial ALS (Borchelt et al., 1994; Yim
et al., 1996). In addition, the mouse knockout for SOD1 developed normally and did not show
signs of motor neuron deficit, although the motor neurons were more susceptible to cell death
upon axonal injury (Reaume et al., 1996). This evidence indicated that a gain-of-function rather
than the loss of function was responsible for motor neuron degeneration in ALS, and that the
gain-of-function could be related to the redox properties of SOD1.
The discovery that mutations on the gene for an antioxidant enzyme such as SOD1 were
associated with a population of familial ALS patients led to speculate on the role of oxidative
stress in the pathogenesis of ALS (Beckman et al., 1993; Deng et al., 1993b; Rosen et al., 1993).
From this original discovery to the present the interest on oxidative stress in ALS has been a
rollercoaster. Several different groups described the presence of a variety of markers for
oxidative stress in human samples and animal models of ALS, including elevated protein
carbonyl and nitrotyrosine levels as well as lipid and DNA oxidation. Oxidation of proteins,
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lipids, and DNA was also found in transgenic mice and cell culture models (Barber and Shaw,
2010). On the other hand, other groups failed to find markers of oxidative damage in animal
models of ALS, casting doubt on the relevance of oxidative stress in the pathogenesis of the
disease (Barber and Shaw, 2010). Currently, a role for oxidative stress in ALS is generally
accepted but whether oxidative stress is responsible for the mutant SOD1 gain-of-function is
still controversial.
2.1. Mutant SOD1 aggregation and Zn-deficiency
Mutant SOD1s have a tendency to aggregate when expressed in bacterial systems and
transfected cells, and the presence of mutant and wild type SOD1-containing aggregates has
been described in animal models of ALS (Bruijn and Cleveland, 1996; Watanabe et al., 2001).
The formation of aggregates clogging the proteasome and containing other relevant proteins
along with mutant SOD1 is one of the possible explanations for SOD1 toxic gain-of-function.
However, in mice expressing the SOD1A4V mutant, the most common mutation linked to
familial ALS in humans, the mutant is expressed at high levels and forms protein aggregates
but does not cause disease (Gurney et al., 1994). Alternatively, other groups proposed a
hypothesis in which the formation of aggregates is a protective mechanism rather than cause
of toxicity. In vitro experiments showed that both wild type SOD1 and SOD1 with mutation of
the cysteine residues involved in protein aggregation were able to stabilize the mutant SOD1
enzymes, increasing their toxicity (Clement et al., 2003; Fukada et al., 2001; Sahawneh et al.,
2010; Witan et al., 2009). Additionally, it was recently described that overexpression of the
deubiquitinating enzyme ataxin-3 stimulates the formation of SOD1-containing aggresomes
by trimming K63-linked polyubiquitin chains. The knockdown of ataxin-3 decreases the
formation of aggresomes and increases cell death induced by mutant SOD1 (Wang et al.,
2012). These results suggest a toxic gain-of-function for the stabilized and soluble mutant
SOD1, rather than toxicity due to aggregation. Indeed, by removing the toxic soluble mutant
SOD1, the formation of aggregates has been proposed to be a protective mechanism (Trumbull
and Beckman, 2009). Further support is provided by recent studies of crossbreeding showing
an acceleration of the disease in mutant SOD1 transgenic mice overexpressing wild type SOD1,
which was linked to the formation of disulfide bridges in the enzyme by oxidation of cysteine
residues, increasing the formation of aggregates (Deng et al., 2006; Furukawa et al., 2006; Wang
et al., 2009). Other investigations reproduced the acceleration of the disease in animals
expressing both wild type and mutant SOD1 but failed to find a correlation between expression
of wild type SOD1 and protein aggregation (Prudencio et al., 2009).
The link between the gain-of-function and the redox activity of soluble mutant SOD1 as a
source of oxidative stress is based on the presence of the copper atom in the active site of the
enzyme as well as the loss of zinc. The requirement for copper was challenged by genetic
experiments in which the chaperone that delivers the copper metal to SOD1 was deleted. The
ablation of the chaperone in the G93A, G85R, or G73R-SOD1 mutant mice decreased the
activity of the enzyme but had no effect on the progression of the disease (Subramaniam et al.,
2002), although it may be possible for SOD1 to acquire copper from an alternative source
(Beckman et al., 2002). The transgenic expression of a SOD1 with mutations that eliminate the
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copper-binding site still produced disease (Prudencio et al., 2012; Wang et al., 2003). In contrast,
another study showed that the mutant enzymes A4V, G85R, and G93A had a higher affinity
for copper than the wild type protein, and that this aberrant copper binding was mediated by
cysteine 111 (Watanabe et al., 2007), implying that the enzyme binds copper in an alternate site
(Figure 1A).
Some SOD1 mutants bind copper and zinc and are fully active (Borchelt et al., 1994; Marklund
et al., 1997) but many mutations affect the binding of zinc while copper remains tightly bound,
thus favoring the formation of Zn-deficient SOD. In the SOD1G93A mouse model of ALS, the
dietary depletion of zinc accelerates the progression of the disease while moderate supplement
of zinc provides protection (Ermilova et al., 2005). Indeed, a peak corresponding to one-metal
SOD1 was detected in vivo in spinal cords from the SOD1G93A rat model using the recently
developed methodology of electrospray mass spectrometry. The one-metal peak was 2-fold
larger in the disease-affected ventral spinal cord compare to that of the dorsal spinal cord
(Rhoads et al., 2011), suggesting that Zn-deficient SOD1 may be present in vivo in the affected
tissue.
ALS-linked mutant SOD1s have 5-50 fold less affinity for zinc than the wild type protein (Crow
et al., 1997a; Lyons et al., 1996). The loss of zinc disorganizes the structure of the active site
leaving the copper metal more expose and accessible to substrates other than superoxide,
decreasing the normal activity of the enzyme. When replete with zinc, SOD1 mutants can
generally fulfill the antioxidant activity of wild type SOD (Crow et al., 1997a). Early studies
showed that mutant SOD1 has an aberrant chemistry and is reduced abnormally fast which
allows the reaction with oxidants such as hydrogen peroxide and peroxynitrite (Crow et al.,
1997a; Crow et al., 1997b; Lyons et al., 1996; Wiedau-Pazos et al., 1996), thus turning the
antioxidant enzyme into a catalyst for oxidation. The conversion of SOD1 from antioxidant to
pro-oxidant due to the loss of zinc is a simple explanation for the gain-of-function attributed
to the ALS-linked SOD mutants, but is still highly controversial.
2.2. Formation of hydroxyl radical from hydrogen peroxide
In normal conditions SOD1 catalyzes the disproportionation of superoxide to hydrogen
peroxide, but due to changes in mutant SOD1 conformation, the mutant enzyme can catalyze
the production of hydroxyl radical from hydrogen peroxide in vitro (Yim et al., 1990) (Figure
1B). The G93A-SOD1 mutant has enhanced free-radical production compare to the wild type
enzyme due to a more open active site, decreasing the Km for hydrogen peroxide (Yim et al.,
1996). Accordingly, an increase in the levels of hydrogen peroxide and hydroxyl radical was
reported in vivo in the spinal cord from mice expressing the G93A mutant (Liu et al., 1999).
The aberrant chemistry of mutant SOD1 was shown to inactivate the glutamate transporter
EAAT2 by oxidative reactions catalyzed by the A4V and I113T-SOD1 mutants and triggered
by hydrogen peroxide (Trotti et al., 1999; Trotti et al., 1996). The function of this transporter is
down regulated in human patients and animal models of ALS and its inactivation results in
neuronal degeneration (Rothstein et al., 2005; Tanaka et al., 1997). Moreover, the aberrant SOD1
chemistry increases the vulnerability of a variety of cells in culture to hydrogen peroxide, with
an increased susceptibility to inhibition by copper chelators. The G37R, G41D, and G85R-SOD1
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mutants induce activation of caspase 1 and promoted apoptosis in N2a cells and tissue
expressing mutant SOD1 when exposed to hydrogen peroxide. In NSC34 cells, a motor neuron
model, mutant SOD1 induces cell death upon exposure of the cells to hydrogen peroxide
(Pasinelli et al., 1998; Wiedau-Pazos et al., 1996). These findings suggest that the ALS pheno‐
type may require both, the genetic background and an additional oxidative challenge.
2.3. Production of peroxynitrite
Nitric oxide alone is not toxic to normal motor neurons (Estévez et al., 1999), but when
superoxide is also produced it can react with nitric oxide to form the powerful oxidant
peroxynitrite, responsible for the induction of cell death. Overexpression of mutant SOD1
makes motor neurons vulnerable to exogenous and endogenous production of nitric oxide.
The increased vulnerability is linked to the activation of the Fas death pathways (Raoul et al.,
2002). More recently it was shown that motor neurons from mutant SOD1 transgenic animals
have lower levels of a calcium-binding ER chaperone calreticulin. A decrease in the expression
of this protein is necessary and sufficient to activate the Fas/NO pathways in motor neurons.
Further evidence in vivo shows that this protein is decreased in the spinal motor neurons of
SOD1G93A transgenic animals prior to muscle denervation (Bernard-Marissal et al., 2012).
Therefore, motor neurons expressing mutant SOD1 may produce superoxide making them
susceptible to the formation of peroxynitrite in the presence of nitric oxide. In the presence of
reductants, Zn-deficient SOD1 is able to produce superoxide. For instance, ascorbate reduces
the copper on Zn-deficient SOD1 from Cu2+ to Cu+. In turn, Zn-deficient SOD1 can transfer
the electrons from ascorbate to oxygen to produce superoxide slowly but significantly over a
period of minutes. Indeed, Zn-deficient SOD1 is able to oxidize ascorbate 3000-fold faster than
mutant or wild type Cu,Zn-SOD1 in vitro (Estévez et al., 1999). In the cells, ascorbate and other
cellular antioxidants such as glutathione, urate, and cysteine could have a similar effect.
Normally, superoxide would be removed by the dismutase activity of the remaining and fully
active Cu,Zn-SOD1. However, if nitric oxide is also produced it can effectively compete with
Cu,Zn-SOD1 for superoxide to produce peroxynitrite. Because nitric oxide is a small molecule
able to diffuse 10-fold faster than a small size protein, the reaction of nitric oxide with super‐
oxide occurs 10 times faster than that with SOD1 (Beckman et al., 2001; Estévez et al., 1999;
Franco and Estévez, 2011; Nauser and Koppenol, 2002) (Figure 1B). Wild type Cu,Zn-SOD1
can also produce peroxynitrite by a similar mechanism but requires superoxide in the initial
step to be efficiently reduced (Beckman et al., 2001).
2.4. Catalysis of tyrosine nitration
Cu,Zn-SOD1 is not only responsible for the production of peroxynitrite but it can also catalyze
tyrosine nitration in vitro (Beckman et al., 1993; Crow et al., 1997b; Ischiropoulos et al., 1992).
The mechanism for tyrosine nitration depends on the copper atom in SOD1 that reacts with
peroxynitrite. The loss of zinc from Cu,Zn-SOD1 increases by 2-fold the efficiency of the
enzyme to catalyze tyrosine nitration (Crow et al., 1997a) (Figure 1B). Moreover, SOD1 is not
inactivated by peroxynitrite and can catalyze tyrosine nitration indefinitely. Indeed, reactivity
for nitrotyrosine was found in vivo in the SOD1G93A mouse model and in patients with ALS
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et al., 1997) but many mutations affect the binding of zinc while copper remains tightly bound,
thus favoring the formation of Zn-deficient SOD. In the SOD1G93A mouse model of ALS, the
dietary depletion of zinc accelerates the progression of the disease while moderate supplement
of zinc provides protection (Ermilova et al., 2005). Indeed, a peak corresponding to one-metal
SOD1 was detected in vivo in spinal cords from the SOD1G93A rat model using the recently
developed methodology of electrospray mass spectrometry. The one-metal peak was 2-fold
larger in the disease-affected ventral spinal cord compare to that of the dorsal spinal cord
(Rhoads et al., 2011), suggesting that Zn-deficient SOD1 may be present in vivo in the affected
tissue.
ALS-linked mutant SOD1s have 5-50 fold less affinity for zinc than the wild type protein (Crow
et al., 1997a; Lyons et al., 1996). The loss of zinc disorganizes the structure of the active site
leaving the copper metal more expose and accessible to substrates other than superoxide,
decreasing the normal activity of the enzyme. When replete with zinc, SOD1 mutants can
generally fulfill the antioxidant activity of wild type SOD (Crow et al., 1997a). Early studies
showed that mutant SOD1 has an aberrant chemistry and is reduced abnormally fast which
allows the reaction with oxidants such as hydrogen peroxide and peroxynitrite (Crow et al.,
1997a; Crow et al., 1997b; Lyons et al., 1996; Wiedau-Pazos et al., 1996), thus turning the
antioxidant enzyme into a catalyst for oxidation. The conversion of SOD1 from antioxidant to
pro-oxidant due to the loss of zinc is a simple explanation for the gain-of-function attributed
to the ALS-linked SOD mutants, but is still highly controversial.
2.2. Formation of hydroxyl radical from hydrogen peroxide
In normal conditions SOD1 catalyzes the disproportionation of superoxide to hydrogen
peroxide, but due to changes in mutant SOD1 conformation, the mutant enzyme can catalyze
the production of hydroxyl radical from hydrogen peroxide in vitro (Yim et al., 1990) (Figure
1B). The G93A-SOD1 mutant has enhanced free-radical production compare to the wild type
enzyme due to a more open active site, decreasing the Km for hydrogen peroxide (Yim et al.,
1996). Accordingly, an increase in the levels of hydrogen peroxide and hydroxyl radical was
reported in vivo in the spinal cord from mice expressing the G93A mutant (Liu et al., 1999).
The aberrant chemistry of mutant SOD1 was shown to inactivate the glutamate transporter
EAAT2 by oxidative reactions catalyzed by the A4V and I113T-SOD1 mutants and triggered
by hydrogen peroxide (Trotti et al., 1999; Trotti et al., 1996). The function of this transporter is
down regulated in human patients and animal models of ALS and its inactivation results in
neuronal degeneration (Rothstein et al., 2005; Tanaka et al., 1997). Moreover, the aberrant SOD1
chemistry increases the vulnerability of a variety of cells in culture to hydrogen peroxide, with
an increased susceptibility to inhibition by copper chelators. The G37R, G41D, and G85R-SOD1
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mutants induce activation of caspase 1 and promoted apoptosis in N2a cells and tissue
expressing mutant SOD1 when exposed to hydrogen peroxide. In NSC34 cells, a motor neuron
model, mutant SOD1 induces cell death upon exposure of the cells to hydrogen peroxide
(Pasinelli et al., 1998; Wiedau-Pazos et al., 1996). These findings suggest that the ALS pheno‐
type may require both, the genetic background and an additional oxidative challenge.
2.3. Production of peroxynitrite
Nitric oxide alone is not toxic to normal motor neurons (Estévez et al., 1999), but when
superoxide is also produced it can react with nitric oxide to form the powerful oxidant
peroxynitrite, responsible for the induction of cell death. Overexpression of mutant SOD1
makes motor neurons vulnerable to exogenous and endogenous production of nitric oxide.
The increased vulnerability is linked to the activation of the Fas death pathways (Raoul et al.,
2002). More recently it was shown that motor neurons from mutant SOD1 transgenic animals
have lower levels of a calcium-binding ER chaperone calreticulin. A decrease in the expression
of this protein is necessary and sufficient to activate the Fas/NO pathways in motor neurons.
Further evidence in vivo shows that this protein is decreased in the spinal motor neurons of
SOD1G93A transgenic animals prior to muscle denervation (Bernard-Marissal et al., 2012).
Therefore, motor neurons expressing mutant SOD1 may produce superoxide making them
susceptible to the formation of peroxynitrite in the presence of nitric oxide. In the presence of
reductants, Zn-deficient SOD1 is able to produce superoxide. For instance, ascorbate reduces
the copper on Zn-deficient SOD1 from Cu2+ to Cu+. In turn, Zn-deficient SOD1 can transfer
the electrons from ascorbate to oxygen to produce superoxide slowly but significantly over a
period of minutes. Indeed, Zn-deficient SOD1 is able to oxidize ascorbate 3000-fold faster than
mutant or wild type Cu,Zn-SOD1 in vitro (Estévez et al., 1999). In the cells, ascorbate and other
cellular antioxidants such as glutathione, urate, and cysteine could have a similar effect.
Normally, superoxide would be removed by the dismutase activity of the remaining and fully
active Cu,Zn-SOD1. However, if nitric oxide is also produced it can effectively compete with
Cu,Zn-SOD1 for superoxide to produce peroxynitrite. Because nitric oxide is a small molecule
able to diffuse 10-fold faster than a small size protein, the reaction of nitric oxide with super‐
oxide occurs 10 times faster than that with SOD1 (Beckman et al., 2001; Estévez et al., 1999;
Franco and Estévez, 2011; Nauser and Koppenol, 2002) (Figure 1B). Wild type Cu,Zn-SOD1
can also produce peroxynitrite by a similar mechanism but requires superoxide in the initial
step to be efficiently reduced (Beckman et al., 2001).
2.4. Catalysis of tyrosine nitration
Cu,Zn-SOD1 is not only responsible for the production of peroxynitrite but it can also catalyze
tyrosine nitration in vitro (Beckman et al., 1993; Crow et al., 1997b; Ischiropoulos et al., 1992).
The mechanism for tyrosine nitration depends on the copper atom in SOD1 that reacts with
peroxynitrite. The loss of zinc from Cu,Zn-SOD1 increases by 2-fold the efficiency of the
enzyme to catalyze tyrosine nitration (Crow et al., 1997a) (Figure 1B). Moreover, SOD1 is not
inactivated by peroxynitrite and can catalyze tyrosine nitration indefinitely. Indeed, reactivity
for nitrotyrosine was found in vivo in the SOD1G93A mouse model and in patients with ALS
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(Beal et al., 1997; Ferrante et al., 1997). In spite of the indirect evidence of mass spectrometry
showing a peak corresponding to a one-metal SOD1 in a rat model of ALS (Rhoads et al.,
2011), whether Zn-deficient SOD1 is present in vivo and catalyzes tyrosine nitration is still
source of debate and remains to be determined.
3. Regulation of NADPH oxidase activity by mutant SOD1
Several lines of evidence support the role of oxidative stress in mutant SOD1 toxicity, but some
evidence suggest that interactions other than the redox properties of the enzyme stimulate
oxidative stress by different mechanisms. Mutant SOD1 can induce oxidative stress by
disruption of the redox-sensitive regulation of NADPH oxidase (Nox) in microglial cells. Noxs
are transmembrane proteins that catalyze the reduction of oxygen to superoxide using
NADPH as an electron donor (Brown and Griendling, 2009). Superoxide is then converted to
hydrogen peroxide by SOD1. Under reducing conditions, SOD1 regulates Nox2 activation by
binding and stabilizing Rac1. The oxidation of Rac1 by hydrogen peroxide disrupts the
complex with SOD1 and inactivates Nox2. Upon expression of certain ALS SOD1 mutants, the
dissociation of Rac1 from SOD1 is impaired and Nox2 remains active (Figure 1C). In addition,
the expression of Nox2 is upregulated in the SOD1G93A mouse model and in ALS patients. In
fact, gene deletion of Nox1 or Nox2 provides the larger protection to date in animal models of
ALS (Harraz et al., 2008; Marden et al., 2007).
4. Mutant SOD1 translocation to mitochondria
Mitochondria are one of the major sources of cellular ROS formed as by-products of oxidative
phosphorylation. Abnormalities in the mitochondrial structure, localization and number as
well as altered activity of the electron transport chain have been described in both, sporadic
and familial ALS (Manfredi and Xu, 2005). The mitochondrial electron transport chain and
ATP synthesis are severely impaired at disease onset in spinal cord and brain of SOD1G93A
transgenic mice (Lin and Beal, 2006). Both, wild type and mutant SOD localize in mitochondria
in the central nervous system (Higgins et al., 2002). Mutant human SOD1 was found in the
mitochondrial outer membrane, intermembrane space and matrix in transgenic mice, while
inactive mutant SOD1 accumulates and forms aggregates in the mitochondrial matrix in the
brain (Vijayvergiya et al., 2005). Aggregates of the mutant enzyme are also selectively found
in the mitochondrial outer membrane in spinal cord from mouse models of ALS (Liu et al.,
2004). Interestingly, the anti-apoptotic protein Bcl-2 binds to mutant SOD1 and aggregates in
spinal cord mitochondria from patients and a mouse model of ALS, suggesting that mutant
SOD1 may be toxic by depleting motor neurons of this anti-apoptotic protein (Pasinelli et al.,
2004). Mutant SOD1 targeted to the mitochondrial intermembrane space in NSC34 cells
induces cell death upon exposure of the cells to hydrogen peroxide (Magrane et al., 2009). In
addition, the increase in carbonylated proteins and lipid hydroperoxides in mitochondria, as
well as the abnormally high rates of production of hydrogen peroxide in SOD1G93A transgenic
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mice (Mattiazzi et al., 2002; Panov et al., 2011) support the mutant SOD1 aberrant catalytic
gain-of-function. Indeed, it was shown that metal-deficient SOD1s are prone to mitochondrial
translocation and are found in the mitochondrial intermembrane space (Okado-Matsumoto
and Fridovich, 2002). The mitochondria contain the majority of the cellular copper because is
required by the oxygen-consuming proteins. The insertion of copper into the translocated
metal-deficient SOD would result in the formation of Zn-deficient SOD inside the mitochon‐
dria (Figure 1A). This could explain why the mitochondria are affected early in the onset of
the disease (Beckman et al., 2002). The ROS-linked toxic gain-of-function of mutant SOD1
would produce hydroxyl radical from H2O2 as well as peroxynitrite in the mitochondria. The
mutant enzyme could then catalyze the nitration of mitochondrial proteins such as cyclophilin
D and the adenine nucleotide translocator (Martin, 2010). Due to these toxic effects of mutant
SOD1 on mitochondria, it has been proposed that the abnormal activity of the mitochondria
in ALS may account for the initiation and progression of the disease. However, whether the
mitochondrial localization of mutant SOD1 is cause or a consequence of pathology needs to
be established.
5. Expression of mutant SOD1 in motor neurons and neighboring cells
A new mechanism integrating the autonomous and non-autonomous induction of motor
neuron death in ALS is emerging. In this scenario, the role of motor neurons and surrounding
cells in the onset and progression of ALS is temporally determined. Several studies were
conducted where mutant SOD1 was selectively expressed in vivo either in motor neurons or
microglia of chimeric mice, or in culture in embryonic primary or stem cell-based models,
allowing the study of the role of individual population of cells in the onset and progression of
ALS. The cell-autonomous degeneration of motor neurons expressing mutant SOD1 seems to
be more relevant for the onset and early progression of the disease, while microglia, peripheral
macrophages, and astrocytes would play a role in the late disease progression.
5.1. Expression of mutant SOD1 in motor neurons
ALS is a motor neuron disease characterized by the gradual and selective loss of both, upper
and lower motor neurons. Expression of mutant SOD1 in spinal motor neurons and inter‐
neurons of chimeric mice is enough to induce neuronal degeneration (Boillee et al., 2006; Wang
et al., 2008). The mice do not develop clinical ALS but the motor neurons expressing mutant
SOD1 exhibit pathological and immunohistochemical abnormalities, while motor neurons
negative for mutant SOD1 expression do not. These observations indicate that in the chimeric
mice the degeneration of motor neurons can be cell-autonomous. The fact that only some of
the motor neurons express mutant SOD1 in this model may explain why the animals do not
develop the disease (Wang et al., 2008). Indeed, normal motor neurons can prevent or delay
the degeneration of mutant SOD1-expressing motor neurons (Clement et al., 2003). In addition,
decreased expression of mutant SOD1 in motor neurons has a modest effect on the duration
of the disease but significantly delay the onset and early phase of the disease progression
(Wang et al., 2008). Similar results were observed in culture, where primary spinal motor
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(Beal et al., 1997; Ferrante et al., 1997). In spite of the indirect evidence of mass spectrometry
showing a peak corresponding to a one-metal SOD1 in a rat model of ALS (Rhoads et al.,
2011), whether Zn-deficient SOD1 is present in vivo and catalyzes tyrosine nitration is still
source of debate and remains to be determined.
3. Regulation of NADPH oxidase activity by mutant SOD1
Several lines of evidence support the role of oxidative stress in mutant SOD1 toxicity, but some
evidence suggest that interactions other than the redox properties of the enzyme stimulate
oxidative stress by different mechanisms. Mutant SOD1 can induce oxidative stress by
disruption of the redox-sensitive regulation of NADPH oxidase (Nox) in microglial cells. Noxs
are transmembrane proteins that catalyze the reduction of oxygen to superoxide using
NADPH as an electron donor (Brown and Griendling, 2009). Superoxide is then converted to
hydrogen peroxide by SOD1. Under reducing conditions, SOD1 regulates Nox2 activation by
binding and stabilizing Rac1. The oxidation of Rac1 by hydrogen peroxide disrupts the
complex with SOD1 and inactivates Nox2. Upon expression of certain ALS SOD1 mutants, the
dissociation of Rac1 from SOD1 is impaired and Nox2 remains active (Figure 1C). In addition,
the expression of Nox2 is upregulated in the SOD1G93A mouse model and in ALS patients. In
fact, gene deletion of Nox1 or Nox2 provides the larger protection to date in animal models of
ALS (Harraz et al., 2008; Marden et al., 2007).
4. Mutant SOD1 translocation to mitochondria
Mitochondria are one of the major sources of cellular ROS formed as by-products of oxidative
phosphorylation. Abnormalities in the mitochondrial structure, localization and number as
well as altered activity of the electron transport chain have been described in both, sporadic
and familial ALS (Manfredi and Xu, 2005). The mitochondrial electron transport chain and
ATP synthesis are severely impaired at disease onset in spinal cord and brain of SOD1G93A
transgenic mice (Lin and Beal, 2006). Both, wild type and mutant SOD localize in mitochondria
in the central nervous system (Higgins et al., 2002). Mutant human SOD1 was found in the
mitochondrial outer membrane, intermembrane space and matrix in transgenic mice, while
inactive mutant SOD1 accumulates and forms aggregates in the mitochondrial matrix in the
brain (Vijayvergiya et al., 2005). Aggregates of the mutant enzyme are also selectively found
in the mitochondrial outer membrane in spinal cord from mouse models of ALS (Liu et al.,
2004). Interestingly, the anti-apoptotic protein Bcl-2 binds to mutant SOD1 and aggregates in
spinal cord mitochondria from patients and a mouse model of ALS, suggesting that mutant
SOD1 may be toxic by depleting motor neurons of this anti-apoptotic protein (Pasinelli et al.,
2004). Mutant SOD1 targeted to the mitochondrial intermembrane space in NSC34 cells
induces cell death upon exposure of the cells to hydrogen peroxide (Magrane et al., 2009). In
addition, the increase in carbonylated proteins and lipid hydroperoxides in mitochondria, as
well as the abnormally high rates of production of hydrogen peroxide in SOD1G93A transgenic
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mice (Mattiazzi et al., 2002; Panov et al., 2011) support the mutant SOD1 aberrant catalytic
gain-of-function. Indeed, it was shown that metal-deficient SOD1s are prone to mitochondrial
translocation and are found in the mitochondrial intermembrane space (Okado-Matsumoto
and Fridovich, 2002). The mitochondria contain the majority of the cellular copper because is
required by the oxygen-consuming proteins. The insertion of copper into the translocated
metal-deficient SOD would result in the formation of Zn-deficient SOD inside the mitochon‐
dria (Figure 1A). This could explain why the mitochondria are affected early in the onset of
the disease (Beckman et al., 2002). The ROS-linked toxic gain-of-function of mutant SOD1
would produce hydroxyl radical from H2O2 as well as peroxynitrite in the mitochondria. The
mutant enzyme could then catalyze the nitration of mitochondrial proteins such as cyclophilin
D and the adenine nucleotide translocator (Martin, 2010). Due to these toxic effects of mutant
SOD1 on mitochondria, it has been proposed that the abnormal activity of the mitochondria
in ALS may account for the initiation and progression of the disease. However, whether the
mitochondrial localization of mutant SOD1 is cause or a consequence of pathology needs to
be established.
5. Expression of mutant SOD1 in motor neurons and neighboring cells
A new mechanism integrating the autonomous and non-autonomous induction of motor
neuron death in ALS is emerging. In this scenario, the role of motor neurons and surrounding
cells in the onset and progression of ALS is temporally determined. Several studies were
conducted where mutant SOD1 was selectively expressed in vivo either in motor neurons or
microglia of chimeric mice, or in culture in embryonic primary or stem cell-based models,
allowing the study of the role of individual population of cells in the onset and progression of
ALS. The cell-autonomous degeneration of motor neurons expressing mutant SOD1 seems to
be more relevant for the onset and early progression of the disease, while microglia, peripheral
macrophages, and astrocytes would play a role in the late disease progression.
5.1. Expression of mutant SOD1 in motor neurons
ALS is a motor neuron disease characterized by the gradual and selective loss of both, upper
and lower motor neurons. Expression of mutant SOD1 in spinal motor neurons and inter‐
neurons of chimeric mice is enough to induce neuronal degeneration (Boillee et al., 2006; Wang
et al., 2008). The mice do not develop clinical ALS but the motor neurons expressing mutant
SOD1 exhibit pathological and immunohistochemical abnormalities, while motor neurons
negative for mutant SOD1 expression do not. These observations indicate that in the chimeric
mice the degeneration of motor neurons can be cell-autonomous. The fact that only some of
the motor neurons express mutant SOD1 in this model may explain why the animals do not
develop the disease (Wang et al., 2008). Indeed, normal motor neurons can prevent or delay
the degeneration of mutant SOD1-expressing motor neurons (Clement et al., 2003). In addition,
decreased expression of mutant SOD1 in motor neurons has a modest effect on the duration
of the disease but significantly delay the onset and early phase of the disease progression
(Wang et al., 2008). Similar results were observed in culture, where primary spinal motor
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neurons as well as embryonic stem cell-derived motor neurons expressing mutant SOD1
showed changes characteristic of neurodegeneration (Di Giorgio et al., 2007; Raoul et al.,
2002). Primary embryonic motor neurons from SOD1G93A and SOD1G85R transgenic animals
exposed to endogenously produced or exogenously added nitric oxide show an increased
susceptibility to cell death in culture (Raoul et al., 2002). Thus, motor neurons expressing
mutant SOD1 are susceptible to cell death stimulated by oxidative stress.
5.2. Expression of mutant SOD1 in glial cells
Neighboring cells also seem to play a role in mutant SOD1 toxicity. Normal motor neurons in
the context of a mutant SOD1-expressing chimera show signs of neurodegeneration, while
non-neuronal cells negative for mutant SOD1 expression delay neuronal degeneration and
significantly extend survival of mutant-expressing motor neurons (Clement et al., 2003). In the
Figure 1. Role of oxidative stress in mutant SOD1 toxic gain-of-function. A. The toxic gain-of-function depends on
the redox properties of the enzyme and relies on the copper atom. The mutant SOD1 translocates to mitochondria,
while the metal-deficient enzyme may translocate and bind copper in the organelle. B. Zn-deficient SOD1 as catalyst
of ROS production and tyrosine nitration. C. Mutant SOD1 regulation of ROS production by Noxs. NO2-Tyr: nitrotyro‐
sine, HO.: hydroxyl radical, O2: molecular oxygen, ONOO-: peroxynitrite, NO.: nitric oxide, O2.-: superoxide.
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last few years, a role for microglia and astrocytes in the induction of motor neuron death has
become evident.
5.2.1. Role of microglia in the induction of motor neuron death
Activated microglia is found in the spinal cord of SOD1G93A transgenic mice, suggesting that
it may play a role in the neurodegeneration of neighboring motor neurons (Beers et al., 2006).
Reducing the expression of mutant SOD1 in microglia and peripheral macrophages in chimeric
mice leads to a delay in the late progression of ALS but has little effect on the onset and early
disease progression (Boillee et al., 2006). Likewise, in the PU.1(-/-)/SOD1G93A mice unable to
synthesize myeloid cells, the replacement of microglia, monocyte, and macrophage lineages
with genotypically identical wild type cells slows disease progression and extends overall
survival (Beers et al., 2006), suggesting that non cell-autonomous effects contribute to ALS
progression independently of disease onset. Comparable findings were observed in co-culture
studies where glial cells expressing mutant-SOD1 had a direct adverse effect on motor neuron
survival (Di Giorgio et al., 2007). Microglia expressing G93A-SOD1 is toxic to primary motor
neurons in vitro. In addition, SODG93A microglia show an increase in superoxide and nitric oxide
production and release respect to wild type microglia. Treatment with lipopolysaccharide
further increases SODG93A microglia activation and induction of motor neuron death (Beers et
al., 2006). Hence, mutant SOD1-expressing microglia is activated, is more susceptible to
activation, and it is capable of inducing motor neuron death in vitro (Beers et al., 2006).
Interestingly, PU.1(-/-) mice transplanted with bone marrow from a SOD1G93A donor do not
develop clinical or pathological evidence of ALS, suggesting that expression of mutant SOD1
in microglia is not enough to induce motor neuron disease in vivo (Beers et al., 2006). The fact
that expression of mutant SOD1 in microglia alone does not induce motor neuron degeneration
suggests that motor neurons and other glial cells play a role in the pathological process. Indeed,
motor neurons expressing mutant SOD1 are more susceptible to cell death induced by
exposure to nitric oxide or Fas activation (Raoul et al., 2002).
5.2.2. Role of astrocytes in the induction of motor neuron death
Astrocytes are the most abundant non-neuronal cells in the nervous system. The co-culture of
normal primary embryonic or stem cell-derived motor neurons with astrocytes expressing
mutant SOD1 result in motor neuron death. The death pathway is triggered by a toxic factor
released by the astrocytes (Aebischer et al., 2011; Nagai et al., 2007). A population of pheno‐
typically aberrant astrocytes was recently described in the SOD1G93A mouse model of ALS
(Diaz-Amarilla et al., 2011). These astrocytes, referred to as “AbA cells”, have an increased
proliferative capacity and secrete soluble factors that are 10 times more potent than neonatal
SOD1G93A astrocytes for the induction of motor neuron death. AbA cells are present in
degenerating spinal cord of SODG93A rats surrounding affected motor neurons, and their
number increases dramatically after disease onset, highlighting the importance of this finding.
Interestingly, the levels of interferon-γ (IFNγ) are significantly increased in mutant SOD1-
expressing astrocytes, and IFNγ induces motor neuron death (Aebischer et al., 2011), suggest‐
ing that this cytokine may be one of the toxic factors mediating induction of cell death (Figure
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Activated microglia is found in the spinal cord of SOD1G93A transgenic mice, suggesting that
it may play a role in the neurodegeneration of neighboring motor neurons (Beers et al., 2006).
Reducing the expression of mutant SOD1 in microglia and peripheral macrophages in chimeric
mice leads to a delay in the late progression of ALS but has little effect on the onset and early
disease progression (Boillee et al., 2006). Likewise, in the PU.1(-/-)/SOD1G93A mice unable to
synthesize myeloid cells, the replacement of microglia, monocyte, and macrophage lineages
with genotypically identical wild type cells slows disease progression and extends overall
survival (Beers et al., 2006), suggesting that non cell-autonomous effects contribute to ALS
progression independently of disease onset. Comparable findings were observed in co-culture
studies where glial cells expressing mutant-SOD1 had a direct adverse effect on motor neuron
survival (Di Giorgio et al., 2007). Microglia expressing G93A-SOD1 is toxic to primary motor
neurons in vitro. In addition, SODG93A microglia show an increase in superoxide and nitric oxide
production and release respect to wild type microglia. Treatment with lipopolysaccharide
further increases SODG93A microglia activation and induction of motor neuron death (Beers et
al., 2006). Hence, mutant SOD1-expressing microglia is activated, is more susceptible to
activation, and it is capable of inducing motor neuron death in vitro (Beers et al., 2006).
Interestingly, PU.1(-/-) mice transplanted with bone marrow from a SOD1G93A donor do not
develop clinical or pathological evidence of ALS, suggesting that expression of mutant SOD1
in microglia is not enough to induce motor neuron disease in vivo (Beers et al., 2006). The fact
that expression of mutant SOD1 in microglia alone does not induce motor neuron degeneration
suggests that motor neurons and other glial cells play a role in the pathological process. Indeed,
motor neurons expressing mutant SOD1 are more susceptible to cell death induced by
exposure to nitric oxide or Fas activation (Raoul et al., 2002).
5.2.2. Role of astrocytes in the induction of motor neuron death
Astrocytes are the most abundant non-neuronal cells in the nervous system. The co-culture of
normal primary embryonic or stem cell-derived motor neurons with astrocytes expressing
mutant SOD1 result in motor neuron death. The death pathway is triggered by a toxic factor
released by the astrocytes (Aebischer et al., 2011; Nagai et al., 2007). A population of pheno‐
typically aberrant astrocytes was recently described in the SOD1G93A mouse model of ALS
(Diaz-Amarilla et al., 2011). These astrocytes, referred to as “AbA cells”, have an increased
proliferative capacity and secrete soluble factors that are 10 times more potent than neonatal
SOD1G93A astrocytes for the induction of motor neuron death. AbA cells are present in
degenerating spinal cord of SODG93A rats surrounding affected motor neurons, and their
number increases dramatically after disease onset, highlighting the importance of this finding.
Interestingly, the levels of interferon-γ (IFNγ) are significantly increased in mutant SOD1-
expressing astrocytes, and IFNγ induces motor neuron death (Aebischer et al., 2011), suggest‐
ing that this cytokine may be one of the toxic factors mediating induction of cell death (Figure
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2). The role of astrocytes in the induction of motor neuron death was recently confirmed in
astrocytes generated from post-mortem tissue of familial and sporadic ALS patients, addi‐
tionally providing an in vitro model system for the study of these mechanisms (Haidet-Phillips
et al., 2011).
Figure 2. Model for the role of motor neurons and glia in the ROS-mediated ALS progression. Different cell types
are affected and play a role at different stages of the disease. During the onset and early disease progression, motor
neurons undergo degeneration and cell death by cell-autonomous mechanisms. Later in the disease progression, acti‐
vated microglia and astrocytes release ROS, RNS, and toxic factors that magnify the injury (cell death amplification
mechanisms).
6. Conclusion
In summary, the mechanism of mutant SOD1 toxicity is unknown and highly controversial
but there is strong evidence suggesting that the mutant SOD1 toxic gain-of-function is related
to an alteration of its redox properties and the induction of oxidative stress. In this scenario,
the aberrant chemistry of mutant SOD1 turns the enzyme from antioxidant to pro-oxidant. Zn-
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deficient SOD1 reacts with hydrogen peroxide, produces superoxide and peroxynitrite, and
is able to catalyze tyrosine nitration, altering the cellular redox balance. In addition, although
not related to the redox properties of the enzyme, the interaction of mutant SOD1 with
mitochondria and Nox, the two major sources of cellular ROS, further support the involvement
of oxidative stress in the toxic gain-of-function. The cell type affected by mutant SOD1 is also
controversial. A picture in which several cell types are affected and play a role at different
stages of the disease seems to be emerging. In this context, during onset and early stages of
the disease SOD1-expressing motor neurons undergo neurodegeneration and cell death by
cell-autonomous processes. The activation of microglia and astrocytes may work as an
amplification mechanism in the induction of motor neuron death in the late progression of the
disease (Figure 2).
Author details
María Clara Franco1,2, Cassandra N. Dennys1,2, Fabian H. Rossi1,2 and Alvaro G. Estévez1,2
1 Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida,
Orlando, FL, USA
2 Orlando VA Healthcare System, Orlando, USA
References
[1] Aebischer, J, Cassina, P, Otsmane, B, Moumen, A, Seilhean, D, Meininger, V, Barbei‐
to, L, Pettmann, B, & Raoul, C. (2011). IFNgamma triggers a LIGHT-dependent selec‐
tive death of motoneurons contributing to the non-cell-autonomous effects of mutant
SOD1. Cell death and differentiation , 18, 754-768.
[2] Barber, S. C, & Shaw, P. J. (2010). Oxidative stress in ALS: key role in motor neuron
injury and therapeutic target. Free radical biology & medicine , 48, 629-641.
[3] Beal, M. F, Ferrante, L. J, Browne, S. E, Matthews, R. T, Kowall, N. W, & Brown, R. H.
(1997). Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral
sclerosis. Ann Neurol , 42, 644-654.
[4] Beckman, J. S, Carson, M, Smith, C. D, & Koppenol, W. H. (1993). ALS, SOD and per‐
oxynitrite. Nature 364:584.
[5] Beckman, J. S, Estévez, A. G, Barbeito, L, & Crow, J. P. (2002). CCS knockout mice
establish an alternative source of copper for SOD in ALS. Free Rad. Biol. Med. , 33,
1433-1435.
Superoxide Dismutase and Oxidative Stress in Amyotrophic Lateral Sclerosis
http://dx.doi.org/10.5772/56488
151
2). The role of astrocytes in the induction of motor neuron death was recently confirmed in
astrocytes generated from post-mortem tissue of familial and sporadic ALS patients, addi‐
tionally providing an in vitro model system for the study of these mechanisms (Haidet-Phillips
et al., 2011).
Figure 2. Model for the role of motor neurons and glia in the ROS-mediated ALS progression. Different cell types
are affected and play a role at different stages of the disease. During the onset and early disease progression, motor
neurons undergo degeneration and cell death by cell-autonomous mechanisms. Later in the disease progression, acti‐
vated microglia and astrocytes release ROS, RNS, and toxic factors that magnify the injury (cell death amplification
mechanisms).
6. Conclusion
In summary, the mechanism of mutant SOD1 toxicity is unknown and highly controversial
but there is strong evidence suggesting that the mutant SOD1 toxic gain-of-function is related
to an alteration of its redox properties and the induction of oxidative stress. In this scenario,
the aberrant chemistry of mutant SOD1 turns the enzyme from antioxidant to pro-oxidant. Zn-
Current Advances in Amyotrophic Lateral Sclerosis150
deficient SOD1 reacts with hydrogen peroxide, produces superoxide and peroxynitrite, and
is able to catalyze tyrosine nitration, altering the cellular redox balance. In addition, although
not related to the redox properties of the enzyme, the interaction of mutant SOD1 with
mitochondria and Nox, the two major sources of cellular ROS, further support the involvement
of oxidative stress in the toxic gain-of-function. The cell type affected by mutant SOD1 is also
controversial. A picture in which several cell types are affected and play a role at different
stages of the disease seems to be emerging. In this context, during onset and early stages of
the disease SOD1-expressing motor neurons undergo neurodegeneration and cell death by
cell-autonomous processes. The activation of microglia and astrocytes may work as an
amplification mechanism in the induction of motor neuron death in the late progression of the
disease (Figure 2).
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1. Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by
death of upper and lower motor neurons, which results in muscle wasting and death from
respiratory failure typically within 2-5 years from diagnosis.
ALS is a multifactorial disease [1] where different cell types, i.e. astrocytes, microglia and
oligodendrocytes, contribute to the pathologic mechanism [2, 3]. For a long time ALS was
thought to be a pure motor neuron disease, however, thorough pathological investigations
and recent findings linking mutations in transactive response DNA-binding protein gene
(TARDBP) to familial and sporadic cases of ALS have relocated this disease within a spec‐
trum of neurological disorders, ranging from pure motor neuron disease to frontotemporal
dementia [4, 5].
Since 1993, when the first mutation in the Cu/Zn superoxide dismutase (SOD1) enzyme was
linked to familial forms of ALS, researchers have tried to unravel the mechanisms underly‐
ing this disease by interrogating in vivo and in vitro models overexpressing human SOD1.
Although these models have highly contributed to understanding the pathogenic mecha‐
nisms involved in motor neuron degeneration, they only account for less than 2% of all cas‐
es. Hence, the ALS field is still lacking effective therapies and a deep understanding of the
etiology of the sporadic disease.
For 15 years the SOD1 models have been the only available, until, in 2008, mutations in
TARDBP were found to be responsible for familial and sporadic forms of ALS [6, 7]. This led
to the discovery that mutations in a second RNA/DNA-binding protein called fused in sar‐
coma (FUS) or translocated in liposarcoma (TLS) were also cause of the disease [8, 9]. More
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to the discovery that mutations in a second RNA/DNA-binding protein called fused in sar‐
coma (FUS) or translocated in liposarcoma (TLS) were also cause of the disease [8, 9]. More
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recently, the field of ALS has seen a breakthrough with the association of GGGGCC-hexanu‐
cleotide repeat expansion in chromosome 9 open reading frame 72 (C9ORF72) to 35-40% of
familial cases and 5-7% of sporadic cases [10-12].
In the same years, from 2007 to present, in vitro technologies to model neurological disor‐
ders have also undergone an impressive development.
With the discovery that adult human fibroblasts could be reprogrammed to induced pluri‐
potent stem (iPS) cells with the use of selected transcription factors [13], the field of ALS saw
the opportunity to finally model not only the familial, but especially the sporadic disease in
vitro. In fact, in 2008, the first human iPS-derived motor neurons from patients were cul‐
tured in a petri dish [14]. Since then, several iPS lines have been produced from patients and
healthy individuals and they have been made commercially available (http://
www.coriell.org/stem-cells).
Moreover, in 2011, neural progenitors cells (NPCs) were isolated from post-mortem spinal
cord samples of ALS patients and successfully cultured and differentiated into motor neu‐
rons, astrocytes and oligodendrocytes in vitro [15]. This technology provided for the first
time the possibility to model all forms of ALS in vitro without inducing major epigenetic al‐
terations in the cells used.
In this chapter we will give an overview of how human tissues have been used so far, what
discoveries they have led to since 2007, and how the recent advances in technology com‐
bined with the recent genetic discoveries, have tremendously widened the horizon of ALS
research.
2. Latest genetic discoveries
Even though Jean-Martin Charcot initially described ALS in 1869, it took more than a centu‐
ry until the first disease-causing gene – the Cu/Zn superoxide dismutase (SOD1) - was iden‐
tified [16]. Mutations in this gene account for approximately 10-20% of the familial ALS
(FALS) cases (Anderson 2006) and about 1% of the sporadic (SALS). Up to now, mutations
in 21 different genes have been linked to ALS, although some of them present with atypical
disease characteristics [17]. FALS is usually inherited in an autosomal-dominant manner,
but in rarer cases, it appears also recessive or X-linked. Along with the rising number of
genes and mutations involved, the differentiation between sporadic and familial ALS be‐
comes increasingly difficult and depends on the definition applied. With the most stringent
classification, a patient is considered to suffer from the familial form if he/she has at least
one first- or second-degree relative affected by ALS [18]. However, other studies define
FALS when at least one relative is affected by motor neuron disease, i.e. ALS, primary later‐
al sclerosis (PLS) or progressive muscular atrophy (PMA) [19]. In addition, several indica‐
tions exist that mutations leading to ALS are also involved in the development of other
neurodegenerative diseases such as different types of dementia or Parkinsons disease. This
further broadens the range of possible familial linkage [19]. Missing family history data and
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the existence of mutations with incomplete penetrance, thus masking inherited genetic
forms of the disease as sporadic, further contribute to complicate the discrimination be‐
tween FALS and SALS.
In the last 20 years, most efforts were concentrated on studying the effect of SOD1 muta‐
tions, resulting in the generation of over 30 different animal models including Drosophila, C.
elegans, D. rerio, mice, rats and dogs [20]. In most cases, expression of human mutant SOD1 in
the animal models led to astrogliosis, inflammation and degeneration of motor neurons in a
similar manner as observed in patients.
The generated SOD1 animal models highly contributed to the understanding of SOD1 func‐
tions in the central nervous system (CNS) leading to the development of potential therapeu‐
tic strategies targeting these pathways. Unfortunately, most of the therapeutics that show an
effect in rodent models, fail in human clinical trials. Overall, SOD1 only accounts for about
2% of all ALS cases, therefore the question arose how applicable the findings from these
models really are for other familial cases and especially for the huge majority of sporadic
ALS cases.
In 2006, the transactive response DNA-binding protein (TDP-43) was identified as a major
component of intraneuronal inclusions, a form of protein aggregates representing a hall‐
mark of SALS and non-SOD1-FALS cases [21]. Soon after, researchers found ALS causing
mutations in this gene [6, 7]. One year later, mutations in a second RNA/DNA-binding pro‐
tein called fused in sarcoma (FUS) or translocated in liposarcoma (TLS) were published [8,
9]. While TDP-43 mutations account for 4% of FALS, FUS mutations are less frequent and
account for approximately 1-2% [22]. The discovery of the involvement of these two genes
can be considered a milestone in ALS research, not necessarily because of the mutation fre‐
quency, but rather because of the wide presence of these proteins in the aggregates charac‐
terizing tissues from sporadic ALS cases. Mutations in TDP-43 and FUS can also be found in
some forms of frontotemporal dementia (FTD), while aggregates of the non-mutated protein
seem to be an even more common feature for neurodegenerative diseases including Hun‐
tington’s, Alzheimer’s and Parkinson’s [23]. As both proteins are involved in RNA metabo‐
lism, a common disease mechanism underlying sporadic and familial forms of ALS might
exist. This link rises hope that a common therapeutic strategy could be developed benefit‐
ting a broad patient population.
The TARDBP gene encoding TDP-43 lies on chromosome 1p36.2. The TDP-43 protein con‐
sists of 414 amino acids and is highly conserved among species [7]. The expression pattern is
almost ubiquitous with high levels during development. Loss of TDP-43 is detrimental in
rodents as knockouts in mice are lethal in both cases, either when performed during embry‐
onic stages, or also as conditional knockouts in the adult mouse [24-26]. As mentioned
above, the protein is involved in RNA metabolism, but therein, various functions including
regulation of alternative splicing, transcription, miRNA levels, RNA stabilization, as well as
formation of stress and RNA granules have been described. TDP-43 seems to preferentially
bind RNAs with unusually long introns and/or such that are involved in neuronal function
like synaptic activity and neuronal development. Some of these RNAs encode proteins
which have previously been shown to be involved in neurodegenerative diseases [27]. Al‐
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tein called fused in sarcoma (FUS) or translocated in liposarcoma (TLS) were published [8,
9]. While TDP-43 mutations account for 4% of FALS, FUS mutations are less frequent and
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seem to be an even more common feature for neurodegenerative diseases including Hun‐
tington’s, Alzheimer’s and Parkinson’s [23]. As both proteins are involved in RNA metabo‐
lism, a common disease mechanism underlying sporadic and familial forms of ALS might
exist. This link rises hope that a common therapeutic strategy could be developed benefit‐
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The TARDBP gene encoding TDP-43 lies on chromosome 1p36.2. The TDP-43 protein con‐
sists of 414 amino acids and is highly conserved among species [7]. The expression pattern is
almost ubiquitous with high levels during development. Loss of TDP-43 is detrimental in
rodents as knockouts in mice are lethal in both cases, either when performed during embry‐
onic stages, or also as conditional knockouts in the adult mouse [24-26]. As mentioned
above, the protein is involved in RNA metabolism, but therein, various functions including
regulation of alternative splicing, transcription, miRNA levels, RNA stabilization, as well as
formation of stress and RNA granules have been described. TDP-43 seems to preferentially
bind RNAs with unusually long introns and/or such that are involved in neuronal function
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though TDP-43 depletion affects the expression and splicing of many different RNAs in the
CNS, the vast majority of the more than 40 ALS causing mutations identified so far, lie with‐
in the C-terminal domain encoding a glycine rich stretch that is important for protein-pro‐
tein interaction. While in healthy individuals TDP-43 is mainly localized in the nucleus, it
gets mislocalized and trapped in cytoplasmic aggregates in ALS patients, leading to reduced
levels in the nucleus [22]. The trapped TDP-43 seems to be heavily modified displaying
ubiquitination, phosphorylation and cleavage and in some cases, misfolding. The exact
meaning of TDP-43 mislocalization in ALS and other neurodegenerative diseases remains to
be elucidated, as so far, it is unclear whether the inclusions actively participate in the disease
development and progression or rather represent a mere indicator of other dysregulated cel‐
lular mechanisms. The observed changes in RNA regulation could arise from both, the mis‐
localization itself, leading to a reduced abundance in the nucleus, or function altering
mutations or modifications of the protein. In addition, it was reported that certain mutations
increase the stability of the protein and therefore its overall abundance in the cell [28], which
might lead to the visible accumulations and alterations in RNA metabolism.
Until now, a plethora of different animal models including Drosophila, mouse and rats has
been generated. Unfortunately at present, TDP-43 models have originated controversial re‐
sults. In fact, overexpressing wild type TDP-43 in the CNS appears to be toxic by itself,
while the effects of the mutant protein vary broadly ranging from no symptoms to severe
neurodegeneration in different regions of the mouse brain [20]. Mostly, it is unclear whether
the toxicity is due to the mutation or the simple presence of the transgene.
The gene  encoding FUS lies  on chromosome 16  in  a  region that  was  already linked to
familial ALS before the first mutations were identified. After the discovery of TDP-43 mu‐
tations, the focus on genes encoding RNA/DNA-binding proteins increased leading to the
fast discovery of mutations in FALS patients by two independent groups [8, 9]. Similar to
TDP-43, more than 40 different FUS mutations have been identified in FALS patients or
patients  suffering  from  FTD.  The  FUS  protein  consists  of  526  amino  acids  and  like
TDP-43,  it  is  widely  expressed  amongst  different  tissues.  Knockout  of  FUS in  different
mouse strains led to differing results, indicating that the genetic background of the used
mouse strain plays an important role as disease modifier. In the inbred strains (C57BL/6
and 129), the knockout causes death at birth, whereas outbred strains survive until adult‐
hood.  In  all  cases,  FUS depletion  seems not  to  induce  classical  neurodegeneration  as  a
primary effect.  Interestingly,  unlike TDP-43,  the ALS related mutations in the FUS gene
do not cluster in the glycine-rich region of the protein, but rather at the very end of the
highly  conserved C-terminus of  the  protein  that  contains  the  nuclear  localization signal
[22].  FUS is  also  mainly  localized in  the  nucleus  of  cells  in  healthy individuals,  but  its
mislocalization and aggregation in cytoplasmic granules in ALS patients leads to a less se‐
vere reduction in the nucleus than TDP-43 [22]. Up to now, only few binding partners of
FUS (RNA or proteins) are known, making it  further challenging to speculate about the
function of the protein, which remains mostly unknown. In general, FUS is thought to be
involved  in  regulation  of  gene  expression,  transcription,  RNA  splicing,  RNA  transport,
translation, miRNA processing as well as DNA damage repair [29]. Interestingly, TDP-43
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and FUS might directly interact with each other as they were detected in the same com‐
plex in cultured cells [28, 30]. Even though further data from patients and animal models
are  needed to  confirm this  finding,  it  is  an interesting observation,  as  TDP-43 does  not
seem to be  mislocalized in  ALS cases  that  have accumulation of  FUS containing aggre‐
gates in the cytoplasm [28].
Following TDP-43 and FUS, the thorough analysis of the cytoplasmic aggregates found in
ALS patients led to the identification of additional common components such as optineurin
and ubiquilin-2. Several of these proteins were afterwards identified to be mutated in a
smaller portion of ALS patients as well [31].
In 2011, the identification of a new ALS gene harboring a different type of mutation was
achieved.  The  association  of  the  chromosomal  locus  9p21.2  with  ALS and FTD had al‐
ready been described in 2006 [32]. The improvement of sequencing techniques and contin‐
uous  research  finally  led  to  the  identification  of  the  disease  causing  gene:  C9ORF72.
While the function of this widely expressed protein is unknown, the type of mutation dif‐
fers from other ALS related genes.  It  consists of a massive GGGGCC-hexanucleotide re‐
peat expansion in intron 1 between two non-coding exons.  Whereas healthy individuals
carry up to about 23 repeats, affected patients have at least 30, but in some cases, many
hundred copies of it [11, 12].
The first reports about the mutation in this gene came from two independent studies analyz‐
ing relatively small cohorts respectively of sporadic and familial ALS cases in Finland and
Europe and ALS/FTD cases in the USA. Both studies started off with re-sequencing of the
9p21.2 locus from well defined families, in which the linkage of the disease to this chromo‐
some 9 location had been previously demonstrated [11, 12]. After the detection of the repeat,
the analyses were expanded to larger cohorts.
The most striking discovery of these studies is the high frequency of mutations in this gene
in the analysed cohorts. Between 9 and 20% of American patients suffering from familial
FTD and up to 38% of familial ALS cases from different European countries resulted posi‐
tive for the new mutation. For the sporadic cases, the percentage lies around 7% for the
American FTD patient population and 21% of sporadic ALS patients in the genetically ho‐
mogenous Finnish population. With these initially published percentages, C9ORF72 muta‐
tions appeared to be the so far most frequent known cause of ALS and FTD. However, the
cohorts were recruited through only few institutions and were rather small. Recently, a
cross-sectional study including more patients from various different countries and with dif‐
fering genetic background has been published. In this study, a total of 588 familial ALS cases
and 403 familial FTD cases were screened for the mutation. For FALS, 37.6% of patients
were identified to carry the pathological repeat, for FTD the percentage was 25.1% [33]. Al‐
though further studies are needed to confirm these findings, they are truly exciting, consid‐
ering the fact that together with SOD1, which accounts for approximately 10-20% of FALS,
almost 50% of the familial disease cases can now be explained by mutations in one of these
two genes.
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The observation that C9ORF72 mutations not only cause ALS, but also FTD and clinically
mixed syndromes such as ALS-FTD, is in line with the clinical spectrum caused by TDP-43
and FUS mutations as well as wild type aggregations in both diseases. This further strength‐
ens the indications that these two clinically distinct syndromes share a common pathogenic
link [19, 34].
Interestingly, the pathological features of C9ORF72 related ALS seem very unusual and dis‐
tinct up to the point that the mutation itself can actually be predicted from the observed
pathology [35]. While the spinal cord shows the typical neuronal loss and TDP-43 positive
cytoplasmic inclusions, other regions of the brain seem to accumulate aggregates that are
widely devoid of TDP-43 and contain p62.
The mechanism through which this expansion repeat conveys toxicity to neurons still has to
be elucidated. Two major hypotheses can be distinguished: 1) The expansion repeat alters or
abolishes expression of all or certain C9ORF72 protein isoforms leading to reduced protein
levels and a loss of functionality, 2) the expanded repeat itself conveys toxicity by sequestra‐
tion of other RNA binding proteins and aggregate formation inside the nucleus, thus inhib‐
iting proper functionality of the bound proteins. To date, it is not known which hypothesis
applies in the case of C9ORF72 expansions, but the experience from various other toxic ex‐
pansion repeat diseases like Huntington’s disease are favoring the second. While Renton et.
al demonstrate the presence of aggregates in the nucleus of fibroblasts from affected pa‐
tients, the results from the second study by DeJesus et al are less clear concerning accumula‐
tion of RNA granules. The latter study also lies more emphasis on a change in the
expression levels of different C9ORF72 mRNA isoforms, which would support the first hy‐
pothesis rather than the second. Currently, the tools for a detailed analysis of protein expres‐
sion and function are still lacking, but considering the importance of the mutation, huge
efforts are put into the development of better antibodies, probes and assays.
Overall, the finding that mutations in TDP43, FUS and C9ORF72 might cause ALS by alter‐
ing the normal interaction of these proteins with RNA or might cause a toxic gain of func‐
tion leading to unexpected protein-RNA interaction opens new avenues for ALS research.
These recent genetic discoveries have shifted the attention to cellular processes, i.e. RNA
metabolism, transport and processing, that were not under investigation in the SOD1 mod‐
els. These pathways might represent a common mechanism for different forms of ALS, as
well as creating a link between ALS and a wider spectrum of neurodegenerative conditions.
3. The role of wild type SOD1 in ALS
In 1993 for the first time mutations in SOD1 were identified as cause of familial ALS and
were found to be responsible for about 20% of familial cases [16]. Since that discovery nearly
twenty years ago, more than 160 mutations in SOD1 have been identified (http://
alsod.iop.kcl.ac.uk/) and cellular and animal models of the disease carrying different forms
of mutant SOD1 have been generated [36, 37]. Experiments using animal models revealed
that the toxicity of mutant SOD1 is not related to a loss of function of the enzyme [38], but
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rather a gain of toxic function. In the past twenty years different forms of mutant SOD1 have
been characterized for their biochemical properties, however no common characteristics be‐
tween mutations have been found. In fact, different mutations seem to cause different
changes in enzymatic function or no change at all [39-41], leading to the conclusion that
SOD1 dismutase activity is not responsible for protein toxicity. Although the nature of the
toxic function gained by mutant SOD1 is still obscure, there is clear evidence that the mutant
enzyme undergoes conformational changes leading to its misfolding and subsequent aggre‐
gation [41, 42]. SOD1 aggregates are, in fact, one of the histological hallmarks of SOD1-relat‐
ed FALS, as well as sporadic cases carrying SOD1 mutations.
Although SOD1 mutations are responsible for less than 2% of ALS cases and this disease is
mainly of sporadic origin, sporadic and familial cases are clinically undistinguishable. More‐
over, with the exception of patients carrying C9ORF72 mutation, which seem to define a
specific clinical subgroup [35], other genetic mutations do not determine different clinical
characteristics. This observation has led to the conclusion that familial and sporadic ALS
must share common pathogenic mechanisms [1]. Consequently, in recent years, efforts have
been made in understanding whether the genes causing familial ALS can be responsible or
can be involved in the pathophysiology of sporadic cases. Recently, strong evidence has
been gathered suggesting that SOD1 might play a crucial role also in SALS.
Wild-type human SOD1 is a 32KDa homodimer known to be one of the most stable proteins
with a melting temperature around 90°C. However, its stability is highly dependent upon
post-translational processes including binding of copper and zinc ions and the formation of
an intramolecular disulfide bond. Impairment or retardation of these post-translational
processes can disrupt SOD1 stability, causing the formation of misfolded structures and ag‐
gregates. Indeed, in 2007, it was shown that oxidised wild-type SOD1 could acquire in vitro
aberrant properties leading to association with poly-ubiquitin, Hsp70 and chromogranin B,
similarly to the mutant enzyme [43]. The same year, another group used covalent chemical
modification to show that spinal cord samples from both familial and sporadic ALS cases
displayed a form of SOD1 that was absent in non-neurological controls as well as in spinal
cord samples from patients affected by other neurodegenerative disorders [44]. Recently,
Guareschi et al [45] managed to immunoprecipitate SOD1 from sporadic and familial ALS
patients’ lymphoblasts and then analysed the presence of oxidized carbonyl groups. A form
of over-oxidized wild-type SOD1 was indeed found in a subset of SALS patients. This post-
translationally modified form of the wild-type enzyme recapitulates some of the toxic prop‐
erties attributed to mutant SOD1, i.e. the ability to cause mitochondrial damage through
interaction with Bcl-2 [45]. Altogether, these findings supported the hypothesis that SOD1
could be a link between familial and sporadic ALS.
On another front, the use of the SOD1 mouse model also provided important clues as to
whether normal SOD1 can play a role in the disease. Surprisingly, overexpression of wild-
type human SOD1 accelerated disease onset in several transgenic mouse models of ALS [46,
47], supporting the involvement of wild type SOD1 in the disease mechanism. However,
these results have to be interpreted with caution, as they might derive by the toxicity of
transgene accumulation rather than a specific SOD1-related mechanism.
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The observation that C9ORF72 mutations not only cause ALS, but also FTD and clinically
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alsod.iop.kcl.ac.uk/) and cellular and animal models of the disease carrying different forms
of mutant SOD1 have been generated [36, 37]. Experiments using animal models revealed
that the toxicity of mutant SOD1 is not related to a loss of function of the enzyme [38], but
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rather a gain of toxic function. In the past twenty years different forms of mutant SOD1 have
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similarly to the mutant enzyme [43]. The same year, another group used covalent chemical
modification to show that spinal cord samples from both familial and sporadic ALS cases
displayed a form of SOD1 that was absent in non-neurological controls as well as in spinal
cord samples from patients affected by other neurodegenerative disorders [44]. Recently,
Guareschi et al [45] managed to immunoprecipitate SOD1 from sporadic and familial ALS
patients’ lymphoblasts and then analysed the presence of oxidized carbonyl groups. A form
of over-oxidized wild-type SOD1 was indeed found in a subset of SALS patients. This post-
translationally modified form of the wild-type enzyme recapitulates some of the toxic prop‐
erties attributed to mutant SOD1, i.e. the ability to cause mitochondrial damage through
interaction with Bcl-2 [45]. Altogether, these findings supported the hypothesis that SOD1
could be a link between familial and sporadic ALS.
On another front, the use of the SOD1 mouse model also provided important clues as to
whether normal SOD1 can play a role in the disease. Surprisingly, overexpression of wild-
type human SOD1 accelerated disease onset in several transgenic mouse models of ALS [46,
47], supporting the involvement of wild type SOD1 in the disease mechanism. However,
these results have to be interpreted with caution, as they might derive by the toxicity of
transgene accumulation rather than a specific SOD1-related mechanism.
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In order to determine whether in vivo wild-type SOD1 can undergo misfolding and can be
detected without altering the original sample, recent studies have focused on the production
and investigation of new antibodies able to distinguish mutant/misfolded/monomeric SOD1
as opposed to its wild-type form. Although some of these antibodies have been tested only
on limited samples and their ability to discriminate between aberrant conformations of
SOD1 is debatable, their use has led to potentially interesting findings. One of the first anti‐
bodies produced to detect abnormalities in SOD1 post-translational processing was the
SOD1-exposed dimer interface (SEDI). This antibody was prepared with the peptide at the
dimer interface of SOD1. When SOD1 is folded as a homodimer in its active state, this site is
inaccessible, while it is exposed upon monomerization [48]. This antibody successfully
stained inclusions in motor neurons from SALS samples, however it did not detect positive
inclusions in SALS spinal cords where no SOD1 mutations were detected [49]. Similarly, an
antibody developed against the region Leu42-His48, which specifically recognizes SOD1 in
which the beta barrel is unfolded, failed to detect misfolded SOD1 in SALS spinal cord sam‐
ples, but succeeded in recognizing aggregates in the FALS samples [50]. Despite these re‐
sults, it could not be concluded that wild-type SOD1 does not contribute to the pathogenic
mechanisms occurring in SALS. Indeed, Forsberg et al. have produced a series of polyclonal
antibodies against several SOD1 peptides that react with the denaturated enzyme, but not
with the wild-type form. Using these antibodies, small inclusions were detected in the motor
neurons of SALS patients [51] as well as in the nuclei of astrocytes, microglia and oligoden‐
drocytes [52]. These studies supported the hypothesis that wild-type SOD1, although not in‐
volved in the formation of Lewy body-like inclusions in SALS, is likely to undergo
conformational changes, thus contributing to the pathologic mechanism.
Another antibody that has been used to detect misfolded SOD1 is C4F6. This peptide was
raised against metal depleted (apo) SOD1 with G93A mutation [53]. Although this antibody
was raised against a specific mutant form of SOD1, it successfully recognised skein-like in‐
clusions in FALS spinal cord samples, as well as inclusions in SALS [54].
Recently, a monoclonal antibody, called 3H1, was used to detect misfolded SOD1 in a subset
of SALS cases displaying TDP-43/FUS-positive inclusions. This antibody recognizes a pep‐
tide corresponding to a structurally disrupted SOD1 electrostatic loop, detectable only when
the protein is misfolded. Spinal cord immunocytochemistry showed that, in some SALS
samples, TDP-43/FUS-positive inclusions were also positive for 3H1 antibody, suggesting
that the pathologic mechanisms involved in ALS might trigger SOD1 misfolding, thus trig‐
gering toxic pathways common to both sporadic and familial ALS [55].
Besides the efforts to generate antibodies able to detect misfolded SOD1, no consensus has
been reached on which antibodies, if any, can reliably and consistently detect the different
forms of misfolded SOD1. Other studies have, therefore, used a different approach, trying to
understand whether normal SOD1 shares common characteristics with the mutant form of
the enzyme. Recently, a novel rare mutation in SOD1 (L117V) was identified in two Syrian
ALS families [39]. Unusually, the disease showed uncommon low penetrance and slow pro‐
gression. Biochemical analysis of L117V SOD1 showed that its properties were indistin‐
guishable from the wild-type form and yet causing the disease. This study highlights that
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normal SOD1 is in the range of protein stability that can cause disease and suggests that mu‐
tant forms of SOD1 with high stability might be related to low penetrance and be therefore
categorized as sporadic forms of ALS. The authors suggest that, similarly, other complex ge‐
netic, environmental and lifestyle factors can influence the stability of normal SOD1 causing
its misfolding in SALS cases. However, this does not exclude that the toxicity related to
L117V mutation could derive by the interaction with other proteins and not by its stability.
The importance of finding common pathways or players between sporadic and familial ALS
is crucial for therapeutic approaches. One recent study explored this possibility [15]. The au‐
thors assessed the toxicity of astrocytes derived from neural progenitors isolated from the
spinal cord of sporadic and familial ALS patients. This study showed for the first time that
astrocytes from sporadic cases of disease are as toxic to motor neurons as astrocytes carrying
mutations in SOD1. As expected, the shRNA mediated reduction of mutated SOD1 led to a
complete rescue of motor neurons in this co-culture system. Of particular interest however,
was the finding that even the knock down of wild type SOD1 in astrocytes from sporadic
patients markedly attenuated toxicity towards motor neurons.
The data summarized in this section provide strong evidence for a pathologic role of wild-
type SOD1 in sporadic disease. This hypothesis opens new frontiers for future therapeutic
approaches in the treatment of ALS.
4. Human samples to study ALS
In ALS the cells mainly affected by the disease, the motor neurons and the glia, are located
in the motor cortex and the spinal cord, which are accessible only post-mortem. The scarce
availability of CNS samples, along with post-mortem delay and different preservation tech‐
niques that can affect the quality of the tissue and limit its use, are great challenges when
studying this disease. Moreover, post-mortem material is only representative of the end
stage of disease and, although used in microarray studies to unravel the mechanisms of neu‐
rodegeneration, it is unlikely to help identify early biomarkers. For these reasons, peripheral
tissues, i.e. blood, fibroblasts and cerebrospinal fluid (CSF) have been preferentially used in
high-throughput screening assays for biomarkers identification as well as gene expression
profiling.
4.1. Gene expression profiling
Multiple research groups have used post-mortem samples to identify the pathways in‐
volved in the neurodegenerative process of ALS. The studies utilizing complex tissues, rep‐
resentative of a mixed cell population, i.e. motor cortex [56] or spinal cord [57], have mainly
recorded gene expression changes indicating the presence of an aggressive inflammatory re‐
action and active astrogliosis. These processes are prevalent in the spinal cord of ALS pa‐
tients and have masked the transcriptional changes occurring in motor neurons. However,
the motor cortex seems to be affected to a lesser extent by astrogliosis and this enabled Le‐
derer and colleagues to identify important changes in transcripts involved in the cytoskele‐
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raised against metal depleted (apo) SOD1 with G93A mutation [53]. Although this antibody
was raised against a specific mutant form of SOD1, it successfully recognised skein-like in‐
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Recently, a monoclonal antibody, called 3H1, was used to detect misfolded SOD1 in a subset
of SALS cases displaying TDP-43/FUS-positive inclusions. This antibody recognizes a pep‐
tide corresponding to a structurally disrupted SOD1 electrostatic loop, detectable only when
the protein is misfolded. Spinal cord immunocytochemistry showed that, in some SALS
samples, TDP-43/FUS-positive inclusions were also positive for 3H1 antibody, suggesting
that the pathologic mechanisms involved in ALS might trigger SOD1 misfolding, thus trig‐
gering toxic pathways common to both sporadic and familial ALS [55].
Besides the efforts to generate antibodies able to detect misfolded SOD1, no consensus has
been reached on which antibodies, if any, can reliably and consistently detect the different
forms of misfolded SOD1. Other studies have, therefore, used a different approach, trying to
understand whether normal SOD1 shares common characteristics with the mutant form of
the enzyme. Recently, a novel rare mutation in SOD1 (L117V) was identified in two Syrian
ALS families [39]. Unusually, the disease showed uncommon low penetrance and slow pro‐
gression. Biochemical analysis of L117V SOD1 showed that its properties were indistin‐
guishable from the wild-type form and yet causing the disease. This study highlights that
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netic, environmental and lifestyle factors can influence the stability of normal SOD1 causing
its misfolding in SALS cases. However, this does not exclude that the toxicity related to
L117V mutation could derive by the interaction with other proteins and not by its stability.
The importance of finding common pathways or players between sporadic and familial ALS
is crucial for therapeutic approaches. One recent study explored this possibility [15]. The au‐
thors assessed the toxicity of astrocytes derived from neural progenitors isolated from the
spinal cord of sporadic and familial ALS patients. This study showed for the first time that
astrocytes from sporadic cases of disease are as toxic to motor neurons as astrocytes carrying
mutations in SOD1. As expected, the shRNA mediated reduction of mutated SOD1 led to a
complete rescue of motor neurons in this co-culture system. Of particular interest however,
was the finding that even the knock down of wild type SOD1 in astrocytes from sporadic
patients markedly attenuated toxicity towards motor neurons.
The data summarized in this section provide strong evidence for a pathologic role of wild-
type SOD1 in sporadic disease. This hypothesis opens new frontiers for future therapeutic
approaches in the treatment of ALS.
4. Human samples to study ALS
In ALS the cells mainly affected by the disease, the motor neurons and the glia, are located
in the motor cortex and the spinal cord, which are accessible only post-mortem. The scarce
availability of CNS samples, along with post-mortem delay and different preservation tech‐
niques that can affect the quality of the tissue and limit its use, are great challenges when
studying this disease. Moreover, post-mortem material is only representative of the end
stage of disease and, although used in microarray studies to unravel the mechanisms of neu‐
rodegeneration, it is unlikely to help identify early biomarkers. For these reasons, peripheral
tissues, i.e. blood, fibroblasts and cerebrospinal fluid (CSF) have been preferentially used in
high-throughput screening assays for biomarkers identification as well as gene expression
profiling.
4.1. Gene expression profiling
Multiple research groups have used post-mortem samples to identify the pathways in‐
volved in the neurodegenerative process of ALS. The studies utilizing complex tissues, rep‐
resentative of a mixed cell population, i.e. motor cortex [56] or spinal cord [57], have mainly
recorded gene expression changes indicating the presence of an aggressive inflammatory re‐
action and active astrogliosis. These processes are prevalent in the spinal cord of ALS pa‐
tients and have masked the transcriptional changes occurring in motor neurons. However,
the motor cortex seems to be affected to a lesser extent by astrogliosis and this enabled Le‐
derer and colleagues to identify important changes in transcripts involved in the cytoskele‐
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tal, mitochondrial and proteasomal functions, as well as ion homeostasis and glycolysis [56],
in agreement with other lines of research in ALS [1].
In order to determine those genes differentially expressed in the cell type most affected in
ALS, i.e. spinal motor neurons, laser capture microdissection (LCM) has been used to isolate
single cells from human post mortem spinal cord samples.
Gene expression profiling of motor neurons has been performed on sporadic ALS cases [58],
as well as ALS cases carrying mutations in the SOD1 and chromatin modifying protein 2B
(CHMP2B) genes [59, 60]. The three studies highlighted the activation of different pathogen‐
ic pathways. The motor neurons isolated from sporadic cases showed decreased expression
of genes associated with the cytoskeleton and transcription, whilst cell death-associated
transcripts were increased. Moreover, genes involved in cell cycle activation and progres‐
sion were found to be upregulated, supporting the theory that inappropriate activation of
the cell cycle in these post-mitotic cells can lead to cell death [58].
In contrast, microarray analysis of motor neurons isolated from SOD1-related ALS cases
highlighted the activation of a cell survival pathway in the motor neurons that were spared
by the disease. The study, in fact, revealed differential expression of genes involved in the
protein kinase B/phosphatidylinositol-3 kinase (AKT/PI3K) pathway, along with decrease in
phophastase and tensin homologue (PTEN) gene, a negative regulator of AKT [60]. The au‐
thors also showed that inhibition of PTEN led to increased activation of the AKT/PI3K path‐
way, with beneficial effects on primary motor neuron survival. Thus, activation of the AKT/
PI3K pathway is a potential candidate for future therapeutic strategies.
Finally, the transcriptional profiles from motor neurons isolated from the CHMP2B-related
ALS cases showed dysregulation of genes involved in p38 MAPK signalling pathway, re‐
duced autophagy and repression of translation [59]. The significant impairment of the au‐
tophagy pathway reflects the function of CHMP2B, the gene mutated in these patient
samples.
In spite of the differences between the pathways described above, dysregulation of calcium
handling and cell cycle, as well as transcription, cytoskeleton assembly and metabolism,
were common between the different genetic subtypes and SALS. Taking into account that
these results derive from end-stage tissues, they support the evidence that etiologically di‐
verse forms of ALS converge into common mechanisms involved in motor neuron death.
4.1.1. Results from use of human peripheral tissue
Gene expression profiling has also been conducted on blood cells from ALS patients in order
to identify biomarkers and/or achieve a better classification of disease subtypes through the
identification of common transcriptional patterns [61-63]. In the study conducted by Saris
and colleagues, microarray analysis of SALS and control whole blood samples was followed
by hierarchical clustering of all differentially expressed transcripts [61]. This approach suc‐
cessfully identified different clusters that were able to differentiate between ALS and control
samples. Interestingly, this study showed that peripheral blood can be used to investigate
the pathways activated during disease, as the blood from ALS patients reveals decrease in
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transcripts involved in RNA processing as well as upregulation of inflammatory genes. This
suggests that the mechanisms affecting motor neurons, also strike other cell type. However,
because of their post-mitotic characteristics and their unique function, motor neurons are the
most susceptible.
A more recent study performed gene expression profiling on peripheral blood mononuclear
cells (PBMCs) from patients with SALS [62]. The results show upregulation of LPS/TLR4-
signaling associated genes in response to elevated LPS plasma levels. A similar transcription
pattern was obtained by culturing PBMCs from normal controls with LPS for a short time in
vitro.
Similarly, Mougeot et al. found that peripheral blood lymphocytes (PBLs) display dysregu‐
lation of the ubiquitin/proteasome system (UPS) [63]. In particular, microarray analysis re‐
vealed upregulation of the ubiquitin-protein ligase E3-alpha-2 (UBR2) expression. UBR2 is
known to act in synergy with UBR1 in a quality control mechanism for degradation of un‐
folded proteins. UBR2 upregulation correlated inversely with time since onset of disease
and directly with the ALS functional rating scale (ALSFRS-R), suggesting that UBR2 is in‐
creased early in the disease course and decreases as disease progresses. The authors con‐
firmed with in vitro experiments that cultured PBMCs from ALS patients accumulated more
ubiquitinated proteins than PBMCs from healthy controls in a serum-dependent manner, as
expected from the transcription data.
Very recently, human samples have been used to interrogate micro RNA (miRNA) expres‐
sion [64, 65]. Two studies successfully identified dysregulation of miRNAs in peripheral leu‐
kocytes [64] and monocytes [65] from SALS samples compared to controls. These miRNA
are involved in pathways relevant to the CNS and, in particular, Butovsky et al. identified
changes relevant for the inflammatory response, similarly to the expression pattern dis‐
played by monocytes isolated from multiple sclerosis (MS) patients. These results suggest
that miRNAs profiles found in the peripheral blood cells can be relevant to understand the
pathogenesis of ALS and/or used as biomarkers of the disease.
4.2. Biomarkers in ALS
ALS is fatal rapidly progressive neurodegenerative disorder, characterized by the activation
of an intricate network of pathways and still lacking an effective treatment beside Riluzole
[1]. The diagnosis of ALS is still mainly based on clinical assessment of progression of symp‐
toms, which results in a delay of about a year from symptom onset to diagnosis. Although
the clinical course of disease can considerably vary from case to case, in the majority of cases
death occurs within 2-5 years [66].
In this scenario, significant effort has been spent trying to identify molecules that could help
classify different forms of ALS and lead to early diagnosis, as well as monitor disease pro‐
gression.
The tissues mainly utilized for biomarker screening in the past five years have been periph‐
eral blood mononuclear cells (PBMCs) and cerebrospinal fluid (CSF). PBMCs have already
been shown to display some of the traits of the disease, such as increase in inflammatory
The Use of Human Samples to Study Familial and Sporadic Amyotrophic Lateral Sclerosis: New Frontiers…
http://dx.doi.org/10.5772/56487
169
tal, mitochondrial and proteasomal functions, as well as ion homeostasis and glycolysis [56],
in agreement with other lines of research in ALS [1].
In order to determine those genes differentially expressed in the cell type most affected in
ALS, i.e. spinal motor neurons, laser capture microdissection (LCM) has been used to isolate
single cells from human post mortem spinal cord samples.
Gene expression profiling of motor neurons has been performed on sporadic ALS cases [58],
as well as ALS cases carrying mutations in the SOD1 and chromatin modifying protein 2B
(CHMP2B) genes [59, 60]. The three studies highlighted the activation of different pathogen‐
ic pathways. The motor neurons isolated from sporadic cases showed decreased expression
of genes associated with the cytoskeleton and transcription, whilst cell death-associated
transcripts were increased. Moreover, genes involved in cell cycle activation and progres‐
sion were found to be upregulated, supporting the theory that inappropriate activation of
the cell cycle in these post-mitotic cells can lead to cell death [58].
In contrast, microarray analysis of motor neurons isolated from SOD1-related ALS cases
highlighted the activation of a cell survival pathway in the motor neurons that were spared
by the disease. The study, in fact, revealed differential expression of genes involved in the
protein kinase B/phosphatidylinositol-3 kinase (AKT/PI3K) pathway, along with decrease in
phophastase and tensin homologue (PTEN) gene, a negative regulator of AKT [60]. The au‐
thors also showed that inhibition of PTEN led to increased activation of the AKT/PI3K path‐
way, with beneficial effects on primary motor neuron survival. Thus, activation of the AKT/
PI3K pathway is a potential candidate for future therapeutic strategies.
Finally, the transcriptional profiles from motor neurons isolated from the CHMP2B-related
ALS cases showed dysregulation of genes involved in p38 MAPK signalling pathway, re‐
duced autophagy and repression of translation [59]. The significant impairment of the au‐
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were common between the different genetic subtypes and SALS. Taking into account that
these results derive from end-stage tissues, they support the evidence that etiologically di‐
verse forms of ALS converge into common mechanisms involved in motor neuron death.
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Gene expression profiling has also been conducted on blood cells from ALS patients in order
to identify biomarkers and/or achieve a better classification of disease subtypes through the
identification of common transcriptional patterns [61-63]. In the study conducted by Saris
and colleagues, microarray analysis of SALS and control whole blood samples was followed
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cessfully identified different clusters that were able to differentiate between ALS and control
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transcripts involved in RNA processing as well as upregulation of inflammatory genes. This
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signaling associated genes in response to elevated LPS plasma levels. A similar transcription
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[1]. The diagnosis of ALS is still mainly based on clinical assessment of progression of symp‐
toms, which results in a delay of about a year from symptom onset to diagnosis. Although
the clinical course of disease can considerably vary from case to case, in the majority of cases
death occurs within 2-5 years [66].
In this scenario, significant effort has been spent trying to identify molecules that could help
classify different forms of ALS and lead to early diagnosis, as well as monitor disease pro‐
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genes [65] and downregulation of Bcl-2 [67] and might, therefore, be used to investigate the
disease during its progression as well as provide unique biomarkers.
Recently, Nardo et al. performed proteomic analysis of PBMCs isolated from 60 sporadic
ALS patients and 30 healthy controls [68]. The authors identified and validated in a second
cohort 14 protein biomarkers, that could discriminate between ALS patients and controls re‐
gardless of age and gender. Remarkably, of these 14 biomarkers, 5 were able to discriminate
between ALS patients and individuals with other neuropathies and 3, among which TDP43,
were markers of disease severity. Notably, these results are consistent with a CSF biomarker
study reporting that TDP43 levels were increased in ALS patients [69]. The value of this re‐
sult goes beyond the finding of a disease biomarker, as it supports the even more interesting
hypothesis that TDP43 could be a common player in early disease in familial as well as
sporadic ALS cases. This would confirm what is already suggested by the presence of
TDP-43 positive aggregates in SALS biopsy samples.
Although there is still no consensus on valid biomarkers for ALS [70], proteome analysis has
recently led to the identification of fetuin-A and transthyretin (TTR) as candidates to distin‐
guish ALS patients with rapid versus slow disease progression. The upregulation of TTR
and fetuin-A, involved in immune regulatory functions, could be associated with the inflam‐
matory state of the CNS. At present, these markers were tested in two independent cohorts
of 18 and 20 patients with a follow up of 2 years [71] and TTR had already been identified as
a potential biomarker for ALS compared to controls in a previous study [72]. Although fur‐
ther validation is needed, these results are encouraging and would provide an invaluable
tool to discriminate between patients with different disease progression rates. This would
help clinician determine the timing for clinical intervention such as gastrostomy and non-
invasive ventilation [73].
5. Stem cell technology for ALS research
Stem cells are defined as a population of cells that maintains the ability to self-renew and
differentiate into several cell types of the adult body. In mammals, several tissues such as
muscle, brain and bone marrow, harbor subtypes of stem cells that can give rise to a rela‐
tively small variety of different cell types. These adult stem cells are committed to certain
cell lineages and do not produce cells from other tissue types under normal conditions. Un‐
like adult stem cells, embryonic stem cells that can be isolated from the inner cell mass of
early stage embryos are pluripotent and can, therefore, still differentiate into virtually any
cell type of the human body. While the collection of embryonic stem cells from mice is a
widely accepted approach used for disease modeling, the use of human embryonic stem
cells is controversial and rises severe ethical concerns. With the discovery that adult human
fibroblasts can be reprogrammed to an embryonic stem cell like state, new hope arose for
stem cell based approaches in human research. Induced pluripotent stem cells (iPS) are usu‐
ally generated by the introduction of 2-5 defined pluripotency transcription factors into fi‐
broblasts or other readily available differentiated cell types. These transcription factors
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drastically alter gene expression in the target cells until some of them eventually become
pluripotent and can then be isolated and amplified. Initially, the transcription factors were
introduced by retroviral or lentiviral constructs leading to the integration of the transgene
into the target genome. As the random integration of additional genes can disrupt/alter the
expression of endogenous genes, more recent approaches rely on less invasive techniques
such as transposons or RNA transfection [74]
The use of stem cell technologies in ALS research started in 2007 when mouse embryonic
stem cells from the most prominent SOD1 model carrying the G93A mutation were estab‐
lished [75]. When differentiated into motor neurons, mild phenotypic differences between
motor neurons expressing human wild type SOD1 or the G93A mutation could be observed.
After several weeks in culture, SOD1 containing inclusions as well as the overall level of
ubiquitinated proteins were more frequent in the motor neurons expressing the mutant hu‐
man protein. In 2009, a human embryonic stem cell line was used to generate motor neurons
that were then transfected with different SOD1 mutation containing constructs [76]. The re‐
searchers observed a reduction in neurite length and in line with the study of the mouse
G93A embryonic stem cell derived motor neurons, reduced survival. However, in the hu‐
man study, it is unclear whether the observed phenotype arises from the mutations or the
increase of SOD1 abundance itself, as a control overexpressing wild type SOD1, was not
generated.
Since the discovery of the iPS technology, huge efforts were put in the generation of patient
specific iPS lines. Up to now, several hundred lines with various mutations have been gener‐
ated and some are now becoming commercially available thereby getting accessible to a
broad scientific community.
In 2008, Dimos et al reported the successful generation of motor neurons and glial cells from
an ALS patient derived iPS line carrying a SOD1 mutation causing a mild disease phenotype
[14]. Surprisingly, unlike the previous studies with mouse and human embryonic stem cells,
no disease related phenotype was reported from these cells until now. This potential lack of
phenotype could in part be explained by the patient’s late onset and mild disease form. An‐
other report from 2011, where motor neurons were generated from a patient harboring a
VAPB mutation, did also not mention any phenotype despite reduced levels of VAPB. As
the levels of this protein were already reduced in the fibroblasts used for the reprogram‐
ming, the lower levels in the resulting motor neurons could either be due to mutation in‐
duced expression or translational changes or could also be explained by an incomplete
reprogramming of this genomic locus in the generated iPS lines [77]. Recently, the first re‐
port of an iPS line harboring a TDP-43 mutation was published [78]. The motor neurons
generated from this line showed elevated TDP-43 levels, but no change in localization or
signs of aggregate formation. In addition, motor neurons from both, control and TDP-43
mutant were phenotypically and functionally similar despite an elevated sensitivity to PI3K
signaling inhibition and elevated cell death. These data suggest that the toxicity of this
TDP-43 mutation might arise from its increased stability leading to a higher overall protein
amount in the cell.
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early stage embryos are pluripotent and can, therefore, still differentiate into virtually any
cell type of the human body. While the collection of embryonic stem cells from mice is a
widely accepted approach used for disease modeling, the use of human embryonic stem
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fibroblasts can be reprogrammed to an embryonic stem cell like state, new hope arose for
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After several weeks in culture, SOD1 containing inclusions as well as the overall level of
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G93A embryonic stem cell derived motor neurons, reduced survival. However, in the hu‐
man study, it is unclear whether the observed phenotype arises from the mutations or the
increase of SOD1 abundance itself, as a control overexpressing wild type SOD1, was not
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specific iPS lines. Up to now, several hundred lines with various mutations have been gener‐
ated and some are now becoming commercially available thereby getting accessible to a
broad scientific community.
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an ALS patient derived iPS line carrying a SOD1 mutation causing a mild disease phenotype
[14]. Surprisingly, unlike the previous studies with mouse and human embryonic stem cells,
no disease related phenotype was reported from these cells until now. This potential lack of
phenotype could in part be explained by the patient’s late onset and mild disease form. An‐
other report from 2011, where motor neurons were generated from a patient harboring a
VAPB mutation, did also not mention any phenotype despite reduced levels of VAPB. As
the levels of this protein were already reduced in the fibroblasts used for the reprogram‐
ming, the lower levels in the resulting motor neurons could either be due to mutation in‐
duced expression or translational changes or could also be explained by an incomplete
reprogramming of this genomic locus in the generated iPS lines [77]. Recently, the first re‐
port of an iPS line harboring a TDP-43 mutation was published [78]. The motor neurons
generated from this line showed elevated TDP-43 levels, but no change in localization or
signs of aggregate formation. In addition, motor neurons from both, control and TDP-43
mutant were phenotypically and functionally similar despite an elevated sensitivity to PI3K
signaling inhibition and elevated cell death. These data suggest that the toxicity of this
TDP-43 mutation might arise from its increased stability leading to a higher overall protein
amount in the cell.
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Despite the growing number of iPS lines from ALS patients available, no further reports of
disease relevant phenotypes or major discoveries of disease mechanisms from the use of
these cells were reported so far. In addition, observations from other neurological disorders
show a similar trend: cells differentiated from embryonic stem cells or induced pluripotent
stem cells often reflect only certain aspects of the disease and sometimes it takes several
weeks before such differences can be recorded and/or the observed symptoms are very mild
[79, 80]. The problems to reproduce patient phenotypes have ameliorated the initial excite‐
ment about this new method to model neurological diseases. More recently, it became clear
that even cells differentiated from individual embryonic stem cell clones or iPS clones from
the same patient can show substantial phenotypic differences, a phenomenon called clonal
variation [81]. Similar observations were made in a study using iPS lines of ALS patients
carrying TDP-43 mutations. After differentiation of individual iPS clones from the same pa‐
tient into motor neurons, the levels of TDP-43 expression as well as aggregate formation and
oxidative stress induced cell death showed substantial variation [82]. Considering the con‐
fusing reports, it has to be assumed that the reprogramming as well as the following differ‐
entiation mechanisms are not yet fully under control and more mechanistic research and
standardization of the protocols will hopefully soon lead to more pronounced and reprodu‐
cible results. Initial steps to improve reproducibility and differentiation are already under
way. The main focus lies on the standardization of the initial characterization of the iPS
clones prior to use as well as the improvement of differentiation protocols by addition of
various small molecules and growth factors [83, 84].
While these approaches emerge, sporadic and familial forms of ALS can be modeled with
cells isolated from human post mortem spinal cord or brain samples. A recent report dem‐
onstrated that post-mortem isolated neuronal progenitor cells from patients with sporadic
or familial ALS, can be differentiated into astrocyte-like cells in vitro. Astrocytes from pa‐
tients, but not from healthy controls conveyed toxicity to wild type mouse motor neurons in
a co-culture [15]. This system provides a promising tool for testing of potential therapeutic
approaches.
5.1. The promises and limitations of stem cells for therapeutic approaches
The disease modeling described in the upper section is in particular important for the huge
proportion of ALS cases, where no causing mutation is known. Until the discovery of the
iPS technology, this lack of knowledge made it impossible to model such cases in vitro in a
cell based assay or with animal models, unless post-mortem cells could be collected. Now
we can use skin fibroblasts or other readily available cell types from affected patients during
different time points of disease progression prior to end stage. From these fibroblasts, vari‐
ous cell types that are known to play a crucial role in ALS can be generated and their behav‐
ior and interplay in a cell culture dish can be studied in-depth.
Despite emerging into an invaluable tool to study disease mechanisms, stem cells also hold
a huge potential for the development of therapeutic approaches for ALS and many other
neurodegenerative diseases. On the one hand, the generated cells can now be used in drug
screenings to identify new target mechanisms or to assess potential new therapeutics. On
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the other hand, the stem cells can be used for cell replacement approaches. For patients with
known mutations, the cells can be genetically modified or corrected prior to reprogramming
and differentiation. Such individualized strategies would allow the use of the patient’s own
cells for transplantation, thereby reducing the risk of graft rejection.
In ALS, a major future goal would be to produce and replace dying motor neurons. A proof
of principle that motor neuron transplantation might become possible came from the obser‐
vation that mouse embryonic stem cell derived motor neurons transplanted into the lumbar
part of paralysed adult rats can actually survive and form functional neuromuscular junc‐
tions leading to phenotypical improvements [85]. However, in human ALS patients, the re‐
placement of motor neurons might be more complicated due to the size differences, amount
of cells needed and distance that the axon would have to grow out. In addition, it becomes
more and more evident that ALS is a non-cell autonomous disease in which astrocytes, mi‐
croglia and oligodendrocytes play a crucial role in modulating disease onset and progres‐
sion [3, 15, 86]. In this context, a strategy approaching several cell types at a time might be
more successful than bringing in healthy motor neurons alone into a heavily diseased envi‐
ronment. A promising candidate that can generate various cell types in the CNS and at the
same time positively stimulate the neuronal environment by producing neuroprotective fac‐
tors, are neuronal progenitor cells (also called neuronal stem cells). Several reports indicate
that transplanted neuronal progenitor cells are able to differentiate into different cell types
in vivo [87, 88]. Further, injection of NPCs has been shown to ameliorate disease progression
in ALS rodent models even if most of the cells do not migrate or differentiate into other cell
types in various neurodegenerative diseases [89]. However, it is not known how these cells
would behave and survive when transplanted into a diseased environment.
One of the largest limitations for cell replacement strategies to date is the lack of efficiency
as well as specificity during the amplification and differentiation step. The differentiation of
ES or iPS cells into various different neurons or neuronal progenitor cells is guided by the
application of different growth factors and small molecules. However, this process usually
generates a mixed population containing many different cell types. The cell type of interest
often represents only 30% or even less of the total population. Therefore, it might be difficult
to generate enough cells for therapeutic applications.
When using ES or iPS lines to generate the cell type of interest, a further drawback is that a
small portion of cells remains undifferentiated and immature, thereby representing a major
risk factor for transplantation [90]. When neuronal progenitor cells derived from mouse iPS
cells were injected into adult mouse brains, they formed tumors in up to 60% of the injected
animals [88]. The use or more restricted cell types such as NPCs on the opposite, appears to
be safer.
Finally, the generation and maintenance of a stable iPS lines from human adult cells is ex‐
pensive and very time consuming [74]. If clinical applications are considered, a thorough
characterization of several individual clones needs to be undertaken prior to use, making a
widespread application of this approach today unlikely. Very recent reports indicate that fi‐
broblasts can be directly differentiated into several types of neurons and even neuronal pro‐
genitor cells in a much faster and more efficient way than through iPSing [91]. It remains to
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different time points of disease progression prior to end stage. From these fibroblasts, vari‐
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Despite emerging into an invaluable tool to study disease mechanisms, stem cells also hold
a huge potential for the development of therapeutic approaches for ALS and many other
neurodegenerative diseases. On the one hand, the generated cells can now be used in drug
screenings to identify new target mechanisms or to assess potential new therapeutics. On
Current Advances in Amyotrophic Lateral Sclerosis172
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to generate enough cells for therapeutic applications.
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cells were injected into adult mouse brains, they formed tumors in up to 60% of the injected
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pensive and very time consuming [74]. If clinical applications are considered, a thorough
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be evaluated to which extent these cells recapitulate neurodegenerative disease phenotypes,
although a first report from fibroblast derived neurons from a familial Alzheimer’s patient
seem promising [92].
In summary, the technique of reprogramming holds great promises in terms of disease mod‐
eling and unraveling of underlying mechanisms of sporadic neurodegenerative diseases
such as ALS. Despite the current confusion due to the various methods used to generate the
lines, the observed clonal variations as well as the limited reflection of disease phenotypes,
the field has advanced with tremendous speed if one considers that the first report about
reprogramming of mouse fibroblasts was published only 6 years ago. With combined efforts
and improved methods, a better understanding and control of the reprogramming mecha‐
nisms can be achieved, thereby facilitating the interpretation and usage of the generated
cells.
6. Future trends in modeling ALS and discovering new therapies
The recent remarkable advancement in the cell biology field that adult fibroblasts can be re‐
programmed to virtually originate all cell types have created a unique opportunity to model
neurological disorders in vitro. iPS technology has already been applied to several neurode‐
generative conditions, from Alzheimer’s disease [93] to Down syndrome [94], as well schizo‐
phrenia [80], Rett syndrome [95] and ALS [14].
Although a large number of iPS cell lines from patients affected by various diseases have
been made commercially available, it is still not clear how robustly these recapitulate the
characteristics specific of each disease. Although the promises of iPS technology are to lead
to high-throughput screenings to find new efficacious therapeutic targets, they are subject to
some main limitations that have already been addressed in other sections of this book chap‐
ter. It is, therefore, of paramount importance that the properties of the differentiated cells
are well characterized and it is verified that they are representative of the disease they are
modeling.
However, some promising results have been obtained from a very recent study suggesting
that iPS-derived motor neurons originated from patients carrying TDP-43 mutations display
abnormalities typical of TDP-43 proteinopathy. These cells display elevated levels of soluble
and detergent-resistant TDP-43 protein, decreased survival, and increased vulnerability to
inhibition of phosphatidylinositol 3-kinase (PI3K) pathway [78] as well as shorter neurites
and TDP-43 cytoplasmic aggregates [82]. These parameters can be used as readout for high-
throughput drug screenings as well as short hairpin RNA (shRNA) library screenings. In‐
deed, Egawa and colleagues performed microarray analysis on iPS-derived motor neurons
transduced with lentivirus expressing green fluorescent protein (GFP) under the control of
the HB9 promoter. Based on the results obtained from gene expression analysis, the authors
tested 4 drugs known to modulate transcription through histone modification and RNA
splicing. Using the high content imaging analyzer InCell 6000, Egawa and colleagues found
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that anacardic acid had protective effects against arsenite-induced motor neuron death and
was able to decrease TDP-43 cytoplasmic aggregates as well as increase neurite length [82].
A different approach was taken in 2011 by Haidet-Phillips and colleagues [15], producing
cells from patients without the use of viral vectors or induction of major epigenetic modi‐
fications.  In  this  study,  astrocytes  were  derived from NPCs isolated  from ALS patients
and it was observed that, regardless of their familial or sporadic origin, these cells were
toxic to wild type murine motor neurons expressing GFP under HB9 promoter [15]. The
authors  found that  SOD1 knockout via  shRNA could rescue motor neurons at  different
extents  depending  on  whether  these  were  co-cultured  on  astrocytes  from  familial  or
sporadic  cases.  This  study overcomes some of  the  major  issues  related to  iPS  cells  and
sets the premises for drug and shRNA screening to target pathways and single genes in‐
volved in astrocyte toxicity.
Concluding, it is clear that in the past five years the ALS field has seen a major change of
scenario, where more tools are available to study more forms of FALS as well as the striking
majority of SALS. As the recent genetic discoveries have highlighted the importance of pre‐
viously unexplored pathways, i.e. RNA metabolism, also common targets linking sporadic
and familial ALS have been identified, i.e. TDP-43 and SOD-1. Moreover, the advances in
highthroughput screening technology with the advent of new gene profiling techniques, i.e.
deep-sequencing, and high content imaging systems are bound to determine the beginning
of a new era for ALS research.
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be evaluated to which extent these cells recapitulate neurodegenerative disease phenotypes,
although a first report from fibroblast derived neurons from a familial Alzheimer’s patient
seem promising [92].
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inhibition of phosphatidylinositol 3-kinase (PI3K) pathway [78] as well as shorter neurites
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that anacardic acid had protective effects against arsenite-induced motor neuron death and
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cells from patients without the use of viral vectors or induction of major epigenetic modi‐
fications.  In  this  study,  astrocytes  were  derived from NPCs isolated  from ALS patients
and it was observed that, regardless of their familial or sporadic origin, these cells were
toxic to wild type murine motor neurons expressing GFP under HB9 promoter [15]. The
authors  found that  SOD1 knockout via  shRNA could rescue motor neurons at  different
extents  depending  on  whether  these  were  co-cultured  on  astrocytes  from  familial  or
sporadic  cases.  This  study overcomes some of  the  major  issues  related to  iPS  cells  and
sets the premises for drug and shRNA screening to target pathways and single genes in‐
volved in astrocyte toxicity.
Concluding, it is clear that in the past five years the ALS field has seen a major change of
scenario, where more tools are available to study more forms of FALS as well as the striking
majority of SALS. As the recent genetic discoveries have highlighted the importance of pre‐
viously unexplored pathways, i.e. RNA metabolism, also common targets linking sporadic
and familial ALS have been identified, i.e. TDP-43 and SOD-1. Moreover, the advances in
highthroughput screening technology with the advent of new gene profiling techniques, i.e.
deep-sequencing, and high content imaging systems are bound to determine the beginning
of a new era for ALS research.
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1. Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease which attacks the
motor system. There is a family history in approximately 10% percent of cases and 20% of such
families have point mutations in the Cu, Zn superoxide dimutase 1 (SOD1) gene. Pre-symp‐
tomatic loss of motor neurons has been identified prior to the onset of symptoms in SOD1
mice. This loss was biphasic with initial loss in the pre-symptomatic phase followed by a period
of stabilisation and then gradual loss at time of weakness to death. (Kong & Xu, 1998).
In order to determine the time course of motor neurone loss prior to symptomatic onset of
disease, a longitudinal study of at-risk asymptomatic individuals (i.e. SOD1 mutation carriers
with no neurological symptoms or signs as determined by a neurologist) was performed. There
was no detectable difference in the number of motor units in SOD1 mutation carriers compared
to their SOD1 negative family controls. (Aggarwal & Nicholson, 2001). This may indicate that
mutation carriers have undetectable loss of motor neurones until rapid and widespread cell
death of motor neurones occurs, coinciding with the onset of symptomatic features. This
implies that the disease is not the end result of the slow attrition of motor neurones. (Aggarwal,
2009).
This longitudinal study was extended on 20 asymptomatic carriers of the Cu, Zn superoxide
dimutase 1 (SOD1) point mutation. There was a sudden reduction in MUNE, several months
prior to the onset of weakness. (Aggarwal & Nicholson 2002) and (Aggarwal, 2009). This
suggests that gradual pre-clinical loss of motor neurones does not occur in asymptomatic SOD1
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mutation carriers and supports the observation that sudden, catastrophic loss of motor
neurones occurs immediately prior to the onset of symptoms and the development of the
disease, rather than a gradual attrition of motor neurones over time. These results suggest that
there may be a biological trigger initiating rapid cell loss, just prior to the onset of symptoms.
Current treatment for sporadic ALS or Cu, Zn superoxide dimutase 1 (SOD 1 mutation) familial
ALS, produces only a modest increase in survival. The excitatory amino acid neurotransmitter,
glutamate, may be involved in the pathogenesis of ALS. Riluzole, an anti-glutamate agent,
remains the only disease modifying therapy available for ALS and has been used since 1995.
(Cheah et al, 2010). Treatment of human ALS patients or transgenic Cu, Zn superoxide
dimutase 1 (SOD 1) mice, most commonly produce a modest but significant increase in
survival. (Bensimon et al, 1994). It has also been shown to have a small beneficial effect on
bulbar function, but not muscle strength.
Using the statistical motor unit number estimation (MUNE) technique, (Daube, 1995), a
longitudinal study was performed to determine whether early institution of Riluzole can
reduce that rate of motor unit loss in familial amyotrophic lateral sclerosis (fALS). Motor unit
numbers were estimated from the right abductor pollicis brevis (APB) and right extensor
digitorum brevis (EDB) muscles. Our subjects had a presumptive diagnosis of fALS, as
electromyography (EMG) was “normal” with an absence of fasciculation and fibrillation
potentials, normal motor unit potentials and normal recruitment. MUNE is more sensitive that
EMG and once changes occur on conventional EMG studies, the window of opportunity to
influence the progression of this condition has been missed. They were all commenced on
Riluzole therapy in the pre-symptomatic phase, as soon as loss of motor units was detected
using motor unit number estimation (MUNE). After commencing Riluzole, “symptomatic”
improvement occurred, especially a decrease in muscle fasciculations and an improvement in
MUNE. Riluzole is not a disease altering agent but possibly if given early in the pre-sympto‐
matic phase of the disease, before significant motor neurone loss has occurred, it may have
some therapeutic benefit.
This effect may have implications for the management of asymptomatic carriers of the SOD 1
gene, as these subjects are at risk of developing ALS.
Regular follow-up of SOD1 carriers with MUNE may lead to early diagnosis, creating an
opportunity for future approaches and therapies aimed at preserving motor neurones rather
than replacing lost motor neurones. Detecting the onset of motor neurone loss in asymptomatic
individuals will identify those who may benefit from early institution of an active management
program to improve their quality of life, until more effective treatment modalities are available
for this devastating condition.
2. Background
Amyotrophic lateral sclerosis (ALS) is a group of fatal, neurodegenerative disorders, which is
characterised pathologically by progressive degeneration and loss of motor neurones in the
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anterior horn cells of the spinal cord, motor nuclei of the brainstem and the descending
pathways within the corticospinal tracts. The term amyotrophic lateral sclerosis (ALS) is used
synonymously with motor neurone disease (MND) in the USA, but in the UK and Australia
is used only to refer to patients who have a combination of upper and lower motor neurone
dysfunction. (Talbot, 2002).
It is primarily a condition of middle to late life, with onset of symptoms between the ages of
50 and 70 and a mean age of onset of 57.4 years. (Ringel et al., 1993). Occasionally, it arises as
early as the 2nd decade or as late as the 9th decade. In a natural history study, the overall median
survival is 4.0 years from the onset of symptoms, but only 2.1 years from the time of diagnosis.
(Ringel et al., 1993). In a study performed at the Mayo clinic, approximately 50% of patients
died within 3 years of referral, but 20% were still alive at 5 years and 10% were still alive at 10
years. (Mulder & Howard, 1976).
Aging, motor neurone diseases and many peripheral neuropathies are all associated with loss
of motor neurones or axons. When the disorders are recent or rapidly progressive, the extent
of the loss may be indicated by weakness and wasting. In slowly progressive denervating
conditions, like MND, loss of more than 50-80% of motor units may occur with little or no
clinically apparent weakness.
It has been showed that patients with substantial chronic denervation could maintain normal
muscle twitch tension until loss of about 70-80% of motor units occurred. (McComas, 1971).
The surviving motor neurones enlarge their territories, through collateral sprouting (reinner‐
vation) to keep pace with cell loss, to maintain the muscle maximum compound muscle action
potential (CMAP), until late in the disease. At this point, collateral reinnervation is no longer
able to provide full functional compensation. (Campbell et al., 1973).
In MND, needle electromyography often reveals evidence of chronic reinnervation (increased
motor unit action potential amplitudes and duration with reduced recruitment), but provides
little direct evidence to the extent of motor neurone and axonal loss. The supramaximal CMAP
amplitude also provides little direct evidence of the extent of motor neurone loss. Normal
CMAP amplitudes might mistakenly suggest that motor neurone loss has not occurred yet.
(Shefner, 2001).
Motor unit number estimation (MUNE) is a more reliable method for following changes in
neurogenic disorders than the CMAP amplitude. It estimates the number of functioning lower
motor neurones innervating a muscle or a group of muscles i.e. the number of motor units,
which can be excited by electrical stimulation. It is therefore an indirect measure of motor
neurone loss, rather than a measure of primary pathology. It can identify that the number of
motor units may be well below normal, in the presence of normal CMAP amplitudes. (Brown,
1972).
Pre-symptomatic loss of motor neurones has been identified in an animal model of the disease
(transgenic mice expressing mutant human SOD1-G93A). The initial loss in the pre-sympto‐
matic phase related to severe motor axonal degeneration due to vacuolar changes in motor
neurones and a slow decrease in CMAP amplitudes. After a period of stabilisation, there was
a gradual loss of motor neurones and a rapid decrease in CMAP amplitude, at the onset of
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weakness due to myelin alteration. At this point, there was a striking loss of motor units. There
was also decrease in evoked motor potentials (an indirect measure of the number of motor
units), prior to the onset of symptoms. The onset of disease in transgenic G93A mice involves
a sharp decline of muscle strength and a transient explosive increase in vacuoles derived from
degenerating mitochondria, but little motor neurone death. These did not die until the terminal
stage. (Kong & Xu, 1998). The decline exhibited kinetics consistent with both a constant and
exponentially decreasing risk of neuronal death. An escalating risk forced by cumulative
damage was not responsible for cell death. (Azzouz et al., 1997).
It is possible that the high metabolic activity in motor neurones, combined with the toxic
oxidative properties of the mutant SOD1, causes massive mitochondrial vacuolation in motor
neurones, resulting in degeneration, earlier than other neurones, triggering the onset of
weakness. The involvement of mitochondrial degeneration in the early stages is consistent
with a direct effect of toxicity, mediated by properties gained by the mutant enzyme in
catalysing redox reactions. (Beckman et al., 1993).
Until recently, it has not been possible to address this in humans, as pre-symptomatic diagnosis
was not possible. Now, with the ability to identify Cu, Zn superoxide dismutase 1, (SOD1)
mutation carriers, a group of human pre-symptomatic subjects can be studied to determine
whether there was gradual lifelong pre-symptomatic loss of motor neurones or whether
sudden catastrophic loss of motor neurones occurs just prior to the onset of clinical symptoms.
3. Familial ALS
The only forms of MND in which a clear cause has been established are the genetic variants.
20% of all familial cases are the dominantly inherited adult onset form of MND, which is
clinically indistinguishable from the sporadic form of MND. These are due to a point mutation
in the cytosolic Cu, Zn superoxide dismutase 1, (SOD1) gene on long arm of chromosome 21
(21q22.1). (Siddique & Deng, 1996). Mutations in other genes, alsin and the heavy subunit of
neurofilament (NEFH) can also result in motor neurone degeneration in humans. Two other
genes that have been investigated are the other isoforms of SOD. MnSOD (SOD2) maps to
chromosome 6q25 and is primarily located in mitochondria and extracellular SOD (SOD3)
maps to chromosome 4p15.2. Neither of these genes have yet to be linked to FALS. (Hand &
Rouleau, 2002). There is however genetic heterogeneous and other causal genes remain to be
found to explain the vast majority of FALS cases. (Siddique et al., 1989).
The initial study to establish a causal link between the SOD1 gene and familial MND (FALS)
identified a total of 11 missense mutations in two exons studied in 13 autosomal dominant
MND families. (Rosen et al., 1993). This led to an explosion of SOD1 gene screening in MND
pedigrees. To date 112 different mutations in the SOD1 have been found which can lead to
changes throughout the protein. There have been 99 substitutions, 5 polymorphisms, 3
insertions, 4 deletions and 1 compound mutation types identified. Mutations have been
identified in all five exons of the gene. These include 20 on exon 1, 13 on exon 2, 8 on exon 3,
39 on exon 4 and 29 on exon 5 (Figure 1). There have also been 2 non-exon mutations identified
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on intron 4 and intron 1 and 14 ‘apparently’ sporadic cases described with 6 different SOD1
mutations. (Shaw et al., 1998).
Figure 1. Number of SOD1 mutations identified for each exon
Most are autosomal dominant in inheritance, but there is one confirmed autosomal recessive
mutation, the D90A mutation in exon 4. This is unique in that it exists in dominant families in
a heterozygous state, but in a number of pedigrees, specifically those of Scandinavian ancestry,
homozygous mutations are required for disease. (Andersen et al., 1997).
Mutations in the heavy polypeptide 200kDa subunit of neurofilaments (NEFH) have been
identified in sporadic MND cases, (Figlewicz et al., 1994) and in one FALS case. (Al-Chalabi
et al., 1999). Accumulation of neurofilaments in cell bodies and axons of motor neurons is a
pathological hallmark of early stages of many neurodegenerative diseases. These mutations
lie in the region of the protein involved in cross-linking and thus may disrupt normal aggre‐
gation of filaments. Thus far, 1 insertion and 5 deletion mutations have been identified on exon
4. Analysis of the NEFH locus on chromosome 22 however has failed to detect linkage in MND
families. (Vechio et al., 1996). Genome search on a large pedigree with autosomal dominant
juvenile onset MND found strong evidence for linkage to chromosome 9q34 (ALS4). The
average age of onset is 17 years, with slow progression of disease. (Chance et al., 1998). There
is also an autosomal recessive, juvenile onset MND, with linkage to a locus on chromosome
15 (ALS5). (Hentati et al., 1998).
The other 90% of all MND patients have the sporadic form. There is no recognisable phenotypic
difference between FALS and sporadic MND. The male: female ratio is 1:1 in FALS and 1.7:1
in sporadic MND. (De Belleroche et al., 1995). This decreases with increasing age of onset and
approaches 1:1 after the age of 70. (Haverkamp et al., 1995). The site of onset is variable.
Survival does not seem to be affected by age or gender, but rather the site of symptom onset.
Generally, bulbar onset disease has a worse prognosis, and upper limb onset is more favour‐
able. (Mulder et al., 1986).
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15 (ALS5). (Hentati et al., 1998).
The other 90% of all MND patients have the sporadic form. There is no recognisable phenotypic
difference between FALS and sporadic MND. The male: female ratio is 1:1 in FALS and 1.7:1
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It has be postulated that sporadic MND may be the final development of a chain of events that
may be set in motion at one or more places in the central nervous system by endogenous and
exogenous causes, or both. The aetiology of MND however remains unknown and is probably
multifactorial. (Eisen 1995). There is no evidence to support the cause of sporadic MND being
due to accumulation of heavy metals in the environment, (Needleman, 1997), deficiencies or
excess of essential trace metals, (Mena et al., 1967) or exposure to environmental poisons and
industrial solvents. (Leigh, 1997). There is also no evidence to support the cause of sporadic
MND being due excessive physical activity or antecedent trauma.
4. Possible patterns of motor neurone loss
In normal healthy individuals, it has been shown that there is little loss of functioning motor
neurones before the age of 60. The normal aging process then accounts for loss of approxi‐
mately 3.9% of the original motor neurone pool per annum after the age of 60. (Brown, 1972).
In this situation, the number of motor neurones remain fairly constant up to the age of 60, after
which there is a gradual steady decline with age.
MND may be due to a slow attrition of motor neurones over time (Pattern 1 in Figure 2). If this
were the case, pre-symptomatic motor neurone loss may be identifiable in SOD1 mutation
carriers, as eventually there may be a gradual decline over time (Figure 2).
Another possible course of MND is that normal numbers of motor neurones are maintained
until sudden, rapid multi-focal cell death of motor neurones occurs, corresponding with the
development of symptoms (Pattern 2 in Figure 2). If this situation, it would be expected that
SOD1 mutation carriers have a normal number of motor neurones during the pre-symptomatic
phase. In this case, cell death occurs as neurones gradually accumulate damage, secondary to
the mutation, which ultimately overwhelms cellular homeostasis. This is the cumulative
damage hypothesis. (Clarke et al., 2000).
One of the mechanisms most frequently proposed to underlie cumulative damage is oxidative
stress, in which an imbalance between the production of reactive oxygen species and cellular
antioxidant mechanisms results in chemical modifications of macromolecules, thereby
disrupting cellular structure and function. (Robberecht, 2000). A key prediction of the cumu‐
lative damage hypothesis is that the probability that any individual neurone will become
committed to apoptosis increases as damage accrues within it. A mutant neurone in an older
patient will have accumulated a greater amount of damage and is therefore be more likely to
die than in a younger patient. Consequently, early in the course of disease, the chance of a cell
containing a sufficient amount of damage to initiate apoptosis is small, and the rate of cell loss
is correspondingly low. However, as the amount of intracellular damage increases, the chance
that a cell will die also increases
It has been shown that the kinetics of neuronal death in a number of inherited neurodegener‐
ative diseases was best explained by models in which the risk of cell death remains constant
throughout life of the neurone and that cell death occurred randomly in time and was
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independent of any other neurone. This implies a “one-hit” biochemical phenomenon in which
the mutant imposes an abnormal mutant steady state on the neurone and a single catastrophic
event randomly initiates cell death and apoptosis. The principal features of the mutant steady
state are that the living mutant neurones function very well for years or even decades and that
the predominant feature of the mutant neurones is that they are all at a risk of death. This
argues against the multiple environmental factors hypothesis as a cause of MND, as a random
process is probably responsible for the initiation of disease. (Clarke et al., 2001).
5. Cu/Zn Superoxide Dismutase (SOD1) mutations
Linkage studies for familial MND (FALS) on chromosome 21q22.1 led to the identification of
point mutations in the gene for Cu/Zn superoxide dismutase (SOD1) as a cause of MND.
(Siddique 1991). Superoxide (O2-) is an unstable and highly active molecule, which causes
Figure 2. Diagrammatic representation of possible patterns for motor neurone loss in an individual.
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is correspondingly low. However, as the amount of intracellular damage increases, the chance
that a cell will die also increases
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process is probably responsible for the initiation of disease. (Clarke et al., 2001).
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(Siddique 1991). Superoxide (O2-) is an unstable and highly active molecule, which causes
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oxidation of cell constituents either directly or through toxic and stable derivatives. The major
superoxide dismutase activity in cytoplasm is from SOD1, which consists of 5 small exons that
encode 153 highly conserved amino acids with a molecular weight of 16Kda. SOD1 is a
homodimer. Within each monomer, there is an active site containing one atom each of copper
and zinc. (Radunovic & Leigh, 1996).
The most common SOD1 gene mutation seen in FALS is an alanine to valine shift at codon 4
(Ala4Val). This accounts for 50% of all mutations in the USA. (Rosen, 1993). Of all the clinical
variables, only bulbar onset and three specific mutations seem to influence age of onset of
MND. Bulbar patients are older when their illness begins, whereas the Gly37Arg and Leu38Val
mutations predict an earlier age of onset.). Leu38Val is associated with the earliest onset (mean
35.5 years) and Ile113Thr with the latest onset (mean 58.9 years).
In terms of survival, Ala4Val correlated with the shortest survival of 1.5 years. Whereas,
Gly37Arg, Gly41Asp, and Gly93Ala mutation predicted longer survival. The mutations that
predict earlier onset are not the same as those that correlate with shortest duration of disease.
(Cudkowicz et al., 1997). This suggests that the factors that influence onset of disease differ
from those that influence the rate of progression of the disease.
Determining the mechanism by which mutations in the Cu/Zn superoxide dismutase (SOD1)
gene triggers the destruction of motor neurones causing MND remains a challenging and
complex problem. Five primary hypotheses have been postulated for the pathogenesis of FALS
(Figure 3). (Hand & Rouleau, 2002). At present the favoured hypotheses is that the mutation
causes disease as a result of a toxic gain of function by the mutant SOD1 provoking selective
neurotoxicity, probably disrupting the intracellular homeostasis of copper and/or protein
aggregation. (Clevland, 1999).
The mutant SOD1 enzyme has altered reactivity with certain substrates, (Noor et al., 2003), in
addition to the major superoxide dismutase activity. The SOD1 enzyme catalyses the reduction
of hydrogen peroxide (H2O2), therefore acting as a peroxidase. This leads to the formation of
hydoxyl radicals that can also alter the neurofilament network. Motor neurones have high-
energy requirements and thus contain many mitochondria that generate superoxide radials
(O2-) through normal metabolism. SOD1 is an anti-oxidant defence which catalyses conversion
of superoxide free radical anion (O2-) to hydrogen peroxide (H2O2), which is reduced to H2O
and O2 by catalse. Mutations at SOD1 binding sites, alter the redox behaviour of the enzyme
and destabilise the SOD1 ligand, leading to increased oxidative damage as hydrogen peroxide
and its derivatives are toxic to the cell. (Yim et al., 1990).
This supports the hypothesis that the pathogenesis of SOD1 related FALS may be due to
increased peroxidase activity of mutant SOD1 resulting in oxidative damage mainly to lipids
of the cell membrane.
Mapping of the mutation sites predicted that these mutations destabilise the protein structure,
leading to a less active enzyme i.e. “loss of function”. This is however not supported by the
fact that transgenic mice over expressing SOD1 gene developed disease similar to MND in
humans, while those over-expressing normal SOD1 remained unaffected. This suggests that
the mutant mice develop the disease independent of the level of SOD1 activity and suggests
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that the mutant protein itself is selectively toxic to motor neurones and that there is a “gain of
toxic function” rather than a “loss of function”. (Gurney et al., 1994). Also, although most
mutations in SOD1 gene cause decrease in steady state of cytosolic SOD1 activity, Gly37Arg
and Asp90Ala, have no significant decrease in SOD1 activity. (Shaw et al., 1998).
As most SOD1 mutations destabilise SOD1 protein (except Asp90Ala), it is possible that the
mutant protein, with altered conformation may become unstable and precipitate to form
aggregates or inclusions in motor neurons. These aggregates may then disturb normal cell
function and lead to cell death. They are easily formed when SOD1 protein stability is
decreased because this protein exists in large amounts accounting for 0.5-1% of total cytosolic
protein in neurons. Alternations in the length of the coding sequence, folding, solubility or
degradation results in the formation of aggregates. (Yim et al., 1990). Structural changes of
mutant SOD1 may distort the rim of the electrostatic guidance channel and allow the catalytic
site to become exposed and shallow. Molecules that are normally excluded may gain access to
the catalytic reactive site. This results in less buffering of copper and zinc, which then become
neurotoxic. (Radunovic & Leigh, 1996).
Figure 3. Pathways that have been implicated in motor neurone cell death in amyotrophic lateral sclerosis (Repro‐
duced from Hand CK. Familial Amyotrophic Lateral Sclerosis. Muscle Nerve 2002; 25:137).
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The nitric oxide (NO) produced by nitric oxide synthase (NOS) reacts spontaneously with O2-
to generate peroxynitrite (ONOO-), which nitrosylates proteins leading to damage. Excess NO
may also cause an increase in O2- production by inhibition of mitochondrial electron flow,
resulting in further generation of peroxynitrite. This facilitates nitrosylation of tyrosine
residues of critical cytosolic proteins thus injuring cells. This reaction is copper dependent. The
source of free copper may be mutant SOD1, which cannot accept the ion from the copper
chaperone (CCS) protein. Mutant SOD1 possibly exhibit metal mediated cytotoxicities by
disrupting the intracellular homeostasis of Cu and Zn, which are potential neurotoxins.
(Gurney & Tomasselli, 1994).
The target proteins for nitrosylation include the neurofilament (NF) subunits, which may result
in abnormal NF accumulation and subsequent disruption of the NF network and axonal
transport, as there is a high neurofilament content in motor neurones. It has also been dem‐
onstrated that transgenes encoding mutant NF subunits can directly cause selective degener‐
ation and death of motor neuones. (Cleveland, 1999). Conformational changes have been
described in the mutations, Ala4Val, Gly37Arg and His6Arg that may affect the rim of the
electrostatic guidance channel coded by exon 3. (Sjalander et al., 1995).
Glutamate is released from the presynaptic terminal activates the glutamate receptor on the
postsynaptic cell membrane. It is then cleared from the synaptic cleft by specific glutamate
transporters such as EAAT2. (Trotti et al., 1999). Astrocyte (glial cell) dysfunction may result
in selective loss of EAAT2, interfering with the normal clearance of glutamate and allowing it
to accumulate in the cell membrane and continue to activate the receptor. (Bruijin et al., 1997).
Once activated, the glutamate receptor causes a calcium influx and a cascade of toxicity. The
neurone does not have the capacity to buffer this efficiently due to a deficiency in calcium
binding proteins (CBP’s). This results in disturbances in mitochondrial metabolism and as a
consequence, motor neurone cell death. (Beal, 1996).
To date, the only effective approved treatment for amyotrophic lateral sclerosis is Riluzole,
(Cheah et al., 2010), which has a neuroprotective role, possibly due to pre-synaptic inhibition
of glutamate release. (Doble, 1996). Treatment of human ALS patients or transgenic Cu, Zn
superoxide dimutase 1 (SOD 1) mice, most commonly produce a modest but significant
increase in survival. (Bensimon et al., 1994). It has also been shown to have a small beneficial
effect on bulbar function, but not muscle strength. (Miller et al., 2007).
Apoptosis is characterised by a series of cellular changes leading to non-inflammatory cell
death. Mitochondrial involvement in the apoptotic pathway also leads to the release of
cytochrome c, an activator of the initiator caspase-9, which in turn activates caspase-3, which
are executioners in the breakdown of essential cellular proteins. There is evidence that the
mutant SOD1 transgene causes motor neurone death in mice through caspase-mediated
programmed cell death. (Li et al., 2000). This may then be a target for inhibiting the apoptotic
cascade, as it has been shown in a SOD1 transgenic mouse model that a small peptide caspase
inhibitor (zVAD-fmk), prolonged survival after onset of disease by nearly 70%. (Kosti et al.,
1997). It has also been reported that there are elevated levels of bax protein in MND spinal
motor neurones, which promotes apoptosis. (Mu et al., 1996).
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6. Methods
The Department of Molecular Medicine at Concord hospital had a large database of family
members with a known family history of MND, who had blood samples collected for DNA,
as part of a previous linkage study. From this database, family members were contacted by
telephone by the department’s genetic counsellor and informed about the study.
The regional committees for Ethics in Medical Research from Central Sydney Area Health
Service, Royal North Shore Hospital and Prince Charles Hospital, approved this study.
All individuals participated without knowledge of their mutation status and on the under‐
standing that this would not be revealed to them. Subjects were also aware that the results
obtained from the study would not be available to them and that the information would only
be used for research purposes. New consents were obtained from all individuals who partici‐
pated in the study. The neurologist performing the MUNE studies also had no knowledge of
their mutation status. The mutation status was only used in the final analysis of results.
Subsequently, they were divided into “SOD1 negative family controls” and “asymptomatic
SOD1 mutation carriers”.
In addition, studies were also carried out on normal individuals, such as department techni‐
cians, spouses of SOD1 family members and individuals from the general population who
attended MND support meeting and had an interest in helping to advance research into MND.
This group was used as “population controls”, to test the validity and reproducibility of the
MUNE technique used.
Sporadic MND subjects were also initially studied once the MUNE technique had been
validated to demonstrate that the MUNE technique used was able to detect a loss of motor
neurones, when present. These were used as “positive controls”.
6.1. Motor unit number estimation
Motor unit number estimation (MUNE) estimates the number of functioning lower motor
neurones innervating a muscle or a group of muscles and is a measure of the primary patho‐
logic process of motor neurone loss. The concept of motor unit number estimation (MUNE)
originated in 1967. At the time there was no satisfactory method of assessing the extent of
denervation in muscles during life. Analysis of the density of the electromyographic interfer‐
ence pattern during maximal effort was not quantitative, and required the full co-operation of
the patient.
The principle of MUNE is that if one can measure the mean single motor unit amplitude
(SMUP), it is possible to obtain an estimate of the total number of motor units in the muscle.
The results achieved were comparable with estimates of alpha motor fibres obtained by
counting axons in specimens of motor nerves. (McComas, 1971).
MUNE has been performed in a number of different ways, each with their advantages and
limitations. (Stein & Yang, 1990). The choice of technique depends on the speed and simplicity
of the technique, as well as its accuracy and reproducibility. Some methods sample a very small
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The nitric oxide (NO) produced by nitric oxide synthase (NOS) reacts spontaneously with O2-
to generate peroxynitrite (ONOO-), which nitrosylates proteins leading to damage. Excess NO
may also cause an increase in O2- production by inhibition of mitochondrial electron flow,
resulting in further generation of peroxynitrite. This facilitates nitrosylation of tyrosine
residues of critical cytosolic proteins thus injuring cells. This reaction is copper dependent. The
source of free copper may be mutant SOD1, which cannot accept the ion from the copper
chaperone (CCS) protein. Mutant SOD1 possibly exhibit metal mediated cytotoxicities by
disrupting the intracellular homeostasis of Cu and Zn, which are potential neurotoxins.
(Gurney & Tomasselli, 1994).
The target proteins for nitrosylation include the neurofilament (NF) subunits, which may result
in abnormal NF accumulation and subsequent disruption of the NF network and axonal
transport, as there is a high neurofilament content in motor neurones. It has also been dem‐
onstrated that transgenes encoding mutant NF subunits can directly cause selective degener‐
ation and death of motor neuones. (Cleveland, 1999). Conformational changes have been
described in the mutations, Ala4Val, Gly37Arg and His6Arg that may affect the rim of the
electrostatic guidance channel coded by exon 3. (Sjalander et al., 1995).
Glutamate is released from the presynaptic terminal activates the glutamate receptor on the
postsynaptic cell membrane. It is then cleared from the synaptic cleft by specific glutamate
transporters such as EAAT2. (Trotti et al., 1999). Astrocyte (glial cell) dysfunction may result
in selective loss of EAAT2, interfering with the normal clearance of glutamate and allowing it
to accumulate in the cell membrane and continue to activate the receptor. (Bruijin et al., 1997).
Once activated, the glutamate receptor causes a calcium influx and a cascade of toxicity. The
neurone does not have the capacity to buffer this efficiently due to a deficiency in calcium
binding proteins (CBP’s). This results in disturbances in mitochondrial metabolism and as a
consequence, motor neurone cell death. (Beal, 1996).
To date, the only effective approved treatment for amyotrophic lateral sclerosis is Riluzole,
(Cheah et al., 2010), which has a neuroprotective role, possibly due to pre-synaptic inhibition
of glutamate release. (Doble, 1996). Treatment of human ALS patients or transgenic Cu, Zn
superoxide dimutase 1 (SOD 1) mice, most commonly produce a modest but significant
increase in survival. (Bensimon et al., 1994). It has also been shown to have a small beneficial
effect on bulbar function, but not muscle strength. (Miller et al., 2007).
Apoptosis is characterised by a series of cellular changes leading to non-inflammatory cell
death. Mitochondrial involvement in the apoptotic pathway also leads to the release of
cytochrome c, an activator of the initiator caspase-9, which in turn activates caspase-3, which
are executioners in the breakdown of essential cellular proteins. There is evidence that the
mutant SOD1 transgene causes motor neurone death in mice through caspase-mediated
programmed cell death. (Li et al., 2000). This may then be a target for inhibiting the apoptotic
cascade, as it has been shown in a SOD1 transgenic mouse model that a small peptide caspase
inhibitor (zVAD-fmk), prolonged survival after onset of disease by nearly 70%. (Kosti et al.,
1997). It has also been reported that there are elevated levels of bax protein in MND spinal
motor neurones, which promotes apoptosis. (Mu et al., 1996).
Current Advances in Amyotrophic Lateral Sclerosis192
6. Methods
The Department of Molecular Medicine at Concord hospital had a large database of family
members with a known family history of MND, who had blood samples collected for DNA,
as part of a previous linkage study. From this database, family members were contacted by
telephone by the department’s genetic counsellor and informed about the study.
The regional committees for Ethics in Medical Research from Central Sydney Area Health
Service, Royal North Shore Hospital and Prince Charles Hospital, approved this study.
All individuals participated without knowledge of their mutation status and on the under‐
standing that this would not be revealed to them. Subjects were also aware that the results
obtained from the study would not be available to them and that the information would only
be used for research purposes. New consents were obtained from all individuals who partici‐
pated in the study. The neurologist performing the MUNE studies also had no knowledge of
their mutation status. The mutation status was only used in the final analysis of results.
Subsequently, they were divided into “SOD1 negative family controls” and “asymptomatic
SOD1 mutation carriers”.
In addition, studies were also carried out on normal individuals, such as department techni‐
cians, spouses of SOD1 family members and individuals from the general population who
attended MND support meeting and had an interest in helping to advance research into MND.
This group was used as “population controls”, to test the validity and reproducibility of the
MUNE technique used.
Sporadic MND subjects were also initially studied once the MUNE technique had been
validated to demonstrate that the MUNE technique used was able to detect a loss of motor
neurones, when present. These were used as “positive controls”.
6.1. Motor unit number estimation
Motor unit number estimation (MUNE) estimates the number of functioning lower motor
neurones innervating a muscle or a group of muscles and is a measure of the primary patho‐
logic process of motor neurone loss. The concept of motor unit number estimation (MUNE)
originated in 1967. At the time there was no satisfactory method of assessing the extent of
denervation in muscles during life. Analysis of the density of the electromyographic interfer‐
ence pattern during maximal effort was not quantitative, and required the full co-operation of
the patient.
The principle of MUNE is that if one can measure the mean single motor unit amplitude
(SMUP), it is possible to obtain an estimate of the total number of motor units in the muscle.
The results achieved were comparable with estimates of alpha motor fibres obtained by
counting axons in specimens of motor nerves. (McComas, 1971).
MUNE has been performed in a number of different ways, each with their advantages and
limitations. (Stein & Yang, 1990). The choice of technique depends on the speed and simplicity
of the technique, as well as its accuracy and reproducibility. Some methods sample a very small
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proportion of the number of motor units innervating a muscle (typically 10-20). The coefficient
of variation associated with different methods range from 10-45%. (McComas, 1991). If the
variability is too large, then the technique cannot be used to follow motor unit loss reliably
over time.
The way the average single motor unit potential (SMUP) size is obtained distinguishes the
several techniques available. Most employ electrical stimulation of the motor nerve to
determine the sizes of the SMUP, but a few use needle EMG.
Each method measures both the average size of the potentials generated by single motor units
- single motor unit potentials (SMUP) and the size of the compound muscle action potential
(CMAP) obtained with maximal stimulation of a motor nerve.
The motor unit number estimate is calculated by:
MUNE= Maximum CMAP amplitude
(or area)
Average single motor unit potential (SMUP) amplitude or area.
Whereas the methods of measuring the average SMUP differ, they have common assumptions
about the measurement of the supramaximal CMAP and the measurement of the average
SMUP.
i. Maximal stimulation of any peripheral motor nerve activates all the muscles inner‐
vated by that nerve distal to the point of stimulation. Therefore, measurements of the
CMAP are the summation of activity from multiple muscles and the MUNE is more
accurately an estimate of the number of motor units in a group of muscles rather than
in a single muscle.
For example, the median CMAP recorded at abductor pollicis brevis (APB) is more correctly
a “thenar MUNE”, as it is a summation of the activity of APB, opponens pollicis, flexor pollicis
brevis, and to a lesser extent, the lateral lumbricals.
Extensor digitorum brevis (EDB) on the other hand, is a muscle innervated by the deep
peroneal nerve. The only source of interfering muscle action potential is from extensor hallucis
longus, which can be reduced by correct position of the stimulating electrodes. The muscle
belly is flat in profile, eliminating deeper motor units as a cause of small potentials. The
recording electrode is placed transversely across the innervation zone, resulting in a simple
biphasic negative-positive M wave.
ii. The motor unit potentials used in the calculation of the average SMUP are represen‐
tative of those generated by the total population of units. All methods, select a subset
of the total population of motor units, measure their sizes and calculate an average
SMUP for that subgroup.
iii. Finally, there is a phenomenon caused “alternation”. This refers to fluctuations in the
CMAP amplitude of the same motor unit with similar stimulation intensities. The
thresholds of the first few motor axons excited are not sufficiently separate from one
another, so that when graded increases in the stimulus intensity occur, the motor
axons excited often overlap and add more than one SMUP to the CMAP being
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recorded. This can result in an underestimation of the mean SMUP size, as it may
appear that there are 7 or 8 motor units when there are only 2 or 3 present, which in
turn results in an over-estimation of the MUNE.
6.2. Statistical MUNE method
We used the statistical electrophysiological technique of motor unit number estimation
(MUNE), (Daube, 1998), was used to estimate the number of motor units in thenar and extensor
digitorum brevis muscles. The statistical method estimates the average size of SMUP’s and the
number of motor units in a group of muscles innervated by the nerve being stimulated, based
on the normal variation of the submaximal CMAP evoked with constant stimuli. No attempt
is made to identify individual motor unit potentials. The method relies on the known relation
between the variance of multiple measures of step functions and the size of the individual
steps when the steps have a Poisson distribution. S.D. Poisson was a French mathematician
(1781-1840).
Poisson statistics are useful when the distribution arising for events occur randomly in time
or when small particles are distributed randomly in space. They have been used to calculate
the number of quanta released from a nerve terminal at the neuromuscular junction when the
individual quanta are too small to be distinguished, as in myasthenia gravis. (Lomen-Hoerth
& Slawnych, 2003).
In pure Poisson statistics, the size of a series of measurements is multiples of the size of a single
component. In a Poisson distribution there is a discrete asymmetrical distribution in which
responses are found at some levels and others where there are no responses (Figure 4). (McNeil,
1996).
A pure Poisson distribution has decreasing numbers at higher values. In Poisson distribution,
the variance of these 30 measurements is equal to the size of the individual components making
up each measurement. The variance can thus provide an estimate of the average size of the
SMUP’s.
The statistical method looks only at variance of the CMAP and does not require identification
of individual components. It can be used when the sizes of SMUP’s are too small to be isolated.
The statistical method assumes that each motor unit has a similar size and that it is the same
size each time it is activated.
Sequences of 30 submaximal stimuli are given. The inherent variability of the threshold of
individual axons causes variations in the size of the CMAP. The average change in the
submaximal CMAP amplitude caused by alternation (addition and subtraction of motor
axons) is derived by Poisson statistics.
The occurrence of alternation with changing units that are activated does not modify the
accuracy of the statistical method, because the method is a statistical measurement, a different
result is found with each series of 30 stimuli. Therefore, multiple trials are needed to obtain
the most accurate measurement. (Olney et al., 2000).
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determine the sizes of the SMUP, but a few use needle EMG.
Each method measures both the average size of the potentials generated by single motor units
- single motor unit potentials (SMUP) and the size of the compound muscle action potential
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The motor unit number estimate is calculated by:
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Average single motor unit potential (SMUP) amplitude or area.
Whereas the methods of measuring the average SMUP differ, they have common assumptions
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i. Maximal stimulation of any peripheral motor nerve activates all the muscles inner‐
vated by that nerve distal to the point of stimulation. Therefore, measurements of the
CMAP are the summation of activity from multiple muscles and the MUNE is more
accurately an estimate of the number of motor units in a group of muscles rather than
in a single muscle.
For example, the median CMAP recorded at abductor pollicis brevis (APB) is more correctly
a “thenar MUNE”, as it is a summation of the activity of APB, opponens pollicis, flexor pollicis
brevis, and to a lesser extent, the lateral lumbricals.
Extensor digitorum brevis (EDB) on the other hand, is a muscle innervated by the deep
peroneal nerve. The only source of interfering muscle action potential is from extensor hallucis
longus, which can be reduced by correct position of the stimulating electrodes. The muscle
belly is flat in profile, eliminating deeper motor units as a cause of small potentials. The
recording electrode is placed transversely across the innervation zone, resulting in a simple
biphasic negative-positive M wave.
ii. The motor unit potentials used in the calculation of the average SMUP are represen‐
tative of those generated by the total population of units. All methods, select a subset
of the total population of motor units, measure their sizes and calculate an average
SMUP for that subgroup.
iii. Finally, there is a phenomenon caused “alternation”. This refers to fluctuations in the
CMAP amplitude of the same motor unit with similar stimulation intensities. The
thresholds of the first few motor axons excited are not sufficiently separate from one
another, so that when graded increases in the stimulus intensity occur, the motor
axons excited often overlap and add more than one SMUP to the CMAP being
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appear that there are 7 or 8 motor units when there are only 2 or 3 present, which in
turn results in an over-estimation of the MUNE.
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We used the statistical electrophysiological technique of motor unit number estimation
(MUNE), (Daube, 1998), was used to estimate the number of motor units in thenar and extensor
digitorum brevis muscles. The statistical method estimates the average size of SMUP’s and the
number of motor units in a group of muscles innervated by the nerve being stimulated, based
on the normal variation of the submaximal CMAP evoked with constant stimuli. No attempt
is made to identify individual motor unit potentials. The method relies on the known relation
between the variance of multiple measures of step functions and the size of the individual
steps when the steps have a Poisson distribution. S.D. Poisson was a French mathematician
(1781-1840).
Poisson statistics are useful when the distribution arising for events occur randomly in time
or when small particles are distributed randomly in space. They have been used to calculate
the number of quanta released from a nerve terminal at the neuromuscular junction when the
individual quanta are too small to be distinguished, as in myasthenia gravis. (Lomen-Hoerth
& Slawnych, 2003).
In pure Poisson statistics, the size of a series of measurements is multiples of the size of a single
component. In a Poisson distribution there is a discrete asymmetrical distribution in which
responses are found at some levels and others where there are no responses (Figure 4). (McNeil,
1996).
A pure Poisson distribution has decreasing numbers at higher values. In Poisson distribution,
the variance of these 30 measurements is equal to the size of the individual components making
up each measurement. The variance can thus provide an estimate of the average size of the
SMUP’s.
The statistical method looks only at variance of the CMAP and does not require identification
of individual components. It can be used when the sizes of SMUP’s are too small to be isolated.
The statistical method assumes that each motor unit has a similar size and that it is the same
size each time it is activated.
Sequences of 30 submaximal stimuli are given. The inherent variability of the threshold of
individual axons causes variations in the size of the CMAP. The average change in the
submaximal CMAP amplitude caused by alternation (addition and subtraction of motor
axons) is derived by Poisson statistics.
The occurrence of alternation with changing units that are activated does not modify the
accuracy of the statistical method, because the method is a statistical measurement, a different
result is found with each series of 30 stimuli. Therefore, multiple trials are needed to obtain
the most accurate measurement. (Olney et al., 2000).
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Experimental testing with trials of >300 stimuli has shown that repeated measurement of
groups of 30 until the standard deviation of the repeated trials is <10% provides a close estimate
of the number obtained with many more stimuli.86 Estimates of the SMUP size and of the
number of motor units are also most reliable if made at multiple different stimulus intensities
to test axons with different thresholds.
MUNE is calculated with the number weighted statistical method, where the mean SMUP
amplitude at each level is multiplied by the number of motor units estimated at each level.
The steps in statistical MUNE are as follows:
1. Recording surface electrodes are applied as for standard nerve conduction studies.
2. An initial scan of the CMAP is performed using a series of 30 submaximal stimuli at 1 Hz,
increasing in equal increments to identify unusually large steps at which further infor‐
mation is required.
3. On the basis of the scan, three or four 10% stimulus ranges are identified, according to an
internal algorithm. Usually, one range includes the smallest step and the other ranges
where the steps are >15% (Figure 4).
4. At each intensity, groups of 30 responses are captured at a rate of 3Hz. Estimates are most
reliable if 10 groups of 30 responses are recorded. To minimise patient discomfort,
however, repetition is repeated until the standard error of the MUNE SMUP size is less
than 10%.
5. Statistical MUNE estimates the average size of SMUP’s and the number of motor units in
a group of muscles innervated by the nerve being stimulated, based on the normal
variation of the sub-maximal CMAP evoked with constant stimuli (Figure 5).
The statistical technique of estimating the size of the SMUP was performed using proprietary
software on a Nicolet Viking IV electromyography machine. This technique uses direct
stimulation of the motor nerve. The low frequency filter was set at 2 Hz and the high frequency
filter at 5 kHz. The gain for extensor digitorum brevis was set at 2 mV/div and for abductor
pollicis brevis studies at 5 mV/div. The sweep speed was 2 ms/div. This method had excellent
test-retest reproducibility (+/-2.8%). The method was quick to use and well tolerated.
This technique has been greatly modified since its original description, but numerous studies
have shown that MUNE can change systematically in ALS patients when used by experienced
technicians, even though evaluator bias needs to be taken into account. (Shefner et al., 2004).
The statistical MUNE method has also been shown to be unreliable in the presence of clinical
weakness due to motor unit instability. (Shefner, 2009).
Our study however was performed on asymptomatic patients, without clinical weakness.
6.3. MUNE Technique
Motor unit numbers were estimated in abductor pollicis brevis (resulting in a thenar MUNE)
and the extensor digitorum brevis (EDB) muscle. These muscles were used, as both are easily
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accessible distal muscles. The electrical activity can be recorded without interference, and in
the case of EDB, the muscle belly is flat.
Self-adhesive surface recording electrodes (G1) were placed transversely across the innerva‐
tion zone of each muscle, resulting in a simple biphasic negative-positive M wave, with G2
placed over a bony prominence. The deep peroneal nerve was stimulated just above the ankle
and the median nerve at the wrist with a surface stimulator. This was performed by strapping
Figure 4. An initial scan of the CMAP (right) recorded from APB muscles in response to 30 sub-maximal stimuli (x-axis)
with equal increments between threshold and maximum stimulation. On the basis of the scan, 10% stimulus ranges
are identified, according to an internal algorithm. The CMAP increments are shown at the top left and the eventual
table of results in the bottom left corner.
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stimulation of the motor nerve. The low frequency filter was set at 2 Hz and the high frequency
filter at 5 kHz. The gain for extensor digitorum brevis was set at 2 mV/div and for abductor
pollicis brevis studies at 5 mV/div. The sweep speed was 2 ms/div. This method had excellent
test-retest reproducibility (+/-2.8%). The method was quick to use and well tolerated.
This technique has been greatly modified since its original description, but numerous studies
have shown that MUNE can change systematically in ALS patients when used by experienced
technicians, even though evaluator bias needs to be taken into account. (Shefner et al., 2004).
The statistical MUNE method has also been shown to be unreliable in the presence of clinical
weakness due to motor unit instability. (Shefner, 2009).
Our study however was performed on asymptomatic patients, without clinical weakness.
6.3. MUNE Technique
Motor unit numbers were estimated in abductor pollicis brevis (resulting in a thenar MUNE)
and the extensor digitorum brevis (EDB) muscle. These muscles were used, as both are easily
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accessible distal muscles. The electrical activity can be recorded without interference, and in
the case of EDB, the muscle belly is flat.
Self-adhesive surface recording electrodes (G1) were placed transversely across the innerva‐
tion zone of each muscle, resulting in a simple biphasic negative-positive M wave, with G2
placed over a bony prominence. The deep peroneal nerve was stimulated just above the ankle
and the median nerve at the wrist with a surface stimulator. This was performed by strapping
Figure 4. An initial scan of the CMAP (right) recorded from APB muscles in response to 30 sub-maximal stimuli (x-axis)
with equal increments between threshold and maximum stimulation. On the basis of the scan, 10% stimulus ranges
are identified, according to an internal algorithm. The CMAP increments are shown at the top left and the eventual
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the stimulating electrode onto the surface of the skin, at the point where the threshold of the
nerve to electrical stimulation was at its’ lowest. A hand-held stimulator was not used, as
reproducibility is enhanced when the stimulating electrodes are fixed to the surface of the skin.
Initially, bilateral thenar and EDB MUNE’s were obtained from all subjects. After the repro‐
ducibility phase of the study, generally only right-sided studies were performed. Once a
Figure 5. At each intensity level (runs 1-4), groups of 30 responses are captured at a rate of 3Hz. The CMAP ampli‐
tudes are shown at the top left, with the histogram of results at the top right. The thenar MUNE results from repeated
trials are shown in the bottom left table.
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reduction in MUNE was identified, bilateral studies were once again performed on selected
subjects. The protocol was also modified depending on the subjects’ tolerance to the procedure.
Median nerve stimulation at the wrist for thenar MUNE was generally well tolerated by most
subjects, as the stimulation intensity required to obtain an adequate response was generally
less than 20mA with duration of 0.05-0.1ms.
Peroneal nerve stimulation required for EDB MUNE resulted in slightly more discomfort, as
the nerve is located further away from the surface of the skin. The stimulus intensity required,
in some cases was up to 50-80mA with duration of between 0.1-0.3ms. Some subjects indicated
that they were unwilling to continue to participate in the study due to the discomfort caused
by performing EDB MUNE. In these subjects, only thenar MUNE’s were performed.
To assess the test-retest reproducibility of the technique, SOD1 family members and popula‐
tion controls were followed over a 1-year period, with thenar and EDB MUNE tests repeated
every 3 to 6 months. The difference between MUNE results from the first and second study,
and if possible, first and third studies were divided by the MUNE of the first study, and
expressed as a percentage change. The results were analysed using Pearson and Spearman
correlation coefficients.
All results were entered into a database and analysed using a standard statistical software
package (SPSS 9.05 for Windows). For the initial part of the study, the MUNE results from
asymptomatic SOD1 mutation carriers were grouped together. Although different mutations
in SOD1 have different effects on the progression of the disease once symptoms occur, these
different mutations do not influence on the age of onset of symptoms.67
Motor unit estimates in carriers were compared to age and sex matched family controls without
the SOD1 mutation, and sporadic (non-SOD1) MND patients. To determine whether groups
had different numbers of motor units, an unpaired t-test was used. Although there were some
outlying results, the distributions were not sufficiently skewed to contradict the use of the t-
test. Statistical significance was accepted at a p-value of <0.05.
The group of asymptomatic SOD1 mutation carriers were followed over the next 2 to 5 years,
depending on the volunteers’ motivation, both clinically and by MUNE. Results were com‐
pared to their initial baseline MUNE and the date of the study when this reduction was first
detected, was used as the date when motor neurone loss commenced.
6.4. Maximal voluntary isometric contraction testing
It has been suggested that the traditional neurological examination is inadequate for docu‐
menting motor performance impairment with reliability. (Hanten et al., 1999). Generally,
manual motor testing used in a standard neurological motor examination does not allow
objective documentation of change in performance, as it may be influenced by the patient’s
history and progress. Major changes are apparent, but subtle changes are difficult to determine
with accuracy.
There are a number of methods that have been developed to quantify maximal voluntary
isometric contraction (MVIC). It has been proposed that this is a clinically useful, reliable,
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less than 20mA with duration of 0.05-0.1ms.
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the nerve is located further away from the surface of the skin. The stimulus intensity required,
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package (SPSS 9.05 for Windows). For the initial part of the study, the MUNE results from
asymptomatic SOD1 mutation carriers were grouped together. Although different mutations
in SOD1 have different effects on the progression of the disease once symptoms occur, these
different mutations do not influence on the age of onset of symptoms.67
Motor unit estimates in carriers were compared to age and sex matched family controls without
the SOD1 mutation, and sporadic (non-SOD1) MND patients. To determine whether groups
had different numbers of motor units, an unpaired t-test was used. Although there were some
outlying results, the distributions were not sufficiently skewed to contradict the use of the t-
test. Statistical significance was accepted at a p-value of <0.05.
The group of asymptomatic SOD1 mutation carriers were followed over the next 2 to 5 years,
depending on the volunteers’ motivation, both clinically and by MUNE. Results were com‐
pared to their initial baseline MUNE and the date of the study when this reduction was first
detected, was used as the date when motor neurone loss commenced.
6.4. Maximal voluntary isometric contraction testing
It has been suggested that the traditional neurological examination is inadequate for docu‐
menting motor performance impairment with reliability. (Hanten et al., 1999). Generally,
manual motor testing used in a standard neurological motor examination does not allow
objective documentation of change in performance, as it may be influenced by the patient’s
history and progress. Major changes are apparent, but subtle changes are difficult to determine
with accuracy.
There are a number of methods that have been developed to quantify maximal voluntary
isometric contraction (MVIC). It has been proposed that this is a clinically useful, reliable,
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reproducible, time efficient and quantitative measure for monitoring disease progression in
MND. (Hoagland et al., 1997). This would be surprising, given that in a slowly progressive
denervating process, patients with substantial chronic denervation could maintain normal
muscle twitch tension until loss of about 70-80% of motor units occurs. (McComas, 1971).
The methods used to quantify maximal voluntary isometric contraction have included an
electronic strain-gauge tensiometer and a hand-held Jamar hydraulic dynamometer. In this
study, maximum bilateral isometric grip strength was obtained using the Jamar hydraulic
dynamometer to determine whether this correlated with the number of functional motor
neurones in the thenar group of muscles, as measured by MUNE. Standardised (middle
handle) positioning and instructions were given to all subjects. Handgrip force was measured
with subjects in the sitting position and with the arm flexed at 90 degrees. Two trials were
performed on each hand, and the best result used for analysis. This method was used as
previous studies of grip strength reliability showed that there was no significant difference in
reliability between one attempt, the mean score of two or three attempts, or the highest score
of three attempts. (Hamilton et al., 1994).
Clinical neurological examination was performed, with power of thumb abduction, finger
flexion and finger abduction measured according to the Medical Research Council (MRC)
grading system and compared to thenar (APB) MUNE.
Felice showed that in twenty one MND patients, changes in thenar MUNE was the most
sensitive outcome measure for following disease progression, when compared to other
quantitative tests, such as CMAP, isometric grip strength, forced vital capacity and Medical
Research Council manual muscle testing. (Felice, 1997).
7. Results
7.1. Demographics
A total of eighty-eight (88) subjects (45 males and 43 females) gave informed consent. The
subjects were divided into four test groups.
1. 24 population controls;
2. 32 SOD1 negative (normal) family controls;
3. 20 asymptomatic (pre-clinical) SOD1 mutation carriers (test group),
a. 5 subjects with point mutation in exon 4, codon 100, GAA to GGA, Glu to Gly) –
glu100gly;
b. 5 subjects with point mutation in exon 4, codon 113, ATT to ACT, Ile to Thr) – ile113thr;
c. 5 subjects with point mutation in exon 5; codon 148, GTA to GGA, Val to Gly) –
val148gly;
d. 5 subjects with point mutation in exon 5, codon 148, GTA to GGA, Val to Ile) val148ile.
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4. 12 sporadic symptomatic MND patients (positive controls).
There was no statistically significant difference in age distribution between these groups, with
a range of 16 to 73 years of age.
7.2. Motor units in asymptomatic FALS (SOD1) carriers
For the initial part of the study, the baseline MUNE results were grouped together and the
means of the groups were compared. The initial aim of the study was to determine if MND
was due to a slow gradual attrition of motor neurones over time. If this were the case, the group
of asymptomatic SOD1 mutation carriers, would be expected to have a reduced number of
motor units, indicating the presence of pre-clinical motor neurone loss. Motor unit estimates
in the group of asymptomatic SOD1 mutation carriers were compared to age and sex matched
family controls without the SOD1 mutation, and sporadic (non-SOD1) MND patients. To
determine whether groups had different numbers of motor units, an unpaired t-test was used.
Statistical significance was accepted at a p-value of <0.05.
The numbers of motor units in the groups of population controls, SOD1 negative family
controls and asymptomatic SOD1 mutation carriers were similar. In population controls the
mean thenar MUNE was 148 with a range of 115 - 254, in SOD1 negative family controls was
138 with a range of 106 - 198 and in asymptomatic SOD1 mutation carriers, 144 with a range
of 109 - 199. There was no detectable difference in the mean number of thenar motor units in
the group of asymptomatic SOD1 mutation carriers compared to the group of SOD1 negative
family controls (thenar p>0.46), or population controls (thenar p>0.70) (Table 1 and Figure 6).
In population controls the mean EDB MUNE was 138 with a range of 119 - 169, in SOD1
negative family controls was 134 with a range of 107 - 180 and in asymptomatic SOD1 mutation
carriers, 136 with a range of 111 - 187.
Once again, there was no detectable difference in the mean number of EBD motor units in the
group of asymptomatic SOD1 mutation carriers compared to the group of SOD1 negative
family controls (EDB p>0.95), or population controls (EDB p>0.50) (Table 2 and Figure 7).
Thenar (APB) muscle
Cases MUNE (Range)
Population Controls 24 148 (115-254)
SOD1 Negative Family Controls 32 138 (106-198)
SOD1 Mutation Carriers 20 144 (109–199)
Sporadic MND patients 12 45 (5–84)
Table 1. Thenar (APB) motor unit number estimates (MUNE number represents mean MUNE).
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4. 12 sporadic symptomatic MND patients (positive controls).
There was no statistically significant difference in age distribution between these groups, with
a range of 16 to 73 years of age.
7.2. Motor units in asymptomatic FALS (SOD1) carriers
For the initial part of the study, the baseline MUNE results were grouped together and the
means of the groups were compared. The initial aim of the study was to determine if MND
was due to a slow gradual attrition of motor neurones over time. If this were the case, the group
of asymptomatic SOD1 mutation carriers, would be expected to have a reduced number of
motor units, indicating the presence of pre-clinical motor neurone loss. Motor unit estimates
in the group of asymptomatic SOD1 mutation carriers were compared to age and sex matched
family controls without the SOD1 mutation, and sporadic (non-SOD1) MND patients. To
determine whether groups had different numbers of motor units, an unpaired t-test was used.
Statistical significance was accepted at a p-value of <0.05.
The numbers of motor units in the groups of population controls, SOD1 negative family
controls and asymptomatic SOD1 mutation carriers were similar. In population controls the
mean thenar MUNE was 148 with a range of 115 - 254, in SOD1 negative family controls was
138 with a range of 106 - 198 and in asymptomatic SOD1 mutation carriers, 144 with a range
of 109 - 199. There was no detectable difference in the mean number of thenar motor units in
the group of asymptomatic SOD1 mutation carriers compared to the group of SOD1 negative
family controls (thenar p>0.46), or population controls (thenar p>0.70) (Table 1 and Figure 6).
In population controls the mean EDB MUNE was 138 with a range of 119 - 169, in SOD1
negative family controls was 134 with a range of 107 - 180 and in asymptomatic SOD1 mutation
carriers, 136 with a range of 111 - 187.
Once again, there was no detectable difference in the mean number of EBD motor units in the
group of asymptomatic SOD1 mutation carriers compared to the group of SOD1 negative
family controls (EDB p>0.95), or population controls (EDB p>0.50) (Table 2 and Figure 7).
Thenar (APB) muscle
Cases MUNE (Range)
Population Controls 24 148 (115-254)
SOD1 Negative Family Controls 32 138 (106-198)
SOD1 Mutation Carriers 20 144 (109–199)
Sporadic MND patients 12 45 (5–84)
Table 1. Thenar (APB) motor unit number estimates (MUNE number represents mean MUNE).
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Symptomatic sporadic MND subjects showed a definite loss of motor units with fewer motor
units compared to all other groups (p<0001) with a mean thenar MUNE of 45 with a range of
5 - 84 and a mean EDB MUNE of 70 with a range of 8 - 82 (Tables 1 and 2).
There was no cross over between thenar and EDB MUNE results in symptomatic and asymp‐
tomatic subjects.
7.3. Reproducibility of MUNE technique
To assess the test-retest reproducibility of the technique, 69 of the 88 SOD1 family members


















Figure 6. Baseline thenar (APB) MUNE subdivided into study groups (The lower boundary of the box is the 25th per‐
centile, and the upper border is the 75th percentile of MUNE. The horizontal line inside the box represents the median
MUNE. The whispers represent the largest and smallest observed values, i.e. the range). Data is shown in Table 1.
Extensor Digitorum Brevis
Cases MUNE (Range)
Population Controls 13 138 (119-169)
SOD1 Negative Family Controls 30 134 (107-180)
SOD1 Mutation Carriers 14 136 (111-187)
Sporadic MND patients 9 70 (8-82)
Table 2. EDB motor unit number estimates (MUNE number represents mean MUNE).
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digitorum brevis (EDB) MUNE tests repeated every 3-6 months, depending on patient
availability. The difference between MUNE results from the first and second study, and if
possible, first and third studies were divided by the MUNE of the first study, and expressed
as a percentage change. The results were analysed using Pearson and Spearman correlation
coefficients.
The test-retest correlation of thenar MUNE in asymptomatic subjects was high with a Pearson
correlation coefficient of 0.93. The mean difference between MUNE results on separate
occasions on the same individual was +/- 3.6%, with a range of 0-11.7% (Table 3).
Number of Cases Mean MUNE
Thenar 1 88 145.7
Thenar 2 69 140.1
Thenar 3 33 140.0
Thenar Change Range (0 - 11.7%) 3.6%
Table 3. Reproducibility of mean thenar (APB) motor unit number estimates in asymptomatic subjects on separate
reviews over a one-year period.
For EDB MUNE, the Pearson correlation coefficient was also high, 0.88, with a mean difference

















Figure 7. Baseline EDB MUNE subdivided into study groups (The lower boundary of the box is the 25th percentile, and
the upper border is the 75th percentile of MUNE. The horizontal line inside the box represents the median MUNE. The
whispers represent the largest and smallest observed values, i.e. the range). Data is shown in Table 2.
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Symptomatic sporadic MND subjects showed a definite loss of motor units with fewer motor
units compared to all other groups (p<0001) with a mean thenar MUNE of 45 with a range of
5 - 84 and a mean EDB MUNE of 70 with a range of 8 - 82 (Tables 1 and 2).
There was no cross over between thenar and EDB MUNE results in symptomatic and asymp‐
tomatic subjects.
7.3. Reproducibility of MUNE technique
To assess the test-retest reproducibility of the technique, 69 of the 88 SOD1 family members


















Figure 6. Baseline thenar (APB) MUNE subdivided into study groups (The lower boundary of the box is the 25th per‐
centile, and the upper border is the 75th percentile of MUNE. The horizontal line inside the box represents the median
MUNE. The whispers represent the largest and smallest observed values, i.e. the range). Data is shown in Table 1.
Extensor Digitorum Brevis
Cases MUNE (Range)
Population Controls 13 138 (119-169)
SOD1 Negative Family Controls 30 134 (107-180)
SOD1 Mutation Carriers 14 136 (111-187)
Sporadic MND patients 9 70 (8-82)
Table 2. EDB motor unit number estimates (MUNE number represents mean MUNE).
Current Advances in Amyotrophic Lateral Sclerosis202
digitorum brevis (EDB) MUNE tests repeated every 3-6 months, depending on patient
availability. The difference between MUNE results from the first and second study, and if
possible, first and third studies were divided by the MUNE of the first study, and expressed
as a percentage change. The results were analysed using Pearson and Spearman correlation
coefficients.
The test-retest correlation of thenar MUNE in asymptomatic subjects was high with a Pearson
correlation coefficient of 0.93. The mean difference between MUNE results on separate
occasions on the same individual was +/- 3.6%, with a range of 0-11.7% (Table 3).
Number of Cases Mean MUNE
Thenar 1 88 145.7
Thenar 2 69 140.1
Thenar 3 33 140.0
Thenar Change Range (0 - 11.7%) 3.6%
Table 3. Reproducibility of mean thenar (APB) motor unit number estimates in asymptomatic subjects on separate
reviews over a one-year period.
For EDB MUNE, the Pearson correlation coefficient was also high, 0.88, with a mean difference

















Figure 7. Baseline EDB MUNE subdivided into study groups (The lower boundary of the box is the 25th percentile, and
the upper border is the 75th percentile of MUNE. The horizontal line inside the box represents the median MUNE. The
whispers represent the largest and smallest observed values, i.e. the range). Data is shown in Table 2.
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of 0-15.7%. The test-retest correlation was high with a Pearson correlation coefficient of 0.91,
when groups were broken down into the different study groups.
7.4. Maximal voluntary isometric contraction
Maximal voluntary isometric contraction (MVIC), using the Jamar hand dynamometer was
used to measure isometric grip strength to determine whether this correlated with the number
of functional motor neurones in the thenar group of muscles as measured by MUNE. Isometric
grip strength tests, thenar MUNE and MRC power were performed on 69 asymptomatic
subjects twice within a 3-6 month period to assess the test-retest reproducibility of this
technique. Pearson correlation coefficients between study 1 and study 2 of right hand grip
strength was 0.941, left hand grip strength 0.910 and thenar MUNE results 0.937. These results
indicate that the reproducibility of these techniques was high.
Right hand grip strength correlated with left hand grip strength, with Pearson correlation
coefficients of 0.959 and Spearman correlation coefficients of 0.956 Two-way analyses of
variance showed a no significant difference between the right and left hands (Figure 8). There
was no correlation between right grip strength and right thenar motor unit number, with
Pearson correlation coefficients of 0.483 and Spearman correlation coefficient of 0.34 (Figure 9).



















Figure 8. Graph showing the correlation between right and left handgrip
7.5. Detection of pre-symptomatic motor neurone loss in SOD1 mutation carriers
The MUNE results, after validating their reproducibility, were used as a baseline to follow the
number of motor units over time in individual pre-symptomatic SOD1 mutation carriers over
the next 2-5 years, to determine whether pattern of motor neurone loss is either a slow attrition
of motor neurones over time or whether normal numbers of motor neurones are maintained
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until sudden, rapid multi-focal cell death of motor neurones occurs, corresponding with the
development of symptoms.
During the course of the study, 5 of the SOD1 mutation carriers developed leg weakness. A
significant fall in motor unit number was detected in these 5 SOD1 mutation carriers, were
there was a detectable reduction of motor units, 4-10 months prior to the onset of weakness
and the diagnosis of familial ALS being made. There was no detectable loss of motor units in
the other 15 SOD1 mutation carriers or in the group of SOD1 mutation negative relatives,
during the study period.
In individual cases, there was:
51% loss of motor units, 4 months prior to onset of weakness in Case 1
37% loss of motor units, 10 months prior to onset of weakness in Case 2
28% loss of motor units, 6 months prior to onset of weakness in Case 3
46% loss of motor units, 6 months prior to onset of weakness in Case 4
68% loss of motor units, 8 months prior to onset of weakness in Case 5
There was further motor unit loss as weakness progressed, at which point the diagnosis of
MND was confirmed.
7.5.1. Case study 1
A 43-year-old sister of case 1. She had the same strong family history of ALS, with a point
mutation in SOD1 gene at val148gly. Her pedigree is shown in Figure 10. She was asympto‐




















Figure 9. Scatter graph showing the lack of correlation between right handgrip and right thenar (APB) MUNE
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wasting, weakness or fasciculation. Her right and left thenar MUNE’s remained stable for the
first 2½ years of the study at around 115-120 motor units. Progress MUNE results are shown
in Table 4 and Figures 11.
Over the next 6 months, there was a reduction in her right thenar MUNE to 96 (20%) and her
left thenar MUNE to 89 (19%), with no detectable weakness. Her right EDB MUNE also
dropped from 111 to 92 (17%), but she only had detectable weakness 10 months later of MRC
grade 4+/5 in right dorsiflexors, at which time her right EDB MUNE had dropped further to
71 motor units (35%). The left EDB MUNE also dropped from a baseline of 112 (2 years
previously) to 89 (20%), but with no detectable weakness.
An independent neurologist performed needle EMG examination, which showed high
amplitude motor units with reduced recruitment in vastus medialis, tibialis anterior and
extensor carpi radialis longus, bilaterally but no fibrillation potentials were seen. It was felt
that these changes were not enough to make the diagnosis of ALS.
In view of her strong family history, a presumed diagnosis of familial ALS was made and she
was commenced on Riluzole in February 2002.
Over the next 3 years, her EDB MUNE results have stabilised. Her weakness has not progressed
significantly. In February 2004, she still had MRC grade 4+/5 power of her right dorsiflexors
and no symptomatically apparent weakness in her left dorsiflexors or upper limbs.
Figure 10. Pedigree of cases 1, 2 and 3
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7.5.2. Case study 2
A 57-year-old man with a strong family history of ALS dating back 3 generations, had a point
mutation in exon 4, codon 100, GAA to GGA, Glu to Gly) – glu100gly. He was initially recruited
into the study in 1998, but as he was unable to tolerate the EDB MUNE test, he elected not to
continue to participate in the study. He represented 11 years later with a 3 month history of
lower limb weakness, which he noticed only when he walked long distances and up stairs. He
had also been experiencing lower limb cramps and muscle fasciculations for years.
On examination, he had no evidence of wasting, but there were muscle fasciculations seen in
his right quadriceps. His tone was normal in the upper and lower limbs and he had MRC grade
5/5 power in all muscle groups, proximally and distally. His sensory examination was normal
to touch, vibration and position. His gait was normal.
Nerve conduction studies performed by independent neurologist were normal, with no
evidence of a large fibre peripheral neuropathy and normal CMAP amplitudes. Needle EMG
studies was also normal, with no evidence of active or chronic denervation in bilateral distal
and proximal muscles sampled. Using the same MUNE machine and computer algorithm, as
1998, a reduction in his APB MUNE was detectable. Despite the “normal EMG” findings, a
presumptive diagnosis of fALS was made. He was commenced on Riluzole therapy 50 mg
twice a day. Within 3 months, he noticed an improvement in the symptoms and there was a
detectable improvement in MUNE by 40-52%. He was able to walk up stairs easier, walk 100
metres without stopping and lower limb cramps and fasciculations disappeared. Unfortu‐
nately, due to poor tolerance, further studies have not been possible. MUNE results are shown
in Table 5.
Months pre and post -42 -40 -37 -29 -20 -10 0 +11 +21 +27
weakness 1st detected
Date of study Oct-98 Dec-98 Mar-99 Nov-99 Jul-00 Jan-01 Nov-01 Oct-02 Aug-03 Feb-04
R Handgrip 60 60 65 65 60 70 65 65 65 65
R Thenar MUNE 111 111 117 119 120 114 96 97 86 85
L Handgrip 60 55 60 65 63 65 65 60 60 60
L Thenar MUNE 117 119 111 89 86 79 81
R EDB power 5/5 5/5 5/5 5/5 5/5 5/5 4+/5 4+/5 4+/5 4+/5
R EDB MUNE 104 111 119 108 104 92 71 75 75 65
L EDB power 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5
L EDB MUNE 112 89 80 80 81
Table 4. Case 1 progressive handgrip, dorsiflexion power and thenar and EDB MUNE results
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7.5.2. Case study 2
A 57-year-old man with a strong family history of ALS dating back 3 generations, had a point
mutation in exon 4, codon 100, GAA to GGA, Glu to Gly) – glu100gly. He was initially recruited
into the study in 1998, but as he was unable to tolerate the EDB MUNE test, he elected not to
continue to participate in the study. He represented 11 years later with a 3 month history of
lower limb weakness, which he noticed only when he walked long distances and up stairs. He
had also been experiencing lower limb cramps and muscle fasciculations for years.
On examination, he had no evidence of wasting, but there were muscle fasciculations seen in
his right quadriceps. His tone was normal in the upper and lower limbs and he had MRC grade
5/5 power in all muscle groups, proximally and distally. His sensory examination was normal
to touch, vibration and position. His gait was normal.
Nerve conduction studies performed by independent neurologist were normal, with no
evidence of a large fibre peripheral neuropathy and normal CMAP amplitudes. Needle EMG
studies was also normal, with no evidence of active or chronic denervation in bilateral distal
and proximal muscles sampled. Using the same MUNE machine and computer algorithm, as
1998, a reduction in his APB MUNE was detectable. Despite the “normal EMG” findings, a
presumptive diagnosis of fALS was made. He was commenced on Riluzole therapy 50 mg
twice a day. Within 3 months, he noticed an improvement in the symptoms and there was a
detectable improvement in MUNE by 40-52%. He was able to walk up stairs easier, walk 100
metres without stopping and lower limb cramps and fasciculations disappeared. Unfortu‐
nately, due to poor tolerance, further studies have not been possible. MUNE results are shown
in Table 5.
Months pre and post -42 -40 -37 -29 -20 -10 0 +11 +21 +27
weakness 1st detected
Date of study Oct-98 Dec-98 Mar-99 Nov-99 Jul-00 Jan-01 Nov-01 Oct-02 Aug-03 Feb-04
R Handgrip 60 60 65 65 60 70 65 65 65 65
R Thenar MUNE 111 111 117 119 120 114 96 97 86 85
L Handgrip 60 55 60 65 63 65 65 60 60 60
L Thenar MUNE 117 119 111 89 86 79 81
R EDB power 5/5 5/5 5/5 5/5 5/5 5/5 4+/5 4+/5 4+/5 4+/5
R EDB MUNE 104 111 119 108 104 92 71 75 75 65
L EDB power 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5
L EDB MUNE 112 89 80 80 81
Table 4. Case 1 progressive handgrip, dorsiflexion power and thenar and EDB MUNE results
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7.5.3. Case study 3
A 43-year old lady with an extensive family history of ALS dating back 4 generations, had a
point mutation in exon 5, codon 148, GTA to GGA, Val to Gly) – val148gly. She presented with
generalised muscle fasciculations, but no weakness or cramps.
On examination, she had no wasting or fasciculations. Her tone, power, reflexes and sensation
in the upper and lower limbs were normal. Her gait was steady and she was able to walk on
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Figure 11. Progressive results of case 1 showing the change in APB and EDB motor unit estimates over time in relation
to handgrip strength and power. There is a reduction of APB and EDB MUNE even though strength has remained sta‐
ble.
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Nerve conduction studies  performed by independent  neurologist  were  normal,  with  no
evidence  of  a  large  fibre  peripheral  neuropathy.  Needle  EMG studies  was  also  normal,
with no evidence of active or chronic denervation in bilateral distal and proximal muscles
sampled.
On her initial MUNE testing, results were within normal values, but 5 months later, there was
a detectable reduction in her MUNE’s from baseline of between 13-23%. As the MUNE change
was greater than our re-retest reliability limits (<5%), a presumptive diagnosis fALS was made
and commenced on Riluzole therapy. This resulted in an improvement in her fasciculations
and MUNE’s over the next 6 months, 14-41%. Her MUNE results have remained stable over
the next 12 months. Progress MUNE results are shown in Table 6.
7.5.4. Case study 4
A 47-year-old lady with a family history of dominantly inherited non-SOD 1 ALS, (father aged
68 and brother aged 45, both died of ALS). A point mutation in the SOD 1 gene has not been
currently detected. She presented with a 1-year history of generalised muscle fasciculations
and occasional lower limb cramps. She had generalised tiredness and muscular aches and
pains, but no weakness, numbness or paraesthesia. Her gait was steady. As a result of her
symptoms, she ceased work in March 2004.
May-98 July-09 Nov-09
Months Baseline 13 months 4 months
Riluzole commenced
R Handgrip 105 95 80
L Handgrip 110 105 90





L APB MUNE 88 124
R ADM MUNE 110 95
L ADM MUNE 85
R EDB MUNE Not tolerated 59
90
(52% increase)
L EDB MUNE 67
94
(40% increase)
Needle EMG Normal Normal
Table 5. showing progressive handgrip, dorsiflexion power, thenar and EDB MUNE and needle EMG results of Case 2
(Normal EMG refers to the absence of fasciculation and fibrillation potentials, normal motor unit potentials and
normal recruitment)
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7.5.3. Case study 3
A 43-year old lady with an extensive family history of ALS dating back 4 generations, had a
point mutation in exon 5, codon 148, GTA to GGA, Val to Gly) – val148gly. She presented with
generalised muscle fasciculations, but no weakness or cramps.
On examination, she had no wasting or fasciculations. Her tone, power, reflexes and sensation
in the upper and lower limbs were normal. Her gait was steady and she was able to walk on
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On examination, she had no evidence of wasting, but there were generalised fasciculations,
especially in the triceps and quadriceps regions. Her tone was normal in the upper and lower
limbs. She had no clinical weakness with MRC grade 5/5 power in all muscle groups, proxi‐
mally and distally. Her sensory examination was normal to touch, vibration and position. Her
reflexes were all present and symmetrical. Her gait was normal, as she was able to walk on
her heels and toes. She was able to perform tandem walking and Romberg’s sign was negative.
Nerve conduction studies performed by independent neurologist were normal, with no
evidence of a large fibre peripheral neuropathy. Needle EMG studies was also normal, with
no evidence of active or chronic denervation in bilateral distal and proximal muscles sampled.
Initial EDB MUNE was reduced with normal APB MUNE’s. Despite this, a clinical diagnosis
on fALS was not made given her normal needle EMG study, and she was observed over the
next 6 months. Over this time, she developed MRC grade 4/5 weakness of ankle dorsiflexion,
bilaterally and her EDB MUNE dropped by 14-20%. Despite this reduction, compound muscle
action potential amplitudes were maintained. Needle EMG studies were repeated and once
again normal there was no spontaneous activity (fibrillation potentials) and motor unit
recruitment was normal, despite the presence of weakness.
Given her family history, a presumptive diagnosis of non-SOD 1 fALS was made and com‐
menced on Riluzole therapy. This resulted in an improvement in clinical symptoms of
tiredness and fasciculations, allowing her to return to work. Her EDB MUNE improved by
34-60%, and increased further over the next year. Despite this, her treating neurologist
considered this was a placebo effect and ceased Riluzole. Within 2 weeks, her generalised aches
Sept-08 Feb-09 Aug-09 Aug-10
Months Baseline 5 months 6 months 12 months
Riluzole commenced
R Handgrip 65 70 68 65
L Handgrip 62 70 62 65

























Table 6. showing progressive handgrip, dorsiflexion power, thenar and EDB MUNE and needle EMG results of Case 3
(Normal EMG refers to the absence of fasciculation and fibrillation potentials, normal motor unit potentials and
normal recruitment)
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and pains and fasciculations recurred. Her subsequent MUNE study was blinded, as the
operator was unaware that Riluzole had been ceased and found that her EDB MUNE’s had
reduced once again. She then had a 3rd needle EMG study, which was once again normal. She
also had a MRI scan of her brain and full spine that showed no significant abnormality. She
was recommenced on Riluzole, which resulted in a slow and steady improvement in her


























Figure 12. showing progressive thenar and EDB MUNE changes in relation to changes in the dose of Riluzole in Case 4
8. Conclusion
Motor neurone disease (MND) is a group of fatal, progressive neurodegenerative disorders,
with an overall median survival is approximately 4.0 years from the onset of symptoms. By
the time most patients with MND are aware of clinical weakness and seek review by their
primary physician or neurologist, a significant proportion of motor units have already been
lost. Early detection of motor neurone loss in clinically apparently unaffected muscles is
therefore important to establish an early diagnosis of the condition.
Motor unit number estimates in the group of asymptomatic SOD1 mutation carriers were
compared to age and sex matched family controls without the SOD1 mutation, and sporadic
(non-SOD1) MND patients. There was no detectable difference in the number of thenar motor
units in the group of asymptomatic SOD1 mutation carriers compared to the group of SOD1
negative family controls (thenar p>0.46), or population controls (thenar p>0.70).. In addition,
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On examination, she had no evidence of wasting, but there were generalised fasciculations,
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Table 6. showing progressive handgrip, dorsiflexion power, thenar and EDB MUNE and needle EMG results of Case 3
(Normal EMG refers to the absence of fasciculation and fibrillation potentials, normal motor unit potentials and
normal recruitment)
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and pains and fasciculations recurred. Her subsequent MUNE study was blinded, as the
operator was unaware that Riluzole had been ceased and found that her EDB MUNE’s had
reduced once again. She then had a 3rd needle EMG study, which was once again normal. She
also had a MRI scan of her brain and full spine that showed no significant abnormality. She
was recommenced on Riluzole, which resulted in a slow and steady improvement in her
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Table 7. showing progressive handgrip, dorsiflexion power, thenar and EDB MUNE and needle EMG results of Case 4
(Normal EMG refers to the absence of fasciculation and fibrillation potentials, normal motor unit potentials and
normal recruitment)
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there was no detectable difference in the number of EBD motor units in the group of asymp‐
tomatic SOD1 mutation carriers compared to the group of SOD1 negative family controls (EDB
p>0.95), or population controls (EDB p>0.50). Symptomatic sporadic MND subjects showed a
definite loss of motor units with fewer motor units compared to all other groups (p<0.001).
There was no overlap between MUNE results in symptomatic and asymptomatic subjects.
These results indicate that the group of asymptomatic carriers of the SOD1 mutation have no
significant difference in the number of motor neurones, when compared to age and sex
matched controls. All carriers had a full complement of motor neurones during the asympto‐
matic phase, indicating that mutation carriers have normal survival of motor neurones and
that symptomatic MND is not the end result of a slow attrition of motor neurones. This implies
that gradual pre-symptomatic loss of motor neurones does not occur in asymptomatic SOD1
mutation carriers. This supports the observation that sudden, catastrophic loss of motor
neurones occurs immediately prior to the onset of symptoms and the development of the
disease, rather than a gradual attrition of motor neurones over time. These results suggest that
there may be a biological trigger initiating rapid cell loss, just prior to the onset of symptoms.
This observation is an important contribution to the current understanding of the pathogenesis
of MND. (Aggarwal & Nicholson, 2001).
The statistical MUNE technique was used for the study. This technique has been greatly
modified since its original description, but numerous studies have shown that MUNE can
change systematically in ALS patients when used by experienced technicians, even though
evaluator bias needs to be taken into account. It has been suggested that the statistical MUNE
is unreliable in the presence of clinical weakness due to motor unit instability. (Shefner, 2009).
The difference is that our study was performed on asymptomatic patients, without clinical
weakness.
MUNE has been performed in a number of different ways over the years, each with their
advantages and limitations. The choice of technique depends largely on the speed and
simplicity of the technique, as well as its accuracy and reproducibility. The way the average
single motor unit potential (SMUP) size is obtained distinguishes the several techniques. Most
employ electrical stimulation of the motor nerve to determine the sizes of the SMUP, but a few
use needle EMG. The statistical MUNE technique was used for the study. (Daube, 1995). This
technique has been compared to the multiple point stimulation method and found to be more
reproducible (7% vs. 12%) and faster to administer. (Lomen-Hoeth & Olney, 2000). The
technique has been greatly modified since its original description, (Shefner et al, 2004), but
numerous studies have shown that MUNE can be used to monitor change in ALS patients
when used by experienced technicians, even though evaluator bias needs to be taken into
account. (Shefner et al., 2004).
There have been studies performed indicating that the statistical MUNE is unreliable in the
presence of clinical weakness due to motor unit instability in ALS. (Shefner et al., 2011). In our
previous study, we showed that there was no detectable difference in the number of motor
units in 19 SOD 1 mutation carriers as a group, compared to their 34 SOD 1 negative family
controls (APB p>0.46 and EDB p>0.95), or 23 population controls (APB, p>0.70 and EDB,
p>0.50). (Aggarwal & Nicholson, 2001). It also showed that MUNE may be used as a reliable
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Table 7. showing progressive handgrip, dorsiflexion power, thenar and EDB MUNE and needle EMG results of Case 4
(Normal EMG refers to the absence of fasciculation and fibrillation potentials, normal motor unit potentials and
normal recruitment)
Current Advances in Amyotrophic Lateral Sclerosis212
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method of pre-symptomatic detection of motor unit loss in SOD1 mutation carriers. Following
69 SOD1 family members and population controls over a 1-year period, with thenar and EDB
MUNE tests repeated every 3 to 6 months, assessed the test-retest reproducibility of the
technique. The mean difference between thenar MUNE results on separate occasions in
asymptomatic subjects was +/- 3.6%, with a range of 0-11.7%, and +/- 4.6%, with a range of
0-15.7% in EDB MUNE. Our test-retest correlation was high, with Pearson correlation coeffi‐
cients of 0.93 for APB MUNE and 0.78 for EDB MUNE. (Aggarwal, 2009). This indicates that
there is reproducibility of our statistical MUNE technique, despite recent revisions and
reservations. The results can be used as a baseline for progressive MUNE studies and any
change in MUNE of greater than 5% should not be considered as a variation in measurement.
This is contrary to a recent report indicating that the statistical MUNE cannot be used to detect
mild to moderate motor unit loss. (Blok et al., 2010).
During the course of the study, a significant fall in motor unit number was detected in 5 of the
SOD1 mutation carriers, several months before the onset of weakness and the diagnosis of
motor neurone disease (MND) being made. There was no detectable loss of motor units in the
other 15 SOD1 mutation carriers or in the group of SOD1 mutation negative relatives. From
the study, a threshold MUNE of less than 100 was considered to imply that symptoms were
imminent.
In individual cases, there was a reduction of 68% 8 months prior, 51% 4 months prior, 46% 6
months prior, 35% 10 months prior and 28% 6 months prior to the onset of weakness. Further
motor unit loss occurred as weakness progressed and the diagnosis of MND being made.
We followed 3 subjects with a family history of ALS, 2 of which had a documented SOD 1
point mutation, who were commenced on Riluzole therapy when loss of motor units were
detected using motor unit number estimation (MUNE), before the onset of symptoms i.e. pre-
symptomatic phase. A reduction in sequential MUNE was shown to improve with a thera‐
peutic intervention, Riluzole. Currently, the only effective approved treatment for MND is
Riluzole, which has a neuroprotective role, possibly due to pre-synaptic inhibition of glutamate
release. Riluzole is an anti-glutamate agent that has been approved for the treatment of patients
with amyotrophic lateral sclerosis in most countries. Treatment of human ALS patients or
transgenic Cu, Zn superoxide dimutase 1 (SOD 1) mice, most commonly produce a modest
but significant increase in survival. (Bensimon et al., 1994). There have been a least three large
randomised trials involving hundreds of patients that have been unable to show that Riluzole
is a disease altering agent nor does it have any restorative reports. (Miller et al., 2007).
Cases 1 and 2 are SOD 1 positive mutation carriers who developed non-specific symptoms of
muscle fasciculations with no clinical weakness, but had reductions in MUNE on sequential
testing. Needle EMG studies were “normal”, with no evidence of active or chronic denervation
in muscles sampled from bilateral distal and proximal muscles. Normal EMG was defined as
the absence of fasciculation and fibrillation potentials, normal motor unit potentials and
normal recruitment. A presumptive diagnosis of fALS was made, even though there are
reports on incomplete penetrance. In case 3, one could argue that there is no clear evidence
that she has fALS, even though she has a strong family history of ALS with an autosomal
dominant pattern of inheritance. Her episodic weakness and fasciculations improved after
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commencing Riluzole and recurred after discontinuing Riluzole. She also had an improvement
in MUNE and subsequent decline in MUNE, which are temporally associated with the
administration of Riluzole.
After commencing Riluzole, there was an improvement in symptoms and MUNE. It is
therefore possible that if treatment is commenced prior to significant motor neurone loss, the
progression of disease can be slowed down.
In case 3, MUNE dropped when treatment was ceased on two separate occasions and improved
when treatment was recommenced, with the operator being unaware of the Riluzole dose
changes.
In our series, we noted an improvement in symptoms, especially a decrease in muscle
fasciculations and an increase in MUNE number after commencing Riluzole. We suggest that
previous trials have been performed in the symptomatic phase of the disease when 70-80% of
motor units have already been lost, rather than in the pre-symptomatic phase of the disease,
when the therapeutic benefit might be possible. If “treatment” is commenced prior to signifi‐
cant motor neurone loss occurring, the progression of disease may be able to slowed down.
MUNE is believed to reduce because of remodelling of the motor units and in our study, the
compound muscle action potential amplitudes were maintained despite a reduction in MUNE.
This is because early in the disease, the rate of cell death is low. (Cheah et al., 2010). The increase
in MUNE may be either due to reinnervation of the damaged muscles or repair of poorly
functioning synapses, at the early stage of the disease, without resulting in a change in CMAP.
In one of the cases in the study, Riluzole was commenced once she developed mild weakness.
At the time, there was a slight reduction in MUNE, but conventional needle EMG examination
did not fulfil the criteria to make the diagnosis of MND. In view of her strong family history
and positive genetic testing, a presumed diagnosis of MND was made. Since commencing
Riluzole there has been no significant reduction in her EDB MUNE over the last 2 years, and
her weakness of right dorsiflexors has only progressed marginally from MRC grade 4+/5 to
4/5 power. It is possible that since “treatment” was commenced prior to the loss of a significant
number of motor neurones, this may have slowed down the progression of the disease in this
individual case. Early in the course of ALS, the rate of cell death is low as the amount of
neuronal damage caused by the mutation is small. As the amount of intracellular damage
increases, a critical threshold is reached, which overwhelms cellular homeostasis, resulting in
rapid apoptosis and cell death. The increase in MUNE numbers may be either due to reinner‐
vation of the damaged muscle or repair of poorly functioning synapses, at the early stage of
the disease, without resulting in a change in CMAP.
Maximum isometric grip strength was also obtained using the Jamar hydraulic dynamometer
with standardised (middle handle) positioning and instructions. Maximum isometric grip
strength did not reduce, even when MUNE dropped, once again supporting McComas’ theory
that patients can maintain normal muscle twitch tension until loss of about 70-80% of motor
units, before collateral reinnervation was unable to provide functional compensation.
(McComas et al., 1971). Maximum isometric grip strength using the Jamar hydraulic dyna‐
mometer also does not correlate with the number of functional motor neurones in thenar group
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commencing Riluzole and recurred after discontinuing Riluzole. She also had an improvement
in MUNE and subsequent decline in MUNE, which are temporally associated with the
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therefore possible that if treatment is commenced prior to significant motor neurone loss, the
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when treatment was recommenced, with the operator being unaware of the Riluzole dose
changes.
In our series, we noted an improvement in symptoms, especially a decrease in muscle
fasciculations and an increase in MUNE number after commencing Riluzole. We suggest that
previous trials have been performed in the symptomatic phase of the disease when 70-80% of
motor units have already been lost, rather than in the pre-symptomatic phase of the disease,
when the therapeutic benefit might be possible. If “treatment” is commenced prior to signifi‐
cant motor neurone loss occurring, the progression of disease may be able to slowed down.
MUNE is believed to reduce because of remodelling of the motor units and in our study, the
compound muscle action potential amplitudes were maintained despite a reduction in MUNE.
This is because early in the disease, the rate of cell death is low. (Cheah et al., 2010). The increase
in MUNE may be either due to reinnervation of the damaged muscles or repair of poorly
functioning synapses, at the early stage of the disease, without resulting in a change in CMAP.
In one of the cases in the study, Riluzole was commenced once she developed mild weakness.
At the time, there was a slight reduction in MUNE, but conventional needle EMG examination
did not fulfil the criteria to make the diagnosis of MND. In view of her strong family history
and positive genetic testing, a presumed diagnosis of MND was made. Since commencing
Riluzole there has been no significant reduction in her EDB MUNE over the last 2 years, and
her weakness of right dorsiflexors has only progressed marginally from MRC grade 4+/5 to
4/5 power. It is possible that since “treatment” was commenced prior to the loss of a significant
number of motor neurones, this may have slowed down the progression of the disease in this
individual case. Early in the course of ALS, the rate of cell death is low as the amount of
neuronal damage caused by the mutation is small. As the amount of intracellular damage
increases, a critical threshold is reached, which overwhelms cellular homeostasis, resulting in
rapid apoptosis and cell death. The increase in MUNE numbers may be either due to reinner‐
vation of the damaged muscle or repair of poorly functioning synapses, at the early stage of
the disease, without resulting in a change in CMAP.
Maximum isometric grip strength was also obtained using the Jamar hydraulic dynamometer
with standardised (middle handle) positioning and instructions. Maximum isometric grip
strength did not reduce, even when MUNE dropped, once again supporting McComas’ theory
that patients can maintain normal muscle twitch tension until loss of about 70-80% of motor
units, before collateral reinnervation was unable to provide functional compensation.
(McComas et al., 1971). Maximum isometric grip strength using the Jamar hydraulic dyna‐
mometer also does not correlate with the number of functional motor neurones in thenar group
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of muscles as measured using the statistical method of MUNE, indicating that MUNE is a more
sensitive test than MVIC for monitoring disease progression in MND. It has also been shown
that MUNE is able to identify deterioration in functional motor units before handgrip maximal
voluntary isometric contraction (MVIC).
This confirms McComas’ observation that patients with substantial chronic denervation could
maintain normal muscle twitch tension until loss of about 70-80% of motor units occurs.
(McComas, 1971). This suggests that handgrip MVIC is not as sensitive as thenar MUNE for
monitoring disease progression, as it is unable to detect early motor neurone loss due to the
presence of compensatory mechanisms. The surviving motor neurones enlarge their territo‐
ries, through collateral sprouting (reinnervation) until late in the disease, when collateral
reinnervation is no longer able to provide full functional compensation. Thenar MUNE
however does examine all of the motor units that are involved in handgrip MVIC, as forearm
flexors and ulnar-innervated muscles are involved in the generation of handgrip MVIC. It also
confirms Felice’s study which showed that in patients with MND, changes in thenar MUNE
was the most sensitive outcome measure for following disease progression, when compared
to other quantitative tests, such as CMAP, isometric grip strength, forced vital capacity and
Medical Research Council manual muscle testing. (Felice, 1997).
This study also shows that there can be substantial loss in MUNE and still have an essentially
normal EMG with minimal signs of acute denervation or motor unit potential remodelling, as
one would expected that at a minimum, the muscles with transiently reduced MUNE numbers
should have reduced recruitment during EMG studies.
As there is no corroboration with needle EMG in the pre-symptomatic stage of the disease in
this study, this requires a paradigm shift in the traditional concept that needle EMG is the
“gold” standard for the diagnosis of ALS. McComas showed that patients with substantial
chronic denervation could maintain normal muscle twitch tension until loss of about 70-80%
of motor units, before collateral reinnervation was unable to provide functional compensation
(McComas, 1971). The function of motor neurons remains normal because the remaining motor
units incorporate more muscle fibres by collateral sprouting. This should result in larger motor
unit potentials, firing at higher rates with fewer motor units active i.e. reduced recruitment.
Traditional neurologists and neurophysiologists will find it hard to understand physiologi‐
cally how there can be substantial loss in MUNE and still have normal EMG with no signs of
acute denervation or motor unit potential remodelling.
As MUNE is a measure of the primary pathologic process of motor neurone loss and can
identify that the number of motor units are reduced, even in the presence of a non-diagnostic
needle EMG. Needle electromyography may reveal evidence of chronic reinnervation, but
provides little direct evidence to the extent of motor neurone and axonal loss. These cases
clearly indicate that loss of motor neurones is detectable in the pre-symptomatic phase, which
is detectable before significant needle EMG changes of pathology. In addition, compound
muscle action potential amplitudes were maintained, despite a significant reduction in MUNE.
Even though some may argue that a reduction in MUNE cannot be used to support the
diagnosis fALS, our previous study, suggests that once changes start to occur on conventional
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EMG studies, the window of opportunity to influence the progression of this condition has
been missed.
We would argue that previous trials have all be performed in the symptomatic phase of the
disease when 70-80% of motor units have already been lost, rather than in the pre-symptomatic
phase of the disease, when the therapeutic benefit might change, as “treatment” is commenced
prior to significant motor neurone loss occurring and therefore, the progression of disease can
be slowed down. MUNE numbers are believed to reduce because of remodelling of the motor
unit and in our study, the compound muscle action potential amplitudes (CMAP) were
retained as early in the course of the disease, the rate of cell death is low. The increase in MUNE
numbers may be either due to reinnervation of the damaged muscle or repair of poorly
functioning synapses, at the early stage of the disease, without resulting in a change in CMAP.
Therapies aimed at preserving motor neurones may be more feasible than trying to replace
lost motor neurones. A number of treatment or preventative strategies have been suggested,
such as measures to diminish SOD 1 aggregation or interactions to specifically reduce
apoptosis in motor neurones. As motor neurone loss at this stage is rapid and precipitous, any
potential treatment ideally should be given much earlier in SOD 1 mutation carriers. Larger
randomised trials are necessary to study this question in a prospective, blinded fashion.
Even though MUNE evaluations were performed in an unblinded fashion, the statistical
MUNE technique is performed with the assistance of an algorithm, which reduces operator
bias. The main author has been using this technique for over 10 years and any operator bias is
unintentional and unlikely to explain the marked differences in sequential MUNE.
Early in the course of ALS, the rate of cell death is low as the amount of neuronal damage
caused by the mutation is small. As the amount of intracellular damage increases, a critical
threshold is reached, which overwhelms cellular homeostasis, resulting in rapid apoptosis and
cell death. (Clarke, 2001). The mutant neurones appear to function normally for decades, with
weakness only occurring once apoptosis and cell death occurs due to a gradual accumulation
of damage within the cell. (Kong & Xu, 1998).
As motor neurone loss once it occurs is rapid and precipitous, any potential treatment will
need to be given early to SOD1 mutation carriers. Once the disease progresses, resulting in
functional impairment and disability, restorative treatments to replace lost motor neurones
becomes less feasible. To date there have been a number of drugs which have undergone
clinical trials in MND, for which there is no evidence of benefit. These include creatinine, high
dose vitamin E, Gabapentin and nerve growth factors such as brain derived neurotrophic
factor and insulin-like growth factor-1. If effective treatment for MND were to be developed
to arrest the process of degeneration, therapies aimed at preserving functional motor neurones
would be more feasible. This requires the ability to be able to identify individuals at risk of
developing the disease, which currently are SOD1 mutation carriers.
This longitudinal study showed that it was possible to detect loss of motor neurones in the
pre-symptomatic stage of MND in humans. This study provided further evidence that
considerable motor neurone loss occurred just before the onset of symptoms or weakness.
(Aggarwal, 2009).
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that MUNE is able to identify deterioration in functional motor units before handgrip maximal
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This confirms McComas’ observation that patients with substantial chronic denervation could
maintain normal muscle twitch tension until loss of about 70-80% of motor units occurs.
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monitoring disease progression, as it is unable to detect early motor neurone loss due to the
presence of compensatory mechanisms. The surviving motor neurones enlarge their territo‐
ries, through collateral sprouting (reinnervation) until late in the disease, when collateral
reinnervation is no longer able to provide full functional compensation. Thenar MUNE
however does examine all of the motor units that are involved in handgrip MVIC, as forearm
flexors and ulnar-innervated muscles are involved in the generation of handgrip MVIC. It also
confirms Felice’s study which showed that in patients with MND, changes in thenar MUNE
was the most sensitive outcome measure for following disease progression, when compared
to other quantitative tests, such as CMAP, isometric grip strength, forced vital capacity and
Medical Research Council manual muscle testing. (Felice, 1997).
This study also shows that there can be substantial loss in MUNE and still have an essentially
normal EMG with minimal signs of acute denervation or motor unit potential remodelling, as
one would expected that at a minimum, the muscles with transiently reduced MUNE numbers
should have reduced recruitment during EMG studies.
As there is no corroboration with needle EMG in the pre-symptomatic stage of the disease in
this study, this requires a paradigm shift in the traditional concept that needle EMG is the
“gold” standard for the diagnosis of ALS. McComas showed that patients with substantial
chronic denervation could maintain normal muscle twitch tension until loss of about 70-80%
of motor units, before collateral reinnervation was unable to provide functional compensation
(McComas, 1971). The function of motor neurons remains normal because the remaining motor
units incorporate more muscle fibres by collateral sprouting. This should result in larger motor
unit potentials, firing at higher rates with fewer motor units active i.e. reduced recruitment.
Traditional neurologists and neurophysiologists will find it hard to understand physiologi‐
cally how there can be substantial loss in MUNE and still have normal EMG with no signs of
acute denervation or motor unit potential remodelling.
As MUNE is a measure of the primary pathologic process of motor neurone loss and can
identify that the number of motor units are reduced, even in the presence of a non-diagnostic
needle EMG. Needle electromyography may reveal evidence of chronic reinnervation, but
provides little direct evidence to the extent of motor neurone and axonal loss. These cases
clearly indicate that loss of motor neurones is detectable in the pre-symptomatic phase, which
is detectable before significant needle EMG changes of pathology. In addition, compound
muscle action potential amplitudes were maintained, despite a significant reduction in MUNE.
Even though some may argue that a reduction in MUNE cannot be used to support the
diagnosis fALS, our previous study, suggests that once changes start to occur on conventional
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EMG studies, the window of opportunity to influence the progression of this condition has
been missed.
We would argue that previous trials have all be performed in the symptomatic phase of the
disease when 70-80% of motor units have already been lost, rather than in the pre-symptomatic
phase of the disease, when the therapeutic benefit might change, as “treatment” is commenced
prior to significant motor neurone loss occurring and therefore, the progression of disease can
be slowed down. MUNE numbers are believed to reduce because of remodelling of the motor
unit and in our study, the compound muscle action potential amplitudes (CMAP) were
retained as early in the course of the disease, the rate of cell death is low. The increase in MUNE
numbers may be either due to reinnervation of the damaged muscle or repair of poorly
functioning synapses, at the early stage of the disease, without resulting in a change in CMAP.
Therapies aimed at preserving motor neurones may be more feasible than trying to replace
lost motor neurones. A number of treatment or preventative strategies have been suggested,
such as measures to diminish SOD 1 aggregation or interactions to specifically reduce
apoptosis in motor neurones. As motor neurone loss at this stage is rapid and precipitous, any
potential treatment ideally should be given much earlier in SOD 1 mutation carriers. Larger
randomised trials are necessary to study this question in a prospective, blinded fashion.
Even though MUNE evaluations were performed in an unblinded fashion, the statistical
MUNE technique is performed with the assistance of an algorithm, which reduces operator
bias. The main author has been using this technique for over 10 years and any operator bias is
unintentional and unlikely to explain the marked differences in sequential MUNE.
Early in the course of ALS, the rate of cell death is low as the amount of neuronal damage
caused by the mutation is small. As the amount of intracellular damage increases, a critical
threshold is reached, which overwhelms cellular homeostasis, resulting in rapid apoptosis and
cell death. (Clarke, 2001). The mutant neurones appear to function normally for decades, with
weakness only occurring once apoptosis and cell death occurs due to a gradual accumulation
of damage within the cell. (Kong & Xu, 1998).
As motor neurone loss once it occurs is rapid and precipitous, any potential treatment will
need to be given early to SOD1 mutation carriers. Once the disease progresses, resulting in
functional impairment and disability, restorative treatments to replace lost motor neurones
becomes less feasible. To date there have been a number of drugs which have undergone
clinical trials in MND, for which there is no evidence of benefit. These include creatinine, high
dose vitamin E, Gabapentin and nerve growth factors such as brain derived neurotrophic
factor and insulin-like growth factor-1. If effective treatment for MND were to be developed
to arrest the process of degeneration, therapies aimed at preserving functional motor neurones
would be more feasible. This requires the ability to be able to identify individuals at risk of
developing the disease, which currently are SOD1 mutation carriers.
This longitudinal study showed that it was possible to detect loss of motor neurones in the
pre-symptomatic stage of MND in humans. This study provided further evidence that
considerable motor neurone loss occurred just before the onset of symptoms or weakness.
(Aggarwal, 2009).
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This study indicates that SOD1 mutation carriers have normal survival of motor neurones,
with as carriers had a full complement of motor neurones during the asymptomatic phase.
Significant pre-symptomatic loss of motor neurones did not occur in asymptomatic SOD1
mutation carriers. Sudden and widespread motor neurone death occurs at the time develop‐
ment of the symptomatic symptoms, rather than life-long motor neurone loss. Sudden,
catastrophic and multifocal loss of motor neurons occurs immediately prior to the onset of
symptoms and the development of MND. This suggests that there may be a biological trigger
initiating rapid cell loss, just prior to the onset of symptoms, rather than life-long motor
neurone loss. Also, if the trigger initiating motor neurone loss can be identified, it may be
possible to prevent motor neurone loss in familial ALS and develop treatments for sporadic
MND. The mutant SOD1 protein itself cannot be the trigger, as it is constantly expressed. There
may however be a gradual accumulation of a toxic product, possibly SOD1, which has changed
into a new toxic conformation or aggregate, resulting in neuronal damage. The possibility of
an individual neuron undergoing apoptosis increases as damage accumulates. This cumula‐
tive damage may be due to oxidative stress, resulting in disruption of the cellular structure
and function.
Neurofilament heavy polypeptide (NF-H) is an abundant stable cytoplasmic protein located
in neuronal cells in large axons and may be used as a cell type marker. Abnormal accumulation
of NF-H in motor neurones is associated with ALS, but it is unclear to what extent these
contribute to human disease. Analysis of blood serum markers looking for increased levels of
NF-H was not performed in this study, but would be interesting to be done in the future to the
compare levels of NF-H in the carriers.
The results of this study indicate that the risk of cell death probably remains constant through‐
out life of the neurone and that cell death occurs randomly in time and is independent of that
of any other neurone. This suggests a “one-hit” biochemical phenomenon in which the
mutation imposes an abnormal mutant steady state on the neurone and a single catastrophic
event randomly initiates cell death and apoptosis. Early in the course of MND, the rate of cell
death is low as the amount of neuronal damage caused by the mutation is small. The delay in
clinical onset was thought to reflect the gradual accumulation of damage within the neurones,
as a result of the mutation, which ultimately overwhelms cellular homeostasis leading to cell
death. The living mutant neurons function very well for years or decades but the probability
that an individual neurone undergoes apoptosis increases as damage accumulates within it.
A mutant neurone in an older patient will have accumulated a greater amount of damage and
will therefore be more likely to die than in a younger patient. Consequently, early in the course
of disease, the chance of a cell containing a sufficient amount of damage to initiate apoptosis
is small, and the rate of cell loss is correspondingly low. The mutant neurones appear to
function normally for decades, with weakness only occurring once apoptosis and cell death
occurs due to a gradual accumulation of damage within the cell. Therapies aimed at preserving
motor neurones may be more feasible than trying to replace lost motor neurones. A number
of treatment or preventative strategies arise, such as measures to diminish SOD1 aggregation
or interactions to specifically reduced apoptosis in motor neurones. As motor neurone loss at
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this stage is rapid and precipitous, any potential treatment will need to be given much earlier
in SOD1 mutation carriers.
Determining the mechanism by which mutations in the Cu/Zn superoxide dismutase (SOD1)
gene triggers the destruction of motor neurones causing MND remains unknown. At present,
the favoured hypothesis is that the mutation causes disease as a result of a toxic gain of function
by the mutant SOD1 provoking selective neurotoxicity, probably disrupting the intracellular
homeostasis of copper and/or protein aggregation. However, as the amount of intracellular
damage increases, the chance that a cell will die also increases. This cumulative damage may
be due to oxidative stress, in which an imbalance between the production of reactive oxygen
species and cellular antioxidant mechanisms results in chemical modifications of macromole‐
cules, thereby disrupting cellular structure and function. It is possible that the high metabolic
activity in motor neurones, combined with the toxic oxidative properties of the mutant SOD1,
causes massive mitochondrial vacuolation in motor neurones, resulting in degeneration,
earlier than other neurones, triggering the onset of weakness. Prominent cytoplasmic intra‐
cellular inclusions in motor neurones and within astrocytes surrounding them developed by
the onset of clinical disease and in some cases represented the first pathological sign of disease.
These aggregates increased in number as the disease progressed. This indicates that the mutant
SOD1 toxicity is mediated by damage to mitochondria in motor neurones and this damage
triggers the functional decline of motor neurones and the clinical onset of symptoms. The
absence of motor neurone death in the early stages of the disease indicates that the majority
of motor neurones could be rescued after early clinical diagnosis.
Regular follow-up of SOD1 carriers with MUNE may lead to early diagnosis, creating an
opportunity for future novel approaches and therapies aimed at preserving motor neurones
rather than replacing lost motor neurones. If the trigger initiating motor neurone loss can be
identified, it may be possible to prevent motor neurone loss in familial ALS. At this stage,
detecting the onset of motor neurone loss in asymptomatic individuals will identify those who
may benefit from early institution of an active management program to improve their quality
of life, until more effective treatment modalities become available for this devastating condi‐
tion This observation is an important contribution to the current understanding of the
pathogenesis of MND, as it shows that motor neurone disease does not seem to be the end
result of slow attrition of motor neurones. MUNE may be able to be used as a method of pre-
symptomatic testing of individuals who on genetic testing are SOD1 mutation carriers. Regular
follow-up of SOD1 carriers with MUNE may lead to early diagnosis, creating an opportunity
for future novel approaches and therapies aimed at preserving motor neurones rather than
replacing lost motor neurones.
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mutation carriers. Sudden and widespread motor neurone death occurs at the time develop‐
ment of the symptomatic symptoms, rather than life-long motor neurone loss. Sudden,
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symptoms and the development of MND. This suggests that there may be a biological trigger
initiating rapid cell loss, just prior to the onset of symptoms, rather than life-long motor
neurone loss. Also, if the trigger initiating motor neurone loss can be identified, it may be
possible to prevent motor neurone loss in familial ALS and develop treatments for sporadic
MND. The mutant SOD1 protein itself cannot be the trigger, as it is constantly expressed. There
may however be a gradual accumulation of a toxic product, possibly SOD1, which has changed
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tive damage may be due to oxidative stress, resulting in disruption of the cellular structure
and function.
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of NF-H in motor neurones is associated with ALS, but it is unclear to what extent these
contribute to human disease. Analysis of blood serum markers looking for increased levels of
NF-H was not performed in this study, but would be interesting to be done in the future to the
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of any other neurone. This suggests a “one-hit” biochemical phenomenon in which the
mutation imposes an abnormal mutant steady state on the neurone and a single catastrophic
event randomly initiates cell death and apoptosis. Early in the course of MND, the rate of cell
death is low as the amount of neuronal damage caused by the mutation is small. The delay in
clinical onset was thought to reflect the gradual accumulation of damage within the neurones,
as a result of the mutation, which ultimately overwhelms cellular homeostasis leading to cell
death. The living mutant neurons function very well for years or decades but the probability
that an individual neurone undergoes apoptosis increases as damage accumulates within it.
A mutant neurone in an older patient will have accumulated a greater amount of damage and
will therefore be more likely to die than in a younger patient. Consequently, early in the course
of disease, the chance of a cell containing a sufficient amount of damage to initiate apoptosis
is small, and the rate of cell loss is correspondingly low. The mutant neurones appear to
function normally for decades, with weakness only occurring once apoptosis and cell death
occurs due to a gradual accumulation of damage within the cell. Therapies aimed at preserving
motor neurones may be more feasible than trying to replace lost motor neurones. A number
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earlier than other neurones, triggering the onset of weakness. Prominent cytoplasmic intra‐
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These aggregates increased in number as the disease progressed. This indicates that the mutant
SOD1 toxicity is mediated by damage to mitochondria in motor neurones and this damage
triggers the functional decline of motor neurones and the clinical onset of symptoms. The
absence of motor neurone death in the early stages of the disease indicates that the majority
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of life, until more effective treatment modalities become available for this devastating condi‐
tion This observation is an important contribution to the current understanding of the
pathogenesis of MND, as it shows that motor neurone disease does not seem to be the end
result of slow attrition of motor neurones. MUNE may be able to be used as a method of pre-
symptomatic testing of individuals who on genetic testing are SOD1 mutation carriers. Regular
follow-up of SOD1 carriers with MUNE may lead to early diagnosis, creating an opportunity
for future novel approaches and therapies aimed at preserving motor neurones rather than
replacing lost motor neurones.
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1. Introduction
Amyotrophic Lateral Sclerosis (ALS) is a fatal, neurodegenerative disorder affecting upper
and lower motor neurons; it’s the commonest of the motor unit (MU) diseases in Europe and
North America, characterized by a broad spectrum of clinical presentations [1, 2]. Striking
asymmetry and selective involvement of individual groups of muscles, especially of hand and
forearm, are typical early features of the disease. On average, delay from onset of symptoms
to diagnosis is about 14 months and expected survival commonly ranges from months to a few
years [3].
Five to ten percent of cases are familial and about 20% of these families have point mutations
in the Cu/Zn superoxide dismutase-1 (SOD-1) gene. In mammalians, there are three SOD
isoenzymes [4]: the cytosolic SOD1 (Cu/Zn-SOD), whose mutations are associated with
familiar ALS, the mitochondrial Mn-SOD (SOD-2) and the secreted extracellular SOD (SOD-3).
Most mutations in SOD-1 gene are autosomal dominant in inheritance, but there is one
confirmed autosomal recessive mutation, predominant in Scandinavian ancestry, the D90A
mutation in exon 4 [5].
More than 130 mutations in SOD-1 have been identified so far [6, 7]. Superoxide dismutase
(SOD-1) is a well characterized enzyme, which exists as a homodimer whose sequence of 153
amino acids is remarkably well conserved across species. Sporadic and familial forms of the
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disease are clinically indistinguishable, suggesting they may share common mechanisms, but
the pathogenic mechanisms underlying disease’s induction in familiar cases are still largely
controversial. The prevailing hypothesis is that familiar ALS, SOD-1 positive, could be caused
by a neuronal damage due to a gradual accumulation of a toxic product SOD-1 derived; this
cumulative damage leads to a disruption of the cytoskeleton and organelle trafficking within
motor neuron dendrites. As the amount increases, a critical threshold may be reached, which
overwhelms cellular homeostasis resulting in fast cell death [8, 9]. Aggregates do not exclu‐
sively occur in neurons, but also in glial cells, raising the question whether mutant SOD-1
expression in neurons is sufficient per se to induce pyramidal degeneration and sustain disease
evolution over time [10-12]. Little is known about the differences both in motor unit loss and
axonal regeneration rate between sporadic and familiar ALS and whether these changes
underlie different pathogenetic mechanisms could represent a fascinating topic of debate.
2. Motor unit changes in familial ALS: What did we learn from animal
studies?
To date, the more exhaustive study on the morphological differences between wild-type (WT)
and transgenic SOD-1 motorneurons was made by Amendola and Durant [13]. By analyzing
the arborizations of motorneurons in SOD-1G85R mutant mice, they showed:
i. a dramatic increase in the total dendritic length;
ii. a significant proliferation of dendritic branches;
iii. a greater dendritic membrane area, as confirmed by intracellular recordings revealing
a lower input resistance when compared with WT cells.
However, it’s unclear whether these changes represent early compensatory modifications or
a disease mechanism. Previous evidence emphasized an increased ratio of inhibitory to
excitatory synapses in organotypic slice cultures derived from embryonic spinal cords of
SOD1G93A mice [14] and a dampening in cholinergic transmission was also described in the
lumbar spinal cord from adult SOD1G93A mice [15]. Conversely, an intrinsic hyperexcitability
of mutant SOD1G93A spinal motorneurons was found in culture and in organotypic slice
cultures [16, 17]. However, as the cells were not recorded from until they had been cultured
for several weeks, the exact time course and progression rate of these changes are still largely
obscure. Recently, Bories and colleagues showed motorneuron dysfunction appears centrally
long before axonal degeneration [18], suggesting a pivotal role of these morphological changes
in the core of disease mechanism.
Schwindt and Crill [19-21] proved that motorneurons have persistent inward currents (PICs)
able both to potentiate and prolong synaptic firing rate after supraspinal input stopped:
these currents are mainly generated in the dendritic regions, suggesting that motorneur‐
ons dendrites are not passive but active integrators of motor control. These conclusions fit
with data in animals showing an increase in dendritic arborization in SOD-1 mutant mice
compared  with  WT  cells.  High  energy  demands,  due  either  to  altered  motorneuron
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excitability or dendritic overbranching, destabilize calcium homeostasis [22-24].  These all
changes  make  motor  cells  more  susceptible  to  the  axon  transport,  mitochondria  and
metabolic dysfunctions prominent in ALS, as motorneurons become heavily dependent on
mitochondria for Ca++ buffering [25, 26].
In humans, these data were only in part reproduced by the pioneering study of Aggarwal [7,
27]. By evaluating MU changes in 87 subjects carrying mutations in SOD-1 gene, he showed
that asymptomatic carriers of the SOD1 mutations, different from patients with sALS, have no
significant difference in the number of motor neurons when compared with age and sex
matched controls; as symptoms develop, a sudden and catastrophic loss of MU occurs.
However, the significance of these differences is still largely misunderstood.
3. Use of Motor Unit Number Estimation (MUNE) and Macro-
electromyography (Macro-EMG) in the diagnosis and management of ALS:
A brief historical overview
Clinical neurophysiology in ALS plays a fundamental role both in the diagnosis of suspected
disease and in the assessment of its severity and progression, offering a promising tool to
quantify muscle involvement and evaluate response to therapy [28-30]. Electromyography
(EMG) investigation, usually performed with concentric needle electrodes [31], plays an
essential role in the diagnosis and monitoring of ALS [32-34]. Amplitude, duration, area, shape,
stability on repeated discharges of MU and activity at full effort are parameters conventionally
used to evaluate disease’s stage. EMG may also assess the presence of activity of the dener‐
vation-reinnervation process and number of functioning motor units by evaluating recruit‐
ment-activation pattern [28, 35]. In Motor Neuron Diseases (MND), standard needle
electromyography often reveals evidence of chronic reinnervation (increased motor unit action
potential amplitudes and duration, with reduced recruitment), eventually associated with
fasciculations and signs of denervation activity in progress, but provides little information
about the extent of both motor neuron loss and axonal regeneration. The supramaximal CMAP
amplitude also provides little evidence of the extent of motor neuron loss and normal CMAP
amplitudes might mistakenly suggest that motor neuron loss has not occurred yet [36, 37].
A particular method to evaluate the full MU is the so-called macro-EMG [38-41]. This technique
provides information from a larger area of the muscle than traditional needle EMG methods.
The signal is recorded by most of the fibers inside the entire MU and is often employed to
follow the degree of reinnervation. That represents a quantitative technique and can be applied
to follow progression and study of putative therapies [33, 42] by evaluating size of individual
MU [39, 43].
Among quantitative electrodiagnostic (EDX) techniques, the methodology of Motor Unit
Number Estimation (MUNE) has been previously and widely employed in measuring loss of
functioning MU in ALS patients [36, 44-49].
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MUNE is very sensitive in documenting disease progression in ALS. Some studies combining
MUNE and standard electromyography showed a highly significant correlation between
motor unit loss, clinical quantitative features and changes in compound motor action potential
(CMAP) amplitude over time [50]. That is not surprising considering their different targets;
while MUNE assesses motor unit loss, changes in CMAP amplitude and duration also account
for collateral reinnervation. A few longitudinal studies using MUNE in some ALS patients
have been reported that MUNE decreases as the disease progresses and that MUNE is a very
reliable and reproducible method in patients with ALS [36, 51-55]. Its inter-individual and
intra-individual reproducibility linearly increases as disease progresses, making this technique
particularly useful in the symptomatic stage of the disease [36, 55-57].
We routinely use the standard incremental technique, known as the McComas technique.
Despite some limitations in comparison with statistical MUNE (alternation of motor unit,
inability to recognize small motor units, small sample size), it is more reliable and less complex;
in addiction, statistical MUNE cannot identify instable MUPs since it is based on the assump‐
tion that variability is due solely to the number of motor units responding in an intermittent
manner [58]. More recently, Shefner and colleagues proposed a new method to follow over
time motor unit loss in patients with ALS [59]: nerves were stimulated at 3 specified locations
and 3 increments were obtained at each location. Average single motor unit action potential
(SMUP) amplitude was calculated by adding the amplitude of the third increment at each
location and dividing by 9; SMUP was divided into maximum CMAP amplitude to determine
the MUNE. This approach needs further validation, but has some unquestionable advantages:
it’s easy to perform, well tolerated by patients and specialized equipment is not necessary.
Most important, by applying the multipoint method MUNE values decline rapidly in patients
with ALS, although the rate of decline is similar to that obtained with the standard incremental
technique.
Use of Macro-EMG is limited to muscles from which electrical activity can be elicited without
any interference from other muscles [60]; moreover, it’s difficult to perform it in the hands
during the course of the disease due to the strong wasting of the intrinsic hand muscles.
Because of these limitations, our twenty-years experience led us to combine the two techniques
in order to improve diagnostic sensitivity each other.
4. Different motor neuron impairment and axonal regeneration rate in
patients with sporadic or familial Amyotrophic Lateral Sclerosis with
SOD-1 mutations
4.1. Background and methodological considerations
In a previous study [61] we found that ALS patients with SOD-1 mutations have a higher
number of MU at moment of diagnosis when compared with sporadic cases, as previously
emerged from the work of Aggarwal in pre-symptomatic SOD-1 mutations carriers [27, 62].
Compared with previous studies, our innovatory ideas were:
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i. taking into consideration simultaneously Macro-EMG and MUNE changes in
proximal and distal muscles in the same sample of patients;
ii. following all our patients with a one-year follow-up;
iii. evaluating Macro-EMG and MUNE changes both in sporadic and familiar cases
(sALs and fALS).
In the group of 15 symptomatic SOD-1 mutation carriers, two were found to have a point
mutation in exon 4, codon 100, GAA to GGA-Glu100Gly; two were found to have a point
mutation in exon 4, codon 113, ATT to ACT-Ile113Thr; five were found to have a point mutation
in exon 5, codon 148, GTA to GGA-Val148Gly, and six with homozygous for aspartate to
alanine mutations in codon 90 (homD90A), representing the most common SOD-1 mutation
with a typical recessive fashion inheritance. Sixty ALS patients (34 males: mean age ± SD 60.0
± 15.5 years; 26 females: mean age ± SD 62.0 ± 9.2 years) were enrolled in the study and
examined basally (T0) and every 4 months (T1, T2, and T3). Fifteen of these patients are familial
(SOD-1 mutation carriers, 9 males: mean age ± 1SD 46.3 ± 14.8 years; 6 females: mean age ±
1SD 49.0 ± 8.5 years). Macro Motor Unit Potentials (macro-MUPs) were derived from Biceps
Brachialis (BB) muscle; MUNE was performed both in BB and Abductor Digiti Minimi (ADM)
muscles of the same side. Thirty-three healthy volunteers (13 females and 20 males, mean age:
57.7 ± 13.8 years) served as controls. All patients had probable or definite ALS, according to
the well known criteria of the World Federation of Neurology [18]. The sample group of
patients included cases with a disease duration from clinical onset of symptoms to the time of
the first examination less than 48 months (mean ± SD: 12.2 ± 11.0 months). Twenty-two patients
presented a bulbar onset and the remaining a spinal one. As concerns symptoms and signs,
among SOD-1 mutation carriers 10 have the spinal type, while only 5 patients have the bulbar
type. Forty patients were in treatment with riluzole (Rilutek®, 50 mg) at a mean daily dosage
of 100 mg throughout the period of EDX follow-up.
Standard macro-EMG method was applied [39]. The SFEMG recording surface was exposed
7.5 mm from the tip and the recording was made using two channels: the first one in whom
the SFEMG activity was displayed (using the cannula as reference) and used to identify the
MU and trigger the averaging procedure (band-pass filter for this channel: 500-10KHz); fiber
density (FD) of the triggering single fibre electrode was recorded. The second channel averaged
the activity from the cannula until a smooth baseline and a constant macro MUP was obtained
(Filter pass-band: 5-10KHz). We measured from the averaged signal the total area between the
curve and the baseline, the maximal peak-to-peak amplitude (macro-MUP) during the total
sweep time of 70ms [63]. Results were expressed as individual area values from at least 20
trials. The relative macro amplitude was expressed as the obtained mean value [39]. Fibre
density was expressed as number of time locked spikes obtained on the SFEMG channel [64].
In twenty-nine patients (subgroup 1: 19 males and 10 females; mean age ± 1SD: 60,0 ± 11,8
years; spinal/bulbar onset: 22/7; mean disease duration 29,7 months) macro-EMG was repeated
after 4 months (T1). Among the second subgroup, eleven patients (subgroup 2: 8 males and 3
females; mean age ± SD: 57,0 ± 12,8 years; range 30–72 years; spinal/bulbar onset: 10/1; mean
disease duration 31 months) were re-tested after 8 months (T2) and in 8 (subgroup 3; 7 males
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muscles of the same side. Thirty-three healthy volunteers (13 females and 20 males, mean age:
57.7 ± 13.8 years) served as controls. All patients had probable or definite ALS, according to
the well known criteria of the World Federation of Neurology [18]. The sample group of
patients included cases with a disease duration from clinical onset of symptoms to the time of
the first examination less than 48 months (mean ± SD: 12.2 ± 11.0 months). Twenty-two patients
presented a bulbar onset and the remaining a spinal one. As concerns symptoms and signs,
among SOD-1 mutation carriers 10 have the spinal type, while only 5 patients have the bulbar
type. Forty patients were in treatment with riluzole (Rilutek®, 50 mg) at a mean daily dosage
of 100 mg throughout the period of EDX follow-up.
Standard macro-EMG method was applied [39]. The SFEMG recording surface was exposed
7.5 mm from the tip and the recording was made using two channels: the first one in whom
the SFEMG activity was displayed (using the cannula as reference) and used to identify the
MU and trigger the averaging procedure (band-pass filter for this channel: 500-10KHz); fiber
density (FD) of the triggering single fibre electrode was recorded. The second channel averaged
the activity from the cannula until a smooth baseline and a constant macro MUP was obtained
(Filter pass-band: 5-10KHz). We measured from the averaged signal the total area between the
curve and the baseline, the maximal peak-to-peak amplitude (macro-MUP) during the total
sweep time of 70ms [63]. Results were expressed as individual area values from at least 20
trials. The relative macro amplitude was expressed as the obtained mean value [39]. Fibre
density was expressed as number of time locked spikes obtained on the SFEMG channel [64].
In twenty-nine patients (subgroup 1: 19 males and 10 females; mean age ± 1SD: 60,0 ± 11,8
years; spinal/bulbar onset: 22/7; mean disease duration 29,7 months) macro-EMG was repeated
after 4 months (T1). Among the second subgroup, eleven patients (subgroup 2: 8 males and 3
females; mean age ± SD: 57,0 ± 12,8 years; range 30–72 years; spinal/bulbar onset: 10/1; mean
disease duration 31 months) were re-tested after 8 months (T2) and in 8 (subgroup 3; 7 males
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and 1 female; mean age ± SD: 58,0 ± 13,6 years; spinal/bulbar onset: 7/1; mean disease duration
37 months) after 12 months from the first examination.
MUNE technique was performed on the same Keypoint® EMG equipment (Medtronic Dantec,
Copenhagen) provided with specific software for data acquisition and processing at same time
and immediately after macro EMG on the same test session. The used technique relayed on
manual incremental stimulation of the motor nerve, known as the McComas technique [46].
The use of specific software for MUNE detects “alternation”, eliminates subjectivity and the
sampling of artifactually small motor units in ALS patients [36, 46, 54]. Percutaneous stimuli
were delivered over musculocutaneous nerve immediately below axilla, recording from BB
muscles, and ulnar nerve at the wrist by recording from the ADM muscle of the same upper
limb [36]. Signals were detected with common surface electrodes, Ag/AgCl type, tapered on
the cutis over target muscles with a common muscle-belly tendon montage.
4.2. Main findings and possible explanations
MUNE values in ALS patients were behind normal limits in 55 (91.7%) and within normal
limits in 5 (8.3%) in biceps brachialis (BB) muscle; in 58 (96.7%) and in 2 (3.3%) in ADM muscle,
respectively [36]. In brief, we can summarize our findings in two main points:
i. MUNE revealed a normal amount of motor units in fALS at the moment of diagnosis,
followed by a dramatic loss of motor units, more pronounced than in patients with
sALS (see Figure 1, top panels);
ii. Macro-EMG in SOD-1 fALS showed increased fiber density and area values when
compared with patients with sALS, likely suggesting a paradoxical more effective
axonal sprouting in fALS (Figure 1, bottom panels).
Functioning MUs number progressively decreased in both muscles throughout the entire
follow-up period. In ALS MUNE exhibited a parallel trends in proximal and distal muscles
(BB and ADM), independently of disease duration; mean step area, instead, increased more in
BB, especially in patients with longer disease duration. The MUNE’s results as concerns
patients with fALS, SOD-1 positive, were 80.2 ± 7.8 (T0), 21.8 ± 2.2 (T1), 16.8 ± 1.0 (T2) and 16.5
± 2.2 (T3) for BB and 42.8 ± 6.6 (T0), 18.4 ± 3.1 (T1), 15.3 ± 2.1 (T2) and 9.0 ± 2.1 (T3) for ADM.
Curiously, SOD-1 fALS patients showed a higher number of functioning motor units in the
early stage of disease (p<0.001) and a more dramatic drop in later phases (Figure 1). These
results suggest a normal pool of motor units in asymptomatic familiar ALS carriers [27]. No
electrodiagnostic difference was found between patients with different SOD-1 point muta‐
tions. Moreover, we did not found any significant difference between spinal and bulbar-onset
fALS in terms of surviving MU, for both BB and ADM muscles (p>0.05, Figure 2), as well as
between males and females (p>0.05, Figure 3).
In sALS patients at T0, both Macro-motor Unit Potentials (Macro-MUPs) area and fiber density
(FD) were above upper normal limits (for a global overview of Macro-EMG in healthy subjects,
see Sartucci et al., 2007 and 2011): macro-MUP area was 4397.6 ± 255.9 μVms, mean FD 2.0 ±
0.2 (a summary of results is given in Figure 2). The macro-MUP area was abnormal in 57 (95.0%)
and normal in 3 (5.0%) patients; in SOD-1 carriers baseline values of MUP area and FD matched
Current Advances in Amyotrophic Lateral Sclerosis232
with those of sALS patients (4378.9 ± 319.6 μVms and 1.9 ± 0.3, for Macro-MUPs area and FD
respectively; p = 0.815 and p = 0.147). In sALS, Macro-MUPs area resulted progressively
increased at every time, especially at T3, compared with T0 (Figure 1, bottom panels): Area: +
45.3% (T1); + 49.0% (T2); + 83.6% (T3); FD showed a trend to increase up to T3: +3.5% (T1);
+15.4% (T2); +22.4% (T3). Interestingly, in SOD-1 carriers there was a much steeper increase at
T1, T2 and T3 in respect to sporadic forms, as concerns both Macro-MUPs area and FD values.
Macro-MUPs area was 7791.0 ± 953.4, 10922.8 ± 1123.7 and 12499.3 ± 1874.4 (p<0.01) μVms and
mean FD 2.5 ± 0.3, 3.5 ± 0.6 and 3.9 ± 0.5 (p>0.01). As a whole, these results account both for a
more severe involvement of alfa-motorneurons pool and a paradoxical more effective axonal
sprouting in fALS compared with sALS.
Figure 1. The top row shows MUNE values both for biceps brachialis, on the left, and abductor digiti minimi muscles,
on the right, at different time points (at the moment of diagnosis and after 4, 8 and 12 months: T0, T1, T2 and T3). At
the moment of diagnosis, motor units number is higher for familiar cases (black lines, fALS) compared with sporadic
ones (gray lines, sALS). Bottom row shows time-trend of Macro-EMG parameters (fiber density, area) over time. All the
values increase more steeply in familiar than in sporadic forms (black and gray lines, respectively), strengthening the
idea that in the first group there is a paradoxical more effective axonal sprouting (modified from Bocci et al., Int J Mol
Sci 2011; *p < 0.05; **p < 0.01).
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and 1 female; mean age ± SD: 58,0 ± 13,6 years; spinal/bulbar onset: 7/1; mean disease duration
37 months) after 12 months from the first examination.
MUNE technique was performed on the same Keypoint® EMG equipment (Medtronic Dantec,
Copenhagen) provided with specific software for data acquisition and processing at same time
and immediately after macro EMG on the same test session. The used technique relayed on
manual incremental stimulation of the motor nerve, known as the McComas technique [46].
The use of specific software for MUNE detects “alternation”, eliminates subjectivity and the
sampling of artifactually small motor units in ALS patients [36, 46, 54]. Percutaneous stimuli
were delivered over musculocutaneous nerve immediately below axilla, recording from BB
muscles, and ulnar nerve at the wrist by recording from the ADM muscle of the same upper
limb [36]. Signals were detected with common surface electrodes, Ag/AgCl type, tapered on
the cutis over target muscles with a common muscle-belly tendon montage.
4.2. Main findings and possible explanations
MUNE values in ALS patients were behind normal limits in 55 (91.7%) and within normal
limits in 5 (8.3%) in biceps brachialis (BB) muscle; in 58 (96.7%) and in 2 (3.3%) in ADM muscle,
respectively [36]. In brief, we can summarize our findings in two main points:
i. MUNE revealed a normal amount of motor units in fALS at the moment of diagnosis,
followed by a dramatic loss of motor units, more pronounced than in patients with
sALS (see Figure 1, top panels);
ii. Macro-EMG in SOD-1 fALS showed increased fiber density and area values when
compared with patients with sALS, likely suggesting a paradoxical more effective
axonal sprouting in fALS (Figure 1, bottom panels).
Functioning MUs number progressively decreased in both muscles throughout the entire
follow-up period. In ALS MUNE exhibited a parallel trends in proximal and distal muscles
(BB and ADM), independently of disease duration; mean step area, instead, increased more in
BB, especially in patients with longer disease duration. The MUNE’s results as concerns
patients with fALS, SOD-1 positive, were 80.2 ± 7.8 (T0), 21.8 ± 2.2 (T1), 16.8 ± 1.0 (T2) and 16.5
± 2.2 (T3) for BB and 42.8 ± 6.6 (T0), 18.4 ± 3.1 (T1), 15.3 ± 2.1 (T2) and 9.0 ± 2.1 (T3) for ADM.
Curiously, SOD-1 fALS patients showed a higher number of functioning motor units in the
early stage of disease (p<0.001) and a more dramatic drop in later phases (Figure 1). These
results suggest a normal pool of motor units in asymptomatic familiar ALS carriers [27]. No
electrodiagnostic difference was found between patients with different SOD-1 point muta‐
tions. Moreover, we did not found any significant difference between spinal and bulbar-onset
fALS in terms of surviving MU, for both BB and ADM muscles (p>0.05, Figure 2), as well as
between males and females (p>0.05, Figure 3).
In sALS patients at T0, both Macro-motor Unit Potentials (Macro-MUPs) area and fiber density
(FD) were above upper normal limits (for a global overview of Macro-EMG in healthy subjects,
see Sartucci et al., 2007 and 2011): macro-MUP area was 4397.6 ± 255.9 μVms, mean FD 2.0 ±
0.2 (a summary of results is given in Figure 2). The macro-MUP area was abnormal in 57 (95.0%)
and normal in 3 (5.0%) patients; in SOD-1 carriers baseline values of MUP area and FD matched
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with those of sALS patients (4378.9 ± 319.6 μVms and 1.9 ± 0.3, for Macro-MUPs area and FD
respectively; p = 0.815 and p = 0.147). In sALS, Macro-MUPs area resulted progressively
increased at every time, especially at T3, compared with T0 (Figure 1, bottom panels): Area: +
45.3% (T1); + 49.0% (T2); + 83.6% (T3); FD showed a trend to increase up to T3: +3.5% (T1);
+15.4% (T2); +22.4% (T3). Interestingly, in SOD-1 carriers there was a much steeper increase at
T1, T2 and T3 in respect to sporadic forms, as concerns both Macro-MUPs area and FD values.
Macro-MUPs area was 7791.0 ± 953.4, 10922.8 ± 1123.7 and 12499.3 ± 1874.4 (p<0.01) μVms and
mean FD 2.5 ± 0.3, 3.5 ± 0.6 and 3.9 ± 0.5 (p>0.01). As a whole, these results account both for a
more severe involvement of alfa-motorneurons pool and a paradoxical more effective axonal
sprouting in fALS compared with sALS.
Figure 1. The top row shows MUNE values both for biceps brachialis, on the left, and abductor digiti minimi muscles,
on the right, at different time points (at the moment of diagnosis and after 4, 8 and 12 months: T0, T1, T2 and T3). At
the moment of diagnosis, motor units number is higher for familiar cases (black lines, fALS) compared with sporadic
ones (gray lines, sALS). Bottom row shows time-trend of Macro-EMG parameters (fiber density, area) over time. All the
values increase more steeply in familiar than in sporadic forms (black and gray lines, respectively), strengthening the
idea that in the first group there is a paradoxical more effective axonal sprouting (modified from Bocci et al., Int J Mol
Sci 2011; *p < 0.05; **p < 0.01).
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Macro-MUP area and FD were beyond upper normal limits, as expected, in ALS [63, 65]. Our
results indicate that carriers of SOD-1 mutations have a higher number of motor units at
moment of diagnosis when compared with sporadic cases. On the other hand, in sALS the
Figure 2. Histogram highlighting MUNE values in both BB (at the top) and ADM (bottom histogram) muscles at every
time of follow-up, in males (gray columns) and females (black columns); the top row shows the evolution of motor
unit loss in the familiar form, whereas the bottom one the trend in sporadic cases (modified from Bocci et al., Int J Mol
Sci 2011).
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macro-EMG parameters progressively increased, displaying a gradual increment of correla‐
tion up to 8 months, suggesting that the process of MU rearrangement begins to fall after 8
months of disease course. In familiar SOD-1 form there isn't a specific time interval in which
the axonal regeneration and the collateral sprouting can balance the neuronal damage.
Paradoxically, despite faster loss of motor units, in fALS we have undisclosed a more effective
axonal sprouting in the few surviving motor fibers. Compared with sporadic forms, in SOD-1
fALS the substantial lack of a fleeting stabilization of motor unit number within eight months
from clinical onset, as emerged from MUNE, could indicate that damage of cell types different
from motor neurons is a critical factor for the progression of corticospinal degeneration [66,
67]. Our results strengthen the idea that accelerated disease progression does not alter the
timing of disease onset. These data are consistent with those reported by Yamanaka and
colleagues [67]: using chimeras derived from embryonic cells of SOD-1G37R mice, they postu‐
lated that multiple cell types drive non-cell-autonomous onset of motor degeneration. That
could also explain the wide variability in terms of age of onset, clinical presentation and rate
of progression in familiar forms of ALS. This is in line with previous papers showing a
differential pyramidal tract degeneration in homozygous SOD-1D90A ALS and sALS [68-70];
e.g., Blain and colleagues have recently reported a marked reduction in fractional anisotropy
in the corticospinal tract in patients with sALS and fALS, despite similar levels of upper motor
neurons dysfunction and overall clinical disability [68]. ALS is featured by repetitive cycles of
denervation/reinnervation and the mechanism lead to a variation in FD within a given motor
unit [33, 42]. SOD-1 carriers had a full complement of motor neurons during the asymptomatic
phase, indicating that SOD-1 mutation carriers have normal survival of motor neurons until
sudden catastrophic cell death occurs. This significant gradual preclinical loss does not occur
in SOD-1 mutation carriers. Despite the small sample of fALS patients, we also tried to detect
significant differences in motor unit pool between spinal and bulbar forms, for both BB and
ADM muscles (Figure 2). Interestingly, we did not found any difference suggesting the rate
and amount of motor units decrease are approximately similar in proximal and distal muscles.
That confirms the non length-dependent and all-or-none nature of pathological processes
underlying progression of fALS. A possible explanation could be based on an epigenetics
approach: it has been proposed that epigenetic silencing of genes vital for motor neuron
function could underlie ALS [44,45]. The promoters of genes thought to be implicated in sALS,
SOD-1 and VEGF, or that of MT-Ia and MT-II (the most common human isoforms of the
metallothionein (MT) family of proteins), have been found with inappropriate methylation
levels [46]. There’s an increasing interest in this field, despite no conclusive remark has been
collected in human models so far. That’s likely due to the discrepancy between humans
patients and animal models, in terms of disease and pre-symptomatic phase duration, absence
of sensitive biological markers and different pathogenesis. Our findings agree with those
described by Aggarwal both in symptomatic and asymptomatic SOD-1 mutation carriers [27]:
symptomatic fALS could represent an all-or none process and it is not the final result of a slow
attrition of motor neurons.
Another interesting finding is about the lack of significant differences in motor unit depletion
over time between females and males in SOD-1 type, both in fALS and sALS form (see Figure
3): the antioxidant effects of estrogens and their proved role in preventing glutamate related
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Macro-MUP area and FD were beyond upper normal limits, as expected, in ALS [63, 65]. Our
results indicate that carriers of SOD-1 mutations have a higher number of motor units at
moment of diagnosis when compared with sporadic cases. On the other hand, in sALS the
Figure 2. Histogram highlighting MUNE values in both BB (at the top) and ADM (bottom histogram) muscles at every
time of follow-up, in males (gray columns) and females (black columns); the top row shows the evolution of motor
unit loss in the familiar form, whereas the bottom one the trend in sporadic cases (modified from Bocci et al., Int J Mol
Sci 2011).
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macro-EMG parameters progressively increased, displaying a gradual increment of correla‐
tion up to 8 months, suggesting that the process of MU rearrangement begins to fall after 8
months of disease course. In familiar SOD-1 form there isn't a specific time interval in which
the axonal regeneration and the collateral sprouting can balance the neuronal damage.
Paradoxically, despite faster loss of motor units, in fALS we have undisclosed a more effective
axonal sprouting in the few surviving motor fibers. Compared with sporadic forms, in SOD-1
fALS the substantial lack of a fleeting stabilization of motor unit number within eight months
from clinical onset, as emerged from MUNE, could indicate that damage of cell types different
from motor neurons is a critical factor for the progression of corticospinal degeneration [66,
67]. Our results strengthen the idea that accelerated disease progression does not alter the
timing of disease onset. These data are consistent with those reported by Yamanaka and
colleagues [67]: using chimeras derived from embryonic cells of SOD-1G37R mice, they postu‐
lated that multiple cell types drive non-cell-autonomous onset of motor degeneration. That
could also explain the wide variability in terms of age of onset, clinical presentation and rate
of progression in familiar forms of ALS. This is in line with previous papers showing a
differential pyramidal tract degeneration in homozygous SOD-1D90A ALS and sALS [68-70];
e.g., Blain and colleagues have recently reported a marked reduction in fractional anisotropy
in the corticospinal tract in patients with sALS and fALS, despite similar levels of upper motor
neurons dysfunction and overall clinical disability [68]. ALS is featured by repetitive cycles of
denervation/reinnervation and the mechanism lead to a variation in FD within a given motor
unit [33, 42]. SOD-1 carriers had a full complement of motor neurons during the asymptomatic
phase, indicating that SOD-1 mutation carriers have normal survival of motor neurons until
sudden catastrophic cell death occurs. This significant gradual preclinical loss does not occur
in SOD-1 mutation carriers. Despite the small sample of fALS patients, we also tried to detect
significant differences in motor unit pool between spinal and bulbar forms, for both BB and
ADM muscles (Figure 2). Interestingly, we did not found any difference suggesting the rate
and amount of motor units decrease are approximately similar in proximal and distal muscles.
That confirms the non length-dependent and all-or-none nature of pathological processes
underlying progression of fALS. A possible explanation could be based on an epigenetics
approach: it has been proposed that epigenetic silencing of genes vital for motor neuron
function could underlie ALS [44,45]. The promoters of genes thought to be implicated in sALS,
SOD-1 and VEGF, or that of MT-Ia and MT-II (the most common human isoforms of the
metallothionein (MT) family of proteins), have been found with inappropriate methylation
levels [46]. There’s an increasing interest in this field, despite no conclusive remark has been
collected in human models so far. That’s likely due to the discrepancy between humans
patients and animal models, in terms of disease and pre-symptomatic phase duration, absence
of sensitive biological markers and different pathogenesis. Our findings agree with those
described by Aggarwal both in symptomatic and asymptomatic SOD-1 mutation carriers [27]:
symptomatic fALS could represent an all-or none process and it is not the final result of a slow
attrition of motor neurons.
Another interesting finding is about the lack of significant differences in motor unit depletion
over time between females and males in SOD-1 type, both in fALS and sALS form (see Figure
3): the antioxidant effects of estrogens and their proved role in preventing glutamate related
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toxicity in vitro [71, 72] could not delay both the early retraction of nerve terminals from
neuromuscular end-plates and the dying-back of axons during asymptomatic phase in vivo.
5. Conclusions and future directions
Although our preliminary results cannot be directly compared with those found in animals,
these data could expand current knowledges about morphological and functional differences
between mutant and wild type motorneurons in ALS.
We speculate that overbranching occurs not only in dendrites but also in the few surviving
axons. This increased complexity of axonal arborization, compared both with healthy and
sALS subjects, is still largely undervalued and whether that represents a pointless neuropro‐
tective response of nervous system or a disease mechanism is an intriguing matter of debate.
However, as suggested in animal models [73], our Macro-EMG data seem to suggest that
overbranching might be one way to mitigate loss of function along corticospinal pathways.
These evidences highlight a novel hypothesis for the adult onset of fALS symptoms, namely
Figure 3. Histogram highlighting MUNE values in both BB (left) and ADM (right) muscles at every time of follow-up, in
males (gray columns) and females (black columns); the top row shows the evolution of motor unit loss in the familiar
form, whereas the bottom one the trend in sporadic cases. The lack of significant differences between males and fe‐
males, in sporadic as well as in familiar forms, is consistent with results recently reported in recent literature [71, 72].
(modified from Bocci et al., Int J Mol Sci 2011: *p<0.05; **p<0.01).
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that they result from age-related factors (e.g., neuron loss or other traumatic insults) that cause
a breakdown of homeostatic compensatory processes for neuronal hyperactivity.
Further studies are needed to solve these dilemmas, especially in familiar forms different from
those related to mutations pertaining to Cu/Zn superoxide dismutase gene. Particularly, it
could be very interesting if a combined MUNE/Macro-EMG protocol was applied to subjects
carrying mutations in C9ORF72 gene; these patients, although very rare in the Mediterranean
area, typically have upper motor neuron-predominant variants, show memory and executive
dysfunctions and account for about 30% of the cases of fALS [74-77]. Most important, the
increasing interest in C9ORF72 mutations are due to the frequent association with extra-
pyramidal features and Frontotemporal Dementia spectrum.
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toxicity in vitro [71, 72] could not delay both the early retraction of nerve terminals from
neuromuscular end-plates and the dying-back of axons during asymptomatic phase in vivo.
5. Conclusions and future directions
Although our preliminary results cannot be directly compared with those found in animals,
these data could expand current knowledges about morphological and functional differences
between mutant and wild type motorneurons in ALS.
We speculate that overbranching occurs not only in dendrites but also in the few surviving
axons. This increased complexity of axonal arborization, compared both with healthy and
sALS subjects, is still largely undervalued and whether that represents a pointless neuropro‐
tective response of nervous system or a disease mechanism is an intriguing matter of debate.
However, as suggested in animal models [73], our Macro-EMG data seem to suggest that
overbranching might be one way to mitigate loss of function along corticospinal pathways.
These evidences highlight a novel hypothesis for the adult onset of fALS symptoms, namely
Figure 3. Histogram highlighting MUNE values in both BB (left) and ADM (right) muscles at every time of follow-up, in
males (gray columns) and females (black columns); the top row shows the evolution of motor unit loss in the familiar
form, whereas the bottom one the trend in sporadic cases. The lack of significant differences between males and fe‐
males, in sporadic as well as in familiar forms, is consistent with results recently reported in recent literature [71, 72].
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a breakdown of homeostatic compensatory processes for neuronal hyperactivity.
Further studies are needed to solve these dilemmas, especially in familiar forms different from
those related to mutations pertaining to Cu/Zn superoxide dismutase gene. Particularly, it
could be very interesting if a combined MUNE/Macro-EMG protocol was applied to subjects
carrying mutations in C9ORF72 gene; these patients, although very rare in the Mediterranean
area, typically have upper motor neuron-predominant variants, show memory and executive
dysfunctions and account for about 30% of the cases of fALS [74-77]. Most important, the
increasing interest in C9ORF72 mutations are due to the frequent association with extra-
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1. Introduction
Recently, eye-gaze input systems have been developed as novel human–machine interfaces
[1-10]. Their operation requires only eye movements by the user. Based upon such systems,
many communication aids have been developed for people with severe physical disabilities,
such as amyotrophic lateral sclerosis (ALS). Eye-gaze input systems commonly employ non-
contact eye-gaze detection for which an incandescent, fluorescent, or LED lamp can be used
as the source of infrared or natural light. Detection based on infrared light can detect eye gaze
with a high degree of accuracy [1-3] but requires an expensive device. Detection based on
natural light uses ordinary devices and is therefore cost-effective [4,5]. However, an eye-gaze
input system for natural light has a low degree of accuracy.
We have previously developed an eye-gaze input system for people with severe physical
disabilities [8-10]. This system uses a personal computer (PC) and a home video camera to
detect eye gaze under natural light. The camera (e.g., a DV camera) can easily be connected to
a PC through an IEEE 1394 interface. The frames taken by the camera can be analyzed in real
time using the DirectShow library by Microsoft. We developed image analysis software to
detect eye gaze. Our eye-gaze input system runs the software on Windows. This system does
not require any special devices and is easily customizable. Therefore, this system is not only
cost-effective but also versatile. Moreover, it can be operated under natural light and thus is
suitable for personal use.
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1. Introduction
Recently, eye-gaze input systems have been developed as novel human–machine interfaces
[1-10]. Their operation requires only eye movements by the user. Based upon such systems,
many communication aids have been developed for people with severe physical disabilities,
such as amyotrophic lateral sclerosis (ALS). Eye-gaze input systems commonly employ non-
contact eye-gaze detection for which an incandescent, fluorescent, or LED lamp can be used
as the source of infrared or natural light. Detection based on infrared light can detect eye gaze
with a high degree of accuracy [1-3] but requires an expensive device. Detection based on
natural light uses ordinary devices and is therefore cost-effective [4,5]. However, an eye-gaze
input system for natural light has a low degree of accuracy.
We have previously developed an eye-gaze input system for people with severe physical
disabilities [8-10]. This system uses a personal computer (PC) and a home video camera to
detect eye gaze under natural light. The camera (e.g., a DV camera) can easily be connected to
a PC through an IEEE 1394 interface. The frames taken by the camera can be analyzed in real
time using the DirectShow library by Microsoft. We developed image analysis software to
detect eye gaze. Our eye-gaze input system runs the software on Windows. This system does
not require any special devices and is easily customizable. Therefore, this system is not only
cost-effective but also versatile. Moreover, it can be operated under natural light and thus is
suitable for personal use.
© 2013 Kiyohiko et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
2. Current eye-gaze input systems
Many systems or devices have been developed as communication aids for ALS patients. For
example, the E-tran (eye transfer) frame is used for communication between ALS patients and
others. The E-tran frame is a conventional device and its structure is very simple. It is a
transparent plastic board with characters, such as the alphabet, printed on it. When using the
E-tran frame, a communication partner (helper) holds it over the user’s face. Specifically, the
user gazes at the place where the character that the user wishes to communicate is positioned.
The helper moves the E-tran frame until the eye gaze of the user corresponds with that of the
helper. Therefore, the helper can determine the character from the user’s eye gaze. A user who
can gaze at the characters on the E-tran frame can also communicate with others. In addition,
the E-tran frame does not require power supply and is therefore highly portable. However,
considerable skill is required to use the E-tran frame.
The row–column scanning system is also used to aid the communication of ALS patients. This
system can be operated with one switch. In other words, the user can input characters or
operate a PC by using their physical residual function. The row–column scanning system is
configured to exploit simple hardware. For example, if the user employs the screen keyboard
that is installed on Windows, the user can operate many of the Windows software applications.
It takes considerable time to input using the row–column scanning system, because this system
operates by scanning the rows and columns of keyboards using only one switch. To improve
upon this situation, a new method for row–column scanning has been reported [11]. This
method optimizes the speed of row-column scanning by using a Bayesian network for machine
learning. However, a patient with severe ALS cannot use the row–column scanning system,
despite its single switch.
Our eye-gaze input system mitigates these weaknesses. In a general eye-gaze input system,
the icons displayed on the PC monitor are selected by the user gazing at them, as shown in
Figure 1. These icons are called indicators and are assigned to characters or functions of the
application program. The eye-gaze input has to detect the user’s gaze in order to ascertain the
selected indicator. Many eye-gaze detection methods have been developed in the past. Several
systems use the EOG(electro-oculogram) method for eye-gaze detection [7], which detects eye
gaze by the difference in the electrical potential between the cornea and the retina. It is a contact
method that uses electrodes placed around the eye. Although cost-effective, some users find
that long-term use of the electrodes is uncomfortable. Therefore, many systems detect eye gaze
using non-contact methods [1-10]. Specifically, the user’s gaze is detected by analyzing images
of the eye (and its surrounding skin) captured by a video camera. To classify the many
indicators, most conventional systems use special devices such as infrared light [1-3] or
multiple cameras [6]. Nevertheless, in order to be suitable for personal use, the system should
be inexpensive and user-friendly. Therefore, a simple system using a single camera in natural
light is desirable [4-6]. However, natural-light systems often have low accuracy and are capable
of classifying only a few indicators [4]. This makes it difficult for users to perform a task that
requires many functions, such as text input. To solve these problems, a simple eye-gaze input
system that can classify many indicators is needed.
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Figure 1. Overview of eye-gaze input
3. Eye-gaze detection by image analysis
Eye gaze is defined as a unit vector in a three-dimensional coordinate space. The origin of this
unit vector is the center of the eyeball. Generally, the user’s gaze is detected on a two-dimen‐
sional plane. It has horizontal and vertical components. The method of tracking the iris (the
colored part of the eye) is the most popular method for eye-gaze detection using image analysis
in natural light [4-6]. For example, if the edge between the iris and the sclera (the white part
of the eye) is estimated by image processing, the appropriately approximated ellipse of the
edge shows the location of the iris. However, it is difficult to distinguish the iris and the sclera
by image analysis, because the edge between the iris and the sclera is not sharp. In addition,
if a large part of the iris is hidden by the upper and lower eyelids, the measurement errors
increase, because the obscuring of the iris by the eyelids causes estimation errors in the
delineation of the iris. To resolve these issues, we propose a new image analysis method for
detecting eye gaze using both the horizontal and vertical directions. This detection method is
based on the limbus tracking method. Our eye-gaze detection method can obtain the coordi‐
nates of the user's gaze point.
In our eye-gaze detection method, the video camera records images of the user’s eye from
a distant  location  (the  distance  between  the  user  and  camera  is  approximately  70  cm),
and then this image is enlarged. The head movements of the user induce a large error in
the detected gaze. We compensated for the head movements by tracing the location of a
corner within the eye.
3.1. Horizontal gaze detection
The limbus tracking method is an eye-gaze detection method using the difference in reflectance
between the iris and the sclera. By this method, eye gaze can be estimated with relative ease,
and therefore it has been used since the 1960s [12]. The general eye-gaze detection system using
the limbus tracking method irradiates an eyeball of a subject with infrared light. The eye gaze
of the subject is detected by measuring the reflected light using optical sensors such as
photodiodes.
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We have developed a new eye-gaze detection method that is used under natural light [8,9].
An overview of the proposed horizontal gaze detection method is shown in Figure 2. The
difference in reflectance between the iris and the sclera is used as follows: the gaze is estimated
from the difference between the integral values of the light intensities in Areas A and B, as
shown in Figure 2. We designate this differential value as the horizontal eye-gaze value, which
gives a value for the horizontal gaze component. The relation between the horizontal eye-gaze





Center of eye 
Figure 2. Detection of horizontal gaze
3.2. Vertical gaze detection
An overview of the proposed vertical gaze detection method is shown in Figure 3. The vertical
eye-gaze is also detected by the limbus tracking method. In other words, the light intensity of
the eye image is used to detect the vertical eye gaze. Specifically, the vertical eye gaze is
estimated from the integral value of the light intensity in Area C that is not hidden by the
eyelids [10]. We designate this integral value as the vertical eye-gaze value, which gives a value
for the vertical gaze component. The relation between the vertical eye-gaze value and the angle
of sight is a characteristic function. Therefore, the system can be calibrated using this relation.
Many application programs for eye-gaze input need low-accuracy measurements that involve
only three directions of vertical eye gaze (top, center, and bottom). Therefore, our practical
eye-gaze input system detects only three general directions of vertical eye gaze.
Area C 
Figure 3. Detection of Vertical gaze (Method 1)
In reality, the light-intensity distribution of the eye image changes with iris movement, and
vertical gaze can be detected using this change [9]. The system stores vertically aligned images
of the eye gazing at the indicators. The light-intensity distributions (the results of a one-
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dimensional projection) are calculated from these eye images as reference data. The user’s
vertical gaze can be detected by pattern matching based on these reference data. An overview
of the method is shown in Figure 4, which illustrates the detection of each of the three gaze
directions: top, center, and bottom. The wave patterns at the right of the eye illustrations show
the light-intensity distributions. We confirmed that with increasing reference data the method
can distinguish five to seven vertical gaze directions.
Center Top Bottom 
Distribution of light intensity 
Figure 4. Detection of Vertical gaze (Method 2)
4. Input interfaces based on eye gaze
We developed a new eye-gaze input system using the methods discussed in Section 3. This
system detects the eye gaze of a user under natural light and operates the application programs
for communication aids such as text input. Two interfaces to operate the application programs
have been developed. One of the interfaces has indicators displayed on the PC monitor. The
functions of application programs are executed by gazing at these indicators. The other
interface allows eye gaze to control the mouse cursor. By means of this interface, a user can
operate the general Windows software. We describe our eye-gaze input system and its input
interface below.
4.1. Eye-gaze input system
Our eye-gaze input system comprises a PC, a home video camera, and an IEEE 1394 interface
for image capture from the camera. For eye-gaze detection, the computer runs image analysis
software on Windows (XP, Vista, or 7). This system (illustrated in Figure 5) does not require a
device exclusively for image processing. The characteristics of eye gaze vary from one
individual to another. Therefore, the eye-gaze input system requires calibration. The indicators
for calibration are shown in Figure 6. Users must calibrate the system before using it for tasks.
After the camera location is adjusted, the calibration begins. While the calibration is being
performed, users gaze at each indicator when its color switches to red. Our eye-gaze input
system has two types of indicators, which are specific to each application. In particular, the
five calibration indicators shown in Figure 6(a) are used for the input interface with a work‐
space displayed at the center of the PC monitor. The workspace is used for displaying an
application software window. In addition, the nine calibration indicators shown in Figure
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the light-intensity distributions. We confirmed that with increasing reference data the method
can distinguish five to seven vertical gaze directions.
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4. Input interfaces based on eye gaze
We developed a new eye-gaze input system using the methods discussed in Section 3. This
system detects the eye gaze of a user under natural light and operates the application programs
for communication aids such as text input. Two interfaces to operate the application programs
have been developed. One of the interfaces has indicators displayed on the PC monitor. The
functions of application programs are executed by gazing at these indicators. The other
interface allows eye gaze to control the mouse cursor. By means of this interface, a user can
operate the general Windows software. We describe our eye-gaze input system and its input
interface below.
4.1. Eye-gaze input system
Our eye-gaze input system comprises a PC, a home video camera, and an IEEE 1394 interface
for image capture from the camera. For eye-gaze detection, the computer runs image analysis
software on Windows (XP, Vista, or 7). This system (illustrated in Figure 5) does not require a
device exclusively for image processing. The characteristics of eye gaze vary from one
individual to another. Therefore, the eye-gaze input system requires calibration. The indicators
for calibration are shown in Figure 6. Users must calibrate the system before using it for tasks.
After the camera location is adjusted, the calibration begins. While the calibration is being
performed, users gaze at each indicator when its color switches to red. Our eye-gaze input
system has two types of indicators, which are specific to each application. In particular, the
five calibration indicators shown in Figure 6(a) are used for the input interface with a work‐
space displayed at the center of the PC monitor. The workspace is used for displaying an
application software window. In addition, the nine calibration indicators shown in Figure
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6(b) are used for the interface to operate the mouse cursor, because this interface requires a





Figure 5. Appearance of proposed system
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Figure 6. Indicators for calibration
4.2. Interface using indicators displayed on PC monitor
An interface suitable for eye-gaze input can be designed when developing application
programs for an eye-gaze input system. For example, an interface using indicators is most
commonly used. The indicators are displayed on the windows of the application program and
are selected by the gaze of the user. The arrangement of indicators depends on the measure‐
ment accuracy of the eye-gaze input system. Our system treats each indicator as one of 27
indicators (3 rows and 9 columns), which permits high accuracy. However, in the interest of
usefulness, our practical eye-gaze input system utilizes an interface with 5 to 12 indicators.
The arrangement patterns of the indicators are shown in Figure 7.
The arrangement pattern in Figure 7(a) is used when the eye-gaze input system needs fewer
than five indicators. This arrangement pattern can be used when the application program
requires a small number of indicators. However, it can demand a wide display area for the
application program. Therefore, this arrangement is best used by application programs such
as a television program viewer. The arrangements in Figures 7(b) and (c) are used when the
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eye-gaze input system needs 6 to 12 indicators. In particular, some kinds of application
programs require 6 to 10 indicators. These application programs utilize the arrangement in
Figure 7(b). For example, fixed-phrase mailers or Web browsers use this arrangement pattern.
(a) (b) (c) 
Figure 7. Arrangement patterns of indicators
In addition, text input is a popular application for eye-gaze input. Around 60 indicators are
required to input Japanese text. In fact, English text input systems require a similar number of
indicators, because the English language contains uppercase letters, lowercase letters, and
punctuation marks. Moreover, control keys are required for text input. If around 60 indicators
are displayed on a screen, the window for text input cannot be arranged on the same screen.
In other words, its operability is greatly decreased. Therefore, we developed a text input system
for Japanese and English using the indicators shown in Figure 7(c). Its interface requires two
selections: one for character group selection and another for character input (the details are
given in Section 5). For an eye-gaze input system with the indicators shown in Figure 7(a),
(b), or (c), there is no necessity to detect eye gaze when the user gazes at the center of the PC
monitor. Therefore, an eye-gaze input system using any of these arrangements is calibrated
with the simple indicators shown in Figure 6(a).
Generally, the eye-gaze input decision with such an interface requires the detection of not only
the user's gaze point but also the user's command for an indicator (assigned character)
selection. An input decision can be made by using eye fixation, measuring the time for which
the eye fixates on a target such as one of the indicators. The abovementioned interface using
indicator selection requires special application programs. However, the operability of the
system can be increased by using suitably designed indicators. The users need to sufficiently
practice operating this system to operate the application programs at a faster pace.
4.3. Interface for mouse operation
When users operate a PC with the mouse, they gaze at the mouse cursor routinely. In other
words, if the mouse cursor can be moved to the user's gaze point, the eye gaze of the user can
be utilized for an input interface. Our eye-gaze input system can obtain the coordinates of the
user's gaze point. In other words, when a user gazes at a point on the PC screen, the mouse
cursor moves to that point.
If the mouse cursor is controlled by eye gaze, the user gazes over the entire area of screen.
Hence, the eye gaze of the user must be detected with a high degree of accuracy. Therefore, a
system with this interface is calibrated using the indicators shown in Figure 6(b). By using an
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Hence, the eye gaze of the user must be detected with a high degree of accuracy. Therefore, a
system with this interface is calibrated using the indicators shown in Figure 6(b). By using an
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interface for mouse operation, the general Windows software can be operated without any
special application programs. In addition, Windows operations such as copying a file can be
performed by eye gaze. The method for operating this interface is clear and simple; therefore,
this interface is user-friendly.
We developed special application programs for eye-gaze input. However, users may want to
run other Windows software. By selecting the abovementioned interface, users can fulfill this
desire. However, the icons and menu items of the general Windows software are small for eye-
gaze input. In other words, it is difficult to select the icons and menu items with mouse
operations by eye gaze. When users gaze at one point on the object viewed, their eye fixation
has micromotions (called involuntary eye movements). Therefore, it is difficult to keep the
mouse cursor on the viewed object for the time required for eye-gaze input. In addition, the
general Windows software and the eye-gaze detection software are executed on Windows
separately. Hence, the general Windows software cannot recognize the icon or menu item that
is gazed at by the user.
To resolve these issues, the interface for mouse operation requires a different method for input
decisions. We think that an eye blink should provide the information used in this input decision
method. The details of this method are given in Section 6.
5. Application programs for eye-gaze input
Our research group has developed application programs for eye-gaze input to assist ALS
patients. The interface of the application programs employs indicators displayed on the PC
monitor, as shown in Section 4-2. We present our application programs below.
5.1. Text input system
Text input is the most important function to aid communication by ALS patients. Inputting
text by eye gaze increases the convenience of their communication. We designed indicators
for text input by eye gaze, considering the success rate of gaze selection with our proposed
system [9]. There are 12 indicators (2 rows and 6 columns). With this system, users can input
Japanese or English text at a faster pace. However, around 60 indicators are required to input
Japanese text. Similarly, 12 indicators are insufficient for English text input, because the English
language contains uppercase letters, lowercase letters, and punctuation marks. To resolve this
problem, we designed a new interface through which users can select any character (English
or Japanese) by first choosing the indicator group. An overview of the interface is shown in
Figure 8.
This interface requires two selections: one for character group selection (e.g., Group “A–E”)
and another for character input. Letters require two selections, and punctuation marks (“etc.”
in Figure 8) also require two. However, commonly used characters such as the space (“SPC”
in Figure 8) require just one selection. To input the character “C,” the user first selects the
indicator for Group “A–E” and then the indicator for the uppercase letter “C.” Japanese
characters can be input in the same way.
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Generally, the eye-gaze input decision with such an interface requires the detection of not only the user's gaze point but also the 
user's command for an indicator (assigned character) selection. An input decision can be made by using eye fixation, measuring the 
time for which the eye fixates on a target such as one of the indicators. The abovementioned interface using indicator selection 
requires special application programs. However, the operability of the system can be increased by using suitably designed 
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software are small for eye-gaze input. In other words, it is difficult to select the icons and menu items with mouse operations by 
eye gaze. When users gaze at one point on the object viewed, their eye fixation has micromotions (called involuntary eye 
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addition, the general Windows software and the eye-gaze detection software are executed on Windows separately. Hence, the 
general Windows software cannot recognize the icon or menu item that is gazed at by the user. 
To resolve these issues, the interface for mouse operation requires a different method for input decisions. We think that an eye 
blink should provide the information used in this input decision method. The details of this method are given in Section 6. 
5. Application programs for eye-gaze input 
Our research group has developed application programs for eye-gaze input to assist ALS patients. The interface of the application 
programs employs indicators displayed on the PC monitor, as shown in Section 4-2. We present our application programs below. 
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Text input is the most important function to aid communication by ALS patients. Inputting text by eye gaze increases the 
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insufficient for English text input, because the English language contains uppercase letters, lowercase letters, and punctuation 
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the space (“SPC” in Figure 8) require just one selection. To input the character “C,” the user first selects the indicator for Group “A–
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5.2. Support system for personal computer operation
If users can operate general Windows functions by eye gaze, they can operate commonly used
application programs such as mailers and Web browsers. Users can input text to these
applications using the abovementioned interface for text input. Such applications are normally
operated by keyboard or mouse, especially the latter. When an eye-gaze input system is used,
the functions of the application programs must be assigned to indicators. We have extended
our system to general Windows functions. Many guidelines have been proposed for the
development of application programs for the disabled. To satisfy these guidelines, we assign
the following Windows functions to indicators: cursor control; execution of application
programs; use of shortcut keys to copy, cut, and paste; and selection of items from a menu bar.
Hence, commercial applications can be used with our system [9]. The Windows functions are
organized as shown in Figure 9, and the user can switch indicator group. The “main operation
screen” has indicators for cursor operation, object selection, decision input (enter), etc. The
“extended operation screen” has indicators for operating the mouse, activating the desktop,
switching, or closing the window, etc. Using these indicators, all general Windows functions
can be performed.
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As described in Section 4-3, general Windows functions can be extended by controlling the mouse cursor by eye gaze. However, 
indicators that include the commonly used functions actualize a comfortable and high-speed operation of Windows. 
5.3. Mailer software for sending fixed phrases 
By using the text input system described in Section 5-1, users can input English text by eye gaze at approximately 16 characters per 
minute [9]. This input rate is not adequate to send an emergency message. To resolve this concern, we developed mailer software 
for sending fixed phrases by eye gaze. This software requires only a few steps for sending a message. In addition, combinations of 
the fixed phrases can be sent, and each phrase is customizable. Users can send a message to a pager or a smart phone outside the 
room. Therefore, users can communicate their requests (such as “I would like a drink of water”) to their helpers. A screenshot of 
this mailer software is shown in Figure 10. 
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interface for mouse operation, the general Windows software can be operated without any
special application programs. In addition, Windows operations such as copying a file can be
performed by eye gaze. The method for operating this interface is clear and simple; therefore,
this interface is user-friendly.
We developed special application programs for eye-gaze input. However, users may want to
run other Windows software. By selecting the abovementioned interface, users can fulfill this
desire. However, the icons and menu items of the general Windows software are small for eye-
gaze input. In other words, it is difficult to select the icons and menu items with mouse
operations by eye gaze. When users gaze at one point on the object viewed, their eye fixation
has micromotions (called involuntary eye movements). Therefore, it is difficult to keep the
mouse cursor on the viewed object for the time required for eye-gaze input. In addition, the
general Windows software and the eye-gaze detection software are executed on Windows
separately. Hence, the general Windows software cannot recognize the icon or menu item that
is gazed at by the user.
To resolve these issues, the interface for mouse operation requires a different method for input
decisions. We think that an eye blink should provide the information used in this input decision
method. The details of this method are given in Section 6.
5. Application programs for eye-gaze input
Our research group has developed application programs for eye-gaze input to assist ALS
patients. The interface of the application programs employs indicators displayed on the PC
monitor, as shown in Section 4-2. We present our application programs below.
5.1. Text input system
Text input is the most important function to aid communication by ALS patients. Inputting
text by eye gaze increases the convenience of their communication. We designed indicators
for text input by eye gaze, considering the success rate of gaze selection with our proposed
system [9]. There are 12 indicators (2 rows and 6 columns). With this system, users can input
Japanese or English text at a faster pace. However, around 60 indicators are required to input
Japanese text. Similarly, 12 indicators are insufficient for English text input, because the English
language contains uppercase letters, lowercase letters, and punctuation marks. To resolve this
problem, we designed a new interface through which users can select any character (English
or Japanese) by first choosing the indicator group. An overview of the interface is shown in
Figure 8.
This interface requires two selections: one for character group selection (e.g., Group “A–E”)
and another for character input. Letters require two selections, and punctuation marks (“etc.”
in Figure 8) also require two. However, commonly used characters such as the space (“SPC”
in Figure 8) require just one selection. To input the character “C,” the user first selects the
indicator for Group “A–E” and then the indicator for the uppercase letter “C.” Japanese
characters can be input in the same way.
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movements). Therefore, it is difficult to keep the mouse cursor on the viewed object for the time required for eye-gaze input. In 
addition, the general Windows software and the eye-gaze detection software are executed on Windows separately. Hence, the 
general Windows software cannot recognize the icon or menu item that is gazed at by the user. 
To resolve these issues, the interface for mouse operation requires a different method for input decisions. We think that an eye 
blink should provide the information used in this input decision method. The details of this method are given in Section 6. 
5. Application programs for eye-gaze input 
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programs employs indicators displayed on the PC monitor, as shown in Section 4-2. We present our application programs below. 
5.1. Text input system 
Text input is the most important function to aid communication by ALS patients. Inputting text by eye gaze increases the 
convenience of their communication. We designed indicators for text input by eye gaze, considering the success rate of gaze 
selection with our proposed system [9]. There are 12 indicators (2 rows and 6 columns). With this system, users can input Japanese 
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5.2. Support system for personal computer operation
If users can operate general Windows functions by eye gaze, they can operate commonly used
application programs such as mailers and Web browsers. Users can input text to these
applications using the abovementioned interface for text input. Such applications are normally
operated by keyboard or mouse, especially the latter. When an eye-gaze input system is used,
the functions of the application programs must be assigned to indicators. We have extended
our system to general Windows functions. Many guidelines have been proposed for the
development of application programs for the disabled. To satisfy these guidelines, we assign
the following Windows functions to indicators: cursor control; execution of application
programs; use of shortcut keys to copy, cut, and paste; and selection of items from a menu bar.
Hence, commercial applications can be used with our system [9]. The Windows functions are
organized as shown in Figure 9, and the user can switch indicator group. The “main operation
screen” has indicators for cursor operation, object selection, decision input (enter), etc. The
“extended operation screen” has indicators for operating the mouse, activating the desktop,
switching, or closing the window, etc. Using these indicators, all general Windows functions
can be performed.
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As described in Section 4-3, general Windows functions can be extended by controlling the mouse cursor by eye gaze. However, 
indicators that include the commonly used functions actualize a comfortable and high-speed operation of Windows. 
5.3. Mailer software for sending fixed phrases 
By using the text input system described in Section 5-1, users can input English text by eye gaze at approximately 16 characters per 
minute [9]. This input rate is not adequate to send an emergency message. To resolve this concern, we developed mailer software 
for sending fixed phrases by eye gaze. This software requires only a few steps for sending a message. In addition, combinations of 
the fixed phrases can be sent, and each phrase is customizable. Users can send a message to a pager or a smart phone outside the 
room. Therefore, users can communicate their requests (such as “I would like a drink of water”) to their helpers. A screenshot of 
this mailer software is shown in Figure 10. 
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As described in Section 4-3, general Windows functions can be extended by controlling the
mouse cursor by eye gaze. However, indicators that include the commonly used functions
actualize a comfortable and high-speed operation of Windows.
5.3. Mailer software for sending fixed phrases
By using the text input system described in Section 5-1, users can input English text by eye
gaze at approximately 16 characters per minute [9]. This input rate is not adequate to send an
emergency message. To resolve this concern, we developed mailer software for sending fixed
phrases by eye gaze. This software requires only a few steps for sending a message. In addition,
combinations of the fixed phrases can be sent, and each phrase is customizable. Users can send
a message to a pager or a smart phone outside the room. Therefore, users can communicate
their requests (such as “I would like a drink of water”) to their helpers. A screenshot of this





Figure 10. Mailer software for sending fixed messages
5.4. Web browser using eye gaze
With the popularization of the Internet, people now frequently browse Web pages to collect
information. We paid great attention to this point; hence, we developed a Web browser for the
eye-gaze input system. Generally, a Web page is related to others via hyperlinks. In addition,
users often input text to a Web page when using a social networking service (SNS), online
shopping, etc. When browsing these Web pages, the users make selections via hyperlinks,
radio buttons, and text boxes that must be detected on the Web pages. Our system determines
the locations of these selectable objects on a Web page. The system then stores the locations of
these objects. Consequently, the mouse cursor jumps to the object of the candidate input.
Therefore, our system enables Web browsing at a faster pace. An overview of the object
selection method that uses information on the arrangement is shown in Figure 11.
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Figure 11. Object selection method using arrangement information
5.5. Television program viewing system
Studies have reported that the three principal functions of an environmental control system
are for a television, reclining bed, and air conditioner. In other words, physically disabled
people such as ALS patients would like to operate the functions of these devices. We focused
our attention on a PC with a television tuner, and developed a television program viewing
system for eye-gaze input. This system displays television programs on the PC screen along
with the indicators for function control. The five indicators for the television program viewing
system are displayed in the upper part of the screen as shown in Figure 12. The functions of a
channel selector, volume control, and power switch are assigned to the five indicators. When
users view television programs, the indicators are not required. Therefore, we set up two
modes designated as viewer mode and control mode. In control mode, the five indicators are
displayed on the screen. In viewer mode, the five indicators are not displayed, but an indicator
for mode change is displayed. If the user gazes at the indicator for mode change, the other five
indicators appear instead.
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6. Next-generation eye-gaze input system 
As described above, we have developed not only an eye-gaze input system for natural light but also an application system. When 
the application programs are used in combination, the quality of life (QoL) of ALS patients is improved. However, in order to 
provide additional improvements in QoL, a more versatile environment for eye-gaze input is required. For example, some users 
would like to explore the newer Web services, such as Facebook and Twitter. It is difficult to develop new software for these users 
individually. To resolve this problem, we need to improve our interface for mouse operation by eye gaze (presented in Section 4-3). 
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6. Next-generation eye-gaze input system
As described above, we have developed not only an eye-gaze input system for natural light
but also an application system. When the application programs are used in combination, the
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As described in Section 4-3, general Windows functions can be extended by controlling the
mouse cursor by eye gaze. However, indicators that include the commonly used functions
actualize a comfortable and high-speed operation of Windows.
5.3. Mailer software for sending fixed phrases
By using the text input system described in Section 5-1, users can input English text by eye
gaze at approximately 16 characters per minute [9]. This input rate is not adequate to send an
emergency message. To resolve this concern, we developed mailer software for sending fixed
phrases by eye gaze. This software requires only a few steps for sending a message. In addition,
combinations of the fixed phrases can be sent, and each phrase is customizable. Users can send
a message to a pager or a smart phone outside the room. Therefore, users can communicate
their requests (such as “I would like a drink of water”) to their helpers. A screenshot of this
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5.4. Web browser using eye gaze
With the popularization of the Internet, people now frequently browse Web pages to collect
information. We paid great attention to this point; hence, we developed a Web browser for the
eye-gaze input system. Generally, a Web page is related to others via hyperlinks. In addition,
users often input text to a Web page when using a social networking service (SNS), online
shopping, etc. When browsing these Web pages, the users make selections via hyperlinks,
radio buttons, and text boxes that must be detected on the Web pages. Our system determines
the locations of these selectable objects on a Web page. The system then stores the locations of
these objects. Consequently, the mouse cursor jumps to the object of the candidate input.
Therefore, our system enables Web browsing at a faster pace. An overview of the object
selection method that uses information on the arrangement is shown in Figure 11.
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quality of life (QoL) of ALS patients is improved. However, in order to provide additional
improvements in QoL, a more versatile environment for eye-gaze input is required. For
example, some users would like to explore the newer Web services, such as Facebook and
Twitter. It is difficult to develop new software for these users individually. To resolve this
problem, we need to improve our interface for mouse operation by eye gaze (presented in
Section 4-3).
As shown in Section 4-2, if a user gazes at the indicator for a desired input, that input is easily
decided upon, because the application program can recognize the indicator viewed. The
interface for mouse operation can move the cursor to the gaze point of the user; however, it is
difficult for this type of interface to recognize the icon viewed. To resolve this problem
fundamentally, we are developing an interface that utilizes information on eye gaze and eye
blinks. Many such interfaces have been proposed, but no truly practical system has been
developed. When using this type of interface, unconscious eye blinks occur. In other words,
the input errors are often attributable to unconscious blinks. This phenomenon is known as
the “Midas touch problem.”
We think that if involuntary (unconscious) blinks can be recognized, the input errors can be
significantly decreased. In fact, we are presently developing an eye-gaze input system that can
recognize voluntary blinks. Most conventional methods for measuring eye blinks analyze
images of the eye (and its surrounding skin) captured by a video camera. Commonly used
NTSC video cameras are capable of detecting eye blinks. However, it is difficult for these
cameras to measure the detailed temporal changes that occur during the process of eye
blinking, because an eye blink occurs relatively fast (within a few hundred milliseconds). The
eye-gaze input system also uses an NTSC camera and therefore it is necessary to take account
of this problem.
NTSC video cameras capture moving images at 60 fields/s, and these field images are mixed
to produce field-interlaced images at a rate of 30 frames/s (fps). We have proposed a new
method for using NTSC video cameras to measure eye blinks [13]. This method utilizes the
non-interlaced eye images captured by an NTSC video camera. These images are odd- and
even-field images in the NTSC format and are generated by splitting NTSC frames (interlaced
images). The proposed method has a time resolution that is twice that of the NTSC format.
Therefore, the detailed temporal changes that occur during the process of eye blinking can be
measured. By using this new method for eye blink detection, we can develop a next-generation
eye-gaze input system that is more user-friendly.
7. Conclusions
We have developed a new eye-gaze input system for people with severe physical disabilities.
This system detects the horizontal and vertical eye-gaze components of users under natural
light such as that from an incandescent, fluorescent, or LED lamp. By using this system, users
can input text or commands to a PC. We have also developed application programs for the
eye-gaze input system, including a text input system, PC operation support system, fixed-
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phrase mailer, Web browser, and television program viewing system. When these programs
are used in combination, the QoL of ALS patients is improved.
Our eye-gaze input system can obtain the coordinates of the user's gaze point. Accordingly,
when a user gazes at a point on the PC screen, the mouse cursor moves to that point. By using
this input interface, users can operate the general application software of Windows. In
addition, our system is expected to contribute to the development of a next-generation eye-
gaze input system. This new eye-gaze input system will be developed using our new method
for eye-gaze and eye-blink detection. We believe that our new eye-gaze input system can
ameliorate the QoL of ALS patients.
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quality of life (QoL) of ALS patients is improved. However, in order to provide additional
improvements in QoL, a more versatile environment for eye-gaze input is required. For
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problem, we need to improve our interface for mouse operation by eye gaze (presented in
Section 4-3).
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decided upon, because the application program can recognize the indicator viewed. The
interface for mouse operation can move the cursor to the gaze point of the user; however, it is
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developed. When using this type of interface, unconscious eye blinks occur. In other words,
the input errors are often attributable to unconscious blinks. This phenomenon is known as
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images of the eye (and its surrounding skin) captured by a video camera. Commonly used
NTSC video cameras are capable of detecting eye blinks. However, it is difficult for these
cameras to measure the detailed temporal changes that occur during the process of eye
blinking, because an eye blink occurs relatively fast (within a few hundred milliseconds). The
eye-gaze input system also uses an NTSC camera and therefore it is necessary to take account
of this problem.
NTSC video cameras capture moving images at 60 fields/s, and these field images are mixed
to produce field-interlaced images at a rate of 30 frames/s (fps). We have proposed a new
method for using NTSC video cameras to measure eye blinks [13]. This method utilizes the
non-interlaced eye images captured by an NTSC video camera. These images are odd- and
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